WO2021065898A1 - アゼパン誘導体 - Google Patents
アゼパン誘導体 Download PDFInfo
- Publication number
- WO2021065898A1 WO2021065898A1 PCT/JP2020/036868 JP2020036868W WO2021065898A1 WO 2021065898 A1 WO2021065898 A1 WO 2021065898A1 JP 2020036868 W JP2020036868 W JP 2020036868W WO 2021065898 A1 WO2021065898 A1 WO 2021065898A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituent
- ddd
- compound
- nmr
- Prior art date
Links
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical class C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 title claims abstract description 8
- 125000001424 substituent group Chemical group 0.000 claims abstract description 271
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 72
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 59
- 150000003839 salts Chemical class 0.000 claims abstract description 38
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 32
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 22
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 19
- 150000001204 N-oxides Chemical group 0.000 claims abstract description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 45
- 125000003277 amino group Chemical group 0.000 claims description 37
- 125000005843 halogen group Chemical group 0.000 claims description 34
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 29
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 26
- 150000001537 azepanes Chemical class 0.000 claims description 25
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 23
- 125000001072 heteroaryl group Chemical group 0.000 claims description 23
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 125000004122 cyclic group Chemical group 0.000 claims description 21
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 18
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 18
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 15
- 102000048260 kappa Opioid Receptors Human genes 0.000 claims description 15
- 108020001588 κ-opioid receptors Proteins 0.000 claims description 15
- 230000000202 analgesic effect Effects 0.000 claims description 14
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 14
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 14
- 125000002252 acyl group Chemical group 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 11
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 10
- 125000006239 protecting group Chemical group 0.000 claims description 10
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 9
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 8
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000003262 carboxylic acid ester group Chemical group [H]C([H])([*:2])OC(=O)C([H])([H])[*:1] 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 claims description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 5
- 125000004442 acylamino group Chemical group 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 3
- 125000004104 aryloxy group Chemical group 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 239000003908 antipruritic agent Substances 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 21
- 150000001875 compounds Chemical class 0.000 description 638
- -1 isooxazolyl group Chemical group 0.000 description 344
- 238000005160 1H NMR spectroscopy Methods 0.000 description 339
- 238000003786 synthesis reaction Methods 0.000 description 336
- 230000015572 biosynthetic process Effects 0.000 description 316
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 300
- 238000000034 method Methods 0.000 description 289
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 278
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 230
- 239000000203 mixture Substances 0.000 description 229
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 214
- 239000000243 solution Substances 0.000 description 178
- 230000002829 reductive effect Effects 0.000 description 120
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 116
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 114
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 113
- 239000011541 reaction mixture Substances 0.000 description 109
- 239000012043 crude product Substances 0.000 description 96
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 95
- 229910052938 sodium sulfate Inorganic materials 0.000 description 95
- 235000011152 sodium sulphate Nutrition 0.000 description 95
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 75
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 74
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 67
- 229920006395 saturated elastomer Polymers 0.000 description 65
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 63
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 60
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 60
- 238000010898 silica gel chromatography Methods 0.000 description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 59
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 58
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 58
- 235000017557 sodium bicarbonate Nutrition 0.000 description 58
- 239000000284 extract Substances 0.000 description 56
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 55
- 229910001868 water Inorganic materials 0.000 description 55
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 54
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 52
- 238000001816 cooling Methods 0.000 description 49
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 48
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 48
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 46
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 42
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 39
- 239000000126 substance Substances 0.000 description 37
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 34
- 239000012044 organic layer Substances 0.000 description 34
- 238000010992 reflux Methods 0.000 description 32
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 32
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 28
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical group CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 26
- 229910000027 potassium carbonate Inorganic materials 0.000 description 26
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 24
- 239000000741 silica gel Substances 0.000 description 23
- 229910002027 silica gel Inorganic materials 0.000 description 23
- JZFSLMDLIPKTAO-UHFFFAOYSA-N 1,3-dihydroazepin-2-one Chemical compound O=C1CC=CC=CN1 JZFSLMDLIPKTAO-UHFFFAOYSA-N 0.000 description 21
- 238000012746 preparative thin layer chromatography Methods 0.000 description 21
- 239000003921 oil Substances 0.000 description 20
- 235000019198 oils Nutrition 0.000 description 20
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 18
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 18
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 18
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 18
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 17
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 16
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 150000002170 ethers Chemical class 0.000 description 16
- 150000002430 hydrocarbons Chemical group 0.000 description 16
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 16
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 16
- 239000008096 xylene Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 239000002798 polar solvent Substances 0.000 description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 14
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 14
- 239000012230 colorless oil Substances 0.000 description 14
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 13
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 13
- 239000012312 sodium hydride Substances 0.000 description 13
- 229910000104 sodium hydride Inorganic materials 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 150000001298 alcohols Chemical class 0.000 description 12
- RIKMMFOAQPJVMX-UHFFFAOYSA-N fomepizole Chemical compound CC=1C=NNC=1 RIKMMFOAQPJVMX-UHFFFAOYSA-N 0.000 description 12
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 12
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 125000001153 fluoro group Chemical group F* 0.000 description 11
- 150000008282 halocarbons Chemical class 0.000 description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 125000001309 chloro group Chemical group Cl* 0.000 description 10
- 229910052731 fluorine Inorganic materials 0.000 description 10
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 10
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 10
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- 229940098779 methanesulfonic acid Drugs 0.000 description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 229910052708 sodium Inorganic materials 0.000 description 9
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 9
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 8
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 8
- 229910052801 chlorine Inorganic materials 0.000 description 8
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 8
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 8
- 229910052808 lithium carbonate Inorganic materials 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 8
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 8
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 8
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 8
- 229960004919 procaine Drugs 0.000 description 8
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 8
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 7
- 206010039897 Sedation Diseases 0.000 description 7
- 150000007513 acids Chemical class 0.000 description 7
- 150000007529 inorganic bases Chemical class 0.000 description 7
- 239000004533 oil dispersion Substances 0.000 description 7
- 229910052763 palladium Inorganic materials 0.000 description 7
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 7
- 230000036280 sedation Effects 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 229960004285 fomepizole Drugs 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
- 150000007530 organic bases Chemical class 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 6
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 5
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 5
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 5
- 239000002841 Lewis acid Substances 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 5
- USLKCMBGQFYUFI-UHFFFAOYSA-N dichloromethane;tribromoborane Chemical compound ClCCl.BrB(Br)Br USLKCMBGQFYUFI-UHFFFAOYSA-N 0.000 description 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 5
- 229930195733 hydrocarbon Natural products 0.000 description 5
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 5
- 150000007517 lewis acids Chemical class 0.000 description 5
- 239000012280 lithium aluminium hydride Substances 0.000 description 5
- XGZZHZMWIXFATA-UEZBDDGYSA-N nalfurafine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3N(C)C(=O)\C=C\C1=COC=C1)CN2CC1CC1 XGZZHZMWIXFATA-UEZBDDGYSA-N 0.000 description 5
- 229960000441 nalfurafine Drugs 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 5
- 239000011592 zinc chloride Substances 0.000 description 5
- 235000005074 zinc chloride Nutrition 0.000 description 5
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 4
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- AEFKZGUOUXFLRE-UHFFFAOYSA-N OC1(C=CN=CCC1(CCN1)C2=C3)C1=CC2=CC=C3O Chemical compound OC1(C=CN=CCC1(CCN1)C2=C3)C1=CC2=CC=C3O AEFKZGUOUXFLRE-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 4
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 4
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 4
- 239000002632 kappa opiate receptor agonist Substances 0.000 description 4
- 229940126470 kappa opioid receptor agonist Drugs 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 125000002757 morpholinyl group Chemical group 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 230000001624 sedative effect Effects 0.000 description 4
- 235000009518 sodium iodide Nutrition 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 3
- FCUDOROFFCNCNP-UHFFFAOYSA-N 2-(4-methylpyrazol-1-yl)acetic acid Chemical compound CC=1C=NN(CC(O)=O)C=1 FCUDOROFFCNCNP-UHFFFAOYSA-N 0.000 description 3
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 239000012448 Lithium borohydride Substances 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 3
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 3
- XUWHAWMETYGRKB-UHFFFAOYSA-N delta-valerolactam Chemical group O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 3
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 150000004820 halides Chemical group 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 150000003951 lactams Chemical group 0.000 description 3
- 229910000103 lithium hydride Inorganic materials 0.000 description 3
- 229960005181 morphine Drugs 0.000 description 3
- 102000051367 mu Opioid Receptors Human genes 0.000 description 3
- NNKPHNTWNILINE-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxopyrazin-1-yl]benzamide Chemical compound CNCCOC1=CC=CC=C1C1(NC=2C(N(C=3C(=C(F)C=C(C=3)C(=O)NC3CC3)C)C=CN=2)=O)CC1 NNKPHNTWNILINE-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 3
- 229910000105 potassium hydride Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 150000003952 β-lactams Chemical group 0.000 description 3
- 150000003953 γ-lactams Chemical group 0.000 description 3
- 150000003954 δ-lactams Chemical group 0.000 description 3
- 108020001612 μ-opioid receptors Proteins 0.000 description 3
- HERZOLAZZJEDON-NJDAHSKKSA-N (1R,9R,10S)-17-(cyclopropylmethyl)-10-hydroxy-4-methoxy-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-13-one Chemical compound C([C@@]12C3=CC(OC)=CC=C3C[C@@]3([C@@]1(CCC(=O)C2)O)[H])CN3CC1CC1 HERZOLAZZJEDON-NJDAHSKKSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 2
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 2
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 2
- TYHOSUCCUICRLM-UHFFFAOYSA-N 1,3-oxazole-2-carbaldehyde Chemical compound O=CC1=NC=CO1 TYHOSUCCUICRLM-UHFFFAOYSA-N 0.000 description 2
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 2
- 125000006017 1-propenyl group Chemical group 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 2
- LXFQSRIDYRFTJW-UHFFFAOYSA-N 2,4,6-trimethylbenzenesulfonic acid Chemical compound CC1=CC(C)=C(S(O)(=O)=O)C(C)=C1 LXFQSRIDYRFTJW-UHFFFAOYSA-N 0.000 description 2
- JEEDFPVACIKHEU-UHFFFAOYSA-N 2-(2h-indazol-3-yl)acetic acid Chemical compound C1=CC=CC2=C(CC(=O)O)NN=C21 JEEDFPVACIKHEU-UHFFFAOYSA-N 0.000 description 2
- WRXIKBHQDRMYJJ-UHFFFAOYSA-N 2-(4-bromopyrazol-1-yl)acetic acid Chemical compound OC(=O)CN1C=C(Br)C=N1 WRXIKBHQDRMYJJ-UHFFFAOYSA-N 0.000 description 2
- XQVSHMJNMUCKGQ-UHFFFAOYSA-N 2-(4-methylpyridin-2-yl)acetaldehyde Chemical compound CC1=CC=NC(CC=O)=C1 XQVSHMJNMUCKGQ-UHFFFAOYSA-N 0.000 description 2
- NRRCYZPJUABYHL-UHFFFAOYSA-N 2-Pyrimidine Acetic Acid Chemical compound OC(=O)CC1=NC=CC=N1 NRRCYZPJUABYHL-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- LOSKNFQZTWYZHI-UHFFFAOYSA-N 2-pyrazol-1-ylacetic acid Chemical compound OC(=O)CN1C=CC=N1 LOSKNFQZTWYZHI-UHFFFAOYSA-N 0.000 description 2
- CIUICCYYGROKEM-UHFFFAOYSA-N 2h-phenanthren-3-one Chemical compound C1=CC=C2C3=CC(=O)CC=C3C=CC2=C1 CIUICCYYGROKEM-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- WUNCUZKDJSLMRK-UHFFFAOYSA-N 3-[4-(trifluoromethyl)pyrazol-1-yl]propanoic acid Chemical compound OC(=O)CCN1C=C(C(F)(F)F)C=N1 WUNCUZKDJSLMRK-UHFFFAOYSA-N 0.000 description 2
- BRARRAHGNDUELT-UHFFFAOYSA-N 3-hydroxypicolinic acid Chemical compound OC(=O)C1=NC=CC=C1O BRARRAHGNDUELT-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- AZYKGQOIAGPVCK-UHFFFAOYSA-N 3-pyridin-1-ium-2-ylpropanoate Chemical compound OC(=O)CCC1=CC=CC=N1 AZYKGQOIAGPVCK-UHFFFAOYSA-N 0.000 description 2
- BMTZEAOGFDXDAD-UHFFFAOYSA-M 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium;chloride Chemical compound [Cl-].COC1=NC(OC)=NC([N+]2(C)CCOCC2)=N1 BMTZEAOGFDXDAD-UHFFFAOYSA-M 0.000 description 2
- SFRZJVGGJFNWHZ-UHFFFAOYSA-N 4-tert-butyl-1h-pyrazole Chemical compound CC(C)(C)C=1C=NNC=1 SFRZJVGGJFNWHZ-UHFFFAOYSA-N 0.000 description 2
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
- YYFJEUYEYNGRCQ-UHFFFAOYSA-N CC(C=C1)=CC(CCC2=NC=CC=C2)=C1S(O)(=O)=O Chemical compound CC(C=C1)=CC(CCC2=NC=CC=C2)=C1S(O)(=O)=O YYFJEUYEYNGRCQ-UHFFFAOYSA-N 0.000 description 2
- 101500007657 Crotalus durissus terrificus Crotoxin chain gamma Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 108010093625 Opioid Peptides Proteins 0.000 description 2
- 102000001490 Opioid Peptides Human genes 0.000 description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
- 229920000388 Polyphosphate Polymers 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- WNAHIZMDSQCWRP-UHFFFAOYSA-N dodecane-1-thiol Chemical compound CCCCCCCCCCCCS WNAHIZMDSQCWRP-UHFFFAOYSA-N 0.000 description 2
- XHQZXHMRBXBPEL-UHFFFAOYSA-N eaton reagent Chemical compound CS(O)(=O)=O.O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 XHQZXHMRBXBPEL-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 125000005956 isoquinolyl group Chemical group 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- BYRPTKZOXNFFDB-UHFFFAOYSA-N lithium;bis(trimethylsilyl)azanide;oxolane Chemical compound [Li+].C1CCOC1.C[Si](C)(C)[N-][Si](C)(C)C BYRPTKZOXNFFDB-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 239000012022 methylating agents Substances 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- FMASTMURQSHELY-UHFFFAOYSA-N n-(4-fluoro-2-methylphenyl)-3-methyl-n-[(2-methyl-1h-indol-4-yl)methyl]pyridine-4-carboxamide Chemical compound C1=CC=C2NC(C)=CC2=C1CN(C=1C(=CC(F)=CC=1)C)C(=O)C1=CC=NC=C1C FMASTMURQSHELY-UHFFFAOYSA-N 0.000 description 2
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000003399 opiate peptide Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- YWWARDMVSMPOLR-UHFFFAOYSA-M oxolane;tetrabutylazanium;fluoride Chemical compound [F-].C1CCOC1.CCCC[N+](CCCC)(CCCC)CCCC YWWARDMVSMPOLR-UHFFFAOYSA-M 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 235000011176 polyphosphates Nutrition 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- SUVIGLJNEAMWEG-UHFFFAOYSA-N propane-1-thiol Chemical compound CCCS SUVIGLJNEAMWEG-UHFFFAOYSA-N 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 2
- CCOXWRVWKFVFDG-UHFFFAOYSA-N pyrimidine-2-carbaldehyde Chemical compound O=CC1=NC=CC=N1 CCOXWRVWKFVFDG-UHFFFAOYSA-N 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- ARUIMKUOHIINGI-UHFFFAOYSA-N trifluoro(methylsulfonyl)methane Chemical compound CS(=O)(=O)C(F)(F)F ARUIMKUOHIINGI-UHFFFAOYSA-N 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- HZQKMZGKYVDMCT-GBXIJSLDSA-N (1s,2s)-2-fluorocyclopropane-1-carboxylic acid Chemical compound OC(=O)[C@@H]1C[C@@H]1F HZQKMZGKYVDMCT-GBXIJSLDSA-N 0.000 description 1
- DOMQFIFVDIAOOT-ROUUACIJSA-N (2S,3R)-N-[4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-1,2,4-triazol-3-yl]-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide Chemical compound COC1=C(C(=CC=C1)OC)N1C(=NN=C1C=1C=NC=C(C=1)C)NS(=O)(=O)[C@@H](C)[C@H](C)C1=NC=C(C=N1)C DOMQFIFVDIAOOT-ROUUACIJSA-N 0.000 description 1
- FTWTWOICXAENQE-UHFFFAOYSA-N (5-ethyl-1,2-oxazol-3-yl)methanol Chemical compound CCC1=CC(CO)=NO1 FTWTWOICXAENQE-UHFFFAOYSA-N 0.000 description 1
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
- FZENGILVLUJGJX-NSCUHMNNSA-N (E)-acetaldehyde oxime Chemical compound C\C=N\O FZENGILVLUJGJX-NSCUHMNNSA-N 0.000 description 1
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
- ZXMGHDIOOHOAAE-UHFFFAOYSA-N 1,1,1-trifluoro-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NS(=O)(=O)C(F)(F)F ZXMGHDIOOHOAAE-UHFFFAOYSA-N 0.000 description 1
- NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical compound C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 description 1
- POTIYWUALSJREP-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinoline Chemical compound N1CCCC2CCCCC21 POTIYWUALSJREP-UHFFFAOYSA-N 0.000 description 1
- CITJCTCNTRIEKZ-UHFFFAOYSA-N 1,2-thiazol-3-ylmethanol Chemical compound OCC=1C=CSN=1 CITJCTCNTRIEKZ-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- CQHYICHMGNSGQH-UHFFFAOYSA-N 1,3-oxazole-2-carboxylic acid Chemical compound OC(=O)C1=NC=CO1 CQHYICHMGNSGQH-UHFFFAOYSA-N 0.000 description 1
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
- ZRHUHDUEXWHZMA-UHFFFAOYSA-N 1,4-dihydropyrazol-5-one Chemical compound O=C1CC=NN1 ZRHUHDUEXWHZMA-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- VFLQQZCRHPIGJU-UHFFFAOYSA-N 1-(2-chloroethyl)piperidine;hydron;chloride Chemical compound Cl.ClCCN1CCCCC1 VFLQQZCRHPIGJU-UHFFFAOYSA-N 0.000 description 1
- QNVZNWVEPSFMRL-UHFFFAOYSA-N 1-(2-hydroxyethyl)pyrazole-4-carbonitrile Chemical compound OCCN1C=C(C#N)C=N1 QNVZNWVEPSFMRL-UHFFFAOYSA-N 0.000 description 1
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
- NDCPERCVXDYEFU-UHFFFAOYSA-N 1-fluorocyclopropane-1-carboxylic acid Chemical compound OC(=O)C1(F)CC1 NDCPERCVXDYEFU-UHFFFAOYSA-N 0.000 description 1
- GQXURJDNDYACGE-UHFFFAOYSA-N 1-hydroxycyclopropane-1-carboxylic acid Chemical compound OC(=O)C1(O)CC1 GQXURJDNDYACGE-UHFFFAOYSA-N 0.000 description 1
- ZHCKPJGJQOPTLB-UHFFFAOYSA-N 1-methyl-4-imidazoleacetic acid Chemical compound CN1C=NC(CC(O)=O)=C1 ZHCKPJGJQOPTLB-UHFFFAOYSA-N 0.000 description 1
- DIZKLZKLNKQFGB-UHFFFAOYSA-N 1-methylcyclopropane-1-carboxylic acid Chemical compound OC(=O)C1(C)CC1 DIZKLZKLNKQFGB-UHFFFAOYSA-N 0.000 description 1
- WSCJKACVICMPQP-UHFFFAOYSA-N 1-pyridin-2-ylcyclopropane-1-carbaldehyde Chemical compound C=1C=CC=NC=1C1(C=O)CC1 WSCJKACVICMPQP-UHFFFAOYSA-N 0.000 description 1
- DHOWKIWZOCQDDV-UHFFFAOYSA-N 1-pyridin-2-ylcyclopropane-1-carboxylic acid Chemical compound C=1C=CC=NC=1C1(C(=O)O)CC1 DHOWKIWZOCQDDV-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- GBBSAMQTQCPOBF-UHFFFAOYSA-N 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane Chemical compound CB1OB(C)OB(C)O1 GBBSAMQTQCPOBF-UHFFFAOYSA-N 0.000 description 1
- JYYNAJVZFGKDEQ-UHFFFAOYSA-N 2,4-Dimethylpyridine Chemical compound CC1=CC=NC(C)=C1 JYYNAJVZFGKDEQ-UHFFFAOYSA-N 0.000 description 1
- HJZDPELYBYVCES-UHFFFAOYSA-N 2,4-bis(phenylsulfanyl)-2,4-bis(sulfanylidene)-1,3,2$l^{5},4$l^{5}-dithiadiphosphetane Chemical compound S1P(=S)(SC=2C=CC=CC=2)SP1(=S)SC1=CC=CC=C1 HJZDPELYBYVCES-UHFFFAOYSA-N 0.000 description 1
- OHEYDQQAGOMBJA-UHFFFAOYSA-N 2-(1,2-thiazol-3-yl)acetic acid Chemical compound OC(=O)CC=1C=CSN=1 OHEYDQQAGOMBJA-UHFFFAOYSA-N 0.000 description 1
- ARPXWCKJHHFNNU-UHFFFAOYSA-N 2-(1,2-thiazol-3-yl)acetonitrile Chemical compound N#CCC=1C=CSN=1 ARPXWCKJHHFNNU-UHFFFAOYSA-N 0.000 description 1
- LRMUYWUZEQHQLA-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)ethanol Chemical compound C1=CC=C2SC(CCO)=NC2=C1 LRMUYWUZEQHQLA-UHFFFAOYSA-N 0.000 description 1
- YXTMFYBABGJSBY-UHFFFAOYSA-N 2-(1,3-thiazol-2-yl)acetic acid Chemical compound OC(=O)CC1=NC=CS1 YXTMFYBABGJSBY-UHFFFAOYSA-N 0.000 description 1
- PISMJKGQNDOCGA-UHFFFAOYSA-N 2-(1,3-thiazol-4-yl)acetic acid Chemical compound OC(=O)CC1=CSC=N1 PISMJKGQNDOCGA-UHFFFAOYSA-N 0.000 description 1
- NWBJZDKKRJFGSH-UHFFFAOYSA-N 2-(1-methylindazol-3-yl)ethanol Chemical compound C1=CC=C2N(C)N=C(CCO)C2=C1 NWBJZDKKRJFGSH-UHFFFAOYSA-N 0.000 description 1
- QOPBEBWGSGFROG-UHFFFAOYSA-N 2-(1h-indol-2-yl)acetic acid Chemical compound C1=CC=C2NC(CC(=O)O)=CC2=C1 QOPBEBWGSGFROG-UHFFFAOYSA-N 0.000 description 1
- NTVKSUPEUFXUGS-UHFFFAOYSA-N 2-(1h-pyrazol-5-yl)acetic acid Chemical compound OC(=O)CC=1C=CNN=1 NTVKSUPEUFXUGS-UHFFFAOYSA-N 0.000 description 1
- HNIGZVZDWCTFPR-UHFFFAOYSA-N 2-(2-fluorophenyl)ethanol Chemical compound OCCC1=CC=CC=C1F HNIGZVZDWCTFPR-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- QHCUWTRWPVJTDN-UHFFFAOYSA-N 2-(2-methoxyphenyl)ethyl 4-methylbenzenesulfonate Chemical compound COC1=CC=CC=C1CCOS(=O)(=O)C1=CC=C(C)C=C1 QHCUWTRWPVJTDN-UHFFFAOYSA-N 0.000 description 1
- FUXGCNHSOSDVCJ-UHFFFAOYSA-N 2-(2h-indazol-3-yl)ethanol Chemical compound C1=CC=CC2=C(CCO)NN=C21 FUXGCNHSOSDVCJ-UHFFFAOYSA-N 0.000 description 1
- JYSWEDYPQJOEPO-UHFFFAOYSA-N 2-(3,5-dimethylpyrazol-1-yl)acetic acid Chemical compound CC=1C=C(C)N(CC(O)=O)N=1 JYSWEDYPQJOEPO-UHFFFAOYSA-N 0.000 description 1
- OPKXCVNZKVPQFE-UHFFFAOYSA-N 2-(3-methoxypyridin-2-yl)acetic acid Chemical compound COC1=CC=CN=C1CC(O)=O OPKXCVNZKVPQFE-UHFFFAOYSA-N 0.000 description 1
- LNJRCXUOOQZWRD-UHFFFAOYSA-N 2-(3-methylpyridin-2-yl)ethanol Chemical compound CC1=CC=CN=C1CCO LNJRCXUOOQZWRD-UHFFFAOYSA-N 0.000 description 1
- XIULETHSPMXOKJ-UHFFFAOYSA-N 2-(3-methylpyrrol-1-yl)ethanol Chemical compound CC=1C=CN(CCO)C=1 XIULETHSPMXOKJ-UHFFFAOYSA-N 0.000 description 1
- PKXUQTSIMIWFRQ-UHFFFAOYSA-N 2-(4-cyclopropylpyrazol-1-yl)acetic acid Chemical compound C1=NN(CC(=O)O)C=C1C1CC1 PKXUQTSIMIWFRQ-UHFFFAOYSA-N 0.000 description 1
- CDUGJIOIHWUWOH-UHFFFAOYSA-N 2-(4-methylpyrazol-1-yl)ethanol Chemical compound CC=1C=NN(CCO)C=1 CDUGJIOIHWUWOH-UHFFFAOYSA-N 0.000 description 1
- WKPGRRKAOCAINH-UHFFFAOYSA-N 2-(4-propan-2-yltriazol-1-yl)acetic acid Chemical compound CC(C)C1=CN(CC(O)=O)N=N1 WKPGRRKAOCAINH-UHFFFAOYSA-N 0.000 description 1
- TVBSUFIGIJZSIB-UHFFFAOYSA-N 2-(5-ethyl-1,2-oxazol-3-yl)acetic acid Chemical compound CCC1=CC(CC(O)=O)=NO1 TVBSUFIGIJZSIB-UHFFFAOYSA-N 0.000 description 1
- ZKFPWDBPZCUNNC-UHFFFAOYSA-N 2-(5-ethyl-1,2-oxazol-3-yl)acetonitrile Chemical compound CCC1=CC(CC#N)=NO1 ZKFPWDBPZCUNNC-UHFFFAOYSA-N 0.000 description 1
- UNFVEYMEZRVVOB-UHFFFAOYSA-N 2-(5-methyl-1,2-oxazol-3-yl)acetic acid Chemical compound CC1=CC(CC(O)=O)=NO1 UNFVEYMEZRVVOB-UHFFFAOYSA-N 0.000 description 1
- FMCBKOOPDBRCGZ-UHFFFAOYSA-N 2-(5-methyl-1,2-oxazol-3-yl)acetonitrile Chemical compound CC1=CC(CC#N)=NO1 FMCBKOOPDBRCGZ-UHFFFAOYSA-N 0.000 description 1
- UEYNKIJIFZUYEO-UHFFFAOYSA-N 2-(5-methyl-1,2-thiazol-3-yl)acetic acid Chemical compound CC1=CC(CC(O)=O)=NS1 UEYNKIJIFZUYEO-UHFFFAOYSA-N 0.000 description 1
- FASROOXDBGEMJX-UHFFFAOYSA-N 2-(5-methyl-1,2-thiazol-3-yl)acetonitrile Chemical compound CC1=CC(CC#N)=NS1 FASROOXDBGEMJX-UHFFFAOYSA-N 0.000 description 1
- ZRXVSPAUYVSVNR-UHFFFAOYSA-N 2-(5-methylpyrazol-1-yl)acetic acid Chemical compound CC1=CC=NN1CC(O)=O ZRXVSPAUYVSVNR-UHFFFAOYSA-N 0.000 description 1
- HDYPXYSHJPMMPI-UHFFFAOYSA-N 2-(6-methoxypyridin-2-yl)acetic acid Chemical compound COC1=CC=CC(CC(O)=O)=N1 HDYPXYSHJPMMPI-UHFFFAOYSA-N 0.000 description 1
- TUDJNSKRXIUOAJ-UHFFFAOYSA-N 2-(bromomethyl)-1,1-difluorocyclopropane Chemical compound FC1(F)CC1CBr TUDJNSKRXIUOAJ-UHFFFAOYSA-N 0.000 description 1
- MZQBNTYWHOHSMS-UHFFFAOYSA-N 2-(furan-2-yl)ethanol Chemical compound OCCC1=CC=CO1 MZQBNTYWHOHSMS-UHFFFAOYSA-N 0.000 description 1
- AUEJAOKPOPOGHM-UHFFFAOYSA-N 2-(triazol-2-yl)acetic acid Chemical compound OC(=O)CN1N=CC=N1 AUEJAOKPOPOGHM-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- WVMGROBMQQTIMY-UHFFFAOYSA-N 2-[1-methyl-5-(trifluoromethyl)pyrazol-3-yl]acetic acid Chemical compound CN1N=C(CC(O)=O)C=C1C(F)(F)F WVMGROBMQQTIMY-UHFFFAOYSA-N 0.000 description 1
- TXIOULNLSCTYNR-UHFFFAOYSA-N 2-[3,5-bis(difluoromethyl)pyrazol-1-yl]acetic acid Chemical compound OC(=O)CN1N=C(C(F)F)C=C1C(F)F TXIOULNLSCTYNR-UHFFFAOYSA-N 0.000 description 1
- GTIGZYNSHOYHSP-UHFFFAOYSA-N 2-[3-(trifluoromethyl)pyrazol-1-yl]acetic acid Chemical compound OC(=O)CN1C=CC(C(F)(F)F)=N1 GTIGZYNSHOYHSP-UHFFFAOYSA-N 0.000 description 1
- HAQGKYLGVJFNQY-UHFFFAOYSA-N 2-[4-(trifluoromethyl)pyrazol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C(F)(F)F)C=N1 HAQGKYLGVJFNQY-UHFFFAOYSA-N 0.000 description 1
- URYBQPIPDBWRIK-UHFFFAOYSA-N 2-[4-methyl-3-(trifluoromethyl)pyrazol-1-yl]acetic acid Chemical compound CC=1C(=NN(C1)CC(=O)O)C(F)(F)F URYBQPIPDBWRIK-UHFFFAOYSA-N 0.000 description 1
- WRPOGLABYJEOEX-UHFFFAOYSA-N 2-[6-(trifluoromethyl)pyridin-2-yl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(F)(F)F)=N1 WRPOGLABYJEOEX-UHFFFAOYSA-N 0.000 description 1
- JBKINHFZTVLNEM-UHFFFAOYSA-N 2-bromoethoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCBr JBKINHFZTVLNEM-UHFFFAOYSA-N 0.000 description 1
- JRQAAYVLPPGEHT-UHFFFAOYSA-N 2-bromoethylcyclohexane Chemical compound BrCCC1CCCCC1 JRQAAYVLPPGEHT-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- NSWLMOHUXYULKL-UHFFFAOYSA-N 2-chloro-1-piperidin-1-ylethanone Chemical compound ClCC(=O)N1CCCCC1 NSWLMOHUXYULKL-UHFFFAOYSA-N 0.000 description 1
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- ZNRZBEVYWWQQMN-UHFFFAOYSA-N 2-indazol-1-ylacetic acid Chemical compound C1=CC=C2N(CC(=O)O)N=CC2=C1 ZNRZBEVYWWQQMN-UHFFFAOYSA-N 0.000 description 1
- TVIFXNAJWOGGEQ-UHFFFAOYSA-N 2-indazol-2-ylacetic acid Chemical compound C1=CC=CC2=NN(CC(=O)O)C=C21 TVIFXNAJWOGGEQ-UHFFFAOYSA-N 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- CVPPUZPZPFOFPK-UHFFFAOYSA-N 2-phenylethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCC1=CC=CC=C1 CVPPUZPZPFOFPK-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005975 2-phenylethyloxy group Chemical group 0.000 description 1
- QPSLGXZIFPDADL-UHFFFAOYSA-N 2-pyrazolo[1,5-a]pyridin-2-ylacetic acid Chemical compound C1=CC=CN2N=C(CC(=O)O)C=C21 QPSLGXZIFPDADL-UHFFFAOYSA-N 0.000 description 1
- PAEXAIBDCHBNDC-UHFFFAOYSA-N 2-pyridin-4-ylacetic acid Chemical compound OC(=O)CC1=CC=NC=C1 PAEXAIBDCHBNDC-UHFFFAOYSA-N 0.000 description 1
- YYIWCGLAEFPUFI-UHFFFAOYSA-N 2-pyrimidin-2-ylethanol Chemical compound OCCC1=NC=CC=N1 YYIWCGLAEFPUFI-UHFFFAOYSA-N 0.000 description 1
- HZYCUVLOBNNEKD-UHFFFAOYSA-N 2-quinolin-2-ylacetaldehyde Chemical compound C1=CC=CC2=NC(CC=O)=CC=C21 HZYCUVLOBNNEKD-UHFFFAOYSA-N 0.000 description 1
- SMJRBWINMFUUDS-UHFFFAOYSA-N 2-thienylacetic acid Chemical compound OC(=O)CC1=CC=CS1 SMJRBWINMFUUDS-UHFFFAOYSA-N 0.000 description 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
- HQRSIMQXCAWAJB-UHFFFAOYSA-N 3,3,3-trifluoro-2-phenylpropanoic acid Chemical compound OC(=O)C(C(F)(F)F)C1=CC=CC=C1 HQRSIMQXCAWAJB-UHFFFAOYSA-N 0.000 description 1
- KVTUSMPNLUCCQO-UHFFFAOYSA-N 3,3-difluoropyrrolidine Chemical compound FC1(F)CCNC1 KVTUSMPNLUCCQO-UHFFFAOYSA-N 0.000 description 1
- YBBLSBDJIKMXNQ-UHFFFAOYSA-N 3,4-dihydro-2h-1,4-benzothiazine Chemical compound C1=CC=C2NCCSC2=C1 YBBLSBDJIKMXNQ-UHFFFAOYSA-N 0.000 description 1
- YRLORWPBJZEGBX-UHFFFAOYSA-N 3,4-dihydro-2h-1,4-benzoxazine Chemical compound C1=CC=C2NCCOC2=C1 YRLORWPBJZEGBX-UHFFFAOYSA-N 0.000 description 1
- OJTQVDTVCPIZQH-UHFFFAOYSA-N 3-(1,3-thiazol-2-yl)propanoic acid Chemical compound OC(=O)CCC1=NC=CS1 OJTQVDTVCPIZQH-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- WDGXIUUWINKTGP-UHFFFAOYSA-N 3-(3-pyridinyl)propanoic acid Chemical compound OC(=O)CCC1=CC=CN=C1 WDGXIUUWINKTGP-UHFFFAOYSA-N 0.000 description 1
- CGBSUTHYRXDSEI-UHFFFAOYSA-N 3-(4-methylpyrazol-1-yl)cyclobutan-1-one Chemical compound CC1=CN(N=C1)C2CC(=O)C2 CGBSUTHYRXDSEI-UHFFFAOYSA-N 0.000 description 1
- RPYHTTYJPSPCFF-UHFFFAOYSA-N 3-(4-methylpyrazol-1-yl)cyclopentan-1-one Chemical compound C1=C(C)C=NN1C1CC(=O)CC1 RPYHTTYJPSPCFF-UHFFFAOYSA-N 0.000 description 1
- VASRUENZDOTUKJ-UHFFFAOYSA-N 3-(chloromethyl)-5-ethyl-1,2-oxazole Chemical compound CCC1=CC(CCl)=NO1 VASRUENZDOTUKJ-UHFFFAOYSA-N 0.000 description 1
- KKAOOGUDSIHEGY-UHFFFAOYSA-N 3-(chloromethyl)-5-methyl-1,2-thiazole Chemical compound CC1=CC(CCl)=NS1 KKAOOGUDSIHEGY-UHFFFAOYSA-N 0.000 description 1
- YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- SMBXPJHSQKKYFY-UHFFFAOYSA-N 3-bromocyclobutan-1-one Chemical compound BrC1CC(=O)C1 SMBXPJHSQKKYFY-UHFFFAOYSA-N 0.000 description 1
- QGMROEZDWJTIDW-UHFFFAOYSA-N 3-bromopropoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCCBr QGMROEZDWJTIDW-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- ICDSWZBXIZCMHR-UHFFFAOYSA-N 3-hydroxypyridine-2-carbaldehyde Chemical compound OC1=CC=CN=C1C=O ICDSWZBXIZCMHR-UHFFFAOYSA-N 0.000 description 1
- YSIKHBWUBSFBRZ-UHFFFAOYSA-N 3-methoxypropanoic acid Chemical compound COCCC(O)=O YSIKHBWUBSFBRZ-UHFFFAOYSA-N 0.000 description 1
- FEKWWZCCJDUWLY-UHFFFAOYSA-N 3-methyl-1h-pyrrole Chemical compound CC=1C=CNC=1 FEKWWZCCJDUWLY-UHFFFAOYSA-N 0.000 description 1
- WSXGQYDHJZKQQB-UHFFFAOYSA-N 3-pyridin-4-ylpropanoic acid Chemical compound OC(=O)CCC1=CC=NC=C1 WSXGQYDHJZKQQB-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- WGNUNYPERJMVRM-UHFFFAOYSA-N 3-pyridylacetic acid Chemical compound OC(=O)CC1=CC=CN=C1 WGNUNYPERJMVRM-UHFFFAOYSA-N 0.000 description 1
- VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical compound C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- ZNBNBTIDJSKEAM-UHFFFAOYSA-N 4-[7-hydroxy-2-[5-[5-[6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3-methyloxolan-2-yl]-5-methyloxolan-2-yl]-2,8-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]-2-methyl-3-propanoyloxypentanoic acid Chemical compound C1C(O)C(C)C(C(C)C(OC(=O)CC)C(C)C(O)=O)OC11OC(C)(C2OC(C)(CC2)C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CC1 ZNBNBTIDJSKEAM-UHFFFAOYSA-N 0.000 description 1
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- IHNXHUNMFYXQCG-UHFFFAOYSA-N 4-ethyl-1h-pyrazole Chemical compound CCC=1C=NNC=1 IHNXHUNMFYXQCG-UHFFFAOYSA-N 0.000 description 1
- RYXJXPHWRBWEEB-UHFFFAOYSA-N 4-fluoro-1h-pyrazole Chemical compound FC=1C=NNC=1 RYXJXPHWRBWEEB-UHFFFAOYSA-N 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- WVMBISZHWMJNNM-UHFFFAOYSA-N 4-propan-2-yl-1h-pyrazole Chemical compound CC(C)C=1C=NNC=1 WVMBISZHWMJNNM-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- HUUDDKIGWVAZNJ-UHFFFAOYSA-N 5-methyl-1,2-thiazole-3-carbaldehyde Chemical compound CC1=CC(C=O)=NS1 HUUDDKIGWVAZNJ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 1
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- DRCUDYWXWZHVFN-UHFFFAOYSA-N C1=CC=C2C=NC(=CC2=C1)CC=O Chemical compound C1=CC=C2C=NC(=CC2=C1)CC=O DRCUDYWXWZHVFN-UHFFFAOYSA-N 0.000 description 1
- ZXCADSUQHGXMSI-UHFFFAOYSA-N CC(C)(C)[Si](C)(C)OCCN1C=C(C)C=C1 Chemical compound CC(C)(C)[Si](C)(C)OCCN1C=C(C)C=C1 ZXCADSUQHGXMSI-UHFFFAOYSA-N 0.000 description 1
- GOHHOLIYTNLGOD-YMPZKCBVSA-N CC(C)(CC[C@@]1(CCN(CC2CC2)[C@@H]2C3)C4=C3C=CC(OC)=C4)C[C@]12O Chemical compound CC(C)(CC[C@@]1(CCN(CC2CC2)[C@@H]2C3)C4=C3C=CC(OC)=C4)C[C@]12O GOHHOLIYTNLGOD-YMPZKCBVSA-N 0.000 description 1
- YGRGVTDVHPSROW-UEVCKROQSA-N CC(C)(C[C@@]([C@@H](C1)N(CC2CC2)CC2)([C@]2(C2)C3=C1C=CC(OC)=C3)O)C2=O Chemical compound CC(C)(C[C@@]([C@@H](C1)N(CC2CC2)CC2)([C@]2(C2)C3=C1C=CC(OC)=C3)O)C2=O YGRGVTDVHPSROW-UEVCKROQSA-N 0.000 description 1
- NQJQHMDXRFUXSE-UHFFFAOYSA-N CC(C=C1)=CC(CCC2=NC=CC=C2F)=C1S(O)(=O)=O Chemical compound CC(C=C1)=CC(CCC2=NC=CC=C2F)=C1S(O)(=O)=O NQJQHMDXRFUXSE-UHFFFAOYSA-N 0.000 description 1
- AISIVIGBUSJDOM-UKDGRICWSA-N CC(C[C@@]([C@@H](C1)N(CC2CC2)CC2)([C@]2(C2)C3=C1C=CC(OC)=C3)O)C2=O Chemical compound CC(C[C@@]([C@@H](C1)N(CC2CC2)CC2)([C@]2(C2)C3=C1C=CC(OC)=C3)O)C2=O AISIVIGBUSJDOM-UKDGRICWSA-N 0.000 description 1
- GRDTZWMVXJSOOK-GQCTYLIASA-N CC1=CC(=NC=C1)/C=C/OC Chemical compound CC1=CC(=NC=C1)/C=C/OC GRDTZWMVXJSOOK-GQCTYLIASA-N 0.000 description 1
- GRDTZWMVXJSOOK-XQRVVYSFSA-N CC1=CC(=NC=C1)/C=C\OC Chemical compound CC1=CC(=NC=C1)/C=C\OC GRDTZWMVXJSOOK-XQRVVYSFSA-N 0.000 description 1
- NNUUWNPTAWVZGK-NSCUHMNNSA-N CC1=CC(=NS1)/C=C/C(=O)O Chemical compound CC1=CC(=NS1)/C=C/C(=O)O NNUUWNPTAWVZGK-NSCUHMNNSA-N 0.000 description 1
- WMUUQRHDRLFSEK-YEPZOZLWSA-N CC1=CN(C(C2)CC2N(CC[C@@H]23)CC[C@@]22C4=CC=CC=C4C[C@H]3N(CC3CC3)CC2)N=C1 Chemical compound CC1=CN(C(C2)CC2N(CC[C@@H]23)CC[C@@]22C4=CC=CC=C4C[C@H]3N(CC3CC3)CC2)N=C1 WMUUQRHDRLFSEK-YEPZOZLWSA-N 0.000 description 1
- CGCJULMTAJTZRK-XYWHMWSZSA-N CC1=CN(N=C1)C2CC(C2)N3CC[C@@]45CCN([C@@H]([C@@]4(CC3)O)CC6=C5C=C(C=C6)O)CC7CC7 Chemical compound CC1=CN(N=C1)C2CC(C2)N3CC[C@@]45CCN([C@@H]([C@@]4(CC3)O)CC6=C5C=C(C=C6)O)CC7CC7 CGCJULMTAJTZRK-XYWHMWSZSA-N 0.000 description 1
- YZJPGBPCXMZIIG-SSDOTTSWSA-N CC1=CN(N=C1)C[C@@H](C)O Chemical compound CC1=CN(N=C1)C[C@@H](C)O YZJPGBPCXMZIIG-SSDOTTSWSA-N 0.000 description 1
- ZBGGOZKULRTRPT-AWEZNQCLSA-N CC1=CN(N=C1)C[C@@H](COCC2=CC=CC=C2)O Chemical compound CC1=CN(N=C1)C[C@@H](COCC2=CC=CC=C2)O ZBGGOZKULRTRPT-AWEZNQCLSA-N 0.000 description 1
- ZBGGOZKULRTRPT-CQSZACIVSA-N CC1=CN(N=C1)C[C@H](COCC2=CC=CC=C2)O Chemical compound CC1=CN(N=C1)C[C@H](COCC2=CC=CC=C2)O ZBGGOZKULRTRPT-CQSZACIVSA-N 0.000 description 1
- GLRBZYVZTORLNP-IUCAKERBSA-N CC1=CN(N=C1)[C@H]2CC[C@@H](C2)O Chemical compound CC1=CN(N=C1)[C@H]2CC[C@@H](C2)O GLRBZYVZTORLNP-IUCAKERBSA-N 0.000 description 1
- VSCQVOJTARPCRW-FRHOWJMSSA-N CC1C[C@]2([C@H]3CC4=C([C@@]2(CCN3CC5CC5)CC1=O)C(=C(C=C4)OC)O)O Chemical compound CC1C[C@]2([C@H]3CC4=C([C@@]2(CCN3CC5CC5)CC1=O)C(=C(C=C4)OC)O)O VSCQVOJTARPCRW-FRHOWJMSSA-N 0.000 description 1
- BHYKPROTEFMGBF-GMKZXUHWSA-N COC1=CC=C(C[C@H]([C@]2([C@@]3(CC4)CCN=CC2)O)N4C(C2=CC=CC=C2)=O)C3=C1 Chemical compound COC1=CC=C(C[C@H]([C@]2([C@@]3(CC4)CCN=CC2)O)N4C(C2=CC=CC=C2)=O)C3=C1 BHYKPROTEFMGBF-GMKZXUHWSA-N 0.000 description 1
- BGDQBHDBNAUDKU-ZRJLEYOISA-N COC1=CC=C(C[C@H]2N(CC3CC3)CC[C@]3(CC(N(CCCN4N=CC=C4)CC4)=O)[C@]24O)C3=C1 Chemical compound COC1=CC=C(C[C@H]2N(CC3CC3)CC[C@]3(CC(N(CCCN4N=CC=C4)CC4)=O)[C@]24O)C3=C1 BGDQBHDBNAUDKU-ZRJLEYOISA-N 0.000 description 1
- JHYJQZDVGDLWNK-QHAWAJNXSA-N COC1=CC=C(C[C@H]2N(CC3CC3)CC[C@]3(CCNCC4)[C@]24O)C3=C1 Chemical compound COC1=CC=C(C[C@H]2N(CC3CC3)CC[C@]3(CCNCC4)[C@]24O)C3=C1 JHYJQZDVGDLWNK-QHAWAJNXSA-N 0.000 description 1
- YFYXUFIMDJMVSE-DSKINZAPSA-N COC1=CC=C(C[C@H]2N(CC3CC3)CC[C@]3(CN4)[C@H]2CCC4=O)C3=C1 Chemical compound COC1=CC=C(C[C@H]2N(CC3CC3)CC[C@]3(CN4)[C@H]2CCC4=O)C3=C1 YFYXUFIMDJMVSE-DSKINZAPSA-N 0.000 description 1
- QIEFOYXAYZOGHC-UHFFFAOYSA-N CS(=O)(=O)OCC1=NSC=C1 Chemical compound CS(=O)(=O)OCC1=NSC=C1 QIEFOYXAYZOGHC-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- JMOXSQYGVIXBBZ-UHFFFAOYSA-N N,N-dimethyl-beta-alanine Chemical compound CN(C)CCC(O)=O JMOXSQYGVIXBBZ-UHFFFAOYSA-N 0.000 description 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- FEYNFHSRETUBEM-UHFFFAOYSA-N N-[3-(1,1-difluoroethyl)phenyl]-1-(4-methoxyphenyl)-3-methyl-5-oxo-4H-pyrazole-4-carboxamide Chemical compound COc1ccc(cc1)N1N=C(C)C(C(=O)Nc2cccc(c2)C(C)(F)F)C1=O FEYNFHSRETUBEM-UHFFFAOYSA-N 0.000 description 1
- YZJPGBPCXMZIIG-ZETCQYMHSA-N N1(C=C(C=N1)C)C[C@@H](O)C Chemical compound N1(C=C(C=N1)C)C[C@@H](O)C YZJPGBPCXMZIIG-ZETCQYMHSA-N 0.000 description 1
- CDSCIFUOHNWPTF-UHFFFAOYSA-N NC(C(C1)=CC=C(C=C2)C1=C1C2=CC=NC=C1)=O Chemical compound NC(C(C1)=CC=C(C=C2)C1=C1C2=CC=NC=C1)=O CDSCIFUOHNWPTF-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- VNIXKWNKZSIEDA-UHFFFAOYSA-N O=C(C1)NC=CC2=C1C1=CC=CC=C1C=C2 Chemical compound O=C(C1)NC=CC2=C1C1=CC=CC=C1C=C2 VNIXKWNKZSIEDA-UHFFFAOYSA-N 0.000 description 1
- FBWDQWRWTJVYAG-UHFFFAOYSA-N O=C1NC2(CCCC2)C=C2C(NCC3)=CC4=CC=CC=C4C23C1 Chemical compound O=C1NC2(CCCC2)C=C2C(NCC3)=CC4=CC=CC=C4C23C1 FBWDQWRWTJVYAG-UHFFFAOYSA-N 0.000 description 1
- PLEQIVWOOKXOJR-MHMHJBCTSA-N OC(=N)C(Cl)(Cl)Cl.COC(=O)[C@H]1O[C@H](O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O Chemical compound OC(=N)C(Cl)(Cl)Cl.COC(=O)[C@H]1O[C@H](O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O PLEQIVWOOKXOJR-MHMHJBCTSA-N 0.000 description 1
- GMAGMPOAZRWSKJ-DNVJHFABSA-N O[C@@]1(CCN(CCC2=NC=CC=C2)CC2)[C@@]22C3=CC(O)=CC=C3C[C@H]1NCC2 Chemical compound O[C@@]1(CCN(CCC2=NC=CC=C2)CC2)[C@@]22C3=CC(O)=CC=C3C[C@H]1NCC2 GMAGMPOAZRWSKJ-DNVJHFABSA-N 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- WXIONIWNXBAHRU-UHFFFAOYSA-N [dimethylamino(triazolo[4,5-b]pyridin-3-yloxy)methylidene]-dimethylazanium Chemical compound C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 WXIONIWNXBAHRU-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- PPTSBERGOGHCHC-UHFFFAOYSA-N boron lithium Chemical compound [Li].[B] PPTSBERGOGHCHC-UHFFFAOYSA-N 0.000 description 1
- FLHFTXCMKFVKRP-UHFFFAOYSA-N bromomethylcyclobutane Chemical compound BrCC1CCC1 FLHFTXCMKFVKRP-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 150000004294 cyclic thioethers Chemical class 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000006637 cyclobutyl carbonyl group Chemical group 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000006638 cyclopentyl carbonyl group Chemical group 0.000 description 1
- 238000006900 dealkylation reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 108700003601 dimethylglycine Proteins 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LBAQSKZHMLAFHH-UHFFFAOYSA-N ethoxyethane;hydron;chloride Chemical compound Cl.CCOCC LBAQSKZHMLAFHH-UHFFFAOYSA-N 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- ZKRJCMKLCDWROR-ONEGZZNKSA-N ethyl (e)-4,4,4-trifluorobut-2-enoate Chemical compound CCOC(=O)\C=C\C(F)(F)F ZKRJCMKLCDWROR-ONEGZZNKSA-N 0.000 description 1
- PSRZMXNNQTWAGB-UHFFFAOYSA-N ethyl 4,4,4-trifluorobutanoate Chemical compound CCOC(=O)CCC(F)(F)F PSRZMXNNQTWAGB-UHFFFAOYSA-N 0.000 description 1
- UBWKBDZVYQXLBF-UHFFFAOYSA-N ethyl 5-ethyl-1,2-oxazole-3-carboxylate Chemical compound CCOC(=O)C=1C=C(CC)ON=1 UBWKBDZVYQXLBF-UHFFFAOYSA-N 0.000 description 1
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 229910000378 hydroxylammonium sulfate Inorganic materials 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- QAFBDRSXXHEXGB-UHFFFAOYSA-N imidazol-1-ylacetic acid Chemical compound OC(=O)CN1C=CN=C1 QAFBDRSXXHEXGB-UHFFFAOYSA-N 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- PRJKNHOMHKJCEJ-UHFFFAOYSA-N imidazol-4-ylacetic acid Chemical compound OC(=O)CC1=CN=CN1 PRJKNHOMHKJCEJ-UHFFFAOYSA-N 0.000 description 1
- 150000003949 imides Chemical group 0.000 description 1
- WQJFIWXYPKYBTO-UHFFFAOYSA-N indole-1-acetic acid Chemical compound C1=CC=C2N(CC(=O)O)C=CC2=C1 WQJFIWXYPKYBTO-UHFFFAOYSA-N 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000004551 isoquinolin-3-yl group Chemical group C1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- FBBDOOHMGLLEGJ-UHFFFAOYSA-N methane;hydrochloride Chemical compound C.Cl FBBDOOHMGLLEGJ-UHFFFAOYSA-N 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- SJFNDMHZXCUXSA-UHFFFAOYSA-M methoxymethyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(COC)C1=CC=CC=C1 SJFNDMHZXCUXSA-UHFFFAOYSA-M 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- CHWRSCGUEQEHOH-UHFFFAOYSA-N potassium oxide Chemical compound [O-2].[K+].[K+] CHWRSCGUEQEHOH-UHFFFAOYSA-N 0.000 description 1
- 229910001950 potassium oxide Inorganic materials 0.000 description 1
- VZOPRCCTKLAGPN-ZFJVMAEJSA-L potassium;sodium;(2r,3r)-2,3-dihydroxybutanedioate;tetrahydrate Chemical compound O.O.O.O.[Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O VZOPRCCTKLAGPN-ZFJVMAEJSA-L 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical class CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 description 1
- ZFCHNZDUMIOWFV-UHFFFAOYSA-N pyrimidine-2-carboxylic acid Chemical compound OC(=O)C1=NC=CC=N1 ZFCHNZDUMIOWFV-UHFFFAOYSA-N 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- ZVQXQPNJHRNGID-UHFFFAOYSA-N tetramethylsuccinonitrile Chemical compound N#CC(C)(C)C(C)(C)C#N ZVQXQPNJHRNGID-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- 150000003852 triazoles Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to an azepane derivative having a kappa opioid receptor agonistic action.
- ⁇ -opioid receptor agonists such as morphine are known to cause adverse events such as dependence formation and respiratory depression via the ⁇ -opioid receptor.
- kappa opioid receptor agonists also have analgesic effects, but are known not to be involved in the adverse events seen in morphine.
- kappa opioid receptor agonists are generally known to exhibit sedative and drug aversive effects.
- Nalfurafine (Patent Document 1) is the only ⁇ opioid receptor agonist that isolates drug aversion.Since nalfurafine has a sedative effect at an analgesic dose, it has been approved as an analgesic, but it is an analgesic. Has not been approved as. That is, there is still no kappa opioid receptor-selective agonist approved as an analgesic. Therefore, a kappa opioid receptor-selective agonist that does not show sedation or drug aversive action is expected to be an excellent therapeutic, ameliorating, or prophylactic agent for diseases and symptoms related to kappa opioid receptors such as analgesics. .. In Patent Document 2, the following equation (A):
- An object of the present invention is to provide a drug effective for treating, ameliorating, or preventing various diseases and symptoms related to kappa opioid receptors, which have suppressed sedation and drug aversive effects.
- the present inventors have conducted diligent studies and found that a specific azepane derivative exhibits strong agonist activity against kappa opioid receptor and high stability in vivo. Furthermore, it was clarified that this azepane derivative exhibits a strong analgesic effect and does not exhibit a sedative effect even at a dose higher than that of nalfurafine (Patent Document 1). As described above, the azepane derivative, which is an analgesic-oriented and highly safe ⁇ opioid receptor agonist, has been found, and the present invention has been completed. [1] That is, the present invention has the following general formula (I),
- R 1 has a hydrogen atom, a C 1-6 alkyl group which may have a substituent, a C 3-6 cycloalkyl group which may have a substituent, and a substituent.
- acyl group or amino-protecting group which may have a group, a substituent, R 2 and R 3 are the same or different hydrogen atom, C 1-6 alkyl group which may have a substituent, C 1-6 alkoxy group which may have a substituent, halogen atom, protected. Hydroxyl groups or R 2 and R 3 may be combined to indicate a carbonyl group, or R 2 and R 3 may be bonded to have a substituent C 3-6 saturated hydrocarbon ring or substituent.
- R 4 and R 5 Indicates a cyclic ketal that may have a group, R 4 and R 5 have the same or different hydrogen atom, a C 1-6 alkyl group which may have a substituent, a C 1-6 alkoxy group which may have a substituent, and a substituent.
- C 3-6 cycloalkyl group which may be, amino group which may have a substituent, protected amino group, halogen atom, hydroxy group which may be protected, carboxy group, carboxylic acid ester group or Indicates a carbamoyl group that may have a substituent
- R 6 is a hydrogen atom, a C 1-6 alkoxy group which may have a substituent, an amino group which may have a substituent, a protected amino group, a halogen atom, and a hydroxy which may be protected.
- R 7 and R 8 are the same or different hydrogen atom, C 1-6 alkyl group which may have a substituent, C 1-6 alkoxy group which may have a substituent, halogen atom, protected.
- R 7 and R 8 optionally together group, which may C 3-6 saturated hydrocarbon by either R 7 and R 8 shows a thiocarbonyl group had bonded to a substituent
- R 9 and R 10 are the same or different hydrogen atom, C 1-6 alkyl group which may have a substituent, C 1-6 alkoxy group which may have a substituent, halogen atom, protected.
- R 9 and R 10 together, which may C 3-6 saturated hydrocarbon by either R 9 and R 10 show a thiocarbonyl group had bonded to a substituent
- R 11 is a hydrogen atom, a C 1-6 alkyl group which may have a substituent, a C 1-6 alkoxy group which may have a substituent, and an aralkyloxy group which may have a substituent.
- a and B are different NR 18 (R 18 represents a hydrogen atom or an amino protecting group), a methylene group, a carbonyl group or the following general formula (II):
- R 12 and R 13 represent C 1-6 alkyl groups that may have the same or different hydrogen atoms, halogen atoms or substituents, or R 12 and R 13 on the same carbon are bonded and substituted.
- a C 3-6 saturated hydrocarbon ring which may have a group and a saturated heterocycle which may have a substituent are shown, or when n is 2 to 3, adjacent sets of R 12s are connected to each other. It can be bonded to form a C 3-6 saturated hydrocarbon ring which may have a substituent or a saturated heterocycle which may have a substituent.
- R 14 is a hydrogen atom, a C 1-6 alkyl group which may have a substituent, a C 3-6 cycloalkyl group which may have a substituent, and a C 2 which may have a substituent.
- a saturated heterocyclic group which may have a substituent and a cyclic amino group which may have a substituent are shown. * Indicates a bond. ) (However, either A or B represents the formula (II)).
- X represents a nitrogen atom or N-oxide
- Y represents a methylene group, a carbonyl group or a thiocarbonyl group which may have a substituent and represents Z indicates an NR 15 , an oxygen atom, a bond, an ethenylene group or an ethynylene group which may have a substituent (however, when m is 0, n is 0 and Z does not indicate NR 15).
- R 15 represents a hydrogen atom, a C 1-6 alkyl group which may have a substituent, or a nitrogen-containing saturated heterocycle in which R 15 and R 14 may be bonded and have a substituent.
- R 17 represents a hydrogen atom, a halogen atom, a hydroxy group which may be protected, an alkoxy group which may have a substituent, or a tetrazolyloxy group which may have a substituent.
- m indicates an integer from 0 to 1 and represents n represents an integer of 0 to 3. (However, when Z is a bond, m and n do not show 0 at the same time.))
- the present invention relates to an azepane derivative represented by and a pharmaceutically acceptable salt thereof.
- R 6 is a hydroxy group, a C 1-6 alkoxy group which may have a substituent, or a carbamoyl group which may have a substituent.
- R 6 is about azepane derivatives and pharmaceutically acceptable salts of the hydroxy group [1] or [2] described.
- the present invention is a C 1-6 alkyl group in which R 1 may have a substituent or a C 3-6 cycloalkyl C 1-6 alkyl group in which R 1 may have a substituent.
- the present invention relates to the azepan derivative according to the above [1] to [3] and a pharmaceutically acceptable salt thereof.
- the present invention also relates to the azepane derivative according to the above [1] to [4] in which Z is a binding agent and a pharmaceutically acceptable salt thereof.
- the present invention also relates to the azepane derivative according to the above [1] to [5], wherein n is 1 to 3, and a pharmaceutically acceptable salt thereof.
- the present invention also relates to the azepane derivative according to the above [1] to [6], wherein R 14 is a heteroaryl group which may have a substituent, and a pharmaceutically acceptable salt thereof.
- the present invention also relates to the azepane derivatives according to the above [1] to [8], wherein R 11 is a hydroxy group, and pharmaceutically acceptable salts thereof.
- the present invention also relates to a pharmaceutical composition containing the azepane derivative according to any one of the above [1] to [9] and a pharmaceutically acceptable salt thereof as an active ingredient.
- the present invention also relates to the medicament according to the above [10], which is a therapeutic or ameliorating agent for a disease related to an opioid ⁇ receptor.
- the present invention also relates to the medicine according to the above [10] or [11], which is an analgesic.
- the present invention also relates to the drug according to the above-mentioned [10] or [11], which is an antipruritic drug.
- Example 22 compound 500 ⁇ g / kg. It is a figure which shows the result of the sedation effect confirmation test by oral administration of Example 50 compound (7000 ⁇ g / kg). It is a figure which shows the result of the sedation effect confirmation test by oral administration of nalfurafine (30, 100, 300 ⁇ g / kg). It is a figure which shows the result of the sedation effect confirmation test by subcutaneous administration of Example 77 compound (400 ⁇ g / kg). It is a figure which shows the result of the sedation effect confirmation test by subcutaneous administration of nalfurafine (3, 10, 30 ⁇ g / kg).
- the azepane derivative represented by the general formula (I) and the pharmaceutically acceptable salt thereof include tautomers, stereoisomers and solvates thereof.
- the C 1-6 alkyl group in the C 1-6 alkyl group which may have the substituents represented by R 1 to R 5 and R 7 to R 15 includes a methyl group, an ethyl group, a propyl group and an isopropyl group.
- the substituent in the C 1-6 alkyl group which may have a substituent includes a halogen atom such as a fluorine atom and a chlorine atom; a hydroxy group; a C 1-6 alkylamino group and a diC 1-6 alkylamino group.
- Amino group which may have a substituent such as an acylamino group; a protected amino group; an acyl group such as a formyl group, an acetyl group, a cyclopropylcarbonyl group and a benzoyl group; Cyclic amino groups such as morpholinyl groups; cyclic lactam groups such as ⁇ -lactam, ⁇ -lactam and ⁇ -lactam, carboxy groups, carboxylic acid ester groups (similar to those described in [0032]) and the like can be mentioned.
- a substituent such as an acylamino group; a protected amino group; an acyl group such as a formyl group, an acetyl group, a cyclopropylcarbonyl group and a benzoyl group; Cyclic amino groups such as morpholinyl groups; cyclic lactam groups such as ⁇ -lactam, ⁇ -lactam and ⁇ -lactam, carboxy
- the C 3-6 cycloalkyl group in the C 3-6 cycloalkyl group which may have the substituents represented by R 1 , R 4 , R 5 and R 14 includes a cyclopropyl group, a cyclobutyl group and a cyclopentyl group. , And a cyclohexyl group, preferably a cyclopropyl group.
- the substituent in the C 3-6 cycloalkyl group which may have the substituents represented by R 1 , R 4 , R 5 and R 14 includes C 1-6 such as a methyl group, an ethyl group and a propyl group.
- Alkyl group Methyl halide group such as fluoromethyl group, difluoromethyl group, trifluoromethyl group; Halogen atom such as fluorine atom, chlorine atom; Hydroxyl group; C 1-6 alkylamino group, di C 1-6 alkylamino Amino group which may have a substituent such as a group and an acylamino group; a protected amino group; an acyl group such as a formyl group, an acetyl group, a cyclopropylcarbonyl group and a benzoyl group; an azetidinyl group, a pyrrolidinyl group and a piperazinyl group.
- Cyclic amino groups such as morpholinyl group; cyclic lactam groups such as ⁇ -lactam, ⁇ -lactam, ⁇ -lactam and the like.
- the C 1-6 alkoxy group in the C 1-6 alkoxy group which may have the substituents represented by R 2 to R 11 , R 14 and R 17 includes a methoxy group, an ethoxy group, a propoxy group and an isopropoxy. Examples thereof include a linear or branched alkoxy group such as a group, a butoxy group and an isobutoxy group, and preferably a methoxy group.
- Examples of the substituent in the C 1-6 alkoxy group which may have a substituent include a C 1-6 alkoxy group such as a methoxy group and an ethoxy group; a phenoxy group; a halogen atom such as a fluorine atom and a chlorine atom. It is preferably a fluorine atom, and examples thereof include a fluoromethoxy group, a difluoromethoxy group, a trifluoromethoxy group, and 2,2,2-trifluoroethoxy group.
- C in a C 6-10 aryl group which may have a substituent represented by R 1 , R 6 and R 14 , and a C 6-10 aryl oxy group which may have a substituent represented by R 6.
- Examples of the 6-10 aryl group include a phenyl group and a naphthyl group.
- heteroaryl group in the heteroaryl group which may have the substituents represented by R 1 , R 6 and R 14 include a furanyl group, a thienyl group, a pyrrolyl group, an imidazolyl group, a pyrazolyl group, an oxazolyl group and an isooxazolyl group.
- 5-membered ring heteroaryl group such as group, thiazolyl group, isothiazolyl group, triazolyl group, tetrazolyl group; 6-membered ring heteroaryl group such as pyridyl group, pyrariainyl group, pyrazinyl group, pyrimidyl group; quinolyl group, isoquinolyl group, quinazolyl group Bicyclic hetero, such as quinoxalyl group, indrill group, indazolyl group, benzoimidazolyl group, benzofuranyl group, benzothienyl group, benzoxazolyl group, benzothiazolyl group, imidazolypyridinyl group, pyrazolopyridinyl group, indazolyl group.
- Examples thereof include a monocyclic or bicyclic heteroaryl group containing 1 to 4 heteroatoms selected from a nitrogen atom such as an aryl group, an oxygen atom and a sulfur atom as ring-constituting atoms.
- a heterovariant may exist depending on the substituents on these heteroaryl groups. For example, when a hydroxy group is substituted on a pyridyl group, a 6-hydroxypyridine-2-yl group and its homomorphs are present. Examples include 6-oxo-1,6-dihydropyridine-2-yl group and 4-hydroxypyridine-2-yl group, and 4-oxo-1,4-dihydropyridine-2-yl group as their tautomers. Be done.
- Preferred R 1 includes a 6-membered ring heteroaryl group such as a pyridyl group, a pyridazinyl group, a pyrazinyl group and a pyrimidyl group.
- Preferred R 14 furanyl, thienyl, pyrrolyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, a triazole group, a pyridyl group, pyridazinyl group, pyrazinyl group, pyrimidyl group, quinolyl group, isoquinolyl group, indolyl group, indazolyl group , Benzoxazolyl group, benzothiazolyl group, imidazolypyridinyl group, pyrazolopyridinyl group, indazole group, more preferably furan-2-yl group, thiazole-2-yl group, thiazole-4- Il
- the C 6-10 aryl group, which may have a substituent represented by R 1 , R 6 and R 14 , and the heteroaryl group, which may have a substituent, are 1 to 3 substituents on the ring.
- a linear or branched C 1-6 alkyl group such as a methyl group, an ethyl group or a propyl group; a fluoromethyl group, a chloromethyl group, a difluoromethyl group, a dichloro Linear or branched alkyl halides such as methyl group and trifluoromethyl group; hydroxymethyl group; hydroxyalkyl group such as hydroxyethyl group and 1-hydroxypropyl group; C such as cyclopropyl group, cyclobutyl group and cyclopentyl group 3-6 cycloalkyl group; linear or branched C 1-6 alkoxy group such as methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy
- the C 3-6 cycloalkyl C 1-6 alkyl group in good C 3-6 cycloalkyl C 1-6 alkyl group optionally having a substituent represented by R 1, cyclopropylmethyl group, cyclopropylethyl Group, cyclopropylpropyl group, cyclobutylmethyl group, cyclobutylethyl group, cyclopentylmethyl group, cyclopentylethyl group, cyclopentylpropyl group, cyclohexylmethyl group, cyclohexylethyl group, cyclohexylpropyl group and the like, preferably cyclopropylmethyl.
- cyclopropylethyl group cyclobutylmethyl group, cyclobutylethyl group, cyclopentylmethyl group, cyclopentylethyl group, more preferably cyclopropylmethyl group, cyclobutylmethyl group, cyclopentylmethyl group, most preferably cyclopropyl.
- Methyl group can be mentioned.
- substituent in the C 3-6 cycloalkyl C 1-6 alkyl group which may have a substituent include a halogen atom such as a fluorine atom and a chlorine atom, and a hydroxy group.
- the number of carbon atoms in the aryl portion is C 6-10 .
- the alkylene moiety has a C 1-5 carbon number, and examples thereof include a benzyl group, a phenylethyl group, a 1-naphthylmethyl group and the like, and a benzyl group is preferable.
- the heteroaryl moiety in the heteroarylalkyl group which may have the substituent represented by R 1 includes 1 to 4 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom as ring-constituting atoms.
- Heteroaryl can be mentioned, and examples of the alkyl moiety include C 1-6 alkyl groups such as a methyl group, an ethyl group, and a propyl group, and examples thereof include (pyridine-2-yl) methyl group and (pyridine-3-yl).
- Aryl and heteroaryl in the above may have a substituent, and such a substituent may have a substituent described in paragraph [0020], which is the same as the substituent in the C 6-10 aryl group and the like. Things can be mentioned.
- the C 2-6 alkenyl group in the optionally C 2-6 alkenyl group which may have a substituent represented by R 1 and R 14, include alkenyl groups of linear or branched C 2-6, Allyl group, vinyl group, 1-propenyl group, 2-butenyl group, 3-butenyl group, 2-pentenyl group, 3-pentenyl group, 4-pentenyl group, 2-hexenyl group, 3-hexenyl group, 4-hexenyl group , 5-Hexenyl groups and other alkenyl groups can be mentioned.
- a substituent represented by R 1 and R 14 a straight-chain or branched alkynyl group C 2-6
- an ethynyl group, a propynyl group, a butynyl group and the like can be mentioned.
- Examples of the group that can be substituted with such an alkenyl group and an alkynyl group include a C 1-6 alkoxycarbonyl group such as a methoxycarbonyl group, an ethoxycarbonyl group and a propoxycarbonyl group, a benzyl group, a 2-phenylethyl group and a 3-phenylpropyl group.
- 4-Phenylbutyl group and other aralkyl groups methoxy group, ethoxy group, propoxy group, butoxy group and other C 1-6 alkoxy groups; benzyloxy group, 2-phenylethyloxy group and other aralkyl group; C 1- Examples thereof include an amino group which may be substituted with a linear or branched alkyl group of 6 ; a halogen atom such as a fluorine atom and a chlorine atom; a carboxy group and a hydroxy group.
- Examples of the acyl group which may have the substituent represented by R 1 include a C 1-6 alkanoyl group such as a formyl group, an acetyl group, a propionyl group, a butanoyl group, a pentanoyl group and a hexanoyl group; a cyclopropylcarbonyl group, C 4-7 cycloalkanoyl group such as cyclobutylcarbonyl group, cyclopentylcarbonyl group; alloyl group such as benzoyl group and naphthoyl group; 5- to 6-membered heteroaroyl group such as floyl group, thiophenecarbonyl group, nicotinyl group and isonicotinoyl group And so on.
- a C 1-6 alkanoyl group such as a formyl group, an acetyl group, a propionyl group, a butanoyl group, a pentan
- Examples of the substituent in the C 1-6 alkanoyl group and the C 4-7 cycloalkanoyl group include the same as the substituent described in paragraph [0015], and the substituent in the aloyl group and the heteroaloyl group includes the above-mentioned paragraph. Examples thereof include the same substituents as described in [0020].
- the substituent in the tetrazolyloxy group which may have a substituent represented by a group, R 6 and R 17 includes a substituent such as a methyl group, an ethyl group, a propyl group and an isopropyl group. Examples thereof include an aryl group such as a C 1-6 alkyl group and a phenyl group, and examples of the substituent in the C 1-6 alkyl group which may have such a substituent include those described in paragraph [0015]. These are listed and may have one or two of these substituents.
- the protecting groups in the amino protecting groups represented by R 1 and R 18 and the protected amino groups represented by R 4 to R 6 , R 11 and R 14 include methoxycarbonyl group, ethoxycarbonyl group and tert-butoxycarbonyl group. , Tert-Amyroxycarbonyl group, 2,2,2-trichloroethoxycarbonyl group, benzyloxycarbonyl group, p-chlorobenzyloxycarbonyl group, p-methoxybenzylcarbonyl group, p-nitrobenzyloxycarbonyl group, p-methoxy Phenylazobenzyloxycarbonyl group, 3,5-dimethoxybenzyloxycarbonyl group, 3,4,5-trimethoxybenzyloxycarbonyl group, p-biphenylisopropyloxycarbonyl group, diisopropylmethyloxycarbonyl group, 2- (trimethylsilyl) ethoxy Carbamate protecting groups such as carbonyl group and 9-flu
- Examples thereof include an aryl group such as a phenyl group and a naphthyl group, a C 1-6 alkanoyloxy C 1-4 lower alkyl group such as an acetoxymethyl group and a pivaloyl
- the cyclic amino group in good cyclic amino group which may have a substituent represented by R 14, azetidinyl, pyrrolidinyl, azepanyl group, a piperidinyl group, piperazinyl group, morpholinyl group, thiomorpholinyl group, oxa azabicyclo-octyl , Azacillinyl group, indolinyl group, isoindryl group and the like, preferably 1-pyrrolidinyl group, 1-piperidinyl group, 2-oxa-5-azabicyclo [2.2.2] octane-5-yl group, 3- Oxa-8-azabicyclo [3.2.1] octane-8-yl group, azacilinan-1-yl group, 1-indolinyl group are mentioned, and more preferably 1-pyrrolidinyl group, 1-piperidinyl group, azacilinan-1.
- a C 1-6 alkyl group which may have a substituent such as a methyl group or an ethyl group ; and a C 1- which may have a substituent such as a methoxy group, an ethoxy group or a propoxy group.
- An alkoxy group; a halogen atom such as a fluorine atom and a chlorine atom; a hydroxy group and the like can be mentioned.
- Examples of the substituent in the C 1-6 alkyl group which may have a substituent include those described in paragraph [0015], and the substituent in the C 1-6 alkoxy group which may have a substituent can be mentioned. Examples include the substituents described in paragraph [0017].
- C 3-6 saturated hydrocarbon ring which may have, is formed by bonding R 12 and R 13 on the same carbon or by bonding adjacent sets of R 12 when n is 2 to 3.
- the saturated heterocyclic ring may have a substituent represented by R 14, include saturated heterocyclic ring of 3 to 6-membered ring, for example aziridine, azetidine, pyrrolidine, piperidine, piperazine, morpholine, etc.
- thiomorpholine examples thereof include cyclic ethers such as cyclic amines, epoxides, oxetane, tetrahydrofuran, tetrahydropyran and dioxane, and cyclic thioethers such as thietan, thiolan and thian.
- cyclic ethers such as cyclic amines, epoxides, oxetane, tetrahydrofuran, tetrahydropyran and dioxane
- cyclic thioethers such as thietan, thiolan and thian.
- saturated heterocycles when the ring has a nitrogen atom as a constituent atom, it further has a linear or branched C 1-6 alkyl group, a substituent such as an acyl group, or an amino protecting group on nitrogen. May be.
- nitrogen-containing saturated heterocycle which may have a substituent formed by combining R 14 and R 15 include a 3- to 6-membered nitrogen-containing saturated heterocycle, for example, aziridine, azetidine, and pyrrolidine.
- Piperidine piperazine, morpholine, thiomorpholine and other cyclic amino groups.
- These nitrogen-containing saturated heterocycles may be further fused with a saturated hydrocarbon ring, a saturated heterocycle, an unsaturated hydrocarbon ring or an unsaturated heterocycle, for example, decahydroquinoline, decahydroisoquinoline, indolin, iso.
- Examples thereof include indolin, 1,2,3,4-tetrahydroquinoline, 1,2,3,4-tetrahydroisoquinoline, benzomorpholine and benzothiomorpholin.
- a nitrogen atom as a constituent atom of the ring in these nitrogen-containing heterocyclic in addition to the nitrogen atom to which R 15 is attached, further straight or branched C 1-6 alkyl group and a substituent such as an acyl group Alternatively, it may have an amino-protecting group on the nitrogen atom.
- a C 3-6 saturated hydrocarbon ring which may have a substituent formed by bonding R 12 and R 13 on the same carbon, and formed by bonding R 12 and R 13 on the same carbon.
- substituents may saturated heterocyclic ring optionally having, n is 2-3 adjacent pair of R 12 are bonded to each other formed substituents optionally may C 3-6 be saturated have when
- Substituents in saturated heterocycles that may have hydrocarbon rings or substituents and in nitrogen-containing saturated heterocycles that may have substituents formed by combining R 14 and R 15 include paragraph [ 0033] Examples of the substituents in the cyclic amino group described above can be mentioned.
- Examples of the cyclic ketal which may have a substituent formed by bonding R 2 and R 3 , R 7 and R 8 and R 9 and R 10 include dioxolane and dioxane.
- Examples of such a substituent include a C 1-6 alkyl group such as a methyl group, an ethyl group and a propyl group.
- a substituent such as a trityl group
- the saccharide represented by R 6, or the like glucuronic acid is represented by R 6, or the like glucuronic acid.
- X represents a nitrogen atom or N-oxide, but a nitrogen atom is preferable.
- Y represents a methylene group, a carbonyl group or a thiocarbonyl group which may have a substituent, but is preferably a methylene group or a carbonyl group which may have a substituent, and particularly preferably a carbonyl group.
- Substituents in the methylene group which may have a substituent include a C 1-6 alkyl group, a hydroxy group which may be protected (an protective group includes those of [0039]), a halogen atom, and the like.
- Examples thereof include a C 1-6 alkyl group substituted with a halogen atom (for example, a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group, a chloromethyl group, a dichloromethyl group, etc.).
- a halogen atom for example, a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group, a chloromethyl group, a dichloromethyl group, etc.
- Z indicates NR 15 , an oxygen atom, a bond, an ethenylene group or an ethynylene group, but preferably an NR 15 , an oxygen atom, a bond or an ethenylene group which may have a substituent.
- substituent in the ethenylene group which may have a substituent include those described in paragraph [0027].
- M indicates an integer from 0 to 1, preferably 1. However, when n is 2, m is preferably 0.
- N represents an integer of 0 to 3, preferably 1 or 2.
- R 1 may have a substituent, C 1-6 alkyl group, and may have a substituent, C 3-6 cycloalkyl. It is a C 1-6 alkyl group, and R 2 and R 3 may have the same or different hydrogen atom or substituent C 1-6 alkyl group, which may have a substituent C 1- 6 It is an alkoxy group, a halogen atom, or a hydroxy group, and R 4 and R 5 may have the same or different hydrogen atom and substituent, and may have a C 1-6 alkyl group and substituent.
- R 6 is a C 1-6 alkoxy group or a substituent which may have a hydroxy group and a substituent. It is a carbamoyl group which may have a group, and R 7 and R 8 may have the same or different hydrogen atom, a C 1-6 alkyl group which may have a substituent, and a substituent.
- X is a nitrogen atom or N-oxide
- Y is a methylene or carbonyl group which may have a substituent
- Z is an NR 15 , oxygen atom, bonder, substituent.
- R 15 is a C 1-6 alkyl group which may have a hydrogen atom and a substituent
- R 17 is a hydrogen atom, a halogen atom and is protected. It is an alkoxy group which may have a hydroxy group or a substituent, where m is an integer of 0 or 1, and n is an integer of 0 to 3.
- R 1 may have a C 1-6 alkyl group which may have a substituent or a C 3-6 cycloalkyl which may have a substituent.
- C 1-6 alkyl groups, R 2 and R 3 are C 1-6 alkyl groups that may have the same or different hydrogen atoms or substituents , and R 4 and R 5 are the same or different. It is a C 1-6 alkyl group which may have a hydrogen atom or a substituent , and R 6 has a hydroxy group and a C 1-6 alkoxy group or a substituent which may have a substituent.
- R 7 and R 8 may have the same or different hydrogen atoms, substituents, C 1-6 alkyl groups or substituents, C 1-6 alkoxy.
- Groups, R 9 and R 10 are C 1-6 alkyl groups that may have the same or different hydrogen atoms or substituents , R 11 is a hydrogen atom or hydroxy group, and R 12 and R Reference numeral 13 is a C 1-6 alkyl group which may have the same or different hydrogen atom or substituent , and R 14 has a C 6-10 aryl group which may have a substituent and a substituent.
- X is a nitrogen atom or an N-oxide
- Y is a methylene group or a carbonyl group which may have a substituent
- Z is an NR 15 , an oxygen atom, an ethenylene group which may have a bond or a substituent
- R 15 is a C 1-6 alkyl group which may have a hydrogen atom and a substituent.
- R 17 is a hydrogen atom, an alkoxy group which may have a hydroxy group or a substituent which may be protected
- m is an integer of 0 or 1
- n is an integer of 0 to 3.
- R 1 may have a substituent C 1-6 alkyl group, and may have a substituent C 3-6 cycloalkyl.
- C 1-6 alkyl groups, R 2 and R 3 are C 1-6 alkyl groups that may have the same or different hydrogen atoms or substituents , and R 4 and R 5 are hydrogen atoms or substituents.
- R 6 is a hydroxy group
- R 7 and R 8 may have the same or different hydrogen atom or substituent C 1- 6 Alkyl groups
- R 9 and R 10 are C 1-6 alkyl groups that may have the same or different hydrogen atoms or substituents
- R 11 is a hydrogen atom or hydroxy group
- R 12 And R 13 are C 1-6 alkyl groups which may have the same or different hydrogen atoms or substituents
- R 14 is a heteroaryl group which may have a substituent
- X is nitrogen. It is an atom
- Y is a methylene group or a carbonyl group which may have a substituent
- Z is a bonder
- R 17 is a hydrogen atom
- m is 0, and n is 1-2. There are cases.
- the pharmaceutically acceptable salt is preferably an acid addition salt
- the acid addition salt is, for example, ( B) Salts with mineral acids such as hydrochloric acid, sulfuric acid and phosphoric acid, salts with organic carboxylic acids such as (b) formic acid, acetic acid, citrate, trichloroacetic acid, trifluoroacetic acid, fumaric acid, maleic acid and tartrate, C) Examples thereof include salts with sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mesitylensulfonic acid and naphthalenesulfonic acid.
- sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mesitylensulfonic acid and naphthalenesulfonic acid.
- the azepane derivative represented by the above general formula (I) and its pharmaceutically acceptable salt include tautomers and stereoisomers such as cis, trans isomers, racemates and optically active isomers.
- the azepane derivative represented by the above general formula (I) and its pharmaceutically acceptable salt can also exist as a hydrate or a solvate. Therefore, the compounds of the present invention include all their crystalline forms and hydrates or solvates.
- the raw material (a) is an aromatic hydrocarbon such as benzene, toluene, xylene; ethers such as diethyl ether, tetrahydrofuran, dioxane, monoglime, diglime; alcohols such as methanol and ethanol; dichloromethane, chloroform, carbon tetrachloride and the like.
- Halogenated hydrocarbons aliphatic hydrocarbons such as pentane, hexane, heptane, ligroine; protic solvents such as water and acetic acid; in aprotic polar solvents such as acetonitrile, N, N-dimethylformamide and dimethyl sulfoxide.
- bases such as potassium bis (trimethylsilyl) amide (KHMDS), lithium diisopropylamide (LDA), lithium hydride, sodium hydride, potassium hydride, etc.
- Compound (b) can be synthesized by reacting with and under heating and reflux for 1 to 24 hours.
- Aromatic hydrocarbons such as benzene, toluene and xylene; ethers such as diethyl ether, tetrahydrofuran, dioxane, monoglime and diglime; halogenated hydrocarbons such as dichloromethane, chloroform and carbon tetrachloride; pentane , Hexane, heptane, ligroine and other aliphatic hydrocarbons; potassium bis (trimethylsilyl) amide (KHMDS), lithium diisopropylamide (LDA) in aprotonic polar solvents such as acetonitrile, N, N-dimethylformamide and dimethylsulfoxide.
- KHMDS potassium bis (trimethylsilyl) amide
- LDA lithium diisopropylamide
- an inorganic base such as potassium oxide, and a reagent represented by the above L-Cl or L 2
- Aromatic hydrocarbons such as benzene, toluene and xylene; ethers such as diethyl ether, tetrahydrofuran, dioxane, monoglyme and jigglime; alcohols such as methanol and ethanol; dichloromethane, chloroform, carbon tetrachloride and the like.
- Halogenized hydrocarbons aliphatic hydrocarbons such as pentane, hexane, heptane, ligroin; solvents such as water and acetic acid; in aprotonic polar solvents such as acetonitrile, N, N-dimethylformamide, dimethylsulfoxide or these.
- Blended acids such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, methanesulfonic acid, p-toluenesulfonic acid; boron trifluoride-diethyl ether complex, aluminum chloride, iron chloride (III).
- Zinc chloride, titanium (IV) chloride and other Lewis acids can be reacted with Lewis acids such as (), zinc chloride and titanium (IV) chloride for 1 to 72 hours at room temperature to heating and refluxing to synthesize compounds (d) and (e), respectively.
- Lewis acids such as (), zinc chloride and titanium (IV) chloride for 1 to 72 hours at room temperature to heating and refluxing to synthesize compounds (d) and (e), respectively.
- 0 reducing agents such as lithium aluminum hydride, borane-tetrahydrofuran complex and borane-dimethylsulfide complex were added to ethers such as diethyl ether, tetrahydrofuran, dioxane, monoglyme and jigglime.
- the invention compounds (f) and (g) can be synthesized by reacting them at ° C. to heating under reflux for 1 to 24 hours, respectively.
- Method B The synthetic intermediates (d) and (e) described in Method A can also be synthesized from compound (b) in one step as described below.
- Aromatic hydrocarbons such as benzene, toluene and xylene; ethers such as diethyl ether, tetrahydrofuran, dioxane, monoglyme and jigglime; alcohols such as methanol and ethanol; dichloromethane, chloroform, carbon tetrachloride and the like.
- Halogenized hydrocarbons aliphatic hydrocarbons such as pentane, hexane, heptane, ligroin; solvents such as water and acetic acid; in aprotonic polar solvents such as acetonitrile, N, N-dimethylformamide, dimethylsulfoxide or these.
- Blended acids such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, etc. in mixed solvent or no solvent; presence of acids such as boron trifluoride-diethyl ether complex, Lewis acid such as aluminum chloride, iron chloride, zinc chloride, etc.
- Compounds (d) and (e) can be synthesized by reacting them under or in the absence of room for 1 to 72 hours at room temperature to heating and refluxing, respectively.
- Method C The synthetic intermediates (d) and (e) described in Method A are synthesized from compound (a) in one step by using sodium azide or trimethylsilyl azide as described below. You can also.
- the raw material (a) is an aromatic hydrocarbon such as benzene, toluene, xylene; ethers such as diethyl ether, tetrahydrofuran, dioxane, monoglime, jigglime; alcohols such as methanol and ethanol; dichloromethane, chloroform, carbon tetrachloride and the like.
- Halogenized hydrocarbons aliphatic hydrocarbons such as pentane, hexane, heptane, ligroin; solvents such as water; in aprotonic polar solvents such as acetonitrile, N, N-dimethylformamide, dimethylsulfoxide, or a mixture thereof.
- Blended acids such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, trichloroacetic acid, polyphosphate, Eaton reagent, methanesulfonic acid, p-toluenesulfonic acid, etc.
- X is a nitrogen atom
- either A or B is N-R 16 (R 16 may have a substituent, a C 1-10 alkyl group, an aralkyl group).
- the invention compounds (d-1) and (e-1) can be synthesized by the methods described below, respectively.
- R 16 may have a substituent, a C 1-10 alkyl group, an aralkyl group (the aryl moiety has a carbon number of C 6-10 , and the alkylene moiety has a carbon number of C 1-5 ) or a hetero.
- the raw material (a) is an aromatic hydrocarbon such as benzene, toluene, xylene; ethers such as diethyl ether, tetrahydrofuran, dioxane, monoglime, diglime; alcohols such as methanol and ethanol; dichloromethane, chloroform, carbon tetrachloride and the like.
- Halogenized hydrocarbons aliphatic hydrocarbons such as pentane, hexane, heptane, ligroin; solvents such as water; in aprotonic polar solvents such as acetonitrile, N, N-dimethylformamide, dimethylsulfoxide, or a mixture thereof.
- Blended acids such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, trichloroacetic acid, polyphosphate, Eaton reagent, methanesulfonic acid, p-toluenesulfonic acid, etc.
- Aromatic hydrocarbons such as benzene, toluene and xylene are added to the compound (d) or (e) obtained in (i) above (both are collectively referred to as (de)); diethyl ether, tetrahydrofuran, dioxane.
- Ethers such as monoglime and jigglime; alcohols such as methanol and ethanol; halogenated hydrocarbons such as dichloromethane, chloroform and carbon tetrachloride; aliphatic hydrocarbons such as pentane, hexane, heptane and ligroin; acetonitrile, N , N-Dimethylformamide, bases such as potassium bis (trimethylsilyl) amide (KHMDS), lithium diisopropylamide (LDA), lithium hydride, sodium hydride, potassium hydride, etc.
- KHMDS potassium bis (trimethylsilyl) amide
- LDA lithium diisopropylamide
- the invented compound (h) can be synthesized by reacting with the alkylating agent represented by (r-1) in the presence or absence of sodium hydride for 1 to 24 hours at room temperature to heating and reflux. ..
- Aromatic hydrocarbons such as benzene, toluene, and xylene to the invention compound (f) or (g) obtained in (i) above (both are collectively referred to as (fg)); diethyl ether, tetrahydrofuran, dioxane.
- Ethers such as monoglime and jigglime; halogenated hydrocarbons such as dichloromethane, chloroform and carbon tetrachloride; alcohols such as methanol and ethanol; aliphatic hydrocarbons such as pentane, hexane, heptane and ligroine; acetonitrile, N , N, N-dimethylaminopyridine, trimethylamine, triethylamine, tributylamine, N, N-diisopropylethylamine, pyridine, N, N-dimethylaniline, N- Organic bases such as methylpiperidin, N-methylmorpholine, diethylamine, cyclohexylamine, procaine; carboxylic acid represented by (r-2) or carboxylic acid (r-3) in the presence of inorganic bases such as potassium carbonate and lithium carbonate.
- halogenated hydrocarbons such as dichloromethane, chloroform and
- the represented acid halides are O- (7-azabenzotriazole-1-yl) -N, N, N', N'-tetramethyluronium hexafluorophosphate (HATU), O- (benzotriazole-).
- Invention compound (i) can be synthesized.
- the compound (i) of the invention includes aromatic hydrocarbons such as benzene, toluene and xylene, ethers such as diethyl ether, tetrahydrofuran, dioxane, monoglime and jigglime; halogenated hydrocarbons such as dichloromethane, chloroform and carbon tetrachloride; pentane.
- Aromatic hydrocarbons such as benzene, toluene, and xylene in addition to the invention compound (f) or (g) obtained in (i) above (both are collectively referred to as (fg)); diethyl ether, tetrahydrofuran, Ethers such as dioxane, monoglime and jigglime; hydrogenated hydrocarbons such as dichloromethane, chloroform and carbon tetrachloride; alcohols such as methanol and ethanol; aliphatic hydrocarbons such as pentane, hexane, heptane and ligroin; acetonitrile, Aprotonic polar solvents such as N, N-dimethylformamide and dimethylsulfoxide; sodium borohydride, sodium cyanoboron
- Aromatic hydrocarbons such as benzene, toluene and xylene are added to the invention compound (f) or (g) obtained in (i) above (both are collectively referred to as (fg)); diethyl ether, tetrahydrofuran, Ethers such as dioxane, monoglime, jigglime; alcohols such as methanol and ethanol; halogenated hydrocarbons such as dichloromethane, chloroform and carbon tetrachloride; aliphatic hydrocarbons such as pentane, hexane, heptane and ligroine; acetonitrile, Bases such as potassium bis (trimethylsilyl) amide (KHMDS), lithium diisopropylamide (LDA), lithium diisopropylamide (LDA), lithium diisopropylamide (LDA)
- Organic bases in the presence or absence of inorganic bases such as sodium hydrogen carbonate, lithium carbonate, sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, potassium iodide or sodium iodide, (r-1).
- the invention compound (k) can be synthesized by reacting with the alkylating agent represented by (1) at room temperature to heating and reflux for 1 to 24 hours.
- the invention compound (k) can be obtained by reducing the amide moiety of the invention compound (i) obtained in the above (iv).
- R 1 to R 14 , R 17 or n indicate the same as above. * Indicates a bond.
- the invention compound (k) can be synthesized by reacting the agent at 0 ° C. to heating and refluxing for 1 to 24 hours.
- (J method) A or B is N-R 16 (R 16 may have a substituent C 1-10 alkyl group, aralkyl group (aryl moiety has C 6-10 , alkylene moiety carbon)
- R 16 may have a substituent C 1-10 alkyl group, aralkyl group (aryl moiety has C 6-10 , alkylene moiety carbon)
- the invention compound (d-1) or (e-1) obtained in (ii) above both combined) the reduction reaction of representing (d 1 -e 1) and), can be synthesized compound (f 1 -g 1).
- Aromatic hydrocarbons such as benzene, toluene and xylene are added to the invention compound (f) or (g) obtained in (i) above (both are collectively referred to as (fg)); diethyl ether, tetrahydrofuran, Ethers such as dioxane, monoglime and jigglime; halogenated hydrocarbons such as dichloromethane, chloroform and carbon tetrachloride; alcohols such as methanol and ethanol; aliphatic hydrocarbons such as pentane, hexane, heptane and ligroine; acetonitrile, N, N-Dimethylaminopyridine, trimethylamine, triethylamine, tributylamine, N, N-diisopropylethylamine, pyridine, N, N-dimethylaniline, N in aprotonic polar solvents such as N, N-di
- Invented compound (l) includes aromatic hydrocarbons such as benzene, toluene and xylene; ethers such as diethyl ether, tetrahydrofuran, dioxane, monoglime and jigglime; halogenated hydrocarbons such as dichloromethane, chloroform and carbon tetrachloride; Alcohols such as methanol and ethanol; aliphatic hydrocarbons such as pentane, hexane, heptane and ligroine; N, N-dimethylaminopyridine in aprotonic polar solvents such as acetonitrile, N, N-dimethylformamide and dimethylsulfoxide.
- aromatic hydrocarbons such as benzene, toluene and xylene
- ethers such as diethyl ether, tetrahydrofuran, dioxane, monoglime and jigglime
- a methylating agent such as methyl iodide, dimethyl sulfate, trifluoromethanesulfonylmethane
- Compound (m) can be synthesized.
- Aromatic hydrocarbons such as benzene, toluene and xylene in the compound (m) of the invention; ethers such as diethyl ether, tetrahydrofuran, dioxane, monoglime and jigglime; halogenated hydrocarbons such as dichloromethane, chloroform and carbon tetrachloride; pentane , Hexane, heptane, ligroin and other aliphatic hydrocarbons; N, N-dimethylaminopyridine, trimethylamine, triethylamine, N, N- in aprotonic polar solvents such as acetonitrile, N, N-dimethylformamide, dimethylsulfoxide and the like.
- Organic bases such as diisopropylethylamine, tributylamine, pyridine, N, N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, diethylamine, cyclohexylamine, procaine; in the presence of inorganic bases such as potassium carbonate, lithium carbonate, etc.
- the invention compound (n) can be synthesized by reacting an amine represented by r-5) or an alcohol represented by (r-6) at 0 ° C. to heating and refluxing for 1 to 12 hours.
- R 6a indicates a C 1-10 alkoxy group
- R 1 to R 14 , R 17 , n, m, Y and Z indicate the same as above. * Indicates a bond.
- the invention compound (o) obtained in the above (i) to (vi) is used as a halogenated hydrocarbon such as dichloromethane, chloroform and carbon tetrachloride; a protic organic solvent such as acetic acid; and an aprotic solvent such as acetonitrile and ethyl acetate. React with boron tribromide, trimethylsilyl iodide, hydrogen bromide, pyridinium hydrochloride, etc.
- the invention compound (p) can be synthesized by reacting at ° C. for 30 minutes to 24 hours.
- the invention compound (q) obtained in the above (i) to (vii) is mixed with a halogenated hydrocarbon solvent such as dichloromethane, chloroform, or carbon tetrachloride, an aqueous solution of hydrogen peroxide (H 2 O 2 ), or m-chloroperoxygen.
- a halogenated hydrocarbon solvent such as dichloromethane, chloroform, or carbon tetrachloride
- an aqueous solution of hydrogen peroxide H 2 O 2
- the invention compound (s) can be synthesized by reacting 1 to 2 equivalents of an oxidizing agent such as benzoic acid (mCPBA) at 0 ° C. to room temperature for 30 minutes to 24 hours.
- the compound obtained by each of the above steps can be purified, for example, by silica gel column chromatography, if necessary. Further, if necessary, an acid addition salt can be formed by a conventional method, for example, the invention compound (I) can be contained in an organic solvent such as ethyl acetate; alcohols such as methanol and ethanol; or in a polar solvent such as water.
- an organic solvent such as ethyl acetate
- alcohols such as methanol and ethanol
- a polar solvent such as water.
- Mineral acids such as hydrochloric acid, sulfuric acid and phosphoric acid, organic carboxylic acids such as formic acid, acetic acid, citric acid, trichloroacetic acid, trifluoroacetic acid, fumaric acid and maleic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid , Mesitylene sulfonic acid, organic sulfonic acid such as naphthalene sulfonic acid, etc., at room temperature or by heating as appropriate.
- the azepane derivative represented by the general formula (I) and its pharmaceutically acceptable salt thereof are used together with a pharmaceutically acceptable carrier for parenteral administration, oral administration in solid or liquid form, etc. to humans.
- the composition can be formulated. It can also be used in combination with other analgesics.
- solid preparations for oral administration include capsules, tablets, pills, powders and granules.
- Excipients, disintegrants, binders, lubricants, pigments and the like can be used in the preparation of this solid preparation.
- lactose, D-mannitol, crystalline cellulose, glucose and the like are used, starch, carboxymethyl cellulose calcium (CMC-Ca) and the like are used as a disintegrant, and magnesium stearate is used as a lubricant.
- the binder include talc and the like, such as hydroxypropyl cellulose (HPC), gelatin, polyvinylpyrrolidone (PVP) and the like.
- a buffer may be further used. Tablets and pills may be enteric coated.
- compositions of the invention for injections include pharmaceutically acceptable sterile water or non-aqueous solutions, suspensions or emulsions.
- suitable non-aqueous carriers, diluents, solvents or vehicles include propylene glycol, polyethylene glycol, vegetable oils such as olive oil and injectable organic esters such as ethyl oleate.
- Such compositions can also contain auxiliary agents such as preservatives, wetting agents, emulsifiers, soothing agents, buffers, preservatives and dispersants.
- compositions are reduced, for example, by filtration through a bacterial retention filter or by mixing the sterilizer in the form of a sterile solid composition that can be dissolved in a sterilizer or some other sterilized injectable medium immediately prior to use.
- a solubilizing agent preferably, in addition to the compound of the present invention, a solubilizing agent, a preservative, an tonicity agent, a thickener and the like can be added.
- Liquid formulations for oral administration include inactive diluents commonly used by those skilled in the art, such as pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs containing water.
- inactive diluents commonly used by those skilled in the art, such as pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs containing water.
- the composition may also contain auxiliaries such as wetting agents, emulsifying and suspending agents, as well as sweetening, seasoning and flavoring agents.
- the preparation for transrectal administration may preferably contain an excipient such as cocoa butter or suppository wax in addition to the compound of the present invention.
- the dose is usually the active ingredient, the azepan derivative represented by the above general formula (I), the tautomer of the compound, the stereoisomer, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof.
- the solvate is 0.01 ⁇ g to 1 g / day, preferably 0.0001 to 200 mg / day for injection, 0.1 ⁇ g to 10 g / day, preferably 0.001 to 2000 mg / day for oral administration. It is administered, but it can be increased or decreased depending on age, symptoms, etc. Further, if desired, this daily dose can be administered in 2 to 4 divided doses.
- Diseases and symptoms related to ⁇ opioid receptors include, for example, cardiovascular disorders, digestive disorders, hematological disorders, respiratory disorders, liver disorders, nervous system disorders, urinary disorders, pain, cough, pruritus, etc. Ischemic brain diseases and the like can be mentioned. Since the compound of the present invention has kappa opioid receptor selectivity and strong agonist activity against kappa opioid receptor, it is effective for the treatment, amelioration, and prevention of these diseases and symptoms.
- Hydroxylamine hydrochloride (1.84 g, 26.4 mmol) was added to a mixed solution of ethanol (111 mL) and water (28 mL) of the compound (4.51 g, 13.2 mmol) obtained in Reference Example 2 for 4 hours. It was heated to reflux. After allowing to cool, the reaction mixture was concentrated under reduced pressure, diluted with ethyl acetate, and washed once with saturated aqueous sodium hydrogen carbonate solution and twice with saturated brine. The organic layer was dried over sodium sulfate and then concentrated under reduced pressure.
- the reaction mixture was concentrated under reduced pressure, diluted with ethyl acetate, and washed twice with saturated aqueous sodium hydrogen carbonate solution and once with saturated brine. The organic layer was dried over sodium sulfate and then concentrated under reduced pressure.
- 2M Hydrochloric acid 40 mL was added to a solution of the obtained concentrated residue in tetrahydrofuran (80 mL), and the mixture was stirred at room temperature for 2 hours. Tetrahydrofuran was distilled off under reduced pressure, the mixture was made basic with potassium carbonate, and extracted with chloroform three times. The combined extracts were dried over sodium sulfate and concentrated under reduced pressure.
- the obtained crude product was purified by silica gel column chromatography (amino group-supported silica gel, 0-10% methanol / chloroform), and the title isomer C (283 mg, 29%) and isomer D (236 mg, 24%) were purified.
- a saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted once with ethyl acetate. The organic layer was washed with saturated brine and water, dried over sodium sulfate, and concentrated under reduced pressure.
- a solution of the obtained crude product (6 mg, 0.013 mmol) in chloroform (1 mL) was added a 1 M boron tribromide-dichloromethane solution (65 ⁇ L, 0.065 mmol) under ice-cooling, and the mixture was stirred at room temperature for 25 minutes.
- a saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted three times with chloroform.
- the combined extracts were dried over sodium sulfate and concentrated under reduced pressure.
- the obtained crude product was purified by silica gel column chromatography (amino group-supported silica gel, 1-10% methanol / chloroform) to obtain the title compound (16 mg, 80%) as a yellow oil.
- Example 2 The isomer C (13 mg, 0.038 mmol) obtained in Example 2 was dissolved in N, N-dimethylformamide (1.0 mL), and oxazole-2-carboxylic acid (7.0 mg, 0.062 mmol), N.
- N-diisopropruethylamine 33 ⁇ L, 0.19 mmol
- 1-hydroxybenzotriazole monohydrate 10 mg, 0.076 mmol
- 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride 14 mg
- N, N-dimethyl-4-aminopyridine 1.0 mg, 0.0080 mmol
- Triethylamine (12.1 ⁇ L, 0.087 mmol) and nicotinic acid chloride hydrochloride (15.4 mg, 0.) were added to a solution of isomer C (9.5 mg, 0.029 mmol) obtained in Example 2 in tetrahydrofuran (1 mL). 087 mmol) was added, and the mixture was stirred at room temperature for 30 minutes. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted 3 times with ethyl acetate. The combined extracts were dried over sodium sulfate and concentrated under reduced pressure.
- a free form (3.4 mg) of the title compound was obtained as a colorless amorphous compound from the compound obtained in Example 12 according to the method described in Example 6.
- the obtained free form was dissolved in methanol (0.5 mL), a 1 M hydrochloric acid-diethyl ether solution (50 ⁇ L) was added, and the mixture was concentrated under reduced pressure. Water (0.2 mL) was added to the obtained concentrated residue, and the mixture was frozen and then freeze-dried to give the title compound (4.0 mg, 54%) as a white solid.
- Example 22 1-((5aS, 6R, 11bR) -14- (cyclopropylmethyl) -5a, 10-dihydroxy-1,2,5,5a, 6,7-hexahydro-6,11b- (epiminoethano) naphtho [1, 2-d] Synthesis of azepine-3 (4H) -yl) -2- (pyridin-2-yl) ethane-1-one
- the obtained crude N, N-dimethylformamide (0.25 mL) solution was added to the compound E (10 mg, 0.03 mmol) and N, N-diisopropylethylamine (21 ⁇ L, 0.12 mmol) obtained in Example 3.
- the mixture was added dropwise to a solution of N, N-dimethylformamide (0.5 mL) under ice-cooling, and the mixture was stirred at room temperature for 16 hours.
- the reaction mixture was diluted with ethyl acetate, washed with saturated aqueous sodium hydrogen carbonate solution, water and saturated brine, dried over sodium sulfate, and concentrated under reduced pressure.
- Example 2 The title compound was obtained from the isomers C and 2- (1H-imidazol-4-yl) acetic acid obtained in Example 2 according to the method described in Example 5.
- the reaction mixture was cooled to 0 ° C., saturated aqueous Rochelle salt solution was added to stop the reaction, the temperature was raised to room temperature, the mixture was stirred overnight, and the mixture was extracted three times with ethyl acetate. The combined extracts were washed with saturated brine, dried over sodium sulfate, and concentrated under reduced pressure.
- the obtained crude product was purified by silica gel column chromatography (18-60% 2M ammonia-methanol solution / ethyl acetate) to give the title compound (3.0 mg, 22%) as a colorless oil.
- Example 70 The title compound was obtained from the compound obtained in Example 70 according to the method described in Example 24.
- Method 1 According to the method described in Example 31, the isomer C obtained in Example 2 and 2- (pyridin-2-yl) ethyl 4-methylbenzenesulfonic acid (Journal of Medicinal Chemistry, 2015, 58, 5842). The title compound was obtained from (synthesis by the method).
- Method 2 Acetic acid (430.1 ⁇ L, 7.52 mmol) and 2-vinylpyridine (807.3 ⁇ L, 7.52 mmol) in an ethanol (10 mL) solution of isomer C (257.7 mg, 0.75 mmol) obtained in Example 2 ) was added, and the mixture was heated under reflux for 3.5 hours. The reaction mixture was allowed to cool and then concentrated under reduced pressure.
- Example 81 The title compound was obtained from the compound obtained in Example 81 according to the method described in Example 24.
- Example 91 The title compound was obtained from the compound obtained in Example 91 according to the method described in Example 24.
- Example 31 the title compound was obtained from the isomer C obtained in Example 2 and 2- (3-fluoropyridine-2-yl) ethyl 4-methylbenzenesulfonic acid.
- Example 10-7 ((5aS, 6R, 11bR) -14- (cyclopropylmethyl) -5a, 10-dihydroxy-1,2,5,5a, 6,7-hexahydro-6,11b- (epiminoethano) naphtho [1,2- d] Synthesis of azepine-3 (4H) -yl) (1- (pyridin-2-yl) cyclopropyl) methanone
- Example 129 To a solution of the compound (5.3 mg, 0.0117 mmol) obtained in Example 129 in chloroform (1 mL) was added a 1 M boron tribromide-dichloromethane solution (70 ⁇ L, 0.070 mmol) under ice-cooling, and the mixture was added at room temperature for 1 hour. Stirred. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture under ice-cooling, and the mixture was extracted three times with ethyl acetate. The combined extracts were dried over sodium sulfate and concentrated under reduced pressure.
- a 1 M boron tribromide-dichloromethane solution 70 ⁇ L, 0.070 mmol
- the obtained concentrated residue was dissolved in methanol (1 mL), 10% palladium-activated carbon (55% wet) (3.4 mg) was added, and the mixture was stirred at room temperature for 15 hours under a hydrogen atmosphere.
- the reaction mixture was filtered through a membrane filter, and the filtrate was concentrated under reduced pressure.
- Example 31 the title compound was prepared from the compound E obtained in Example 3 and 2-chloro-1- (piperidine-1-yl) ethane-1-one (synthesized by the method described in WO2018148576). Obtained.
- Example 132 The title compound was obtained from the compound obtained in Example 132 according to the method described in Example 24.
- Example 2 According to the method described in Example 2, the title compound was obtained as a colorless amorphous substance from the isomers G and H described in Example 134.
- Example 31 the title compound was obtained from the isomer D obtained in Example 2 and 2- (pyridin-2-yl) ethyl 4-methylbenzenesulfonic acid.
- a chloroform (400 mL) solution of the compound (14 g, 39.3 mmol) obtained in Reference Example 3 under ice-cooling. 8 mmol) was added, and the mixture was stirred at room temperature for 17 hours.
- the reaction mixture was concentrated under reduced pressure, 2M hydrochloric acid (160 mL) was added to a solution of the obtained concentrated residue in tetrahydrofuran (250 mL), and the mixture was stirred at room temperature for 71 hours.
- the reaction mixture was washed three times with a mixed solution of ethyl acetate / heptane (2/1), the aqueous layer was made basic with potassium carbonate, and then extracted twice with ethyl acetate and once with chloroform. The combined extracts were dried over sodium sulfate and concentrated under reduced pressure.
- the obtained crude product was suspended in ethyl acetate (50 mL), stirred for 1 hour, and then the insoluble material was collected by filtration, and 4-methylbenzenesulfonate (5.15 g, 25%) of the title compound was used as a colorless solid. Obtained.
- Example 24 the same reaction as described in Example 24 was carried out on the title compound 4-methylbenzenesulfonate, and the title compound (509.3 mg, recovery rate 10%) was used as an unreacted recovery raw material in a colorless amorphous state. Obtained as.
- Example 147 The compound obtained in Example 147 (20 mg, 0.049 mmol), potassium carbonate (102 mg, 0.735 mmol), 4-tert-butylpyrazole (61 mg, 0.490 mmol), sodium iodide (9 mg, 0.059 mmol).
- acetonitrile (1 mL) and stirred at 60 ° C. for 16 hours under a nitrogen atmosphere.
- the reaction mixture was diluted with ethyl acetate, washed with saturated aqueous sodium hydrogen carbonate solution, the obtained organic layer was dried over sodium sulfate, and concentrated under reduced pressure.
- Diisopropyl azodicarboxylate (40% toluene solution, about 1.9 mol / L, 768 ⁇ L, 1.46 mmol) was added to a toluene (7 mL) solution of the compound (410 mg, 0.73 mmol) obtained in Example 151, and 100 The mixture was stirred at ° C. for 90 minutes. The reaction mixture was concentrated under reduced pressure, ethanol (14 mL) and pyridine hydrochloride (888 mg, 7.7 mmol) were added, and the mixture was stirred at 40 ° C. for 18 hours. Water and potassium carbonate were added to the reaction mixture to adjust the pH to 11, and the mixture was extracted three times with chloroform.
- Zinc powder (895 mg, 13.7 mmol) was added to a solution of the compound (346 mg, 0.68 mmol) obtained in Example 152 in acetic acid (30 mL), and the mixture was stirred at room temperature for 4 hours. The reaction mixture was filtered through Celite to remove zinc and concentrated under reduced pressure. A saturated aqueous sodium hydrogen carbonate solution was added to the obtained crude product, and the mixture was extracted three times with chloroform. The organic layers were combined, dried over sodium sulfate, and concentrated under reduced pressure.
- the obtained crude product was purified by silica gel column chromatography (amino group-supported silica gel, 0-50% methanol / chloroform) to give the title compound (187 mg, 83%) as a colorless amorphous substance.
- Example 15-7 1-((5aS, 6R, 11bR) -14- (cyclopropylmethyl) -5a, 10-dihydroxy-1,2,5,5a, 6,7-hexahydro-6,11b- (epiminoethano) naphtho [1, 2-d] Synthesis of azepine-3 (4H) -yl) -3- (1H-pyrazole-1-yl) propan-1-one
- Benzoic anhydride (236 mg, 1.04 mmol), 4-dimethylaminopyridine (127 mg, 1.04 mmol) and N, N in a xylene (10 mL) solution of the compound (270 mg, 0.52 mmol) obtained in Example 150.
- -Diisopropylethylamine (182 ⁇ L, 1.04 mmol) was added, and the mixture was stirred at 140 ° C. for 18 hours.
- Example 170 The title compound was obtained from the compound obtained in Example 170 according to the method described in Example 152.
- Example 171 The title compound was obtained from the compound obtained in Example 171 according to the method described in Example 153.
- Example 172 The title compound was obtained from the compound obtained in Example 172 and 2- (4-methyl-1H-pyrazole-1-yl) acetic acid according to the method described in Example 5.
- the organic layer was dried over sodium sulfate and then concentrated under reduced pressure.
- the obtained crude product was purified by silica gel column chromatography (amino group-supported silica gel, 1-100% methanol / chloroform) to obtain the title compound (30 mg, 50%) as a pale yellow amorphous substance.
- Example 180 The title compound was obtained from the compound obtained in Example 180 and 4-fluoro-1H-pyrazole according to the methods described in Examples 181 and 182.
- Example 180 The title compound was obtained from the compound obtained in Example 180 and 4-ethyl-1H-pyrazole according to the method described in Example 181.
- Example 180 The title compound was obtained from the compound obtained in Example 180 and 4-isopropyl-1H-pyrazole according to the method described in Example 181.
- Example 140 The title compound was obtained from the compound obtained in Example 140 and (3-bromopropoxy) (tert-butyl) dimethylsilane according to the method described in Example 141.
- the obtained crude product was purified by silica gel column chromatography (amino group-supported silica gel, 0-50% methanol / chloroform) to give the title compound (99.5 mg, 92%) as a colorless amorphous substance.
- the obtained crude product was purified by silica gel column chromatography (amino group-supported silica gel, 0-20% methanol / chloroform) to give the title compound (8.0 mg, 84%) as a colorless amorphous substance.
- Example 202 The title compound was obtained from the compound obtained in Example 202 according to the method described in Example 6.
- 1 1 H-NMR (400 MHz, DMSO-d6) ⁇ (ppm): 0.08-0.19 (m, 2H), 0.46-0.58 (m, 2H), 0.82-0.92 ( m, 1H), 1.06-1.38 (m, 1H), 1.58-1.89 (m, 4H), 1.99-2.19 (m, 2H), 2.04 (s, 3H), 2.28-2.45 (m, 2H), 2.52-2.62 (m, 2H), 2.75-2.88 (m, 2H), 2.94-3.07 ( m, 3H), 3.26-3.36 (m, 1H), 3.37-3.46 (m, 1H), 3.56 (d, J 15Hz, 1H), 3.61-3.
- Triethyl phosphonoacetate (189 ⁇ L, 0.94 mmol) under ice-cooling was added dropwise to a suspension of potassium tert-butoxide (106 mg, 0.94 mmol) in tetrahydrofuran (1 mL), and the mixture was stirred at 0 ° C. for 30 minutes. Then, a solution of 5-methylisothiazole-3-carbaldehyde (100 mg, 0.79 mmol) in THF (1 mL) was added dropwise, and the mixture was stirred at room temperature for 5 hours. Under ice-cooling, saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted three times with ethyl acetate.
- Example 21-7 1-((5aS, 6R, 11bR) -14- (cyclopropylmethyl) -5a, 10-dihydroxy-1,2,5,5a, 6,7-hexahydro-6,11b- (epiminoethano) naphtho [1, 2-d] Synthesis of azepine-3 (4H) -yl) -3- (5-methylisothiazole-3-yl) propan-1-one
- the obtained product was dissolved in a solution of methanol (1 mL), 10% palladium-activated carbon (55% wet, 13.2 mg) was added, and the mixture was stirred at room temperature for 19 hours under a hydrogen atmosphere.
- the reaction mixture was filtered through a membrane filter, and the filtrate was concentrated under reduced pressure.
- the obtained crude product was purified by silica gel column chromatography (amino group-supported silica gel, 0-5% methanol / chloroform) to obtain the title compound (5.4 mg, 39%) as a white solid.
- Example 176 The title compound was obtained from the compound obtained in Example 176 and 2- (bromomethyl) -1,1-difluorocyclopropane according to the method described in Example 161.
- a saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted three times with chloroform. The combined extracts were dried over sodium sulfate and concentrated under reduced pressure. The obtained crude product was used in the next reaction without purification.
- a 0.91 M borane-tetrahydrofuran complex tetrahydrofuran solution (0.44 mL, 0.40 mmol) was added to a solution of the obtained crude product in tetrahydrofuran (0.5 mL), and the mixture was heated under reflux for 6 hours. The reaction mixture was allowed to cool and then concentrated under reduced pressure. 6M Hydrochloric acid (2 mL) was added to the concentrated residue, and the mixture was heated under reflux for 1 hour.
- Example 176 The title compound was obtained from the compound obtained in Example 176 and 1-methylcyclopropane-1-carboxylic acid according to the method described in Example 219.
- E Ethyl (E) -4,4,4-trifluorocrotonate (210 ⁇ L, 1.46 mmol) in a solution of compound C (98.2 mg, 0.287 mmol) obtained in Example 2 in acetonitrile (3.0 mL). And cesium carbonate (467 mg, 1.43 mmol) was added, and the mixture was stirred at 85 ° C. for 2 hours. Under ice-cooling, water (10 mL) was added to the reaction mixture, and the mixture was extracted 3 times with ethyl acetate. The organic layers were combined, washed with saturated brine, dried over sodium sulfate, and concentrated under reduced pressure.
- Lithium borohydride (4M tetrahydrofuran solution, 380 ⁇ L, 1.52 mmol) was added to a solution of the compound (154 mg, 0.301 mmol) obtained in Example 222 in tetrahydrofuran (3.0 mL), and the mixture was stirred at room temperature for 5 hours. Then, lithium borohydride (4M tetrahydrofuran solution, 380 ⁇ L, 1.52 mmol) was added, and the mixture was stirred at room temperature for 2 hours. Under ice-cooling, water (10 mL) was added to the reaction mixture, and the mixture was extracted 3 times with ethyl acetate.
- N, N-diisopropylethylamine (31.2 ⁇ L, 179 ⁇ mol) and methanesulfonic anhydride (16.0 mg, 91.9 ⁇ mol) were added to a solution of the obtained crude product in chloroform (1.0 mL) at 0 ° C. The mixture was stirred at 0 ° C. for 2.5 hours. Then, methanesulfonic acid anhydride (6.0 mg, 34.4 ⁇ mol) was added, and the mixture was stirred at 0 ° C. for 40 minutes. Saturated aqueous sodium hydrogen carbonate solution (3 mL) and water (2 mL) were added to the reaction mixture, and the mixture was extracted 3 times with ethyl acetate.
- Example 50 The compound (25.2 mg, 0.058 mmol) obtained in Example 50 was dissolved in N, N-dimethylformamide (1 mL) to potassium carbonate (23.9 mg, 0.17 mmol) and 5-chloro-1-phenyl. -1H-tetrazole (31.3 mg, 0.17 mmol) was added, and the mixture was stirred at room temperature for 19 hours. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed three times with saturated brine, dried over sodium sulfate, and concentrated under reduced pressure.
- N, N-diisopropylethylamine (34.0 ⁇ L, 0.197 mmol) and methanesulfonic anhydride (35.0 mg, 0.201 mmol) were added again, and the mixture was stirred at room temperature for 1 hour.
- the obtained crude product was purified by silica gel column chromatography (amino group-supported silica gel, 50-100% ethyl acetate / heptane) to obtain the title compound K (176 mg, 36%) and the title compound L (190 mg, 49%). Each was obtained as colorless amorphous.
- the obtained crude product was purified by silica gel column chromatography (amino group-supported silica gel, 20-50% ethyl acetate / heptane) to give the title compound (359 mg, 86%) as a colorless amorphous substance.
- Example 240 The compounds obtained in Example 240 (299 mg, 0.533 mmol), zinc cyanide (190 mg, 1.62 mmol), tris (dibenzylideneacetone) dipalladium (0) (48.8 mg, 53.3 ⁇ mol) and ( ⁇ ). ) -BINAP (66.9 mg, 0.107 mmol) was dissolved in N, N-dimethylformamide (3.0 mL) and stirred at 150 ° C. for 1 hour. The reaction mixture was allowed to cool to room temperature and filtered through Celite. The filtrate was washed with water and saturated brine, dried over sodium sulfate, and concentrated under reduced pressure.
- Example 241 The compound (222 mg, 0.507 mmol), palladium acetate (24.0 mg, 0.107 mmol) and triphenylphosphine (53.5 mg, 0.204 mmol) obtained in Example 241 were dissolved in toluene (3.0 mL). , Acetaldoxime (93.0 ⁇ L, 1.52 mmol) was added, the mixture was heated to 80 ° C., and the mixture was stirred for 1 hour. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure.
- the obtained crude product was purified by silica gel column chromatography (6-50% 10% aqueous ammonia-methanol / 50% ethyl acetate-heptane) to give the title compound (210 mg, 91%) as a yellow amorphous substance.
- Example 242 The compound (210 mg, 0.461 mmol) obtained in Example 242 was dissolved in dichloromethane (3.0 mL), trifluoroacetic acid (0.6 mL) was added under cooling, and the mixture was added at 0 ° C. for 30 minutes and at room temperature for 1 hour. Stirred. Under cooling, water was added to the reaction mixture to stop the reaction, and the organic layer was separated. A saturated aqueous sodium hydrogen carbonate solution was added to the aqueous layer to make it basic, and then the mixture was extracted with dichloromethane, chloroform, chloroform / methanol (10/1), and chloroform / methanol (5/1).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本願は、2019年9月30日に日本に出願された、特願2019-179727号に基づき優先権主張し、その内容をここに援用する。
一方κオピオイド受容体アゴニストも鎮痛作用を示すが、モルヒネで見られる有害事象には関与しないことが知られている。
その一方、κオピオイド受容体アゴニストは一般に鎮静作用や薬物嫌悪作用を示すことが知られている。唯一、薬物嫌悪性を分離したκオピオイド受容体アゴニストとしてナルフラフィン(特許文献1)があげられるが、ナルフラフィンは鎮痛用量において鎮静作用を示すため、止痒薬としての承認は得られたが、鎮痛薬としての承認は受けていない。つまり、鎮痛薬として承認を受けたκオピオイド受容体選択的なアゴニストはいまだ存在しない。
従って、鎮静作用や薬物嫌悪作用を示さないκオピオイド受容体選択的なアゴニストは、鎮痛薬をはじめとするκオピオイド受容体に関連する疾患や症状の優れた治療又は改善、予防薬として期待される。
特許文献2には、次式(A):
また、特許文献3には、次式(B):
また特許文献4及び非特許文献1には、次式で表される化合物(C):
上市されている鎮痛薬のうち、高いκオピオイド受容体アゴニスト活性を有する薬剤はいまだ存在しない。
従って、鎮痛薬を志向する上で、κオピオイド受容体に対し選択性及び高い活性を示し、かつ生体内での安定性に優れ鎮静作用や薬物嫌悪作用が乖離した化合物が望まれている。
[1]即ち、本発明は、次の一般式(I)、
R2及びR3は同一又は異なって水素原子、置換基を有していてもよいC1-6アルキル基、置換基を有していてもよいC1-6アルコキシ基、ハロゲン原子、保護されていてもよいヒドロキシ基又はR2及びR3が一緒になってカルボニル基を示すかR2及びR3が結合して置換基を有していてもよいC3-6飽和炭化水素環又は置換基を有していてもよい環状ケタールを示し、
R4及びR5は同一又は異なって水素原子、置換基を有していてもよいC1-6アルキル基、置換基を有していてもよいC1-6アルコキシ基、置換基を有していてもよいC3-6シクロアルキル基、置換基を有していてもよいアミノ基、保護されたアミノ基、ハロゲン原子、保護されていてもよいヒドロキシ基、カルボキシ基、カルボン酸エステル基又は置換基を有していてもよいカルバモイル基を示し、
R6は水素原子、置換基を有していてもよいC1-6アルコキシ基、置換基を有していてもよいアミノ基、保護されたアミノ基、ハロゲン原子、保護されていてもよいヒドロキシ基、置換基を有していてもよいテトラゾリルオキシ基、シアノ基、カルボキシ基、カルボン酸エステル基、置換基を有していてもよいカルバモイル基、置換基を有していてもよいC6-10アリール基、置換基を有していてもよいヘテロアリール基、C6-10アリールオキシ基又は糖類を示し、
R7及びR8は同一又は異なって水素原子、置換基を有していてもよいC1-6アルキル基、置換基を有していてもよいC1-6アルコキシ基、ハロゲン原子、保護されていてもよいヒドロキシ基又はR7及びR8が一緒になってカルボニル基、チオカルボニル基を示すかR7及びR8が結合して置換基を有していてもよいC3-6飽和炭化水素環又は置換基を有していてもよい環状ケタールを示し、
R9及びR10は同一又は異なって水素原子、置換基を有していてもよいC1-6アルキル基、置換基を有していてもよいC1-6アルコキシ基、ハロゲン原子、保護されていてもよいヒドロキシ基又はR9及びR10が一緒になってカルボニル基、チオカルボニル基を示すかR9及びR10が結合して置換基を有していてもよいC3-6飽和炭化水素環又は置換基を有していてもよい環状ケタールを示し、
R11は水素原子、置換基を有していてもよいC1-6アルキル基、置換基を有していてもよいC1-6アルコキシ基、置換基を有していてもよいアラルキルオキシ基、置換基を有していてもよいアミノ基、保護されたアミノ基、ハロゲン原子、保護されていてもよいヒドロキシ基又はシアノ基を示し、
A及びBは異なってNR18(R18は水素原子又はアミノ保護基を示す。)、メチレン基、カルボニル基又は下記一般式(II):
R14は水素原子、置換基を有していてもよいC1-6アルキル基、置換基を有していてもよいC3-6シクロアルキル基、置換基を有していてもよいC2-6アルケニル基、置換基を有していてもよいC2-6アルキニル基、置換基を有していてもよいC1-6アルコキシ基、置換基を有していてもよいアミノ基、保護されたアミノ基、ハロゲン原子、保護されていてもよいヒドロキシ基、置換基を有していてもよいC6-10アリール基、置換基を有していてもよいヘテロアリール基、置換基を有していてもよい飽和複素環基、置換基を有していてもよい環状アミノ基を示す。*は結合手を示す。)で表される基を示し(ただし、A、Bのいずれか一方は式(II)を示す)、
Xは窒素原子又はN-オキシドを示し、
Yは置換基を有していてもよいメチレン基、カルボニル基又はチオカルボニル基を示し、
ZはNR15、酸素原子、結合手、置換基を有しても良いエテニレン基又はエチニレン基を示し(ただし、mが0の時はnは0及びZはNR15を示さない。)、
R15は水素原子、置換基を有していてもよいC1-6アルキル基を示すか、R15とR14が結合して置換基を有していてもよい含窒素飽和複素環を示し、
R17は水素原子、ハロゲン原子、保護されていてもよいヒドロキシ基、置換基を有していてもよいアルコキシ基又は置換基を有していてもよいテトラゾリルオキシ基を示し、
mは0~1の整数を示し、
nは0~3の整数を示す。
(ただし、Zが結合手の場合、mとnは同時に0を示さない。))
で表されるアゼパン誘導体及びその薬学的に許容される塩に関する。
[2]また本発明は、R6がヒドロキシ基、置換基を有していてもよいC1-6アルコキシ基又は置換基を有していてもよいカルバモイル基である前記[1]記載のアゼパン誘導体及びその薬学的に許容される塩に関する。
[3]また本発明は、R6がヒドロキシ基である前記[1]又は[2]記載のアゼパン誘導体及びその薬学的に許容される塩に関する。
[4]また本発明は、R1が置換基を有していてもよいC1-6アルキル基又は置換基を有していてもよいC3-6シクロアルキルC1-6アルキル基である前記[1]~[3]記載のアゼパン誘導体及びその薬学的に許容される塩に関する。
[5]また本発明は、Zが結合手である前記[1]~[4]記載のアゼパン誘導体及びその薬学的に許容される塩に関する。
[6]また本発明は、nが1~3である前記[1]~[5]記載のアゼパン誘導体及びその薬学的に許容される塩に関する。
[7]また本発明は、R14が置換基を有していてもよいヘテロアリール基である前記[1]~[6]記載のアゼパン誘導体及びその薬学的に許容される塩に関する。
[8]また本発明は、Aが請求項1記載の一般式(II)で表される基を示し、Bがメチレン基を示す前記[1]~[7]記載のアゼパン誘導体及びその薬学的に許容される塩に関する。
[9]また本発明は、R11がヒドロキシ基である前記[1]~[8]記載のアゼパン誘導体及びその薬学的に許容される塩に関する。
[10]また本発明は、前記[1]~[9]いずれか1項記載のアゼパン誘導体及びその薬学的に許容される塩を有効成分として含有する医薬組成物に関する。
[11]また本発明は、 オピオイドκ受容体に関連する疾患の治療又は改善、予防剤である前記[10]記載の医薬に関する。
[12]また本発明は、鎮痛薬である前記[10]又は[11]記載の医薬に関する。
[13]また本発明は、止痒薬である前記[10]又は[11]記載の医薬に関する。
上記一般式(I)で表されるアゼパン誘導体及びその薬学的に許容される塩には、互変異性体、立体異性体及びそれらの溶媒和物を含む。
R1~R5、R7~R15で示される置換基を有していてもよいC1-6アルキル基におけるC1-6アルキル基としては、メチル基、エチル基、プロピル基、イソプロピル基、ブチル基、イソブチル基、tert-ブチル基、ペンチル基、ヘキシル基等の直鎖又は分岐のアルキル基が挙げられ、好ましくはメチル基、エチル基、プロピル基が挙げられ、より好ましくはメチル基が挙げられる。
置換基を有していてもよいC1-6アルキル基における置換基としては、フッ素原子、塩素原子等のハロゲン原子;ヒドロキシ基;C1-6アルキルアミノ基、ジC1-6アルキルアミノ基、アシルアミノ基等の置換基を有していてもよいアミノ基;保護されたアミノ基;ホルミル基、アセチル基、シクロプロピルカルボニル基、ベンゾイル基等のアシル基;アゼチジニル基、ピロリジニル基、ピペラジニル基、モルホリニル基等の環状アミノ基;β-ラクタム、γ-ラクタム、δ-ラクタム等の環状ラクタム基、カルボキシ基、カルボン酸エステル基([0032]記載と同様)等が挙げられる。
R1、R4、R5及びR14で示される置換基を有していてもよいC3-6シクロアルキル基における置換基としては、メチル基、エチル基、プロピル基等のC1-6アルキル基;フルオロメチル基、ジフルオロメチル基、トリフルオロメチル基等のハロゲン化メチル基;フッ素原子、塩素原子等のハロゲン原子;ヒドロキシ基;C1-6アルキルアミノ基、ジC1-6アルキルアミノ基、アシルアミノ基等の置換基を有していてもよいアミノ基;保護されたアミノ基;ホルミル基、アセチル基、シクロプロピルカルボニル基、ベンゾイル基等のアシル基;アゼチジニル基、ピロリジニル基、ピペラジニル基、モルホリニル基等の環状アミノ基;β-ラクタム、γ-ラクタム、δ-ラクタム等の環状ラクタム基等が挙げられる。
置換基を有していてもよいC1-6アルコキシ基における置換基としては、メトキシ基、エトキシ基等のC1-6アルコキシ基;フェノキシ基;フッ素原子、塩素原子等のハロゲン原子が挙げられ、好ましくはフッ素原子であり、例えば、フルオロメトキシ基、ジフルオロメトキシ基、トリフルオロメトキシ基、2,2,2-トリフルオロエトキシ基等が挙げられる。
また、これらのヘテロアリール基上の置換基によっては互変異性体が存在しえ、例えばピリジル基上にヒドロキシ基が置換する場合、6-ヒドロキシピリジン-2-イル基と、その互変異性体として6-オキソ-1,6-ジヒドロピリジン-2-イル基、および4-ヒドロキシピリジン-2-イル基と、その互変異性体として4-オキソ-1,4-ジヒドロピリジン-2-イル基が挙げられる。
好ましいR1としては、ピリジル基、ピリダジニル基、ピラジニル基、ピリミジル基等の6員環ヘテロアリール基が挙げられる。
好ましいR14としては、フラニル基、チエニル基、ピロリル基、イミダゾリル基、ピラゾリル基、チアゾリル基、トリアゾール基、ピリジル基、ピリダジニル基、ピラジニル基、ピリミジル基、キノリル基、イソキノリル基、インドリル基、インダゾリル基、ベンゾオキサゾリル基、ベンゾチアゾリル基、イミダゾピリジニル基、ピラゾロピリジニル基、インダゾール基が挙げられ、より好ましくはフラン-2-イル基、チアゾール-2-イル基、チアゾール-4-イル基、1H-イミダゾール-4-イル基、1H-ピラゾール-3-イル基、1H-ピラゾール-1-イル基、2H-1,2,3-トリアゾール-2-イル基、ピリジン-2-イル基、ピリミジン-2-イル基、ピラジン-2-イル基、1H-インダゾール-3-イル基、イミダゾ[1,2-a]ピリジン-2-イル基、ピラゾロ[1,5-a]1H-インダゾール-1-イル基、キノリン-2-イル基、イソキノリン-3-イル基、インドリン-1-イル基、ベンゾ[d]チアゾール-2-イル基が挙げられる。
置換基を有していてもよいC3-6シクロアルキルC1-6アルキル基における置換基としては、フッ素原子、塩素原子等のハロゲン原子、ヒドロキシ基等が挙げられる。
また、C1-6アルカノイル基、C4―7シクロアルカノイル基における置換基としては、段落[0015]記載の置換基と同様のものが挙げられ、アロイル基、ヘテロアロイル基における置換基としては、段落[0020]記載の置換基と同様のものが挙げられる。
置換基としては、メチル基、エチル基等の置換基を有していてもよいC1-6アルキル基;メトキシ基、エトキシ基、プロポキシ基等の置換基を有していてもよいC1-6アルコキシ基;フッ素原子、塩素原子等のハロゲン原子;ヒドロキシ基等が挙げられる。
置換基を有していてもよいC1-6アルキル基における置換基としては、段落[0015]記載のものが挙げられ、置換基を有していてもよいC1-6アルコキシ基における置換基としては段落[0017]記載の置換基が挙げられる。
これらの飽和複素環のうち、環の構成原子として窒素原子を有する場合には、さらに直鎖又は分岐のC1-6アルキル基、アシル基等の置換基又はアミノ保護基を窒素上に有していてもよい。これらの置換基等は段落[0015]、[0028]及び[0030]記載のものを示す。
これらの含窒素飽和複素環は、さらに飽和炭化水素環、飽和複素環、不飽和炭化水素環又は不飽和複素環と縮環していてもよく、例えばデカヒドロキノリン、デカヒドロイソキノリン、インドリン、イソインドリン、1,2,3,4-テトラヒドロキノリン、1,2,3,4-テトラヒドロイソキノリン、ベンゾモルホリン、ベンゾチオモルホリン等が挙げられる。
これらの含窒素複素環においてR15が結合している窒素原子以外に環の構成原子として窒素原子を有する場合には、さらに直鎖又は分岐のC1-6アルキル基及びアシル基等の置換基又はアミノ保護基を窒素原子上に有していてもよい。これらの置換基等は段落[0015]、[0028]及び[0030]記載のものを示す。
置換基を有していてもよいメチレン基における置換基としては、C1-6アルキル基、保護されていてもよいヒドロキシ基(保護基としては[0039]のものが挙げられる)、ハロゲン原子、(例えば、フッ素原子等)、ハロゲン原子で置換されたC1-6アルキル基(例えば、フルオロメチル基、ジフルオロメチル基、トリフルオロメチル基、クロロメチル基、ジクロロメチル基等)等が挙げられる。
置換基を有しても良いエテニレン基における置換基としては、段落[0027]記載のものが挙げられる。
(A法)化合物(a)を出発原料とし、以下に記載した方法により発明化合物(f)及び(g)を得ることができる。
(第一工程)
原料(a)を、ベンゼン、トルエン、キシレン等の芳香族炭化水素類;ジエチルエーテル、テトラヒドロフラン、ジオキサン、モノグライム、ジグライム等のエーテル類;メタノール、エタノール等のアルコール類;ジクロロメタン、クロロホルム、四塩化炭素等のハロゲン化炭化水素類;ペンタン、ヘキサン、ヘプタン、リグロイン等の脂肪族炭化水素類;水、酢酸等のプロトン性溶媒;アセトニトリル、N,N-ジメチルホルムアミド、ジメチルスルホキシド等の非プロトン性極性溶媒中又はこれらの混合溶媒中、カリウムビス(トリメチルシリル)アミド(KHMDS)、リチウムジイソプロピルアミド(LDA)、水素化リチウム、水素化ナトリウム、水素化カリウム等の塩基;トリメチルアミン、トリエチルアミン、トリブチルアミン、N,N-ジイソプロピルエチルアミン、ピリジン、N,N-ジメチルアニリン、N,N-ジメチルアミノピリジン、N-メチルピペリジン、N-メチルモルホリン、ジエチルアミン、シクロヘキシルアミン、プロカイン、ナトリウムメトキシド、ナトリウムエトキシド、ナトリウムtert-ブトキシド、カリウムtert-ブトキシド等の有機塩基;炭酸リチウム、炭酸ナトリウム、炭酸カリウム、水酸化ナトリウム、水酸化カリウム、酢酸ナトリウム等の無機塩基の存在下又は非存在下、ヒドロキシルアミン塩酸塩又はヒドロキシルアミン硫酸塩等と、室温~加熱還流下で1~24時間反応させることで化合物(b)を合成することができる。
(第二工程)
化合物(b)を、ベンゼン、トルエン、キシレン等の芳香族炭化水素類;ジエチルエーテル、テトラヒドロフラン、ジオキサン、モノグライム、ジグライム等のエーテル類;ジクロロメタン、クロロホルム、四塩化炭素等のハロゲン化炭化水素類;ペンタン、ヘキサン、ヘプタン、リグロイン等の脂肪族炭化水素類;アセトニトリル、N,N-ジメチルホルムアミド、ジメチルスルホキシド等の非プロトン性極性溶媒中、カリウムビス(トリメチルシリル)アミド(KHMDS)、リチウムジイソプロピルアミド(LDA)、水素化リチウム、水素化ナトリウム、水素化カリウム等の塩基;トリメチルアミン、トリエチルアミン、トリブチルアミン、N,N-ジイソプロピルエチルアミン、ピリジン、N,N-ジメチルアニリン、N,N-ジメチルアミノピリジン、N-メチルピペリジン、N-メチルモルホリン、ジエチルアミン、シクロヘキシルアミン、プロカイン、ナトリウムメトキシド、ナトリウムエトキシド、ナトリウムtert-ブトキシド、カリウムtert-ブトキシド等の有機塩基;炭酸リチウム、炭酸ナトリウム、炭酸カリウム、水酸化ナトリウム、水酸化カリウム等の無機塩基の存在下、上記L-Cl又はL2Oで表される試薬と、-78℃~加熱還流下で1~24時間反応させることで化合物(c)を合成することができる。
(第三工程)
化合物(c)を、ベンゼン、トルエン、キシレン等の芳香族炭化水素類;ジエチルエーテル、テトラヒドロフラン、ジオキサン、モノグライム、ジグライム等のエーテル類;メタノール、エタノール等のアルコール類;ジクロロメタン、クロロホルム、四塩化炭素等のハロゲン化炭化水素類;ペンタン、ヘキサン、ヘプタン、リグロイン等の脂肪族炭化水素類;水、酢酸等の溶媒;アセトニトリル、N,N-ジメチルホルムアミド、ジメチルスルホキシド等の非プロトン性極性溶媒中又はこれらの混合溶媒中又は無溶媒中、塩酸、硫酸、酢酸、トリフルオロ酢酸、メタンスルホン酸、p-トルエンスルホン酸等のブレンステッド酸;三フッ化ホウ素-ジエチルエーテル錯体、塩化アルミニウム、塩化鉄(III)、塩化亜鉛、塩化チタン(IV)等のルイス酸と、室温~加熱還流下で1~72時間反応させることで化合物(d)及び(e)をそれぞれ合成することができる。
(第四工程)
化合物(d)及び(e)それぞれに対し、ジエチルエーテル、テトラヒドロフラン、ジオキサン、モノグライム、ジグライム等のエーテル類中、水素化アルミニウムリチウム、ボラン-テトラヒドロフラン錯体、ボラン-ジメチルスルフィド錯体等の還元剤を、0℃~加熱還流下で1~24時間反応させることにより、発明化合物(f)及び(g)をそれぞれ合成することができる。
化合物(b)を、ベンゼン、トルエン、キシレン等の芳香族炭化水素類;ジエチルエーテル、テトラヒドロフラン、ジオキサン、モノグライム、ジグライム等のエーテル類;メタノール、エタノール等のアルコール類;ジクロロメタン、クロロホルム、四塩化炭素等のハロゲン化炭化水素類;ペンタン、ヘキサン、ヘプタン、リグロイン等の脂肪族炭化水素類;水、酢酸等の溶媒;アセトニトリル、N,N-ジメチルホルムアミド、ジメチルスルホキシド等の非プロトン性極性溶媒中又はこれらの混合溶媒中又は無溶媒中、塩酸、硫酸、酢酸、トリフルオロ酢酸等のブレンステッド酸;三フッ化ホウ素-ジエチルエーテル錯体、塩化アルミニウム、塩化鉄、塩化亜鉛等のルイス酸等の酸の存在下もしくは非存在下、室温~加熱還流下で1~72時間反応させることで化合物(d)及び(e)をそれぞれ合成することができる。
原料(a)を、ベンゼン、トルエン、キシレン等の芳香族炭化水素類;ジエチルエーテル、テトラヒドロフラン、ジオキサン、モノグライム、ジグライム等のエーテル類;メタノール、エタノール等のアルコール類;ジクロロメタン、クロロホルム、四塩化炭素等のハロゲン化炭化水素類;ペンタン、ヘキサン、ヘプタン、リグロイン等の脂肪族炭化水素類;水等の溶媒;アセトニトリル、N,N-ジメチルホルムアミド、ジメチルスルホキシド等の非プロトン性極性溶媒中又はこれらの混合溶媒中又は無溶媒中、塩酸、硫酸、酢酸、トリフルオロ酢酸、トリクロロ酢酸、ポリリン酸、Eaton試薬、メタンスルホン酸、p-トルエンスルホン酸等のブレンステッド酸;三フッ化ホウ素-ジエチルエーテル錯体、塩化アルミニウム、塩化鉄、塩化亜鉛、塩化チタン(IV)等のルイス酸の存在下又は非存在下、アジ化ナトリウム(NaN3)又はトリメチルシリルアジド(TMSN3)と、0℃~加熱還流下で1~24時間反応させることで化合物(d)及び(e)をそれぞれ合成することができる。
(D法)化合物(a)を出発原料とし、以下に記載した方法により、発明化合物(d-1)及び(e-1)をそれぞれ合成することができる。
原料(a)を、ベンゼン、トルエン、キシレン等の芳香族炭化水素類;ジエチルエーテル、テトラヒドロフラン、ジオキサン、モノグライム、ジグライム等のエーテル類;メタノール、エタノール等のアルコール類;ジクロロメタン、クロロホルム、四塩化炭素等のハロゲン化炭化水素類;ペンタン、ヘキサン、ヘプタン、リグロイン等の脂肪族炭化水素類;水等の溶媒;アセトニトリル、N,N-ジメチルホルムアミド、ジメチルスルホキシド等の非プロトン性極性溶媒中又はこれらの混合溶媒中又は無溶媒中、塩酸、硫酸、酢酸、トリフルオロ酢酸、トリクロロ酢酸、ポリリン酸、Eaton試薬、メタンスルホン酸、p-トルエンスルホン酸等のブレンステッド酸;三フッ化ホウ素-ジエチルエーテル錯体、塩化アルミニウム、塩化鉄、塩化亜鉛、塩化チタン(IV)等のルイス酸の存在下又は非存在下、R16-N3で表されるアジ化物と、0℃~加熱還流下で1~24時間反応させることで発明化合物(d-1)及び(e-1)をそれぞれ合成することができる。
(E法)上記(i)で得られた化合物(d)又は(e)(両者を合わせて(d-e)と表す)のアルキル化反応により、発明化合物(h)を合成することができる。
上記(i)で得られた化合物(d)又は(e)(両者を合わせて(d-e)と表す)に、ベンゼン、トルエン、キシレン等の芳香族炭化水素類;ジエチルエーテル、テトラヒドロフラン、ジオキサン、モノグライム、ジグライム等のエーテル類;メタノール、エタノール等のアルコール類;ジクロロメタン、クロロホルム、四塩化炭素等のハロゲン化炭化水素類;ペンタン、ヘキサン、ヘプタン、リグロイン等の脂肪族炭化水素類;アセトニトリル、N,N-ジメチルホルムアミド、ジメチルスルホキシド等の非プロトン性極性溶媒中、カリウムビス(トリメチルシリル)アミド(KHMDS)、リチウムジイソプロピルアミド(LDA)、水素化リチウム、水素化ナトリウム、水素化カリウム等の塩基;トリメチルアミン、トリエチルアミン、トリブチルアミン、N,N-ジイソプロピルエチルアミン、ピリジン、N,N-ジメチルアニリン、N,N-ジメチルアミノピリジン、N-メチルピペリジン、N-メチルモルホリン、ジエチルアミン、シクロヘキシルアミン、プロカイン、ナトリウムメトキシド、ナトリウムエトキシド、ナトリウムtert-ブトキシド、カリウムtert-ブトキシド等の有機塩基;炭酸水素ナトリウム、炭酸リチウム、炭酸ナトリウム、炭酸カリウム、水酸化ナトリウム、水酸化カリウム等の無機塩基の存在下、ヨウ化カリウム又はヨウ化ナトリウム存在下又は非存在下、(r-1)で表されるアルキル化剤と、室温~加熱還流下で1~24時間反応させることで発明化合物(h)を合成することができる。
(F法)上記(i)で得られた発明化合物(f)又は(g)(両者を合わせて(f-g)と表す)と(r-2)又は(r-3)の反応により、発明化合物(i)及び(j)を得ることができる。
(第一工程)
上記(i)で得られた発明化合物(f)又は(g)(両者を合わせて(f-g)と表す)にベンゼン、トルエン、キシレン等の芳香族炭化水素類;ジエチルエーテル、テトラヒドロフラン、ジオキサン、モノグライム、ジグライム等のエーテル類;ジクロロメタン、クロロホルム、四塩化炭素等のハロゲン化炭化水素類;メタノール、エタノール等のアルコール類;ペンタン、ヘキサン、ヘプタン、リグロイン等の脂肪族炭化水素類;アセトニトリル、N,N-ジメチルホルムアミド、ジメチルスルホキシド等の非プロトン性極性溶媒中、N,N-ジメチルアミノピリジン,トリメチルアミン、トリエチルアミン、トリブチルアミン、N,N-ジイソプロピルエチルアミン、ピリジン、N,N-ジメチルアニリン、N-メチルピペリジン、N-メチルモルホリン、ジエチルアミン、シクロヘキシルアミン、プロカイン等の有機塩基;炭酸カリウム、炭酸リチウム等の無機塩基の存在下、(r-2)で表されるカルボン酸又は(r-3)で表される酸ハロゲン化物を、O-(7-アザベンゾトリアゾール-1-イル)-N,N,N’,N’-テトラメチルウロニウムヘキサフルオロホスファート(HATU)、O-(ベンゾトリアゾール-1-イル)-N,N,N’,N’-テトラメチルウロニウムヘキサフルオロホスファート(HBTU)、N,N’-ジシクロへキシルカルボジイミド(DCC)、1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド塩酸塩(WSC)、4-(4,6-ジメトキシ-1,3,5-トリアジン-2-イル)-4-メチルモルフォリニウムクロライドn水和物(DMT-MM)等の縮合剤存在下又は非存在下、(r-2)で表されるカルボン酸又は(r-3)で表される酸ハロゲン化物を、0℃~加熱還流下で1~12時間反応させることにより、発明化合物(i)を合成することができる。
(第二工程)
発明化合物(i)はベンゼン、トルエン、キシレン等の芳香族炭化水素類、ジエチルエーテル、テトラヒドロフラン、ジオキサン、モノグライム、ジグライム等のエーテル類;ジクロロメタン、クロロホルム、四塩化炭素等のハロゲン化炭化水素類;ペンタン、ヘキサン、ヘプタン、リグロイン等の脂肪族炭化水素類中、五硫化二リン、ローソン試薬、デービー試薬、ジャパニーズ試薬、ベレオー試薬等の硫化剤を用い、0℃~加熱還流下で1~12時間反応させることにより、発明化合物(j)に変換することができる。
(G法)上記(i)で得られた発明化合物(f)又は(g)(両者を合わせて(f-g)と表す)とアルデヒド(r-4)との還元的アミノ化反応により、発明化合物(k)を得ることができる。
上記(i)で得られた発明化合物(f)又は(g)(両者を合わせて(f-g)と表す)に、ベンゼン、トルエン、キシレン等の芳香族炭化水素類;ジエチルエーテル、テトラヒドロフラン、ジオキサン、モノグライム、ジグライム等のエーテル類;ジクロロメタン、クロロホルム、四塩化炭素等のハロゲン化炭化水素類;メタノール、エタノール等のアルコール類;ペンタン、ヘキサン、ヘプタン、リグロイン等の脂肪族炭化水素類;アセトニトリル、N,N-ジメチルホルムアミド、ジメチルスルホキシド等の非プロトン性極性溶媒;酢酸等の溶媒中又はこれらの混合溶媒中、水素化ホウ素ナトリウム、シアノ水素化ホウ素ナトリウム、水素化トリアセトキシホウ素ナトリウム、水素化トリ(sec-ブチル)ホウ素リチウム、水素化トリ(sec-ブチル)ホウ素カリウム等のヒドリド還元剤の存在下、(r-4)で表されるアルデヒドを0℃~加熱還流下で1~12時間反応させることにより、発明化合物(k)を合成することができる。
上記(i)で得られた発明化合物(f)又は(g)(両者を合わせて(f-g)と表す)に、ベンゼン、トルエン、キシレン等の芳香族炭化水素類;ジエチルエーテル、テトラヒドロフラン、ジオキサン、モノグライム、ジグライム等のエーテル類;メタノール、エタノール等のアルコール類;ジクロロメタン、クロロホルム、四塩化炭素等のハロゲン化炭化水素類;ペンタン、ヘキサン、ヘプタン、リグロイン等の脂肪族炭化水素類;アセトニトリル、N,N-ジメチルホルムアミド、ジメチルスルホキシド等の非プロトン性極性溶媒中、カリウムビス(トリメチルシリル)アミド(KHMDS)、リチウムジイソプロピルアミド(LDA)等の塩基;トリメチルアミン、トリエチルアミン、トリブチルアミン、N,N-ジイソプロピルエチルアミン、ピリジン、N,N-ジメチルアニリン、N,N-ジメチルアミノピリジン、N-メチルピペリジン、N-メチルモルホリン、ジエチルアミン、シクロヘキシルアミン、プロカイン、ナトリウムメトキシド、ナトリウムエトキシド、カリウムtert-ブトキシド等の有機塩基;炭酸水素ナトリウム、炭酸リチウム、炭酸ナトリウム、炭酸カリウム、水酸化ナトリウム、水酸化カリウム等の無機塩基の存在下、ヨウ化カリウム又はヨウ化ナトリウム存在下又は非存在下、(r-1)で表されるアルキル化剤と、室温~加熱還流下で1~24時間反応させることで発明化合物(k)を合成することができる。
上記(iv)で得られた発明化合物(i)に対し、ジエチルエーテル、テトラヒドロフラン、ジオキサン、モノグライム、ジグライム等のエーテル類中、水素化アルミニウムリチウム、ボラン-テトラヒドロフラン錯体、ボラン-ジメチルスルフィド錯体等の還元剤を、0℃~加熱還流下で1~24時間反応させることにより、発明化合物(k)を合成することができる。
(K法)上記(i)で得られた発明化合物(f)又は(g)(両者を合わせて(f-g)と表す)を用い、以下に記載した方法により、発明化合物(n)を得ることができる。
(第一工程)
上記(i)で得られた発明化合物(f)又は(g)(両者を合わせて(f-g)と表す)に、ベンゼン、トルエン、キシレン等の芳香族炭化水素類;ジエチルエーテル、テトラヒドロフラン、ジオキサン、モノグライム、ジグライム等のエーテル類;ジクロロメタン、クロロホルム、四塩化炭素等のハロゲン化炭化水素類;メタノール、エタノール等のアルコール類;ペンタン、ヘキサン、ヘプタン、リグロイン等の脂肪族炭化水素類;アセトニトリル、N,N-ジメチルホルムアミド、ジメチルスルホキシド等の非プロトン性極性溶媒中、N,N-ジメチルアミノピリジン,トリメチルアミン、トリエチルアミン、トリブチルアミン、N,N-ジイソプロピルエチルアミン、ピリジン、N,N-ジメチルアニリン、N-メチルピペリジン、N-メチルモルホリン、ジエチルアミン、シクロヘキシルアミン、プロカイン等の有機塩基;炭酸カリウム、炭酸リチウム等の無機塩基の存在下、カルボジイミダゾールを0℃~加熱還流下で1~12時間反応させることにより、発明化合物(l)を合成することができる。
(第二工程)
発明化合物(l)に、ベンゼン、トルエン、キシレン等の芳香族炭化水素類;ジエチルエーテル、テトラヒドロフラン、ジオキサン、モノグライム、ジグライム等のエーテル類;ジクロロメタン、クロロホルム、四塩化炭素等のハロゲン化炭化水素類;メタノール、エタノール等のアルコール類;ペンタン、ヘキサン、ヘプタン、リグロイン等の脂肪族炭化水素類;アセトニトリル、N,N-ジメチルホルムアミド、ジメチルスルホキシド等の非プロトン性極性溶媒中、N,N-ジメチルアミノピリジン,トリメチルアミン、トリエチルアミン、トリブチルアミン、N,N-ジイソプロピルエチルアミン、ピリジン、N,N-ジメチルアニリン、N-メチルピペリジン、N-メチルモルホリン、ジエチルアミン、シクロヘキシルアミン、プロカイン等の有機塩基;炭酸カリウム、炭酸リチウム等の無機塩基の存在下又は非存在下、ヨウ化メチル、硫酸ジメチル、トリフルオロメタンスルホニルメタン、meerwein試薬等のメチル化剤を、0℃~加熱還流下で12~48時間反応させることにより、発明化合物(m)を合成することができる。
(第三工程)
発明化合物(m)にベンゼン、トルエン、キシレン等の芳香族炭化水素類;ジエチルエーテル、テトラヒドロフラン、ジオキサン、モノグライム、ジグライム等のエーテル類;ジクロロメタン、クロロホルム、四塩化炭素等のハロゲン化炭化水素類;ペンタン、ヘキサン、ヘプタン、リグロイン等の脂肪族炭化水素類;アセトニトリル、N,N-ジメチルホルムアミド、ジメチルスルホキシド等の非プロトン性極性溶媒中、N,N-ジメチルアミノピリジン、トリメチルアミン、トリエチルアミン、N,N-ジイソプロピルエチルアミン、トリブチルアミン、ピリジン、N,N-ジメチルアニリン、N-メチルピペリジン、N-メチルモルホリン、ジエチルアミン、シクロヘキシルアミン、プロカイン等の有機塩基;炭酸カリウム、炭酸リチウム等の無機塩基の存在下、(r-5)で表されるアミン又は(r-6)で表されるアルコールを、0℃~加熱還流下で1~12時間反応させることにより、発明化合物(n)を合成することができる。
(L法)上記(i)~(vi)で得られた発明化合物(o)の脱アルキル化反応により、発明化合物(p)を合成することができる。
上記(i)~(vi)で得られた発明化合物(o)を、ジクロロメタン、クロロホルム、四塩化炭素等のハロゲン化炭化水素類;酢酸等のプロトン性有機溶媒;アセトニトリル、酢酸エチル等の非プロトン性極性溶媒中又は無溶媒中、三臭化ホウ素、トリメチルシリルヨージド、臭化水素、塩酸ピリジニウム等と、-30~180℃で30分~24時間反応させるか、あるいはN,N-ジメチルホルムアミド、ジメチルアセトアミド、N-メチルピロリドン、ジメチルスルホキシド等の非プロトン性極性溶媒中、カリウムtert-ブトキシド、ナトリウムtert-ブトキシド等の有機塩基存在下、1-プロパンチオール、1-ドデカンチオール等を100℃~180℃で30分~24時間反応させることにより、発明化合物(p)を合成することができる。
(M法)上記(i)~(vii)で得られた発明化合物(q)の酸化反応により、発明化合物(s)を合成することができる。
上記(i)~(vii)で得られた発明化合物(q)を、ジクロロメタン、クロロホルム、四塩化炭素等のハロゲン化炭化水素溶媒中、過酸化水素(H2O2)水溶液又はm-クロロ過安息香酸(mCPBA)等の酸化剤1~2当量を、0℃~室温で30分~24時間反応させることにより、発明化合物(s)を合成することができる。
さらに必要に応じて常法により酸付加塩を形成することができ、例えば発明化合物(I)を、酢酸エチル等の有機溶媒;メタノール、エタノール等のようなアルコール類;あるいは水等の極性溶媒中、塩酸、硫酸、リン酸等の鉱酸、ギ酸、酢酸、クエン酸、トリクロロ酢酸、トリフルオロ酢酸、フマール酸、マレイン酸等の有機カルボン酸、メタンスルホン酸、ベンゼンスルホン酸、p-トルエンスルホン酸、メシチレンスルホン酸、ナフタレンスルホン酸等の有機スルホン酸等の存在下、室温又は適宜加熱することにより行われる。
これら組成物は例えば細菌保持フィルターによる濾過により、又は使用直前に減菌剤あるいは若干の他の減菌注射可能な媒質に溶解し得る無菌固形組成物の形態で減菌剤を混入することにより減菌することができる。
トリフルオロメタンスルホン酸(4bR,8aS,9R)-11-(シクロプロピルメチル)-8a-ヒドロキシ-3-メトキシ-6-オキソ-6,7,8,8a,9,10-テトラヒドロ-5H-9,4b-(エピミノエタノ)フェナントレン-4-イルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.09-0.18(m,2H),0.52-0.59(m,2H),0.81-0.93(m,1H),1.65-1.87(m,3H),2.03-2.14(m,2H),2.20(ddd,J=5,13,13Hz,1H),2.39(d,J=7Hz,2H),2.66-2.73(m,1H),2.77(ddd,J=8,13,14Hz,1H),2.88(dd,J=7,19Hz,1H),3.01-3.18(m,3H),3.52(dd,J=2,14Hz,1H),3.80(s,3H),4.75(s,1H),6.85(d,J=8Hz,1H),7.05(d,J=8Hz,1H).
(4bR,8aS,9R)-11-(シクロプロピルメチル)-8a-ヒドロキシ-3-メトキシ-8,8a,9,10-テトラヒドロ-5H-9,4b-(エピミノエタノ)フェナントレン-6(7H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.09-0.18(m,2H),0.50-0.59(m,2H),0.80-0.93(m,1H),1.13-1.27(m,1H),1.72-1.93(m,2H),2.02-2.22(m,3H),2.40(d,J=7Hz,2H),2.55-2.63(m,1H),2.70-2.86(m,3H),3.01-3.17(m,3H),3.77(s,3H),4.87(br s,1H),6.69(d,J=9Hz,1H),6.80(s,1H),6.99(d,J=9Hz,1H).
(4bR,8aS,9R)-11-(シクロプロピルメチル)-8a-ヒドロキシ-3-メトキシ-8,8a,9,10-テトラヒドロ-5H-9,4b-(エピミノエタノ)フェナントレン-6(7H)-オン オキシムの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.17(m,2H),0.48-0.58(m,2H),0.79-0.90(m,1H),1.10-1.21(m,1H),1.50-1.67(m,2.3H),2.07-2.26(m,2.7H),2.33-2.42(m,2.7H),2.53-2.81(m,3.3H),2.98-3.14(m,2.3H),3.73(d,J=16Hz,0.7H),3.76(s,0.9H),3.77(s,2.1H),4.80(br s,1H),6.67-6.71(m,1H),6.84(d,J=3Hz,0.3H),6.92-7.02(m,2H),7.10(d,J=3Hz,0.7H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オン(異性体A)および(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-c]アゼピン-3(4H)-オン(異性体B)の混合物の合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.19(m,2H),0.46-0.57(m,2H),0.77-0.90(m,1H),0.93-1.01(m,0.3H),1.11-1.18(m,0.7H),1.50-1.61(m,1H),1.68-1.84(m,1H),1.98-2.19(m,2.3H),2.30-2.45(m,2H),2.54-2.67(m,1.7H),2.73-3.23(m,4H),3.45-3.53(m,1H),3.76(s,0.9H),3.79(s,2.1H),3.82-3.89(m,0.7H),4.06-4.15(m,0.3H),5.99(br s,0.7H),6.20(br s,0.3H),6.52(d,J=3Hz,0.3H),6.68-6.72(m,1H),6.96(d,J=8Hz,0.7H),7.01(d,J=8Hz,0.3H),7.14-7.16(m,0.7H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オール(異性体C)および(5aS,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-c]アゼピン-5a(1H)-オール(異性体D)の合成
(異性体C)
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.15(m,2H),0.46-0.55(m,2H),0.80-0.87(m,1H),1.04-1.11(m,1H),1.57(ddd,J=4,4,14Hz,1H),1.68-1.79(m,1H),1.96-2.08(m,3H),2.27-2.39(m,3H),2.49-2.56(m,1H),2.76-2.87(m,2H),2.89-3.03(m,4H),3.05-3.14(m,1H),3.78(s,3H),4.51(br s,1H),6.69-6.74(m,2H),7.02(d,J=8Hz,1H).
(異性体D)
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.16(m,2H),0.45-0.56(m,2H),0.77-0.91(m,1H),0.94-1.01(m,1H),1.46-1.72(m,3H),1.91(ddd,J=5,12,12Hz,1H),1,98(ddd,J=3,12,12Hz,1H),2.19-2.32(m,1H),2.34(dd,J=7,13Hz,1H),2.38(dd,J=6,13Hz,1H),2.53-2.61(m,1H),2.70(ddd,J=7,9,14Hz,1H),2.80(dd,J=6,18Hz,1H),2.91(d,J=6Hz,1H),2.94-3.02(m,1H),2.98(d,J=18Hz,1H),3.14(d,J=15Hz,1H),3.18(d,J=15Hz,1H),3.78(s,3H),4.65(br s,1H),6.73(dd,J=2,8Hz,1H),6.75(d,J=2Hz,1H),7.03(d,J=8Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオール(化合物E)および1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)エタン-1-オン(化合物F)の合成
(化合物E)
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.14(m,2H),0.47-0.55(m,2H),0.75-0.88(m,1H),1.04-1.14(m,1H),1.47-1.58(m,1H),1.70-1.82(m,1H),1.92-2.14(m,3H),2.15-2.27(m,1H),2.34(d,J=7Hz,2H),2.48-2.59(m,1H),2.67-2.86(m,3H),2.89(d,J=6Hz,1H),2.97(d,J=18Hz,1H),3.07(ddd,J=4,4,14Hz,1H),3.18(ddd,J=3,13,13Hz,1H),4.54(br s,1H),6.56(d,J=2Hz,1H),6.63(dd,J=2,8Hz,1H),6.92(d,J=8Hz,1H).
(化合物F)
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.18(m,2H),0.45-0.58(m,2H),0.75-2.41(m,13H),2.49-3.07(m,5H),3.22-3.98(m,2.3H),4.35(dd,J=5,15Hz,0.7H),6.45(dd,J=3,8Hz,0.3H),6.60(d,J=3Hz,0.3H),6.69(dd,J=3,8Hz,0.7H),6.86(d,J=8Hz,0.3H),6.95(d,J=8Hz,0.7H),7.00(d,J=2Hz,0.7H).
((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)(3-ヒドロキシピリジン-2-イル)メタノンの合成
1H-NMR(400MHz,CD3OD)δ(ppm):0.13-0.22(m,2H),0.50-0.61(m,2H),0.84-0.96(m,1H),0.98-1.05(m,0.5H),1.09-1.13(m,0.5H),1.49-1.56(m,0.5H),1.66-1.73(m,0.5H),1.93-2.23(m,4H),2.25-2.36(m,0.5H),2.38-2.59(m,2.5H),2.60-2.69(m,1H),2.78-2.89(m,1H),2.98-3.09(m,2H),3.31-3.45(m,1.5H),3.53-3.67(m,1H),3.74-3.83(m,0.5H),3.92-4.02(m,0.5H),4.07-4.15(m,0.5H),6.42(d,J=2Hz,0.5H),6.58(dd,J=2,8Hz,0.5H),6.62(dd,J=2,8Hz,0.5H),6.68(d,J=2Hz,0.5H),6.96(d,J=8Hz,0.5H),6.98(d,J=8Hz,0.5H),7.06-7.19(m,2H),7.69(d,J=4Hz,0.5H),7.74(d,J=4Hz,0.5H).
((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)(ピリミジン-2-イル)メタノンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.18(m,2H),0.41-0.58(m,2H),0.73-0.91(m,1H),0.98-1.16(m,1H),1.21-1.80(m,1H),1.84-2.12(m,4H),2.16-2.63(m,4H),2.71-3.07(m,3H),3.22-3.52(m,2H),3.60-3.83(m,3.5H),3.86-3.93(m,1H),4.24-4.34(m,0.5H),6.36(d,J=2Hz,0.5H),6.65-6.78(m,1.5H),6.99-7.08(m,1H),7.26-7.35(m,1H),8.73-8.82(m,2H).
((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)(ピリミジンピリジン-2-イル)メタノンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.18(m,2H),0.38-0.58(m,2H),0.71-0.94(m,1H),0.96-1.18(m,1H),1.19 -1.80(m,1H),1.83-2.12(m,3.5H),2.14-2.66(m,4.5H),2.67-3.04(m,3H),3.24-3.52(m,2H),3.69-3.82(m,0.5H),3.83-3.93(m,1H),4.23-4.38(m,0.5H),6.33(d,J=3Hz,0.5H),6.67-6.69(m,1H),6.78-6.84(m,0.5H),6.91-7.00(m,1H),7.28-7.34(m,1H),8.75-8.83(m,2H).
((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)(オキサゾール-2-イル)メタノンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.17(m,2H),0.45-0.56(m,2H),0.76-0.93(m,1H),1.03-1.15(m,1H),1.64-1.74(m,1H),1.93-2.14(m,3.6H),2.21(dd,J=5,16Hz,0.4H),2.28-2.68(m,4H),2.83(ddd,J=6,12,18Hz,1H),2.91-3.05(m,2H),3.43(dd,J=12,12Hz,0.4H),3.64(s,1.8H),3.67-3.84(m,1H),3.79(s,1.2H),3.96-4.04(m,0.6H),4.06-4.23(m,2H),6.46-6.55(m,0.6H)6.60-6.67(m,0.6H),6.69-6.74(m,0.8H),7.00(d,J=7Hz,0.6H),7.02(d,J=8Hz,0.4H),7.20(s,0.4H),7.22(s,0.6H),7.68(s,0.6H),7.71(s,0.4H).
((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)(オキサゾール-2-イル)メタノンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.17(m,2H),0.43-0.57(m,2H),0.73-0.93(m,1H),1.04-1.09(m,0.4H),1.13-1.19(m,0.6H),1.64-1.76(m,1H),1.93-2.14(m,4H),2.27-2.48(m,3H),2.49-2.62(m,1H),2.83(dd,J=6,9Hz,0.6H),2.78(dd,J=6,9Hz,0.4H),2.89-3.05(m,2H),3.40(dd,J=12,15Hz,0.6H),3.72-3.81(m,0.8H),3.98(ddd,J=4,4,14Hz,0.6H),4.03-4.21(m,0.8H),4.22-4.29(m,0.6H),4.31-4.40(m,0.6H),6.51(d,J=2Hz,0.4H),6.57(dd,J=2,8Hz,0.4H),6.70(dd,J=2,8Hz,0.6H),6.93(d,J=8Hz,0.4H),6.97(d,J=8Hz,0.6H),7.00(d,J=2Hz,0.6H),7.22(s,0.4H),7.24(s,0.6H),7.71(s,0.4H),7.77(s,0.6H).
((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)(ピリジン-3-イル)メタノンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.15(m,2H),0.48-0.55(m,2H),0.76-0.90(m,1H),0.97-1.02(m,0.7H),1.12-1.16(m,0.3H),1.49(ddd,J=4,,4,15Hz,0.3H),1.68-1.96(m,2.7H),2.02-2.12(m,2H),2.20-2.48(m,2.7H),2.50-2.60(m,1H),2.67-2.81(m,1H),2.82-2.87(m,0.3H),2.88-2.95(m,1H),2.96-3.04(m,1H),3.23-3.32(m,0.7H),3.47(s,2.1H),3.49-3.54(m,1.3H),3.60-3.69(m,0.7H),3.71-3.79(m,0.3H),3.80(s,0.9H),3.95-4.03(m,0.7H),4.14-4.21(m,0.3H),4.53(br s,1H),6.20(d,J=3Hz,0.7H),6.70(dd,J=3,8Hz,0.7H),6.72-6.77(m,0.6H),7.03(d,J=8Hz,0.7H),7.05(d,J=8Hz,0.3H),7.15-7.25(m,1.4H),7.28-7.32(m,0.3H),7.71(ddd,J=2,2,8Hz,0.3H),8.27-8.29(m,0.7H),8.58-8.61(m,1.3H).
((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)(ピリジン-3-イル)メタノンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.16(m,2H),0.47-0.55(m,2H),0.76-0.86(m,1H),0.97-1.04(m,0.7H),1.13-1.18(m,0.3H),1.49(ddd,J=3,3,15Hz,0.3H),1.69-1.77(m,1.4H),1.88-2.16(m,3.3H),2.20-2.41(m,2.7H),2.49-2.59(m,1H),2.70-2.87(m,1.3H),2.87-2.94(m,1H),2.95-3.04(m,1H),3.25-3.33(m,0.7H),3.38-3.47(m,1.3H),3.61-3.80(m,1H),4.05-4.11(m,1H),4.58(br s,1H),6.19(d,J=2Hz,0.7H),6.67(dd,J=2,8Hz,0.7H),6.68-6.70(m,0.3H),6.85(d,J=2Hz,0.3H),6.96(d,J=8Hz,0.7H),6.97(d,J=8Hz,0.3H),7.29-7.34(m,1H),7.41(ddd,J=2,2,8Hz,0.7H),7.73(ddd,J=2,2,8Hz,0.3H),8.01(d,J=1Hz,0.7Hz),8.50(dd,J=1,5Hz,0.7H),8.59-8.62(m,0.6H).
((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)(イミダゾ[1,2-a]ピリジン-3-イル)メタノンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.19(m,2H),0.44-0.61(m,2H),0.76-0.93(m,1H),1.02-1.19(m,1H),1.58-1.78(m,2H),1.90-2.14(m,3H),2.24-2.44(m,3H),2.47-2.59(m,1H),2.81-3.08(m,4H),3.39-3.56(m,1H),3.73-3.87(m,1H),3.91-4.05(m,1H),4.70-4.93(m,1H),6.38-6.50(m,1H),6.59(s,1H),6.86-7.02(m,2H),7.68(s,1H),8.26-8.39(m,1H),8.61(s,1H).
((5aS,6R,11bS)-3-ベンジル-14-(シクロプロピルメチル)-10-メトキシ-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
の合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.03(d,J=13Hz,1H),1.45-1.55(m,1H),1.80-1.90(m,2H),1.99(ddd,J=3,11,12Hz,1H),2.10(ddd,J=5,13,13Hz,1H),2.30-2.70(m,6H),2.75-2.90(m,2H),2.90-3.00(m,2H),3.00-3.10(m,1H),3.54(s,2H),3.68(s,3H),4.80(br s,1H),6.61(d、J=2Hz,1H),6.71(dd,J=2,8Hz,1H),7.00-7.10(m,3H),7.15-7.25(m,3H).
((5aS,6R,11bS)-3-ベンジル-14-(シクロプロピルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオール二塩酸塩の合成
1H-NMR(400MHz,CD3OD)δ(ppm):0.40-0.60(m,2H),0.70-1.00(m,4H),1.00-1.15(m,1H),1.20-1.45(m,2H),1.80-2.70(m,4H),2.80-3.00(m,1H),3.00-3.60(m,6H),3.60-3.90(m,2H),4.10-4.50(m,2H),6.61(s,1H),6.77(d,J=8Hz,1H),7.13(d,J=8Hz,1H),7.40-7.60(m,5H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-3-(ピリジン-2-イルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.17(m,2H),0.44-0.56(m,2H),0.78-0.91(m,1H),1.01-1.09(m,1H),1.51(ddd,J=2,5,14Hz,1H),1.81-1.97(m,2H),1.98-2.03(m,1H),2.10(ddd,J=5,13,13Hz,1H),2.34(dd,J=6.13Hz,1H),2.36(dd,J=6,13Hz,1H),2.44-2.59(m,3H),2.68(ddd,J=4,4,13Hz,1H),2.79-2.95(m,2H),2.95(d,J=6Hz,1H),2.99(d,J=18Hz,1H),3.19(ddd,J=2,12,14Hz,1H),3.68(s,3H),3.70(d,J=14Hz,1H),3.74(d,J=14Hz,1H),6.62(d,J=2Hz,1H),6.72(dd,J=2,8Hz,1H),6.92(d,J=8Hz,1H),7.02-7.06(m,1H),7.07(ddd,J=1,5,7Hz,1H),7.47(ddd,J=2,7,7Hz,1H),8.45(ddd,J=1,2,5Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(ピリジン-2-イルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.15(m,2H),0.42-0.57(m,2H),0.76-0.89(m,1H),0.91-1.00(m,1H),1.46(ddd,J=2,5,14Hz,1H),1.53(ddd,J=2,5,16Hz,1H),1.85(ddd,J=3,12,14Hz,1H),1.93-2.07(m,2H),2.28-2.40(m,3H),2.47-2.81(m,5H),2.88(d,J=6Hz,1H),2.93(d,J=18Hz,1H),3.22(ddd,J=1,11,13Hz,1H),3.76(s,2H),4.73(br s,1H),6.25(d,J=2Hz,1H),6.56(dd,J=2,8Hz,1H),6.90(d,J=8Hz,1H),7.12(ddd,J=1,5,8Hz,1H),7.16-7.21(m,1H),7.57(ddd,J=2,8,8Hz,1H),8.48(ddd,J=1,2,5Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-3-(ピリジン-4-イルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.17(m,2H),0.45-0.56(m,2H),0.78-0.91(m,1H),1.02-1.10(m,1H),1.49(ddd,J=2,5,14Hz,1H),1.77-1.84(m,1H),1.88(ddd,J=3,12,15Hz,1H),1.99(ddd,J=2,13,13Hz,1H),2.03(ddd,J=4,13,13Hz,1H),2.35(dd,J=6,13Hz,1H),2.35(dd,J=6,13Hz,1H),2.43(ddd,J=4,4,13Hz,1H),2.47-2.60(m,3H),2.85-2.95(m,1H),2.86(dd,J=6,18Hz,1H),2.94(d,J=6Hz,1H),3.00(d,J=18Hz,1H),3.11(ddd,J=1,11,13Hz,1H),3.51(d,J=15Hz,1H),3.56(d,J=15Hz,1H),3.69(s,3H),6.61(d,J=3Hz,1H),6.75(dd,J=3,8Hz,1H),6.86-6.91(m,2H),7.06(d,J=8Hz,1H),8.35-8.41(m,2H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(ピリジン-4-イルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.17(m,2H),0.44-0.57(m,2H),0.78-0.88(m,1H),1.00-1.07(m,1H),1.54(dd,J=4,14Hz,1H),1.65(ddd,J=2,5,16Hz,1H),1.98(ddd,J=3,12,14Hz,1H),1.99-2.10(m,2H),2.32-2.40(m,1H),2.33(dd,J=6,13Hz,1H),2.36(dd,J=6,13Hz,1H),2.45-2.61(m,3H),2.81-2.91(m,2H),2.94(d,J=6Hz,1H),2.97(d,J=18Hz,1H),3.19(dd,J=12,12Hz,1H),3.52 (d,J=15Hz,1H),3.66(d,J=15Hz,1H),6.48(d,J=2Hz,1H),6.70(dd,J=2,8Hz,1H),6.84-6.91(m,2H),6.96(d,J=8Hz,1H),8.30-8.42(m,2H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-3-(ピリミジン-2-イルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.16(m,2H),0.42-0.56(m,2H),0.79-0.92(m,1H),0.98-1.10(m,1H),1.48(ddd,J=2,5,14Hz,1H),1.84-2.03(m,3H),2.12(ddd,J=5,13,13Hz,1H),2.33-2.44(m,3H),2.56(ddd,J=2,5,12Hz,1H),2.73-2.84(m,2H),2.85-3.02(m,4H),3.32(ddd,J=3,11,13Hz,1H),3.75(s,3H),3.92(d,J=15Hz,1H),3.96(d,J=15Hz,1H),6.63(d,J=3Hz,1H),6.69(dd,J=3,8Hz,1H),7.00(d,J=8Hz,1H),7.13(t,J=5Hz,1H),8.68(d,J=5Hz,2H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(ピリミジン-2-イルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm): 0.05-0.14(m,2H),0.46-0.53(m,2H),0.78-0.92(m,1H),0.96-1.03(m,1H),1.47(ddd,J=2,5,15Hz,1H),1.75(dd,J=5,15Hz,1H),1.87(ddd,J=3,11,14Hz,1H),1.98(ddd,J=3,12,12Hz,1H),2.08(ddd,J=4,12,12Hz,1H),2.29-2.40(m,3H),2.55(dd,J=3,11Hz,1H),2.74(dd,J=5,18Hz,1H),2.80-2.98(m,5H),3.32(ddd,J=2,11,13Hz,1H),3.95(d,J=14Hz,1H),4.00(d,J=14Hz,1H),6.44(d,J=3Hz,1H),6.57(dd,J=3,8Hz,1H),6.89(d,J=8Hz,1H),7.15(t,J=5Hz,1H),8.69(d,J=5Hz,2H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(ピリミジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.15(m,2H),0.47-0.55(m,2H),0.76-0.92(m,1H),1.00-1.13(m,1H),1.53-1.66(m,1H),1.81(ddd,J=3,12,15Hz,0.4H),1.86-2.10(m,3.6H),2.18-2.24(m,1H),2.26-2.40(m,2H),2.50-2.63(m,1H),2.68-3.09(m,2.6H),2.74(ddd,J=6,16,16Hz,1H),3.33-3.45(m,1.4H),3.63-3.76(m,0.4H),3.84(d,J=15Hz,0.4H),3.90-4.01(m,1H),3.96(d,J=15Hz,0.4H),4.11(s,1.2H),4.26-4.35(m,0.6H),4.48(br s,1H),6.57-6.64(m,1.4H),6.83(d,J=2Hz,0.6H),6.91(d,J=8Hz,1H),7.17(t,J=5Hz,0.4H),7.18(t,J=5Hz,0.6H),8.67(d,J=5Hz,0.8H),8.70(d,J=5Hz,1.2H).
1-((5aS,6R,11bS)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(ピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.16(m,2H),0.43-0.56(m,2H),0.76-0.87(m,1H),1.00-1.12(m,1H),1.55(ddd,J=3,4,15Hz,0.5H),1.63(ddd,J=2,5,15Hz,0.5H),1.75(ddd,J=4,12,14Hz,0.5H),1.82(ddd,J=2,12,14Hz,0.5H),1.92-2.11(m,2.5H),2.12(ddd,J=2,5,16Hz,0.5H),2.24-2.40(m,2.5H),2.46(ddd,J=6,10,16Hz,0.5H),2.51-2.60(m,1H),2.70(dd,J=6,18Hz,0.5H),2.80(dd,J=6,18Hz,0.5H),2.86(d,J=6Hz,0.5H),2.92(d,J=6Hz,0.5H),2.96(d,J=18Hz,0.5H),2.98(d,J=18Hz,0.5H),3.23(ddd,J=2,12,14Hz,0.5H),3.48(ddd,J=4,4,13Hz,0.5H),3.53(ddd,J=2,12,14Hz,0.5H),3.57-3.67(m,1H),3.68(d,J=15Hz,0.5H),3.76(s,1.5H),3.78(s,1.5H),3.80-3.94(m,2.5H),4.10(ddd,J=3,6,15Hz,0.5H),4.47(br s,1H),6.63(d,J=2Hz,0.5H),6.66-6.73(m,1.5H),6.99(d,J=9Hz,0.5H),7.01(d,J=9Hz,0.5H),7.09-7.15(m,1.5H),7.18-7.22(m,0.5H),7.55(ddd,J=2,6,8Hz,0.5H),7.57(ddd,J=2,6,8Hz,0.5H),8.49(ddd,J=1,2,5Hz,0.5H),8.49(ddd,J=1,2,5Hz,0.5H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(ピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.15(m,2H),0.43-0.56(m,2H),0.75-0.88(m,1H),1.00-1.12(m,1H),1.53(ddd,J=4,4,15Hz,0.5H),1.59(ddd,J=1,5,15Hz,0.5H),1.72-2.07(m,3.5H),2.13(ddd,J=2,6,16Hz,0.5H),2.20-2.39(m,2.5H),2.47(dd,J=6,12Hz,0.5H),2.49-2.58(m,1H),2.65(dd,J=6,18Hz,0.5H),2.76(dd,J=6,19Hz,0.5H),2.83(d,J=6Hz,0.5H),2.90(d,J=6Hz,0.5H),2.92(d,J=19Hz,0.5H),2.95(d,J=18Hz,0.5H),3.28(ddd,J=2,12,14Hz,0.5H),3.32-3.43(m,1H),3.48(ddd,J=3,3,14Hz,0.5H),3.69(d,J=15Hz,0.5H),3.72-3.81(m,0.5H),3.78(d,J=15Hz,0.5H),3.82-3.94(m,1H),3.88(d,J=15Hz,0.5H),3.93(d,J=15Hz,0.5H),4.08(ddd,J=2,5,15Hz,0.5H),4.44(br s,0.5H),4.51(br s,0.5H),6.63(dd,J=2,8Hz,0.5H),6.64(dd,J=2,8Hz,0.5H),6.71(d,J=2Hz,0.5H),6.81(d,J=2Hz,0.5H),6.89(d,J=8Hz,0.5H),6.90(d,J=8Hz,0.5H),7.13(ddd,J=1,5,8Hz,0.5H),7.15-7.21(m,1H),7.22-7.26(m,0.5H),7.57(ddd,J=2,8,8Hz,0.5H),7.62(ddd,J=2,8,8Hz,0.5H),8.46-8.50(m,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(チオフェン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CD3Cl)δ(ppm):0.06-0.17(m,2H),0.45-0.55(m,2H),0.76-0.89(m,1H),1.01-1.13(m,1H),1.57-1.67(m,1H),1.76-1.85(m,1H),1.92-2.40(m,6H),2.52-2.61(m,1.5H),2.68-3.03(m,2.5H),3.11-3.18(m,0.5H),3.36-3.53(m,1.5H),3.60(dd,J=1,16Hz,0.5H),3.68-3.82(m,1H),3.78(s,3H),3.86-3.95(m,2H),4.11-4.20(m,0.5H),4.50(br s,1H),6.64(d,J=3Hz,0.5H),6.68-6.74(m,2H),6.78-6.80(m,0.5H),6.87-6.91(m,1H),6.99-7.02(m,1H),7.13-7.17(m,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-3-(2-(チオフェン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CD3Cl)δ(ppm):0.05-0.16(m,2H),0.44-0.58(m,2H),0.78-0.92(m,1H),1.05-1.08(m,1H),1.45-1.54(m,1H),1.76-2.14(m,5H),2.31-2.42(m,3H),2.48-2.60(m,2H),2.67-2.79(m,3H),2.80-3.02(m,5H),3.12-3.21(m,1H),3.77(s,3H),4.67(br s,1H),6.66-6.74(m,3H),6.82-6.87(m,1H),6.97-7.06(m,2H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(チオフェン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CD3Cl)δ(ppm):0.04-0.15(m,2H),0.45-0.53(m,2H),0.78-0.90(m,1H),0.99-1.07(m,1H),1.47-1.54(d,J=4,15Hz,1H),1.77-1.87(m,2H),1.97-2.08(m,2H),2.30-2.39(m,3H),2.48-2.58(m,1H),2.68-3.08(m,10H),3.21(dd,J=11,11Hz,1H),4.82(br s,1H),6.42(d,J=2Hz,1H),6.56(dd,J=2,8Hz,1H),6.77(d,J=3Hz,1H),6.87-6.91(m,2H),7.09(dd,J=1,5Hz,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(1H-ピラゾール-3-イル)エタン-1-オンの合成
の合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.55(m,2H),0.75-0.90(m,1H),1.01(d,J=10Hz,0.5H),1.10(d,J=13Hz,0.5H),1.50-2.40(m,7.5H),2.40-2.60(m,1.5H),2.72(ddd,J=4,12,12Hz,1H),2.80-3.00(m,2H),3.28(t,J=12Hz,1H),3.37(t,J=12Hz,0.5H),3.45-3.55(m,1H),3.60-4.00(m,3.5H),6.11(s,1H),6.55-6.70(m,1.5H),6.76(s,0.5H),6.87(d,J=8Hz,0.5H),6.91(d,J=8Hz,0.5H),7.44(s,0.5H),7.49(s,0.5H).
(5aS,6R,11bS)-3-(2-(1H-ピラゾール-3-イル)エチル)-14-(シクロプロピルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm): 0.00-0.15(m,2H),0.45-0.55(m,2H),0.75-0.90(m,1H),1.00-1.15(m,1H),1.20-1.40(m,2H),1.57(d,J=14Hz,1H),1.80-2.00(m,1H),2.00-2.10(m,3H),2.20-2.40(m,3H),2.40-3.10(m,9H),3.16(ddd,J=7,19,19Hz,1H),5.98(s,1H),6.67(d,J=8Hz,1H),6.73(s,1H),6.97(d,J=8Hz,1H),7.43(s,1H).
(E)-1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-3-(フラン-3-イル)プロプ-2-エン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.18(m,2H),0.43-0.58(m,2H),0.76-0.90(m,1H),1.04-1.09(m,0.2H),1.16-1.23(m,0.8H),1.61-1.71(m,1H),1.83-2.48(m,7H),2.55(dd,J=4,12Hz,1H),2.79(dd,J=6,18Hz,1H),2.88-2.96(m,1.2H),2.99-3.10(m,1.6H),3.48(ddd,J=3,3,12Hz,0.8H),3.52-3.68(m,0.4H),3.76-3.85(m,0.2H),3.91(ddd,J=3,3,14Hz,0.2H),4.11(ddd,J=3,12,12Hz,0.8H),4.51(dd,J=6,14Hz,0.8H),6.51(d,J=16Hz,0.2H),6.55(dd,J=3,8Hz,0.2H),6.57(s,0.8H),6.64(d,J=15Hz,0.8H),6.65-6.68(m,0.2H),6.71(dd,J=2,8Hz,0.8H),6.89(d,J=8Hz,0.2H),6.97(d,J=8Hz,0.8H),7.10-7.15(m,0.8H),7.24-7.32(m,0.4H),7.38(s,0.2H),7.40(s,0.8H),7.54(d,J=15Hz,0.8H),7.55(s,0.2H),7.65(s,0.8H).
((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)(フェニル)メタノンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.17(m,2H),0.45-0.58(m,2H),0.75-0.91(m,1H),0.96-1.02(m,0.7H),1.10-1.16(m,0.3H),1.46(ddd,J=3,3,14Hz,0.3H),1.71(dd,J=4,14Hz,0.7H),1.74-2.14(m,3.7H),2.21(dd,J=5,15Hz,0.3H),2.27-2.61(m,3.3H),2.69(ddd,J=6,12,17Hz,0.7H),2.76(dd,J=6,18Hz,0.3H),2.83-3.04(m,2.7H),3.26-3.36(m,0.6H),3.40-3.67(m,2.1H),3.42(s,2.1H),3.71-3.82(m,0.3H),3.80(s,0.9H),4.01(ddd,J=2,4,14Hz,0.7H),4.17(ddd,J=1,5,14Hz,0.3H),6.20(d,J=2Hz,0.7H),6.66-6.78(m,1.3H),6.92-6.98(m,1.3H),7.02(d,J=8Hz,0.7H),7.04(d,J=8Hz,0.3H),7.24-7.40(m,3.7H).
((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)(フェニル)メタノンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.15(m,2H),0.42-0.55(m,2H),0.74-0.92(m,1H),0.93-1.00(m,0.4H),1.15-1.23(m,0.6H),1.48(ddd,J=4,4,15Hz,0.6H),1.66-1.79(m,0.8H),1.88-2.13(m,3.4H),2.26-2.66(m,4.4H),2.73(dd,J=6,18Hz,0.6H),2.79-3.04(m,2.4H),3.24-3.36(m,1.2H),3.38-3.60(m,1H),3.81(ddd,J=4,13,13Hz,0.6H),3.93-4.01(m,0.4H),4.29-4.38(m,0.6H),6.20(d,J=2Hz,0.4H),6.61(dd,J=2,8Hz,0.4H),6.65(dd,J=2,8Hz,0.6H),6.94(d,J=8Hz,0.6H),6.95(d,J=8Hz,0.4H),6.97-7.02(m,0.6H),7.06(d,J=2Hz,0.6H),7.29-7.45(m,4.4H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(チアゾール-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.17(m,2H),0.45-0.56(m,2H),0.77-0.92(m,1H),0.97-1.08(m,1H),1.17-1.73(m,1H),1.76-1.93(m,2H),1.94-2.11(m,2H),2.28-3.00(m,12H),3.01-3.23(m,3H),4.64(br s,1H),6.53-6.59(m,1H),6.61(dd,J=3,8Hz,1H),6.93(d,J=8Hz,1H),7.09(d,J=3Hz,1H),7.61(d,J=4Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(フラン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.04(d,J=11Hz,1H),1.40-1.60(m,1H),1.80-1.95(m,2H),1.95-2.10(m,3H),2.20-2.40(m,3H),2.50-2.60(m,1H),2.70-3.00(m,10H),3.20-3.45(m,1H),5.96(d,J=3Hz,1H),6.20-6.25(m,1H),6.50-6.55(m,1H),6.58(dd,J=3,8Hz,1H),6.90(d,J=8Hz,1H)
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(チアゾール-4-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm): 0.04-0.14(m,2H),0.43-0.56(m,2H),0.76-0.87(m,1H),1.01-1.15(m,1H),1.53-1.65(m,1H),1.77-2.10(m,3H),2.16-2.40(m,3H),2.48-2.60(m,1.4H),2.69(dd,J=6,18Hz,0.6H),2.77(dd,J=6,18Hz,0.4H),2.86(d,J=6Hz,0.6H),2.91(d,J=6Hz,0.4H),2.92(d,J=18Hz,0.4H),2.97(d,J=18Hz,0.6H),3.12-3.30(m,1.4H),3.37-3.46(m,0.6H),3.49(ddd,J=4,4,13Hz,0.6H),3.67(d,J=16Hz,0.4H),3.72-3.83(m,0.4H),3.84(d,J=16Hz,0.4H),3.85-3.99(m,1H),3.90(d,J=16Hz,0.6H),4.00(d,J=16Hz,0.6H),4.11-4.19(m,0.6H),6.61(dd,J=3,8Hz,0.4H),6.63-6.68(m,1H),6.85(d,J=3Hz,0.6H),6.90(d,J=8Hz,0.4H),6.92(d,J=8Hz,0.6H),7.07-7.11(m,1H),8.73(d,J=2Hz,0.6H),8.74(d,J=2Hz,0.4H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(チアゾール-4-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.16(m,2H),0.42-0.56(m,2H),0.76-0.88(m,1H),0.98-1.08(m,1H),1.49(dd,J=5,14Hz,1H),1.75-1.86(m,2H),1.94-2.08(m,2H),2.28-2.41(m,3H),2.49-2.58(m,1H),2.68-2.80(m,2H),2.73(dd,J=6,18Hz,1H),2.85-3.05(m,7H),3.16(dd,J=12,12Hz,1H),4.72(br s,1H),6.46(s,1H),6.59(d,J=8Hz,1H),6.84(s,1H),6.89(d,J=8Hz,1H),8.68(s,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(1-メチル-5-(トリフルオロメチル)-1H-ピラゾール-3-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.20(m,2H),0.45-0.61(m,2H),0.76-0.92(m,1H),1.01-1.10(m,1H),1.21-1.91(m,2.5H),1.93-2.44(m,5.5H),2.47-2.62(m,1.5H),2.69-3.07(m,3H),3.08-3.20(m,0.5H),3.36-3.97(m,10.5H),4.06-4.17(m,0.5H),6.41(s,0.5H),6.54(s,0.5H),6.62-6.75(m,2H),6.97-7.06(m,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(1-メチル-5-(トリフルオロメチル)-1H-ピラゾール-3-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.18(m,2H),0.47-0.59(m,2H),0.75-0.94(m,1H),0.99-1.17(m,1H),1.22-2.40(m,8H),2.47-2.64(m,1.4H),2.66-2.83(m,1H),2.84-3.07(m,2H),3.09-3.27(m,0.6H),3.35-3.59(m,2H),3.62-3.81(m,1.6H),3.83-4.01(m,4H),4.07-4.22(m,0.4H),4.38-4.57(m,1H),6.45(s,0.4H),6.53(s,0.6H),6.56-6.67(m,1.4H),6.79(d,J=2Hz,0.6H),6.88-6.97(m,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(1-メチル-5-(トリフルオロメチル)-1H-ピラゾール-3-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.18(m,2H),0.41-0.57(m,2H),0.74-0.91(m,1H),0.97-2.15(m,6H),2.26-2.42(m,3H),2.45-2.60(m,1H),2.67-3.02(m,10H),3.10-3.25(m,1H),3.88(s,3H),4.74(br s,1H),6.35(s,1H),6.45(d,J=2Hz,1H),6.55(dd,J=2,8Hz,1H),6.89(d,J=8Hz,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(1H-イミダゾール-4-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.17(m,2H),0.46-0.58(m,2H),0.77-0.90(m,1H),1.01-1.17(m,1H),1.48-3.19(m,13H),3.36-4.82(m,8H),6.56-6.88(m,3H),6.97-7.09(m,1H),7.48-7.54(m,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(1H-イミダゾール-4-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.15(m,2H),0.43-0.55(m,2H),0.72-0.89(m,1H),0.98-1.13(m,1H),1.51-1.64(m,1H),1.69-3.00(m,11H),3.23-3.91(m,6H),6.56-6.69(m,3H),6.85(d,J=8Hz,0.6H),6.97(d,J=8Hz,0.4H),7.37(s,0.6H),7.40(s,0.4H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(1-メチル-1H-イミダゾール-4-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.15(m,2H),0.45-0.54(m,2H),0.73-0.92(m,1H),0.99-1.14(m,1H),1.51-1.65(m,1H),1.71-2.60(m,8H),2.73(ddd,J=2,8,8Hz,1H),2.82-3.03(m,2H),3.14-3.25(m,0.4H),3.28-3.99(m,8.2H),4.04-4.17(m,0.4H),6.63(dd,J=3,8Hz,0.6H),6.67(dd,J=3,8Hz,0.4H),6.70-6.77(m,1.6H),6.82(d,J=3Hz,0.4H),6.87(d,J=8Hz,0.6H),6.91(d,J=8Hz,0.4H),7.31(s,0.4H),7.36(s,0.6H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(1-メチル-1H-イミダゾール-4-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.15(m,2H),0.41-0.58(m,2H),0.72-1.56(m,3H),1.74-2.12(m,4H),2.24-2.39(m,3H),2.47-2.58(m,1H),2.66-3.02(m,10H),3.17-3.30(m,1H),3.58(s,3H),6.51(s,1H),6.54(s,1H),6.60(d,J=8Hz,1H),6.87(d,J=8Hz,1H),7.29(s,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(1H-ピラゾール-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.55(m,2H),0.75-0.90(m,1H),1.00-1.15(m,1H),1.50-1.70(m,2H),1.75-1.90(m,1H),1.90-2.40(m,3H),2.50-2.65(m,1.4H),2.70-3.10(m,4.6H),3.30-3.60(m,1.4H),3.60-3.70(m,0.6H),3.75-3.95(m,4.6H),4.10-4.20(m,0.4H),4.49(br s,1H),4.59(d,J=16Hz,0.6H),4.80-5.05(m,1.4H),6.20-6.30(m,1H),6.65-6.80(m,2H),7.00-7.10(m,1H),7.40-7.55(m,2H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(1H-ピラゾール-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.13(m,2H),0.47-0.54(m,2H),0.76-0.86(m,1H),1.03-1.10(m,1H),1.52-1.63(m,1H),1.76-2.25(m,4.5H),2.26-2.39(m,2H),2.50-2.65(m,1.5H),2.68-2.79(m,1H),2.86-2.95(m,1.5H),2.98(d,J=18Hz,0.5H),3.09-3.19(m,0.5H),3.25-3.39(m,1.5H),3.62-3.73(m,0.5H),3.81-3.89(m,1H),4.01-4.09(m,0.5H),4.52(br s,1H),4.66(d,J=16Hz,0.5H),4.81(d,J=16Hz,0.5H),4.95(d,J=16Hz,0.5H),4.99(d,J=16Hz,0.5H),6.26-6.29(m,1H),6.62-6.68(m,2H),6.90-6.95(m,1H),7.33(dd,J=2,2Hz,0.5H),7.41(d,J=2Hz,0.5H),7.55(dd,J=2,4Hz,1H).
(5aS,6R,11bS)-3-(2-(1H-ピラゾール-1-イル)エチル)-14-(シクロプロピルメチル)-10-メトキシ-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.55(m,2H),0.75-0.90(m,1H),1.03(d,J=13Hz,1H),1.40-1.50(m,1H),1.75(ddd,J=3,11,14Hz,1H),1.86(ddd,J=4,4,12Hz,1H),1.90-2.10(m,2H),2.34(d,J=6Hz,2H),2.40-2.50(m,2H),2.50-2.60(m,1H),2.64(dt,J=13,4Hz,1H),2.70-2.90(m,3H),2.90-3.00(m,3H),3.14(ddd,J=1,11,12Hz,1H),3.76(s,3H),4.00-4.10(m,2H),4.59(br s,1H),6.04(t,J=2Hz,1H),6.68(d,J=2Hz,1H),6.72(dd,J=2,8Hz,1H),6.91(d,J=2Hz,1H),7.03(d,J=8Hz,1H),7.40(d,J=2Hz,1H).
(5aS,6R,11bS)-3-(2-(1H-ピラゾール-1-イル)エチル)-14-(シクロプロピルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.55(m,2H),0.75-0.85(m,1H),1.00(d,J=11Hz,1H),1.44(dd,J=3,15Hz,1H),1.70-1.85(m,2H),1.90-2.10(m,3H),2.30-2.45(m,3H),2.45-2.55(m,2H),2.61(dt,J=13,4Hz,1H),2.75(dd,J=6,18Hz,1H),2.80-3.00(m,4H),3.10-3.20(m,1H),4.05-4.15(m,2H),6.09(t,J=2Hz,1H),6.55(d,J=2Hz,1H),6.61(dd,J=2,8Hz,1H),6.93(d,J=8Hz,1H),7.05(d,J=2Hz,1H),7.41(d,J=2Hz,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(3-メチル-1H-ピラゾール-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.07(d,J=12Hz,1H),1.50-1.65(m,1H),1.70-2.40(m,9.4H),2.50-2.80(m,2.6H),2.80-3.15(m,2.6H),3.20-3.40(m,1.4H),3.60-3.75(m,0.6H),3.75-3.90(m,1H),4.00-4.15(m,0.4H),4.53(br s,1H),4.60(d,J=16Hz,0.6H),4.70(d,J=16Hz,0.6H),4.85(d,J=16Hz,0.4H),4.90(d,J=16Hz,0.4H),6.05(s,1H),6.60-6.70(m,2H),6.85-7.00(m,1H),7.20-7.35(m,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(3-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.03(d,J=11Hz,1H),1.48(dd,J=8.14Hz,1H),1.70-1.85(m,2H),1.90-2.10(m,2H),2.23(s,3H),2.30-2.45(m,3H),2.50-2.70(m,3H),2.70-3.00(m,6H),3.10-3.25(m,1H),3.95-4.10(m,2H),5.88(d,J=2Hz,1H),6.55(d,J=2Hz,1H),6.62(dd,J=2,8Hz,1H),6.93(d,J=8Hz,1H),6.99(s,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(4-メチル-1H-ピラゾール-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.15(m,2H),0.47-0.55(m,2H),0.77-0.88(m,1H),1.04-1.12(m,1H),1.56-1.63(m,1H),1.77-1.87(m,1H),1.92-2.02(m,1.5H),2.04(s,1.5H),2.07(s,1.5H),2.09-2.22(m,1.5H),2.27-2.40(m,2H),2.52-2.62(m,1H),2.713.00(m,3.5H),3.02-3.10(m,0.5H),3.35(ddd,J=4,4,13Hz,0.5H),3.39-3.47(m,0.5H),3.48-3.54(m,0.5H),3.59-3.72(m,0.5H),3.77(s,1.5H),3.79(s,1.5H),3.80-3.91(m,1.5H),4.10-4.17(m,0.5H),4.51(d,J=16Hz,0.5H),4.83(d,J=16Hz,0.5H),4.87(d,J=16Hz,0.5H),4.93(d,J=16Hz,0.5H),6.67(d,J=6Hz,0.5H),6.68(d,J=6Hz,0.5H),6.70-6.75(m,1H),7.01-7.05(m,1.5H),7.20(s,0.5H),7.27(s,0.5H),7.30(s,0.5H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(4-メチル-1H-ピラゾール-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.14(m,2H),0.48-0.54(m,2H),0.77-0.86(m,1H),1.02-1.11(m,1H),1.55-1.62(m,1H),1.75-1.88(m,1.5H),1.91-2.08(m,2.5H),2.04(s,1.5H),2.06(s,1.5H),2.10-2.40(m,3.5H),2.50-2.65(m,1.5H),2.85-3.00(m,2H),3.09-3.16(m,0.5H),3.22-3.30(m,1H),3.31-3.39(m,0.5H),3.64-3.74(m,0.5H),3.78-3.87(m,1H),4.00-4.07(m,0.5H),4.56(d,J=16Hz,0.5H),4.74(d,J=16Hz,0.5H),4.86(d,J=16Hz,0.5H),4.91(d,J=16Hz,0.5H),6.62-6.68(m,2H),6.90-6.95(m,1H),7.11(s,0.5H),7.16(s,0.5H),7.29(m,0.5H),7.30(s,0.5H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.55(m,2H),0.75-0.90(m,1H),1.02(d,J=11Hz,1H),1.45(dd,J=3,14Hz,1H),1.70-1.85(m,2H),1.90-2.10(m,2H),2.00(s,3H),2.30-2.40(m,3H),2.50-2.70(m,3H),2.75(dd,J=6,18Hz,1H),2.80-3.00(m,5H),3.13-3.25(m,1H),4.00-4.15(m,2H),6.54(d,J=3Hz,1H),6.61(dd,J=3,8Hz,1H),6.85-6.95(m,2H),7.24(s,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(5-メチル-1H-ピラゾール-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.55(m,2H),0.80-0.90(m,1H),1.06(d,J=11Hz,1H),1.50-1.90(m,3H),1.90-2.10(m,2H),2.01(s,1.2H),2.08(s,1.8H),2.20-2.40(m,4H),2.50-2.80(m,2H),2.80-3.00(m,1.6H),3.15-3.50(m,1.4H),3.60-4.00(m,2H),4.53(d,J=16Hz,0.6H),4.72(d,J=16Hz,0.6H),4.85(d,J=16Hz,0.4H),4.90(d,J=16Hz,0.4H),5.99(s,0.4H),6.02(s,0.6H),6.60-6.75(m,2H),6.90-7.00(m,1H),7.38(s,0.4H),7.41(s,0.6H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(5-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
を得た。
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.55(m,2H),0.75-0.90(m,1H),1.02(d,J=10Hz,1H),1.40-1.50(m,1H),1.75-1.90(m,2H),1.95-2.10(m,3H),2.20(s,3H),2.20-2.40(m,3H),2.50-2.80(m,4H),2.80-3.00(m,4H),3.15-3.35(m,1H),4.07(t,J=8Hz,2H),5.95(s,1H),6.54(s,1H),6.60-6.65(m,1H),6.91(d,J=8Hz,1H),7.36(s,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(3-(トリフルオロメチル)-1H-ピラゾール-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.55(m,2H),0.75-0.90(m,1H),1.05-1.15(m,1H),1.50-2.40(m,7H),2.50-2.70(m,1.5H),2.70-2.85(m,1.5H),2.85-3.05(m,2H),3.05-3.15(m,0.5H),3.30-3.50(m,1.5H),3.60-3.75(m,0.5H),3.80-3.90(m,1H),4.00-4.15(m,0.5H),4.72(d,J=16Hz,0.5H),4.89(d,J=16Hz,0.5H),5.01(d,J=16Hz,0.5H),5.02(d,J=16Hz,0.5H),,6.51(d,J=2Hz,0.5H),6.54(d,J=2Hz,0.5H),6.60-6.70(m,2H),6.95(s,0.5H),6.97(s,0.5H),7.37(d,J=1Hz,0.5H),7.50(d,J=1Hz,0.5H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(3-(トリフルオロメチル)-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.55(m,2H),0.70-1.00(m,1H),1.02(d,J=13Hz,1H),1.40-1.55(m,1H),1.65-1.85(m,2H),1.90-2.10(m,2H),2.30-2.65(m,6H),2.75-3.05(m,6H),3.05-3.20(m,1H),4.00-4.15(m,2H),6.26(s,1H),6.60-6.70(m,2H),6.86(s,1H),6.98(d,J=8Hz,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(3,5-ジメチル-1H-ピラゾール-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.55(m,2H),0.80-0.90(m,1H),1.00-1.10(m,1H),1.45-1.70(m,1.6H),1.75-1.90(m,1.4H),1.90-2.40(m,4.6H),1.94(s,1.2H),2.01(s,1.8H),2.17(s,1.2H),2.22(s,1.8H),2.45-3.00(m,4.4H),3.15-3.45(m,2H),3.60-4.00(m,2H),4.47(d,J=16Hz,0.6H),4.62(d,J=16Hz,0.6H),4.75(d,J=16Hz,0.4H),4.82(d,J=16Hz,0.4H),5.77(s,0.4H),5.80(s,0.6H),6.60-6.70(m,2H),6.85-6.95(m,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(3,5-ジメチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
を得た。
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.55(m,2H),0.70-0.90(m,1H),1.00-1.10(m,1H),1.40-1.50(m,1H),1.70-1.90(m,2H),1.95-2.10(m,2H),2.14(s,3H),2.19,(s,3H),2.20-2.40(m,3H),2.50-2.60(m,1H),2.60-3.00(m,8H),3.20-3.30(m,1H),4.00(t,J=7Hz,2H),5.74(s,1H),6.53(s,1H),6.61(d,J=8Hz,1H),6.90(d,J=8Hz,1H).
2-(3,5-ビス(ジフルオロメチル)-1H-ピラゾール-1-イル)-1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.10(d,J=12Hz,1H),1.75-1.90(m,1H),1.90-2.40(m,6H),2.50-3.10(m,5H),3.15-3.25(m,0.5H),3.30-3.55(m,1.5H),3.65-3.75(m,0.5H),3.80-3.90(m,1H),3.95-4.05(m,0.5H),4.72(d,J=16Hz,0.5H),4.98(d,J=16Hz,0.5H),5.00(d,J=16Hz,0.5H),5.15(d,J=16Hz,0.5H),6.40-6.80(m,5H),6.90-7.00(m,1H).
(5aS,6R,11bS)-3-(2-(3,5-ビス(ジフルオロメチル)-1H-ピラゾール-1-イル)エチル)-14-(シクロプロピルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.00(d,J=10Hz,1H),1.40-1.50(m,1H),1.65-2.10(m,4H),2.20-2.40(m,2H),2.45-2.60(m,2H),2.62(ddd,J=4,5,13Hz,1H),2.75(dd,J=6,8Hz,1H),2.80-3.00(m,5H),3.18(ddd,J=2,12,12Hz,1H),3.55-3.80(m,1H),4.16(t,J=6Hz,2H),6.50-6.90(m,5H),6.93(d,J=8Hz,1H).
2-(4-ブロモ-1H-ピラゾール-1-イル)-1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.00-1.15(m,1H),1.55-1.65(m,1H),1.75-2.40(m,7H),2.50-3.10(m,4.5H),3.30-3.55(m,1.5H),3.60-3.75(m,0.5H),3.75-3.90(m,1H),3.78(s,1.5H),3.79(s,1.5H),4.10-4.20(m,0.5H),4.40-4.60(br s,1H),4.54(d,J=16Hz,0.5H),4.84(d,J=16Hz,0.5H),4.94(d,J=16Hz,0.5H),4.94(d,J=16Hz,0.5H),6.65-6.70(m,1H),6.70-6.75(m,1H),7.00-7.05(m,1H),7.25(s,0.5H),7.42(s,0.5H),7.45(s,0.5H),7.47(s,0.5H).
2-(4-ブロモ-1H-ピラゾール-1-イル)-1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.00-1.15(m,1H),1.50-1.70(m,1H),1.70-2.45(m,7H),2.50-2.85(m,2H),2.85-3.00(m,2H),3.12-3.22(m,0.5H),3.30-3.45(m,1.5H),3.65-3.75(m,0.5H),3.75-3.90(m,1H),3.95-4.05(m,0.5H),4.61(d,J=16Hz,0.5H),4.79(d,J=16Hz,0.5H),4.92(s,1H),6.60-6.70(m,2H),6.90-7.00(m,1H),7.33(s,0.5H),7.43(s,1H),7.46(s,0.5H).
(5aS,6R,11bS)-3-(2-(4-ブロモ-1H-ピラゾール-1-イル)エチル)-14-(シクロプロピルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.65(m,2H),0.75-0.90(m,1H),1.02(d,J=10Hz,1H),1.40-1.50(m,1H),1.65-1.85(m,2H),1.90-2.10(m,2H),2.25-2.40(m,3H),2.40-2.60(m,3H),2.70-3.20(m,7H),3.80-3.95(m,1H),3.95-4.05(m,1H),6.60-6.70(m,2H),6.71(s,1H),7.03(d,J=8Hz,1H),7.35(s,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(1H-イミダゾール-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.10-1.25(m,2H),1.80-2.00(m,2.8H),2.00-2.15(m,2.2H),2.25-2.45(m,2H),2.50-2.65(m,0.8H),2.70-2.95(m,3.2H),3.00-3.10(m,0.2H),3.13-3.22(m,0.8H),3.25-3.35(m,0.2H),3.40(dd,J=8,14Hz,0.8H),3.70-3.80(m,0.2H),3.85-4.05(m,1.8H),4.43(d,J=16Hz,0.8H),4.67(d,J=16Hz,0.2H),4.75-4.90(m,1H),6.57(d,J=2Hz,0.2H),6.65-6.75(m,1H),6.81(dd,J=2,8Hz,0.8H),6.85-6.95(m,1.8H),6.95-7.05(m,1.2H),7.35(s,0.8H),7.48(s,0.2H).
(5aS,6R,11bS)-3-(2-(1H-イミダゾール-1-イル)エチル)-14-(シクロプロピルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.55(m,2H),0.70-0.90(m,1H),1.04(d,J=10Hz,1H),1.51(dd,J=5,14Hz,1H),1.65-1.75(m,1H),1.82(ddd,J=3,11,14Hz,1H),1.95-2.05(m,2H),2.30-2.45(m,3H),2.45-2.55(m,3H),2.60-2.75(m,2H),2.80-3.00(m,4H),3.08-3.18(m,1H),3.78(t,J=6Hz,2H),6.60(s,1H),6.64(d,J=3Hz,1H),6.73(dd,J=3,8Hz,1H),6.91(s,1H),6.97(d,J=8Hz,1H),7.08(s,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(2H-1,2,3-トリアゾール-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.55(m,2H),0.75-0.90(m,1H),1.00-1.10(m,1H),1.50-1.70(m,1H),1.75-1.85(m,0.4H),1.90-2.20(m,3.6H),2.25-2.45(m,2H),2.50-2.70(m,1.4H),2.70-3.10(m,4.6H),3.20-3.35(m,0.4H),3.35-3.50(m,0.6H),3.60-3.70(m,0.4H),3.76(s,1.8H),3.81(s,1.2H),3.85-3.95(m,1H),4.20-4.30(m,0.6H),4.50(br s,1H),4.94(d,J=16Hz,0.4H),5.19(d,J=16Hz,0.4H),5.28(d,J=16Hz,0.6H),5.38(d,J=16Hz,0.6H),6.60-6.80(m,2H),7.00-7.10(m,1H),7.61(s,0.8H),7.66(s,1.2H).
(5aS,6R,11bS)-3-(2-(2H-1,2,3-トリアゾール-2-イル)エチル)-14-(シクロプロピルメチル)-10-メトキシ-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
を得た。
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.55(m,2H),0.75-0.90(m,1H),1.02(d,J=11Hz,1H),1.40-1.50(m,1H),1.70-2.10(m,4H),2.20-2.40(m,3H),2.50-2.60(m,2H),2.65-3.10(m,7H),3.11-3.23(m,1H),3.77(s,3H),4.35-4.50(m,2H),6.63(d,J=2Hz,1H),6.68(dd,J=2,8Hz,1H),6.98(d,J=8Hz,1H),7.52(s,2H).
(5aS,6R,11bS)-3-(2-(2H-1,2,3-トリアゾール-2-イル)エチル)-14-(シクロプロピルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.55(m,2H),0.75-0.90(m,1H),1.03(d,J=11Hz,1H),1.20-1.30(m,1H),1.40-1.50(m,1H),1.70-1.90(m,2H),1.90-2.10(m,3H),2.20-2.40(m,4H),2.50-3.25(m,7H),4.40-4.60(m,2H),6.51(d,J=2Hz,1H),6.59(dd,J=2,8Hz,1H),6.91(d,J=8Hz,1H),7.54(s,2H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-3-(ピリジン-2-イル)プロパン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.16(m,2H),0.45-0.57(m,2H),0.76-0.88(m,1H),1.01-1.12(m,1H),1.54-1.65(m,1H),1.78(ddd,J=2,12,15Hz,0.5H),1.87(ddd,J=4,12,16Hz,0.5H),1.91-2.23(m,3.5H),2.29(dd,J=6,12Hz,0.5H),2.30-2.40(m,1.5H),2.41-2.60(m,2H),2.66-3.18(m,7H),3.34(ddd,J=4,4,14Hz,0.5H),3.39-3.49(m,0.5H),3.50(ddd,J=4,4,14Hz,0.5H),3.61-3.73(m,0.5H),3.70(s,1.5H),3.77(s,1.5H),3.80-3.92(m,1H),4.17(ddd,J=3,5,15Hz,0.5H),4.48(br s,1H),6.63(d,J=2Hz,0.5H),6.64-6.73(m,1.5H),7.00(d,J=8Hz,0.5H),7.01(d,J=8Hz,0.5H),7.04-7.10(m,1H),7.13(d,J=8Hz,0.5H),7.20(d,J=8Hz,0.5H),7.51-7.59(m,1H),8.46-8.51(m,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-3-(3-(ピリジン
-2-イル)プロピル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.16(m,2H),0.44-0.55(m,2H),0.79-0.91(m,1H),1.00-1.09(m,1H),1.50(ddd,J=3,5,15Hz,1H),1.74-2.03(m,5H),2.09(ddd,J=5,13,13Hz,1H),2.29-2.52(m,6H),2.55(ddd,J=2,6,11Hz,1H),2.59-2.69(m,3H),2.75-2.86(m,2H),2.95(d,J=6Hz,1H),2.98(d,J=18Hz,1H),3.09(ddd,J=2,10,13Hz,1H),3.76(s,3H),6.64-6.71(m,2H),6.97-7.01(m,1H),7.00(d,J=8Hz,1H),7.06(ddd,J=1,5,7Hz,1H),7.54(ddd,J=2,7,7Hz,1H),8.49(ddd,J=1,2,5Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(3-(ピリジン-2-イル)プロピル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm): 0.06-0.17(m,2H),0.45-0.55(m,2H),0.77-0.88(m,1H),0.97-1.07(m,1H),1.47(ddd,J=1,6,14Hz,1H),1.73-1.90(m,4H),1.95-2.09(m,3H),2.32-2.68(m,9H),2.76(dd,J=6,18Hz,1H),2.90(d,J=6Hz,1H),2.94-3.08(m,2H),2.95(d,J=18Hz,1H),4.73(br s,1H),6.59(dd,J=2,8Hz,1H),6.62(d,J=2Hz,1H),6.89(d,J=8Hz,1H),7.07-7.12(m,1H),7.11(dd,J=5,8Hz,1H),7.58(ddd,J=2,8,8Hz,1H),8.48-8.51(m,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-3-(ピリジン-3-イル)プロパン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.16(m,2H),0.46-0.57(m,2H),0.77-0.88(m,1H),1.01-1.12(m,1H),1.57(ddd,J=3,3,14Hz,0.5H),1.63(ddd,J=2,5,15Hz,0.5H),1.78(ddd,J=2,12,14Hz,0.5H),1.84-2.23(m,4.5H),2.24-2.86(m,7H),2.87-3.05(m,3.5H),3.24(ddd,J=4,4,13Hz,0.5H),3.32-3.43(m,1H),3.65-3.76(m,0.5H),3.70(s,1.5H),3.79(s,1.5H),3.83(ddd,J=3,13,13Hz,0.5H),3.91(ddd,J=3,4,14Hz,0.5H),4.22(ddd,J=2,5,14Hz,0.5H),6.62(d,J=2Hz,0.5H),6.67(dd,J=2,8Hz,0.5H),6.69-6.74(m,1H),7.01(d,J=8Hz,0.5H),7.03(d,J=8Hz,0.5H),7.18(dd,J=5,8Hz,1H),7.45(ddd,J=2,2,8Hz,0.5H),7.53(ddd,J=2,2,8Hz,0.5H),8.38-8.49(m,2H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-3-(3-(ピリジン-3-イル)プロピル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.16(m,2H),0.45-0.56(m,2H),0.79-0.91(m,1H),1.02-1.09(m,1H),1.51(ddd,J=3,4,14Hz,1H),1.59-1.72(m,2H),1.84(ddd,J=4,11,14Hz,1H),1.90(ddd,J=4,4,16Hz,1H),1.98(ddd,J=3,11,12Hz,1H),2.09(ddd,J=4,12,12Hz,1H),2.32-2.46(m,8H),2.52-2.62(m,2H),2.78-2.90(m,2H),2.96(d,J=6Hz,1H),2.99(d,J=18Hz,1H),3.06(ddd,J=2,12,13Hz,1H),3.75(s,3H),6.67(dd,J=2,8Hz,1H),6.71(d,J=2Hz,1H),7.01(d,J=8Hz,1H),7.16(dd,J=5,8Hz,1H),7.35(ddd,J=2,2,8Hz,1H),8.29-8.31(m,1H),8.38-8.41(m,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(3-(ピリジン-3-イル)プロピル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.16(m,2H),0.44-0.55(m,2H),0.77-0.89(m,1H),0.98-1.06(m,1H),1.51(dd,J=5,14Hz,1H),1.59-1.77(m,3H),1.78-1.87(m,1H),1.96-2.07(m,2H),2.28-2.47(m,7H),2.49-2.58(m,3H),2.78(dd,J=6,18Hz,1H),2.84-2.95(m,1H),2.90(d,J=6Hz,1H),2.95(d,J=18Hz,1H),2.98-3.07(m,1H),4.72(br s,1H),6.56-6.61(m,2H),6.91(d,J=8Hz,1H),7.18(dd,J=5,7Hz,1H),7.41(d,J=7Hz,1H),8.18(s,1H),8.38(d,J=5Hz,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-3-(ピリジン-4-イル)プロパン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.16(m,2H),0.45-0.58(m,2H),0.76-0.91(m,1H),1.01-1.13(m,1H),1.58(ddd,J=4,4,14Hz,0.5H),1.63(ddd,J=2,5,15Hz,0.5H),1.77(ddd,J=3,12,15Hz,0.5H),1.84-2.23(m,4H),2.25-3.06(m,11H),3.25(ddd,J=4,4,13Hz,0.5H),3.36(ddd,J=1,12,14Hz,0.5H),3.41(ddd,J=3,6,14Hz,0.5H),3.66-3.80(m,0.5H),3.69(s,1.5H),3.78(s,1.5H),3.83(ddd,J=3,13,13Hz,0.5H),3.91(ddd,J=3,5,14Hz,0.5H),4.22(ddd,J=3,5,14Hz,0.5H),6.63(d,J=3Hz,0.5H),6.67(dd,J=3,8Hz,0.5H),6.69-6.75(m,1H),6.99-7.06(m,2H),7.11-7.14(m,1H),8.44-8.48(m,2H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-3-(3-(ピリジン-4-イル)プロピル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.17(m,2H),0.45-0.56(m,2H),0.78-0.90(m,1H),1.01-1.09(m,1H),1.51(ddd,J=3,5,14Hz,1H),1.55-1.72(m,2H),1.84(ddd,J=4,11,14Hz,1H),1.89(ddd,J=4,4,16Hz,1H),1.98(ddd,J=3,11,11Hz,1H),2.09(ddd,J=5,13,13Hz,1H),2.29-2.46(m,8H),2.52-2.61(m,2H),2.82(dd,J=6,18Hz,1H),2.82-2.91(m,1H),2.95(d,J=6Hz,1H),2.99(d,J=18Hz,1H),3.04(ddd,J=2,12,14Hz,1H),3.75(s,3H),6.66(dd,J=2,8Hz,1H),6.71(d,J=2Hz,1H),6.94-6.98(m,2H),7.01(d,J=8Hz,1H),8.41-8.45(m,2H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(3-(ピリジン-4-イル)プロピル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm): 0.05-0.16(m,2H),0.45-0.55(m,2H),0.78-0.88(m,1H),0.95-1.05(m,1H),1.51(dd,J=5,14Hz,1H),1.63-1.81(m,3H),1.83(ddd,J=3,12,14Hz,1H),1.95-2.08(m,2H),2.29-2.50(m,7H),2.51-2.62(m,3H),2.77(dd,J=6,18Hz,1H),2.85-2.94(m,1H),2.90(d,J=6Hz,1H),2.94(d,J=18Hz,1H),2.99-3.08(m,1H),4.74(br s,1H),6.53(d,J=2Hz,1H),6.56(dd,J=2,8Hz,1H),6.88(d,J=8Hz,1H),6.97-7.00(m,2H),8.41-8.44(m,2H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-3-(2-(ピリジン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
実施例31に記載した方法に従い、実施例2で得られた異性体C及び4-メチルベンゼンスルホン酸2-(ピリジン-2-イル)エチル(Journal of Medicinal Chemistry,2015,58,5842に記載の方法で合成)より表題化合物を得た。
(方法2)
実施例2で得られた異性体C(257.7mg,0.75mmol)のエタノール(10mL)溶液に、酢酸(430.1μL,7.52mmol)および2-ビニルピリジン(807.3μL,7.52mmol)を加え、3.5時間加熱還流した。反応液を放冷後、減圧下濃縮した。得られた濃縮残渣をシリカゲルカラムクロマトグラフィー(アミノ基担持シリカゲル、0-3%メタノール/クロロホルム)で精製し、表題化合物(357.3mg,定量的)を淡黄色油状物として得た。
1H-NMR(400MHz,CDCl3)δ(ppm): 0.05-0.13(m,2H),0.44-0.55(m,2H),0.79-0.90(m,1H),1.00-1.07(m,1H),1.49(ddd,J=3,4,14Hz,1H),1.81(ddd,J=4,11,15Hz,1H),1.91-2.02(m,2H),2.08(ddd,J=4,12,12Hz,1H),2.28-2.40(m,3H),2.50-2.61(m,2H),2.71-2.91(m,7H),2.94(d,J=6Hz,1H),2.97(d,J=18Hz,1H),3.20(ddd,J=3,10,13Hz,1H),3.77(s,3H),4.68(br s,1H),6.66-6.71(m,2H),6.98-7.04(m,2H),7.05(dd,J=5,8Hz,1H),7.50(ddd,J=2,8,8Hz,1H),8.45-8.49(m,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(ピリジン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.15(m,2H),0.44-0.54(m,2H),0.76-0.89(m,1H),1.00-1.08(m,1H),1.50(ddd,J=2,6,15Hz,1H),1.78-1.89(m,2H),1.96-2.08(m,2H),2.25-2.39(m,3H),2.48-2.58(m,1H),2.72-2.84(m,2H),2.73(dd,J=6,18Hz,1H),2.86-3.00(m,7H),3.21(ddd,J=2,11,11Hz,1H),4.73(br s,1H),6.48(d,J=2Hz,1H),6.57(dd,J=2,8Hz,1H),6.87(d,J=8Hz,1H),7.08-7.13(m,2H),7.56(ddd,J=2,8,8Hz,1H),8.46-8.49(m,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(ピリジン-3-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.55(m,2H),0.75-0.90(m,1H),1.03(d,J=13Hz,1H),1.45-1.55(m,1H),1.80-1.90(m,2H),1.99(ddd,J=4,11,11Hz,1H),2.10(ddd,J=3,13,13Hz,1H),2.30-2.70(m,6H),2.70-2.90(m,2H),2.90-3.00(m,2H),3.07(ddd,J=3,11,13Hz,1H),3.54(s,2H),3.68(s,3H),4.78(br s,1H),6.62(d,J=2Hz,1H),6.71(dd,J=2,8Hz,1H),7.00-7.10(m,3H),7.10-7.25(m,2H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-3-(2-(ピリジン-3-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.55(m,2H),0.75-0.90(m,1H),1.00-1.10(m,1H),1.20-1.30(m,1H),1.65-1.80(m,2H),1.80-1.95(m,2H),1.95-2.10(m,1H),2.30-2.45(m,2H),2.50-2.55(m,1H),2.60-2.85(m,7H),2.85-3.10(m,3H),3.10-3.25(m,1H),3.77(s,3H),6.55-6.65(m,2H),7.00-7.05(m,2H),7.05-7.10(m,1H),7.10-7.15(m,1H),7.25-7.40(m,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(ピリジン-3-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.55(m,2H),0.80-0.90(m,1H),1.04(d,J=11Hz,1H),1.50(dd,J=5,14Hz,1H),1.70-1.90(m,2H),1.95-2.10(m,3H),2.30-2.40(m,3H),2.50-2.60(m,1H),2.60-2.80(m,6H),2.85-3.00(m,3H),3.15-3.25(m,1H),6.56(d,J=2Hz,1H),6.63(dd,J=2,8Hz,1H),6.93(d,J=8Hz,1H),7.16(dd,J=6,8Hz,1H),7.42(ddd,J=2,2,6Hz,1H),8.35(d,J=2Hz,1H),8.40(dd,J=2,6Hz,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(ピリジン-4-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.00-1.10(m,1H),1.50-1.70(m,1H),1.70-1.90(m,1H),1.90-2.50(m,5H),2.50-2.75(m,1.5H),2.75-3.05(m,2.5H),3.10-3.25(m,0.5H),3.25-3.35(m,0.5H),3.35-3.50(m,2H),3.65-4.00(m,3.5H),3.75(s,1.5H),3.79(s,1.5H),4.05-4.20(m,0.5H),4.50(br s,1H),6.61(d,J=3Hz,0.5H),6.65-6.75(m,1.5H),6.90-7.00(m,1H),7.03(d,J=8Hz,1H),7.08(d,J=6Hz,1H),8.40-8.50(m,2H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(ピリジン-4-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.55(m,2H),0.75-0.90(m,1H),1.00-1.10(m,1H),1.45-1.55(m,1H),1.70-1.90(m,2H),1.90-2.10(m,3H),2.20-2.50(m,3H),2.50-2.85(m,7H),2.85-3.15(m,4H),4.65(br s,1H),6.52-6.65(m,2H),6.93(d,J=8Hz,1H),6.98(d,J=8Hz,2H),8.37(d,J=5Hz,2H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(ピリミジン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.05(d,J=10Hz,1H),1.51(dd,J=6,15Hz,1H),1.80-2.10(m,4H),2.25-2.40(m,3H),2.54(d,J=7Hz,1H),2.73(dd,J=6,17Hz,1H),2.80-3.00(m,5H),3.10-3.25(m,4H),3.25-3.40(t,J=11Hz,1H),6.52(s,1H),6.55(d,J=8Hz,1H),6.86(d,J=8Hz,1H),7.10(t,J=5Hz,1H),8.62(d,J=5Hz,2H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(ピラジン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.02(d,J=9Hz,1H),1.50(dd,J=4,14Hz,1H),1.70-1.90(m,2H),1.90-2.10(m,2H),2.30-2.40(m,3H),2.50-2.60(m,1H),2.70-2.85(m,3H),2.85-3.05(m,7H),3.24(t,J=12Hz,1H),6.49(d,J=2Hz,1H),6.57(dd,J=2,8Hz,1H),6.89(d,J=8Hz,1H),8.30-8.40(m,2H),8.40-8.50(m,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(6-メトキシピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.18(m,2H),0.43-0.58(m,2H),0.75-0.93(m,1H),0.98-1.15(m,1H),1.17-2.21(m,5.5H),2.24-3.04(m,6.5H),3.25-3.34(m,0.5H),3.40-3.99(m,7.5H),4.02-4.18(m,1H),6.51-6.84(m,4H),6.88-6.98(m,1H),7.39-7.50(m,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(6-メトキシピリジン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.17(m,2H),0.41-0.56(m,2H),0.76-0.91(m,1H),0.94-2.11(m,6H),2.26-2.40(m,3H),2.47-2.58(m,1H),2.67-3.03(m,10H),3.13-3.25(m,1H),3.89(s,3H),4.73(br s,1H),6.44-6.53(m,2H),6.56(dd,J=2,8Hz,1H)6.65(d,J=7Hz,1H),6.89(d,J=8Hz,1H),7.37-7.45(m,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(6-(トリフルオロメチル)ピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.17(m,2H),0.44-0.57(m,2H),0.74-0.93(m,1H),1.01-1.13(m,1H),1.19-1.69(m,1H),1.70-1.89(m,1H),1.90-2.19(m,3H),2.22-2.42(m,2.6H),2.45-2.59(m,1.4H),2.61-3.02(m,3H),3.24-3.48(m,1H),3.49-3.61(m,1H),3.64-4.08(m,4H),4.28-4.60(m,1H),6.58-6.68(m,1.4H),6.73(d,J=2Hz,0.6H),6.87-6.97(m,1H),7.37-7.45(m,1H),7.49-7.56(m,1H),7.75(dd,J=8,8Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(6-(トリフルオロメチル)ピリジン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.02-0.16(m,2H),0.41-0.56(m,2H),0.75-0.91(m,1H),0.95-1.07(m,1H),1.15-2.11(m,5H),2.26-2.42(m,3H),2.46-2.57(m,1H),2.66(ddd,J=3,5,13Hz,1H),2.69-2.80(m,2H),2.85-3.03(m,7H),3.10-3.22(m,1H),4.68(br s,1H),6.48-6.60(m,2H),6.94(d,J=8Hz,1H),7.20(d,J=8Hz,1H),7.44(d,J=8Hz,1H),7.65(dd,J=8,8Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-3-フェネチル-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm): 0.05-0.15(m,2H),0.45-0.55(m,2H),0.79-0.91(m,1H),1.01-1.08(m,1H),1.50(ddd,J=3,5,15Hz,1H),1.84(ddd,J=4,12,15Hz,1H),1.92-2.03(m,2H),2.09(ddd,J=5,13,13Hz,1H),2.29-2.38(m,3H),2.52-2.60(m,2H),2.62-2.83(m,6H),2.87(ddd,J=2,11,13Hz,1H),2.94(d,J=6Hz,1H),2.98(d,J=18Hz,1H),3.21(ddd,J=3,12,13Hz,1H),3.77(s,3H),4.72(br s,1H),6.68-6.73(m,2H),6.99-7.04(m,1H),7.07-7.17(m,3H),7.19-7.25(m,2H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-フェネチル-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm): 0.03-0.13(m,2H),0.43-0.54(m,2H),0.75-0.87(m,1H),0.97-1.06(m,1H),1.41-1.52(m,1H),1.70-1.85(m,2H),1.92-2.04(m,2H),2.16-2.37(m,3H),2.45-2.55(m,1H),2.62-2.97(m,10H),3.07-3.21(m,1H),4.79(br s,1H),6.42(s,1H),6.53(d,J=8Hz,1H),6.84(d,J=8Hz,1H),7.10-7.19(m,3H),7.23(d,J=8Hz,2H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-3-フェニルプロパン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.16(m,2H),0.46-0.56(m,2H),0.76-0.88(m,1H),1.01-1.12(m,1H),1.56(ddd,J=3,3,15Hz,0.5H),1.63(ddd,J=2,5,15Hz,0.5H),1.79(ddd,J=3,12,15Hz,0.5H),1.83-2.03(m,2H),2.08(ddd,J=5,13,13Hz,0.5H),2.15-2.20(m,1H),2.26-2.66(m,5.5H),2.68(ddd,J=4,6,10Hz,0.5H),2.73-3.05(m,5.5H),3.25(ddd,J=4,4,13Hz,0.5H),3.34-3.45(m,1H),3.64-3.74(m,0.5H),3.69(s,1.5H),3.79(s,1.5H),3.83(ddd,J=3,12,12Hz,0.5H),3.91(ddd,J=2,4,14Hz,0.5H),4.21(ddd,J=3,5,14Hz,0.5H),6.62(d,J=3Hz,0.5H),6.68(dd,J=3,8Hz,0.5H),6.70-6.74(m,1H),7.01(d,J=8Hz,0.5H),7.02(d,J=8Hz,0.5H),7.12-7.32(m,5H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-3-(3-フェニルプロピル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm): 0.05-0.16(m,2H),0.45-0.54(m,2H),0.80-0.91(m,1H),1.01-1.09(m,1H),1.50(ddd,J=3,4,15Hz,1H),1.62-1.72(m,2H),1.84(ddd,J=4,12,15Hz,1H),1.89-2.02(m,2H),2.10(ddd,J=5,13,13Hz,1H),2.29-2.48(m,8H),2.55(ddd,J=2,5,11Hz,1H),2.62(ddd,J=4,4,13Hz,1H),2.76-2.85(m,2H),2.96(d,J=6Hz,1H),2.98(d,J=18Hz,1H),3.07(ddd,J=3,11,13Hz,1H),3.76(s,3H),4.79(br s,1H),6.67(dd,J=3,8Hz,1H),6.70(d,J=3Hz,1H),7.00(d,J=8Hz,1H),7.06-7.10(m,2H),7.14(tt,J=2,7Hz,1H),7.21-7.27(m,2H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(3-フェニルプロピル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.17(m,2H),0.46-0.54(m,2H),0.78-0.88(m,1H),0.95-1.03(m,1H),1.48(ddd,J=2,6,15Hz,1H),1.71-1.88(m,4H),1.98-2.04(m,2H),2.25-2.39(m,3H),2.48-2.64(m,5H),2.66-2.77(m,3H),2.83-2.92(m,1H),2.88(d,J=6Hz,1H),2.93(d,J=18Hz,1H),3.05-3.15(m,1H), 4.80(br s,1H),6.42(d,J=3Hz,1H),6.53(dd,J=3,8Hz,1H),6.87(d,J=8Hz,1H),7.11-7.18(m,3H),7.21-7.28(m,2H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-フルオロフェネチル)-10-メトキシ-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.04(d,J=14Hz,1H),1.45-1.55(m,1H),1.75-1.90(m,1H),1.90-2.15(m,3H),2.25-2.40(m,2H),2.50-2.60(m,2H),2.60-3.00(m,9H),3.15-3.25(m,1H),3.77(s,3H),3.80-3.90(m,1H),4.70(br s,1H),6.65-6.75(m,2H),6.90-7.20(m,5H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-フルオロフェネチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.04(d,J=11Hz,1H),1.52(dd,J=4,15Hz,1H),1.80-1.90(m,2H),1.95-2.10(m,2H),2.25-2.40(m,3H),2.50-2.60(m,1H),2.70-3.10(m,10H),3.18-3.33(m,1H),4.75(br s,1H),6.47(d,J=3Hz,1H),6.57(dd,J=3,8Hz,1H),6.89(d,J=8Hz,1H),6.95-7.05(m,2H),7.10-7.20(m,2H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-メトキシフェネチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.15(m,2H),0.45-0.54(m,2H),0.77-0.88(m,1H),1.00-1.07(m,1H),1.52(ddd,J=2,6,14Hz,1H),1.78-1.88(m,2H),1.96-2.09(m,2H),2.27-2.41(m,3H),2.46-2.61(m,1H),2.69-3.04(m,10H),3.26(dd,J=12,12Hz,1H),3.78(s,3H),4.79(br s,1H),6.47(d,J=2Hz,1H),6.56(dd,J=2,8Hz,1H),6.79-6.90(m,3H),7.10(dd,J=1,7Hz,1H),7.16(ddd,J=1,8,8Hz,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(3-メトキシピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.16(m,2H),0.43-0.57(m,2H),0.76-0.87(m,1H),1.00-1.11(m,1H),1.52(ddd,J=4,4,15Hz,0.6H),1.52-1.61(m,0.4H),1.76-1.90(m,1H),1.91-2.08(m,2.4H),2.09-2.18(m,0.6H),2.19-2.43(m,2.6H),2.47-2.59(m,1.4H),2.69(dd,J=6,18Hz,0.6H),2.76(dd,J=6,18Hz,0.4H),2.84(d,J=6Hz,0.6H),2.88-2.95(m,0.8H),2.96(d,J=18Hz,0.6H),3.08-3.23(m,0.6H),3.27-3.45(m,1.4H),3.64(d,J=16Hz,0.4H),3.64-3.76(m,0.4H),3.73(s,3H),3.80(d,J=16Hz,0.4H),3.85-3.98(m,2.2H),4.22(ddd,J=2,5,14Hz,0.6H),6.59(dd,J=2,8Hz,0.6H),6.61(dd,J=2,8Hz,0.4H),6.66(d,J=2Hz,0.4H),6.80(d,J=2Hz,0.6H),6.88(d,J=8Hz,0.4H),6.89(d,J=8Hz,0.6H),7.07-7.17(m,2H),8.06-8.10(m,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(3-メトキシピリジン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.14(m,2H),0.44-0.54(m,2H),0.77-0.88(m,1H),1.01-1.07(m,1H),1.51(ddd,J=2,5,14Hz,1H),1.80-1.92(m,2H),1.96-2.09(m,2H),2.26-2.39(m,3H),2.50-2.55(m,1H),2.72(dd,J=6,18Hz,1H),2.81-3.10(m,9H),3.21-3.30(m,1H),3.78(s,3H),4.78(br s,1H),6.47(d,J=2Hz,1H),6.55(dd,J=2,8Hz,1H),6.85(d,J=8Hz,1H),7.08(dd,J=2,8Hz,1H),7.10(dd,J=4,8Hz,1H),8.07(dd,J=2,4Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(3-フルオロピリジン-2-イル)エチル)-10-メトキシ-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.14(m,2H),0.44-0.55(m,2H),0.78-0.90(m,1H),0.98-1.07(m,1H),1.51(ddd,J=3,4,15Hz,1H),1.82(ddd,J=4,12,15Hz,1H),1.92-2.01(m,2H),2.08(ddd,J=5,13,13Hz,1H),2.25-2.40(m,3H),2.54(ddd,J=2,4,11Hz,1H),2.61(ddd,J=4,4,13Hz,1H),2.72-3.02(m,9H),3.20(ddd,J=3,12,13Hz,1H),3.77(s,3H),4.67(br s,1H),6.65-6.69(m,2H),6.98(d,J=9Hz,1H),7.09(ddd,J=4,4,8Hz,1H),7.26(ddd,J=1,8,10Hz,1H),8.29(ddd,J=1,1,4Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(3-フルオロピリジン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.16(m,2H),0.43-0.54(m,2H),0.77-0.88(m,1H),0.99-1.09(m,1H),1.51(ddd,J=2,5,15Hz,1H),1.78-1.90(m,2H),1.96-2.09(m,2H),2.27-2.39(m,3H),2.49-2.59(m,1H),2.73(dd,J=6,18Hz,1H),2.82(ddd,J=3,6,13Hz,1H),2.85-3.09(m,8H),3.19-3.28(m,1H),4.73(br s,1H),6.45(d,J=3Hz,1H),6.54(dd,J=3,8Hz,1H),6.86(d,J=8Hz,1H),7.12(ddd,J=4,4,8Hz,1H),7.29(ddd,J=1,8,10Hz,1H),8.29(ddd,J=1,1,4Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-3-(2-(3-メチルピリジン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.16(m,2H),0.45-0.55(m,2H),0.79-0.90(m,1H),1.01-1.09(m,1H),1.50(ddd,J=3,5,15Hz,1H),1.84(ddd,J=4,12,15Hz,1H),1.93-2.03(m,2H),2.10(ddd,J=5,13,13Hz,1H),2.27(s,3H),2.29-2.39(m,3H),2.52-2.59(m,1H),2.64(ddd,J=4,4,13Hz,1H),2.73-3.04(m,9H),3.28(ddd,J=3,12,13Hz,1H),3.77(s,3H),4.75(br s,1H),6.66-6.72(m,2H),6.97-7.03(m,2H),7.34-7.39(m,1H),8.32(dd,J=1,5Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(3-メチルピリジン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.16(m,2H),0.43-0.54(m,2H),0.77-0.89(m,1H),0.98-1.09(m,1H),1.51(ddd,J=2,5,15Hz,1H),1.80-1.93(m,2H),1.95-2.11(m,2H),2.23(s,3H),2.26-2.40(m,3H),2.48-2.59(m,1H),2.73(dd,J=6,18Hz,1H),2.83-3.04(m,9H),3.23-3.32(m,1H),4.76(br s,1H),6.49(d,J=2Hz,1H),6.58(dd,J=2,8Hz,1H),6.77(d,J=8Hz,1H),7.05(dd,J=5,8Hz,1H),7.38-7.43(m,1H),8.33(dd,J=1,5Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-3-(2-(6-メチルピリジン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.14(m,2H),0.45-0.54(m,2H),0.79-0.90(m,1H),0.99-1.07(m,1H),1.49(ddd,J=3,4,15Hz,1H),1.82(ddd,J=4,11,15Hz,1H),1.90-2.03(m,2H),2.09(ddd,J=5,13,13Hz,1H),2.28-2.40(m,3H),2.49(s,3H),2.51-2.61(m,2H),2.71-2.90(m,7H),2.94(d,J=6Hz,1H),2.97(d,J=18Hz,1H),3.18(ddd,J=3,11,13Hz,1H),3.76(s,3H),4.69(br s,1H),6.67-6.71(m,2H),6.82(d,J=8Hz,1H),6.91(d,J=8Hz,1H),6.98-7.02(m,1H),7.38(dd,J=8,8Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(6-メチルピリジン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.16(m,2H),0.44-0.55(m,2H),0.77-0.89(m,1H),0.98-1.11(m,1H),1.49(ddd,J=2,5,14Hz,1H),1.78-1.89(m,2H),1.96-2.09(m,2H),2.24-2.39(m,3H),2.49-2.56(m,1H),2.51(s,3H),2.65-2.97(m,10H),3.16-3.26(m,1H),4.73(br s,1H),6.48(d,J=2Hz,1H),6.56(dd,J=2,8Hz,1H),6.86(d,J=8Hz,1H),6.90(d,J=8Hz,1H),6.96(d,J=8Hz,1H),7.45(dd,J=8,8Hz,1H).
(E)-2-(2-メトキシビニル)-4-メチルピリジン(異性体G)及び(Z)-2-(2-メトキシビニル)-4-メチルピリジン(異性体H)の合成
1H-NMR(400MHz,CDCl3)δ(ppm):2.29(s,3H),3.73(s,3H),5.83(d,J=13Hz,1H),6.84(dd,J=1,5Hz,1H),6.90(d,J=1Hz,1H),7.56(d,J=13Hz,1H),8.29(d,J=5Hz,1H).
(異性体H)
1H-NMR(400MHz,CDCl3)δ(ppm):2.33(s,3H),3.84(s,3H),5.47(d,J=7Hz,1H),6.32(d,J=7Hz,1H),6.85(dd,J=1,5Hz,1H),7.70(d,J=1Hz,1H),8.36(d,J=5Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(4-メチルピリジン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.17(m,2H),0.42-0.56(m,2H),0.76-1.12(m,2H),1.42-2.11(m,5H),2.20-2.41(m,6H),2.46-2.60(m,1H),2.66-3.01(m,10H),3.17-3.27(m,1H),4.74(br s,1H),6.48(d,J=2Hz,1H),6.57(dd,J=2,8Hz,1H),6.87(d,J=8Hz,1H),6.90-6.97(m,2H),8.33(d,J=5Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2,2-ジフルオロ-2-(ピリジン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.12(m,2H),0.45-0.51(m,2H),0.76-0.84(m,1H),0.94-1.00(m,1H),1.26-1.33(m,1H),1.46(ddd,J=3,11,15Hz,1H),1.71(ddd,J=3,3,16Hz,1H),1.90-2.02(m,2H),2.23-2.33(m,3H),2.46-2.52(m,1H),2.56(ddd,J=4,4,13Hz,1H),2.62(dd,J=6,18Hz,1H),2.76-2.83(m,2H),2.90(d,J=18Hz,1H),2.94-3.02(m,1H),3.13-3.21(m,1H),3.23-3.42(m,2H),4.64(br s,1H),6.51(d,J=2Hz,1H),6.60(dd,J=2,8Hz,1H),6.89(d,J=8Hz,1H),7.24-7.30(m,2H),7.63(ddd,J=2,8,8Hz,1H),8.57-8.62(m,1H).
((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)(1-(ピリジン-2-イル)シクロプロピル)メタノンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.15(m,2H),0.38-0.54(m,2.4H),0.74-0.97(m,1.8H),1.14-1.30(m,1.2H),1.38(ddd,J=3,3,15Hz,0.6H),1.41-1.49(m,0.6H),1.52-1.80(m,2.8H),1.83-2.11(m,2.6H),2.19-2.58(m,4.6H),2.62(dd,J=6,18Hz,0.6H),2.76(dd,J=6,18Hz,0.4H),2.78(d,J=6Hz,0.6H),2.87(d,J=6Hz,0.4H),2.90(d,J=18Hz,0.4H),2.94-3.04(m,0.4H),2.96(d,J=18Hz,0.6H),3.08(ddd,J=4,4,14Hz,0.6H),3.21(dd,J=12,14Hz,0.6H),3.40(ddd,J=2,12,14Hz,0.4H),3.78(ddd,J=4,14,14Hz,0.4H),3.90-4.01(m,1H),4.25-4.38(m,1H),4.51(br s,1H),6.55(d,J=3Hz,0.4H),6.63(dd,J=3,8Hz,0.4H),6.69(d,J=2,8Hz,0.6H),6.89(d,J=8Hz,0.4H),6.93(d,J=8Hz,0.6H),7.01-7.09(m,1.2H),7.10(d,J=2Hz,0.6H),7.13(ddd,J=1,5,7Hz,0.4H),7.19-7.23(m,0.4H),7.48(ddd,J=2,8,8Hz,0.6H),7.60(ddd,J=2,8,8Hz,0.4H),8.44(ddd,J=1,2,5Hz,0.6H),8.45(ddd,J=1,2,5Hz,0.4H).
((5aS,6R,11bS)-14-(シクロプロピルメチル)-3-((1-(ピリジン-2-イル)シクロプロピル)メチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.14(m,2H),0.45-0.51(m,2H),0.74-0.87(m,2H),0.92-0.98(m,1H),1.15-1.23(m,2H),1.38-1.45(m,1H),1.65-1.77(m,1H),1.90-2.04(m,2H),2.20-2.29(m,1H),2.31(d,J=7Hz,2H),2.46-2.53(m,1H),2.62-2.73(m,3H),2.78(d,J=13Hz,1H),2.78-2.84(m,1H),2.85(d,J=5Hz,1H),2.88(d,J=18Hz,1H),2.91(d,J=13Hz,1H),2.95-3.04(m,1H),3.67-3.74(m,2H),6.33(d,J=3Hz,1H),6.50(dd,J=3,8Hz,1H),6.83(d,J=8Hz,1H),6.93(ddd,J=1,5,8Hz,1H),7.23-7.28(m,1H),7.38(ddd,J=2,8,8Hz,1H),8.35-8.38(m,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(1H-インドール-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.15(m,2H),0.49-0.55(m,2H),0.78-0.90(m,1H),1.04-1.11(m,1H),1.56-1.67(m,1.4H),1.78-1.90(m,0.6H),1.91-2.08(m,3H),2.12-2.40(m,3H),2.46-2.58(m,1.4H),2.68(dd,J=6,18Hz,0.6H),2.81(dd,J=7,19Hz,0.4H),2.88-2.96(m,1.6H),2.97-3.00(m,0.4H),3.20(ddd,J=3,11,14Hz,0.6H),3.49(ddd,J=4,4,13Hz,0.6H),3.54-3.64(m,1H),3.65-3.72(m,0.4H),3.74-3.76(m,0.4H),3.76(s,1.2H),3.79(s,1.8H),3.80-3.90(m,1.6H),3.97(ddd,J=3,12,12Hz,0.6H),4.06-4.14(m,0.4H),6.21-6.25(m,1H),6.62-6.70(m,2H),6.90(d,J=8Hz,0.6H),6.99-7.13(m,2.4H),7.26-7.30(m,1H),7.49-7.53(m,1H),8.94(br s,0.4H),9.23(br s,0.6H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(1H-インドール-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.15(m,2H),0.47-0.57(m,2H),0.78-0.90(m,1H),1.00-1.12(m,1H),1.56-1.67(m,1.2H),1.79-2.12(m,3.8H),2.13-2.40(m,3.8H),2.44-2.56(m,1.2H),2.62(dd,J=5,18Hz,0.8H),2.77(dd,J=6,18Hz,0.2H),2.86-2.99(m,2H),3.12-3.30(m,0.8H),3.41-3.59(m,1.2H),3.65-3.75(m,0.2H),3.79-3.92(m,1.8H),3.96-4.17(m,1H),4.82(br s,1H),6.17(s,0.2H),6.27(s,0.8H),6.49(d,J=8Hz,0.2H),6.60-6.72(m,1H),6.73-6.81(m,0.8H),6.86-6.92(m,1H),6.99-7.13(m,2H),7.15-7.20(m,0.2H),7.21-7.29(m,0.8H),7.43-7.52(m,1H),8.83(br s,0.2H),9.49(br s,0.8H).
3-(2-ヒドロキシエチル)-1H-インダゾール-1-カルボン酸tert-ブチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):1.72(s,9H),2.63(t,J=6Hz,1H),3.23(t,J=6Hz,2H),4.13(dt,J=6,6Hz,2H),7.32(t,J=8Hz,1H),7.51-7.56(m,1H),7.70(d,J=8Hz,1H),8.12(d,J=9Hz,1H).
3-(2-(トシロキシ)エチル)-1H-インダゾール-1-カルボン酸tert-ブチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):1.72(s,9H),2.41(s.3H),3.56(t,J=7Hz,2H),4.47(t,J=7Hz,2H),7.17-7.34(m,3H),7.52(ddd,J=1,7,9Hz,1H),7.61-7.68(m,3H),8.05(d,J=9Hz,1H).
3-(2-((5aS,6R,11bS)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)エチル)-1H-インダゾール-1-カルボン酸tert-ブチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.18(m,2H),0.46-0.55(m,2H),0.77-0.92(m,1H),0.99-1.10(m,1H),1.20-1.65(m,1H),1.72(s,9H),1.79-2.14(m,4H),2.30-2.45(m,3H),2.50-2.59(m,1H),2.61-2.71(m,1H),2.73-3.12(m,9H),3.19-3.33(m,1H),3.76(s,3H),6.62-6.69(m,2H),6.98(d,J=9Hz,1H),7.21-7.31(m,1H),7.48(ddd,J=1,7,8Hz,1H),7.63(d,J=8Hz,1H),8.05(d,J=8Hz,1H).
(5aS,6R,11bS)-3-(2-(1H-インダゾール-3-イル)エチル)-14-(シクロプロピルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.17(m,2H),0.44-0.56(m,2H),0.77-0.95(m,1H),0.99-1.08(m,1H),1.18-2.13(m,5H),2.24-2.39(m,3H),2.49-2.58(m,1H),2.59-2.69(m,1H),2.70-2.81(m,2H),2.83-3.02(m,5H),3.06-3.17(m,2H),3.19-3.32(m,1H),4.79(br s,1H),6.56-6.66(m,2H),6.93(d,J=9Hz,1H),7.07-7.14(m,1H),7.30-7.38(m,1H),7.43-7.52(m,1H),7.66(d,J=8Hz,1H).
メタンスルホン酸2-(1-メチル-1H-インダゾール-3-イル)エチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):2.92(s,3H),3.43(t,J=7Hz,2H),4.03(s,3H),4.63(t,J=7Hz,2H),7.16(ddd,J=1,6,8Hz,1H),7.33-7.44(m,2H),7.70(d,J=8Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(1-メチル-1H-インダゾール-3-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.17(m,2H),0.43-0.56(m,2H),0.75-0.93(m,1H),0.95-1.08(m,1H),1.12-2.10(m,5H),2.25-2.41(m,3H),2.45-2.59(m,1H),2.74(dd,J=6,18Hz,1H),2.80-3.07(m,7H),3.10-3.33(m,3H),3.98(s,3H),4.75(br s,1H),6.43-6.61(m,2H),6.89(d,J=8Hz,1H),7.03-7.12(m,1H),7.27-7.39(m,2H),7.63(d,J=8Hz,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(1H-インダゾール-3-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.19(m,2H),0.43-0.59(m,2H),0.74-1.12(m,2H),1.13-2.18(m,6H),2.23-2.44(m,2H),2.46-2.81(m,2H),2.83-3.02(m,2H),3.11-3.30(m,1H),3.46-4.08(m,5H),6.58-6.76(m,2H),6.88(d,J=8Hz,1H),7.02-7,13(m,1H),7.24-7.45(m,2H),7.63(d,J=8Hz,0.4H),7.72(d,J=8Hz,0.6H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(イミダゾ[1,2-a]ピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.18(m,2H),0.41-0.59(m,2H),0.71-0.92(m,1H),0.96-1.10(m,1H),1.49-1.66(m,1H),1.73-2.14(m,5H),2.23-2.97(m,6H),3.26-4.01(m,6H),4.52(br s,1H),6.59(dd,J=2,8Hz,0.6H),6.64(dd,J=3,8Hz,0.4H),6.68-6.82(m,2.4H),6.86(d,J=8Hz,0.6H),7.07-7.19(m,1H),7.38(s,0.4H),7.43(s,0.6H),7.48(d,J=9Hz,0.4H),7.52(d,J=9Hz,0.6H),7.94-8.04(m,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(イミダゾ[1,2-a]ピリジン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.15(m,2H),0.42-0.53(m,2H),0.74-1.04(m,2H),1.42-1.54(m,1H),1.67-1.91(m,2H),1.92-2.09(m,2H),2.26-2.38(m,3H),2.43-2.99(m,11H),3.10-3.26(m,1H),6.54(d,J=2Hz,1H),6.65(dd,J=2,8Hz,1H),6.70(ddd,J=1,1,7Hz,1H),6.89(d,J=8Hz,1H),7.09(ddd,J=1,7,9Hz,1H),7.19(s,1H),7.47(d,J=8Hz,1H),7.98-8.04(m,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(ピラゾロ[1,5-a]ピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.55(m,2H),0.75-0.90(m,1H),0.95-1.10(m,1H),1.50-1.65(m,1H),1.70-1.90(m,3H),1.90-2.05(m,2H),2.20-2.40(m,3H),2.45-2.65(m,2H),2.70-3.00(m,2H),3.20-3.55(m,2H),3.60-4.00(m,3H),4.05-4.15(m,1H),6.32(s,0.5H),6.33(s,0.5H),6.50-6.75(m,2.5H),6.80-6.95(m,1.5H),7.00-7.10(m,1H),7.40(d,J=3Hz,1H),8.30-8.40(m,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(ピラゾロ[1,5-a]ピリジン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.20(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),0.95-1.10(m,1H),1.40-1.60(m,1H),1.75-1.90(m,2H),1.95-2.05(m,2H),2.30-2.40(m,3H),2.45-2.55(m,1H),2.70-2.85(m,3H),2.85-3.05(m,7H),3.15-3.28(m,1H),4.74(br s,1H),6.23(s,1H),6.51(d,J=3Hz,1H),6.57(dd,J=3,8Hz,1H),6.65(ddd,J=1,6,6Hz,1H),6.89(d,J=8Hz,1H),7.00-7.10(m,1H),7.39(d,J=8Hz,1H),8.33(d,J=6Hz,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(2H-インダゾール-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.55(m,2H),0.75-0.90(m,1H),1.04(d,J=10Hz,1H),1.50-1.90(m,2H),1.90-2.10(m,2H),2.20-2.40(m,2H),2.50-2.70(m,2H),2.70-3.00(m,2H),3.10-3.25(m,2.6H),3.37(ddd,J=4,4,12Hz,0.4H),3.77(ddd,J=5,12,12Hz,0.6H),3.80-4.00(m,2.4H),4.80(d,J=16Hz,0.6H),5.02(d,J=16Hz,0.6H),5.19(s,0.8H),6.50-6.75(m,2H),6.88(d,J=8Hz,0.4H),6.97(d,J=8Hz,0.6H),7.10-7.35(m,4H),7.68(d,J=8Hz,1H).
(5aS,6R,11bS)-3-(2-(2H-インダゾール-2-イル)エチル)-14-(シクロプロピルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.55(m,2H),0.80-0.90(m,1H),1.01(d,J=9Hz,1H),1.35-1.45(m,1H),1.60-1.80(m,2H),1.90-2.10(m,3H),2.30-2.65(m,5H),2.77(dd,J=6,18Hz,1H),2.85-3.10(m,5H),3.10-3.20(m,1H),4.20-4.40(m,2H),6.60-6.70(m,2H),7.00-7.10(m,2H),7.20-7.30(m,1H),7.36(s,1H),7.56(d,J=8Hz,1H),7.63(d,J=8Hz,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(1H-インダゾール-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.55(m,2H),0.80-0.90(m,1H),1.00-1.05(m,1H),1.50-2.10(m,5H),2.15-2.40(m,3H),2.50-2.70(m,2H),2.70-3.00(m,2.6H),3.10-3.35(m,1.4H),3.35-3.45(m,0.4H),3.60-3.70(m,0.6H),3.80-3.90(m,0.6H),3.90-4.00(m,0.4H),4.87(d,J=16Hz,0.6H),5.03(d,J=16Hz,0.6H),5.20(d,J=16Hz,0.4H),5.26(d,J=16Hz,0.4H),6.60-6.70(m,2H),6.85-6.95(m,1H),7.00-7.10(m,1H),7.10-7.20(m,1H),7.60-7.70(m,2H),7.84(s,0.6H),7.92(s,0.4H).
(5aS,6R,11bS)-3-(2-(1H-インダゾール-1-イル)エチル)-14-(シクロプロピルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.55(m,2H),0.75-0.90(m,1H),1.01(d,J=9Hz,1H),1.20-1.90(m,3H),1.90-2.10(m,3H),2.25-2.45(m,3H),2.50-2.80(m,3H),2.80-3.10(m,5H),3.15-3.30(m,1H),4.30-4.50(m,2H),6.50-6.70(m,2H),6.91(d,J=8Hz,1H),7.11(dd,J=6,6Hz,1H),7.20-7.40(m,2H),7.69(d,J=8Hz,1H),7.96(s,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(イソキノリン-3-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.15(m,2H),0.40-0.55(m,2H),0.74-0.92(m,1H),0.97-1.09(m,1H),1.51(dd,J=3,15Hz,1H),1.80-2.10(m,4H),2.26-2.40(m,3H),2.44-2.56(m,1H),2.72(dd,J=2,18Hz,1H),2.81-3.17(m,9H),3.22-3.33(m,1H),4.75(br s,1H),6.48(d,J=3Hz,1H),6.55(dd,J=3,8Hz,1H),6.84(d,J=8Hz,1H),7.47(s,1H),7.48-7.56(m,1H),7.60-7.68(m,1H),7.72(d,J=8Hz,1H),7.90(d,J=8Hz,1H),9.15(s,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(キノリン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.15(m,2H),0.44-0.55(m,2H),0.75-0.90(m,1H),0.95-1.07(m,1H),1.42-1.60(m,1H),1.75-1.90(m,2H),1.94-2.09(m,2H),2.26-2.41(m,3H),2.49-2.59(m,1H),2.73(dd,J=6,18Hz,1H),2.77-3.18(m,9H),3.22-3.33(m,1H),6.51(d,J=2Hz,1H),6.59(dd,J=3,8Hz,1H),6.86(d,J=8Hz,1H),7.22(d,J=8Hz,1H),7.45-7.53(m,1H),7.62-7.70(m,1H),7.77(dd,J=1,8Hz,1H),8.03(d,J=8Hz,2H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(1H-インドール-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.00-1.10(m,1H),1.40-1.50(m,1H),1.60-1.85(m,2H),1.90-2.15(m,2H),2.15-2.40(m,3H),2.50-3.00(m,4.4H),3.10-3.35(m,1.8H),3.72(ddd,J=6,13,13Hz,0.4H),3.84(ddd,J=3,13,13Hz,0.4H),3.90-4.00(m,1H),4.51(d,J=16Hz,0.6H),4.64(d,J=16Hz,0.6H),4.82(d,J=16Hz,0.4H),4.90(d,J=16Hz,0.4H),6.48(d,J=8Hz,0.4H),6.50(d,J=8Hz,0.6H),6.54(d,J=2Hz,0.4H),6.59(d,J=2Hz,0.6H),6.65(ddd,J=3,8,8Hz,1H),6.88(d,J=3Hz,1H),6.90-7.00(m,2H),7.00-7.20(m,2H),7.59(t,J=8Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(インドリン-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,2H),0.45-0.60(m,2H),0.75-1.00(m,2H),1.40-1.90(m,5H),1.90-2.05(m,2H),2.20-2.40(m,3H),2.45-2.60(m,1H),2.65-3.00(m,9H),3.10-3.40(m,4H),4.72(br s,1H),6.45(d,J=8Hz,1H),6.50(d,J=3Hz,1H),6.56(dd,J=3,8Hz,1H),6.61(dd,J=8,8Hz,1H),6.89(d,J=8Hz,1H),7.00-7.05(m,2H).
(5aS,6R,11bS)-3-(2-(ベンゾ[d]チアゾール-2-イル)エチル)-14-(シクロプロピルメチル)-10-メトキシ-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.17(m,2H),0.45-0.55(m,2H),0.78-0.90(m,1H),1.01-1.08(m,1H),1.55(ddd,J=2,5,14Hz,1H),1.86-2.03(m,3H),2.09(ddd,J=5,13,13Hz,1H),2.35(dd,J=6,13Hz,1H),2.367(dd,J=6,13Hz,1H),2.45-2.58(m,2H),2.61(ddd,J=3,5,13Hz,1H),2.72(ddd,J=4,4,13Hz,1H),2.78-2.91(m,3H),2.95(d,J=6Hz,1H),2.98(d,J=18Hz,1H),3.04(ddd,J=3,12,12Hz,1H),3.12-3.21(m,3H),3.72(s,3H),6.68-6.72(m,2H),6.99-7.03(m,1H),7.31(ddd,J=1,7,8Hz,1H),7.40(ddd,J=1,7,8Hz,1H),7.75-7.79(m,1H),7.88-7.92(m,1H).
(5aS,6R,11bS)-3-(2-(ベンゾ[d]チアゾール-2-イル)エチル)-14-(シクロプロピルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.16(m,2H),0.42-0.56(m,2H),0.76-0.88(m,1H),0.96-1.06(m,1H),1.51(dd,J=4,14Hz,1H),1.71-1.80(m,1H),1.89(ddd,J=3,12,14Hz,1H),1.95-2.09(m,2H),2.34(dd,J=6,12Hz,1H),2.34(dd,J=6,12Hz,1H),2.42(ddd,J=4,12,16Hz,1H),2.48-2.58(m,1H),2.59-2.70(m,2H),2.76(dd,J=6,18Hz,1H),2.83-2.98(m,5H),3.10-3.22(m,3H),4.70(br s,1H),6.55(d,J=2Hz,1H),6.62(dd,J=2,8Hz,1H),6.91(d,J=8Hz,1H),7.30(dd,J=8,8Hz,1H),7.39(dd,J=8,8Hz,1H),7.78(d,J=8Hz,1H),7.91(d,J=8Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-3-(2-(ピペリジン-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.17(m,2H),0.44-0.55(m,2H),0.77-0.94(m,1H),0.98-1.09(m,1H),1.19-1.71(m,10Hz),1.75-2.15(m,3H),2.22-2.42(m,8H),2.46-2.88(m,6H),2.90-3.02(m,2H),3.06-3.21(m,1H),3.77(s,3H),6.63-6.71(m,2H),6.99(d,J=8Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(ピペリジン-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.17(m,2H),0.44-0.55(m,2H),0.76-0.92(m,1H),0.95-1.08(m,1H),1.14-1.91(m,10H),1.93-2.10(m,2H),2.14-3.02(m,17H),3.07-3.22(m,1H),4.75(br s,1H),6.46(d,J=2Hz,1H),6.55(dd,J=2,8Hz,1H),6.89(d,J=8Hz,1H).
2-((5aS,6R,11bS)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-1-(ピペリジン-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.17(m,2H),0.43-0.56(m,2H),0.75-0.91(m,1H),0.96-1.06(m,1H),1.08-2.15(m,12H),2.33(d,J=6Hz,1H),2.42-2.61(m,4H),2.72-2.84(m,1H),2.85-3.20(m,6H),3.15(d,J=13Hz,1H),3.23(d,J=13Hz,1H),3.33-3.51(m,2H),4.63(br s,1H),6.57-6.70(m,2H),6.91(d,J=8Hz,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(4,4-ジメチル-1,4-アザシリナン-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.15(m,8H),0.46-0.56(m,2H),0.61-0.92(m,5H),1.01-1.13(m,1H),1.22-1.86(m,2H),1.89-2.19(m,3H),2.25-2.41(m,2.6H),2.48-2.69(m,5.4H),2.71-2.84(m,1H),2.86-3.27(m,4H),3.28-3.48(m,1H),3.51-3.71(m,1.4H),3.72-3.85(m,1H),3.89-4.00(m,0.6H),4.49-4.534.51(m,1H),6.54-6.69(m,1.4H),6.76-6.81(m,0.6H),6.90-6.96(m,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(4,4-ジメチル-1,4-アザシリナン-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.19(m,8H),0.43-0.55(m,2H),0.66-0.90(m,5H),0.95-1.07(m,1H),1.16-2.11(m,5H),2.23-2.41(m,3H),2.45-2.98(m,15H),3.09-3.22(m,1H),4.76(br s,1H),6.46(d,J=2Hz,1H),6.56(dd,J=2,8Hz,1H),6.89(d,J=8Hz,1H).
(5aR,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-c]アゼピン-3(4H)-オン(異性体G)および(5aR,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オン(異性体H)の混合物の合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.20(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.20-1.80(m,3H),1.86(ddd,J=5,12,12Hz,1H),1.90-2.10(m,2H),2.25-2.35(m,1H),2.35-2.70(m,3H),2.70-2.90(m,2.5H),3.00-3.05(m,0.5H),3.05-3.15(m,1.5H),3.30-3.40(m,0.5H),3.40-3.60(m,1H),3.76(s,1.5H),3.79(s,1.5H),5.81(br s,0.5H),5.92(br s,0.5H),6.52(d,J=3Hz,0.5H),6.68(dd,J=3,8Hz,1H),6.94(d,J=8Hz,0.5H),6.99(d,J=8Hz,0.5H),7.10(d,J=3Hz,0.5H).
(5aR,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-1,2,3,4,5,5a,6,7-オクタヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-c]アゼピンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.00-0.20(m,2H),0.45-0.55(m,2H),0.75-0.90(m,1H),1.20-1.50(m,3H),1.65-2.20(m,6H),2.30(dd,J=7,12Hz,1H),2.55(dd,J=6,13Hz,1H),2.60-2.70(m,2H),2.70-2.90(m,3H),3.04(dd,J=5,13Hz,1H),3.18(br s,1H),3.45(d,J=14Hz,1H),3.78(s,3H),6.50-6.70(m,2H),7.02(d,J=8Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-2-(2-(ピリジン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-c]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.16(m,2H),0.43-0.55(m,2H),0.78-1.00(m,2H),1.45-1.69(m,3H),1.71-1.82(m,1H),1.91-2.14(m,3H),2.28-2.40(m,2H),2.51-2.85(m,5H),2.86-3.31(m,6H),3.73(s,3H),6.67(dd,J=3,8Hz,1H),6.78(d,J=3Hz,1H),6.96(d,J=8Hz,1H),7.08(dd,J=5,8Hz,1H),7.14-7.18(m,1H),7.54(ddd,J=2,8,8Hz,1H),8.52(ddd,J=1,2,5Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-2-(2-(ピリジン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-c]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.18(m,2H),0.44-0.55(m,2H),0.78-0.99(m,2H),1.39-1.47(m,1H),1.56-1.65(m,1H),1.69(ddd,J=2,12,13Hz,1H),1.88(ddd,J=6,13,13Hz,1H),2.14(ddd,J=4,12,12Hz,1H),2.23-2.42(m,3H),2.54-2.81(m,6H),2.84-3.09(m,5H),3.44(d,J=15Hz,1H),6.72(dd,J=2,8Hz,1H),6.88(d,J=2Hz,1H),6.93(d,J=8Hz,1H),7.08-7.13(m,1H),7.18(ddd,J=1,5,8Hz,1H),7.63(ddd,J=2,8,8Hz,1H),8.53-8.58(m,1H).
1-((5aS,6R,11bS)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-c]アゼピン-2(1H)-イル)-2-(ピリミジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.17(m,2H),0.45-0.57(m,2H),0.77-0.92(m,1H),1.06-1.13(m,1H),1.55-1.72(m,2H),1.76(dd,J=6,13Hz,1H),1.92-2.10(m,2H),2.23-2.42(m,3H),2.55-2.63(m,1H),2.79(dd,J=6,18Hz,1H),2.90-3.06(m,3H),3.64(d,J=15Hz,1H),3.69-3.81(m,1H),3.71(s,3H),3.95(d,J=15Hz,1H),4.09(d,J=15Hz,1H),4.79(d,J=15Hz,1H),6.69(dd,J=3,8Hz,1H),6.89(d,J=3Hz,1H),6.94(d,J=8Hz,1H),7.15(t,J=5Hz,1H),8.65(d,J=5Hz,2H).
1-((5aS,6R,11bS)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-c]アゼピン-2(1H)-イル)-2-(ピリミジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm): 0.06-0.17(m,2H),0.45-0.58(m,2H),0.78-0.93(m,1H),1.10-1.17(m,1H),1.52-1.63(m,1H),1.65-1.74(m,1H),1.78(dd,J=6,13Hz,1H),2.02(ddd,J=4,12,12Hz,1H),2.11(ddd,J=3,12,12Hz,1H),2.19-2.32(m,1H),2.35(dd,J=6,13Hz,1H),2.36(dd,J=7,13Hz,1H),2.55-2.63(m,1H),2.65-2.74(m,1H),2.78(dd,J=7,18Hz,1H),2.98(d,J=7Hz,1H),3.00(d,J=18Hz,1H),3.54(dd,J=4,12Hz,1H),3.78(d,J=15Hz,1H),3.89(d,J=16Hz,1H),3.96(d,J=16Hz,1H),4.62(d,J=15Hz,1H),6.65(d,J=3Hz,1H),6.74(dd,J=3,8Hz,1H),6.97(d,J=8Hz,1H),7.29(t,J=5Hz,1H),8.76(d,J=5Hz,2H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オン(単一の異性体A)の合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.08-0.16(m,2H),0.50-0.57(m,2H),0.78-0.92(m,1H),1.10-1.18(m,1H),1.23-1.33(m,1H),1.78(ddd,J=2,11,14Hz,1H),2.07-2.13(m,2H),2.34-2.42(m,2H),2.56-2.63(m,2H),2.72-2.82(m,1H),2.83-2.97(m,2H),3.02(d,J=18Hz,1H),3.51(d,J=15Hz,1H),3.80(s,3H),3.87(ddd,J=3,11,15Hz,1H),5.62-5.71(m,1H),6.71(dd,J=3,8Hz,1H),6.97(d,J=8Hz,1H),7.15(d,J=3Hz,1H).
(5aS,6R,11bR)-3-ベンジル-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.15(m,2H),0.44-0.53(m,2H),0.72-0.91(m,1H),1.15-1.49(m,3H),2.00-2.15(m,2H),2.33(d,J=7Hz,2H),2.52-2.66(m,2H),2.77(d,J=15Hz,1H),2.78-2.92(m,2H),2.94(d,J=18Hz,1H),3.62(d,J=15Hz,1H),3.82(d,J=15Hz,1H),3.85(s,3H),4.06(dd,J=11,15Hz,1H),5.05(d,J=15Hz,1H),6.62(d,J=8Hz,2H),6.79(dd,J=3,8Hz,1H),6.97(d,J=9Hz,1H),7.01(t,J=8Hz,2H),7.09(t,J=7Hz,1H),7.32(d,J=3Hz,1H).
(5aS,6R,11bR)-3-ベンジル-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.12(m,2H),0.44-0.55(m,2H),0.71-0.93(m,1H),1.08-1.50(m,3H),2.02-2.12(m,2H),2.33(d,J=6Hz,2H),2.50-2.64(m,2H),2.71(d,J=15Hz,1H),2.78-2.98(m,3H),3.60(d,J=15Hz,1H),3.84(d,J=15Hz,1H),4.07(dd,J=11,15Hz,1H),5.03(d,J=14Hz,1H),6.65(d,J=8Hz,2H),6.78(dd,J=3,8Hz,1H),6.95(d,J=8Hz,1H),7.03(t,J=7Hz,2H),7.11(t,J=7Hz,1H),7.18(d,J=2Hz,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(4-(トリフルオロメチル)-1H-ピラゾール-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.05-1.15(m,1H),1.30-2.50(m,7H),2.50-2.85(m,2.5H),2.90-3.15(m,2.5H),3.30-3.40(m,1H),3.40-3.50(m,1H),3.70-3.80(m,0.5H),3.80-3.95(m,1H),4.05-4.15(m,0.5H),4.66(d,J=16Hz,0.5H),4.86(d,J=16Hz,0.5H),4.94(d,J=16Hz,0.5H),5.00(d,J=16Hz,0.5H),6.60-6.70(m,2H),6.90-7.00(m,1H),7.59(s,0.5H),7.66(s,0.5H),7.69(m,0.5H),7.78(s,0.5H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(4-(トリフルオロメチル)-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,2H),0.75-1.00(m,1H),1.00-1.10(m,1H),1.40-2.20(m,4H),2.25-2.50(m,5H),2.50-2.70(m,2H),2.75-3.15(m,6H),3.15-3.30(m,1H),3.90-4.05(m,1H),4.10-4.20(m,1H),6.60-6.70(m,2H),6.99(d,J=8Hz,1H),7.17(s,1H),7.62(s,1H).
(5aS,6R,11bR)-3-(2-シクロヘキシルエチル)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.15(m,2H),0.45-0.55(m,2H),0.65-1.77(m,17H),1.99-2.12(m,2H),2.35(dd,J=7,13Hz,1H),2.36(dd,J=7,13Hz,1H),2.53-2.61(m,1H),2.66(d,J=15Hz,1H),2.74(dd,J=6,18Hz,1H),2.83-2.97(m,3H),3.01(d,J=18Hz,1H),3.46-3.64(m,2H),3.81(s,3H),4.06(dd,J=11,15Hz,1H),6.68(dd,J=3,8Hz,1H),6.94(d,J=8Hz,1H),7.20(d,J=3Hz,1H).
(5aS,6R,11bR)-3-(2-シクロヘキシルエチル)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.14(m,2H),0.46-0.55(m,2H),0.64-0.90(m,4H),0.97-1.30(m,6H),1.35-1.46(m,1H),1.47-1.65(m,5H),1.67-1.79(m,1H),1.96-2.12(m,2H),2.35(dd,J=7,13Hz,1H),2.36(dd,J=7,13Hz,1H),2.51-2.61(m,1H),2.66(d,J=15Hz,1H),2.73(dd,J=6,18Hz,1H),2.84-3.04(m,4H),3.44-3.58(m,2H),4.07(dd,J=11,15Hz,1H),6.68(dd,J=2,8Hz,1H),6.91(d,J=8Hz,1H),7.16(d,J=2Hz,1H).
2-クロロ-1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,2H),0.75-1.00(m,1H),1.08(d,J=12Hz,0.3H),1.16(d,J=12Hz,0.7H),1.40-2.50(m,8H),2.55-2.70(m,1.3H),2.75-2.85(m,1H),2.90-3.15(m,2.7H),3.30-4.00(m,4.3H),4.17(s,1H),4.20-4.30(m,0.7H),6.55-6.65(m,0.6H),6.71(dd,J=3,8Hz,0.7H),6.90(d,J=3Hz,0.7H),6.94(d,J=8Hz,0.3H),6.98(d,J=8Hz,0.7H).
2-(4-(tert-ブチル)-1H-ピラゾール-1-イル)-1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,2H),0.75-1.00(m,1H),1.00-1.10(m,1H),1.22(s,6.3H),1.24(s,2.7H),1.40-2.20(m,8H),2.25-2.50(m,1.3H),2.50-2.70(m,1H),2.70-2.90(m,0.7H),2.90-3.30(m,3H),3.30-3.40(m,0.3H),3.70-3.80(m,0.7H),3.80-3.95(m,0.7H),4.05-4.15(m,0.3H),4.57(d,J=16Hz,0.7H),4.69(d,J=16Hz,0.7H),4.88(s,0.6H),6.60-6.70(m,2H),6.94(d,J=8Hz,0.7H),6.98(d,J=8Hz,0.3H),7.16(s,0.7H),7.24(s,0.3H),7.36(s,0.7H),7.37(s,0.3H).
(5aS,6R,11bS)-3-(2-(4-(tert-ブチル)-1H-ピラゾール-1-イル)エチル)-14-(シクロプロピルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,2H),0.75-1.00(m,1H),1.03(d,J=11Hz,1H),1.21(s,9H),1.40-2.10(m,5H),2.20-2.40(m,3H),2.50-2.70(m,3H),2.74(dd,J=6,18Hz,1H),2.80-3.00(m,5H),3.10-3.30(m,1H),4.00-4.10(m,2H),6.54(d,J=3Hz,1H),6.60(dd,J=3,8Hz,1H),6.91(d,J=8Hz,1H),7.10(s,1H),7.25(s,1H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-カルボン酸2,2,2-トリクロロエチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.17(m,2H),0.45-0.55(m,2H),0.76-0.88(m,1H),0.96-2.12(m,6H),2.26-2.59(m,4H),2.73-3.05(m,3H),3.51-3.77(m,4H),3.77(s,1.5H),3.79(s,1.5H),4.47(d,J=12Hz,0.5H),4.52(br s,1H),4.62(s,1H),4.79(d,J=12Hz,0.5H),6.64-6.71(m,2H),6.95-7.02(m,1H).
(5aS,6R,11bR)-5a-アセトキシ-14-(シクロプロピルメチル)-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-カルボン酸2,2,2-トリクロロエチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.02-0.11(m,2H),0.38-0.52(m,2H),0.68-0.91(m,1H),1.05-3.80(m,15H),2.09(s,1.5H),2.13(s,1.5H),3.79(s,3H),3.86-3.99(m,1H),4.22(d,J=6Hz,0.5H),4.27(d,J=6Hz,0.5H),4.62(d,J=12Hz,0.5H),4.69(d,J=12Hz,0.5H),4.71(d,J=12Hz,0.5H),4.90(d,J=12Hz,0.5H),6.69-6.76(m,2H),6.97-7.07(m,1H).
(5aS,6R,11bR)-14-アセチル-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-カルボン酸2,2,2-トリクロロエチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):1.04-1.30(m,1H),1.52-4.84(m,19H),3.79(s,1.5H),3.80(s,1.5H),6.67-6.77(m,2H),6.96-7.15(m,1H).
1-((5aS,6R,11bS)-5a-ヒドロキシ-10-メトキシ-1,2,3,4,5,5a,6,7-オクタヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-14-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):1.04-1.14(m,1H),1.50-2.47(m,6H),2.11(s,1.5H),2.20(s,1.5H),2.53-3.00(m,4H),3.02-3.14(m,1H),3.24-3.36(m,1H),3.42-3.50(m,0.5H),3.80(s,3H),3.89(d,J=7Hz,0.5H),4.33-4.40(m,0.5H),4.87(d,J=6Hz,0.5H),6.76(dd,J=2,8Hz,1H),6.80-6.83(m,1H),7.05(d,J=8Hz,0.5H),7.06(d,J=8Hz,0.5H).
1-((5aS,6R,11bS)-5a-ヒドロキシ-10-メトキシ-3-(2-(ピリジン-2-イル)エチル)-1,2,3,4,5,5a,6,7-オクタヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-14-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.97-1.11(m,1H),1.50-3.15(m,15H),2.09(s,1.5H),2.18(s,1.5H),3.19-3.33(m,1H),3.39-3.48(m,0.5H),3.79(s,1.5H),3.79(s,1.5H),3.85(d,J=6Hz,0.5H),4.31-4.38(m,0.5H),4.87(d,J=6Hz,0.5H),6.71-6.77(m,1H),6.78-6.82(m,1H),7.01-7.07(m,1H),7.10-7.20(m,2H),7.57-7.65(m,1H),8.49-8.56(m,1H).
(5aS,6R,11bR)-10-メトキシ-3-(2-(ピリジン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.92-1.00(m,1H),1.48(dd,J=7,14Hz,1H),1.72-1.93(m,3H),2.28(dd,J=4,15Hz,1H),2.40-2.71(m,5H),2.82-3.00(m,7H),3.19(dd,J=7,18Hz,1H),3.79(s,3H),4.81(br s,1H),6.72(dd,J=3,8Hz,1H),6.75(d,J=3Hz,1H),7.06(d,J=8Hz,1H),7.12-7.20(m,2H),7.63(ddd,J=2,7,7Hz,1H),8.54-8.57(m,1H).
(5aS,6R,11bR)-3-(2-(ピリジン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオール(化合物I)及び(5aS,6R,11bS)-14-メチル-3-(2-(ピリジン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオール(化合物J)の合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.93-1.03(m,1H),1.47(dd,J=7,15Hz,1H),1.60-1.71(m,1H),1.77-1.92(m,2H),2.19(dd,J=4,15Hz,1H),2.32-2.63(m,5H),2.75-3.01(m,7H),3.18(dd,J=7,18Hz,1H),6.64(dd,J=2,8Hz,1H),6.69(d,J=2Hz,1H),6.96(d,J=8Hz,1H),7.14-7.22(m,2H),7.66(ddd,J=2,8,8Hz,1H),8.53-8.58(m,1H).
1H-NMR(400MHz,CDCl3)δ(ppm):0.96-1.08(m,1H),1.41-1.54(m,1H),1.76-2.09(m,4H),2.16-2.38(m,2H),2.33(s,3H),2.61(d,J=6Hz,1H),2.63-2.96(m,8H),3.03(d,J=18Hz,1H),3.11-3.23(m,1H),4.58(br s,1H),6.53(d,J=2Hz,1H),6.59(dd,J=2,8Hz,1H),6.91(d,J=8Hz,1H),7.07-7.14(m,2H),7.56(ddd,J=2,7,7Hz,1H),8.46-8.51(m,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-3-(1H-ピラゾール-1-イル)プロパン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.15(m,2H),0.48-0.53(m,2H),0.78-0.88(m,1H),1.06-1.14(m,1H),1.52-1.65(m,1.3H),1.78-1.93(m,1.7H),1.94-2.20(m,2.3H),2.26-2.48(m,2.7H),2.50-2.58(m,1H),2.68-2.81(m,1.3H),2.82-2.99(m,3.7H),3.00-3.22(m,1.3H),3.26-3.33(m,0.7H),3.67-3.82(m,1H),3.86-3.99(m,1.3H),4.07(br s,0.3H),4.20-4.29(m,0.7H),4.40-4.48(m,1H),4.53(br s,0.7H),6.17(s,0.3H),6.22(s,0.7H),6.65-6.76(m,1.3H),6.77-6.81(m,0.7H),6.91-6.98(m,1H),7.37(s,0.7H),7.42(s,0.3H),7.47(s,0.3H),7.56(s,0.7H),7.89(br s,0.7H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(チアゾール-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.08-0.12(m,2H),0.49-0.53(m,2H),0.77-0.88(m,1H),1.05-1.10(m,1H),1.23-1.28(m,1H),1.60-1.64(m,1H),1.79-2.15(m,4H),2.24-2.39(m,2H),2.52-2.64(m,1H),2.69-2.80(m,1H),2.88-3.00(m,2H),3.25-3.50(m,2H),3.82-4.15(m,4H),6.60(dd,J=2,8Hz,0.6H),6.65(dd,J=2,8Hz,0.4H),6.69(d,J=2Hz,0.6H),6.72(d,J=2Hz,0.4H),6.88-6.92(m,1H),7.25-7.28(m,1H),7.67-7.69(m,1H).
(5aS,6R,11bS)-14-プロピル-3-(2-(ピリジン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
得られた粗生成物のクロロホルム(2mL)溶液に、氷冷下1M三臭化ホウ素-ジクロロメタン溶液(500μL,0.50mmol)を加え、室温で30分間撹拌した。反応混合物に氷冷下28%アンモニア水溶液を加え、クロロホルムで三回抽出した。有機層を合わせて硫酸ナトリウムで乾燥後、減圧下にて濃縮した。得られた粗生成物を分取薄層クロマトグラフィー(クロロホルム:2Mアンモニア-メタノール溶液=10:1)で精製し、表題化合物(4.9mg,45%)を無色アモルファスとして得た。
1H-NMR(400MHz,CDCl3)δ(ppm):0.90(t,J=7Hz,3H),0.98-1.05(m,1H),1.41-1.52(m,3H),1.79-2.05(m,4H),2.27-2.44(m,4H),2.66(d,J=6Hz,1H),2.75(dd,J=6,18Hz,1H),2.80-3.02(m,8H),3.32(dd,J=11,11Hz,1H),6.49(d,J=3Hz,1H),6.58(dd,J=3,8Hz,1H),6.89(d,J=8Hz,1H),7.07-7.14(m,2H),7.55(ddd,J=2,8,8Hz,1H),8.45-8.48(m,1H).
2-(4-シクロプロピル-1H-ピラゾール-1-イル)-1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,4H),0.75-0.95(m,3H),1.00-1.15(m,1H),1.50-2.40(m,8.4H),2.50-2.65(m,1.6H),2.65-2.85(m,1H),2.85-3.05(m,2H),3.05-3.40(m,2H),3.60-3.75(m,0.6H),3.75-3.90(m,1H),4.00-4.10(m,0.4H),4.55(d,J=16Hz,0.6H),4.70(d,J=16Hz,0.6H),4.85(d,J=16Hz,0.4H),4.89(d,J=16Hz,0.4H),6.60-6.70(m,2H),6.85-7.00(m,1H),7.10(s,0.6H),7.16(s,0.4H),7.26(s,1H).
(5aS,6R,11bS)-14-(シクロブチルメチル)-10-メトキシ-3-(2-(ピリジン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.94-1.07(m,1H),1.20-1.32(m,1H),1.40-1.51(m,1H),1.58-2.11(m,10H),2.27-2.68(m,7H),2.71-2.95(m,6H),3.01(d,J=18Hz,1H),3.14-3.26(m,1H),3.76(s,3H),4.63(br s,1H),6.66(d,J=2Hz,1H),6.69(dd,J=3,8Hz,1H),6.98-7.08(m,3H),7.49(ddd,J=2,8,8Hz,1H),8.44-8.47(m,1H).
(5aS,6R,11bS)-14-(シクロブチルメチル)-3-(2-(ピリジン-2-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.96-1.03(m,1H),1.20-1.28(m,1H),1.41-1.52(m,1H),1.56-1.69(m,2H),1.75-2.10(m,8H),2.28-2.50(m,5H),2.60(d,J=6Hz,1H),2.73(dd,J=6,18Hz,1H),2.80-3.04(m,7H),3.31(dd,J=12,12Hz,1H),6.47(d,J=2Hz,1H),6.58(dd,J=2,8Hz,1H),6.88(d,J=8Hz,1H),7.07-7.15(m,2H),7.56(ddd,J=2,8,8Hz,1H),8.44-8.47(m,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(4-メチル-3-(トリフルオロメチル)-1H-ピラゾール-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.08-0.13(m,2H),0.49-0.54(m,2H),0.79-0.84(m,1H),1.07-1.10(m,1H),1.23-1.28(m,1H),1.56-2.07(m,5H),2.11(s,1.5H),2.14(s,1.5H),2.20-2.39(m,2H),2.53-2.67(m,1H),2.75(ddd,J=6,19,19Hz,1H),2.88-3.02(m,2H),3.12-3.18(m,0.5H),3.32-3.42(m,1.5H),3.65-3.75(m,0.5H),3.79-3.86(m,1H),4.02-4.07(m,0.5H),4.64(d,J=16Hz,0.5H),4.79(d,J=16Hz,0.5H),4.90(d,J=16Hz,0.5H),4.95(d,J=16Hz,0.5H),5.90(br s,0.5H),6.62-6.67(m,2H),6.95(dd,J=2,8Hz,1H),7.16(s,0.5H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(4-メチル-3-(トリフルオロメチル)-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.09-0.13(m,2H),0.49-0.53(m,2H),0.81-0.89(m,1H),1.01-1.04(m,1H),1.22-1.28(m,1H),1.46(dd,J=4,14Hz,1H),1.72-1.85(m,2H),2.00-2.05(m,2H),2.05(s,3H),2.37-3.03(m,11H),3.20(dd,J=12,12Hz,1H),3.99-4.13(m,2H),6.60(s,1H),6.62(d,J=8Hz,1H),6.83(s,1H),6.97(d,J=8Hz,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(4-イソプロピル-1H-1,2,3-トリアゾール-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.09-0.14(m,2H),0.49-0.55(m,2H),0.79-0.87(m,1H),1.09-1.12(m,1H),1.20-1.28(m,6H),1.58-1.66(m,1H),1.81-2.11(m,4H),2.22-2.39(m,2.2H),2.54-2.80(m,3H),2.90-3.07(m,3.2H),3.30-3.42(m,1.6H),3.85-3.97(m,1.6H),4.12-4.15(m,0.4H),4.56(br s,1H),4.67(d,J=16Hz,0.6H),5.12(d,J=16Hz,0.4H),5.25(d,J=16Hz,0.4H),5.29(d,J=16Hz,0.6H),6.65-6.69(m,1H),6.78(s,0.6H),6.91-6.95(m,1.4H),7.26(s,0.6H),7.39(s,0.4H).
1-(2-((tert-ブチルジメチルシリル)オキシ)エチル)-3-メチル-1H-ピロールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.90(s,9H),0.93(s,3H),1.59(s,3H),2.10(s,3H),3.78-3.85(m,2H),3.89-3.95(m,2H),5.94-5.98(m,1H),6.43-6.47(m,1H),6.56-6.59(m,1H).
2-(3-メチル-1H-ピロール-1-イル)エタン-1-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):2.10(s,3H),3.83(t,J=5Hz,2H),3.95(t,J=5Hz,2H),5.98-6.02(m,1H),6.46-6.49(m,1H),6.58-6.61(m,1H).
4-メチルベンゼンスルホン酸2-(3-メチル-1H-ピロール-1-イル)エチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):2.04(s,3H),2.44(s,3H),4.05(t,J=6Hz,2H),4.20(t,J=6Hz,2H),5.90-5.94(m,1H),6.30-6.33(m,1H),6.44-6.48(m,1H),7.29(d,J=8Hz,2H),7.66(d,J=8Hz,2H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(3-メチル-1H-ピロール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.16(m,2H),0.46-0.54(m,2H),0.76-0.90(m,1H),0.98-1.07(m,1H),1.42-1.51(m,1H),1.74-1.84(m,2H),1.95-2.06(m,2H),2.05(s,3H),2.28-2.39(m,3H),2.49-2.57(m,1H),2.62-2.98(m,8H),3.13-3.22(m,1H),3.85(t,J=7Hz,2H),4.72(br s,1H),5.89(dd,J=2,2Hz,1H),6.30-6.34(m,1H),6.42-6.45(m,1H),6.45-6.48(m,1H),6.58(dd,J=2,8Hz,1H),6.92(d,J=8Hz,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2,2,2-トリフルオロエタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.19(m,2H),0.43-0.60(m,2H),0.75-0.95(m,1H),1.01-1.78(m,3H),1.79-2.24(m,4H),2.27-2.47(m,3H),2.48-2.66(m,1H),2.70-2,85(m,1H),2.86-3.06(m,2H),3.27-3.36(m,0.5H),3.42-3.69(m,1.5H),3.69-3.89(m,1H),3.91-4.09(m,1H),6.58(d,J=2Hz,0.5H),6.60-6.70(m,1.5H),6.91-7.02(m,1H).
3-(クロロメチル)-5-メチルイソチアゾールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):2.58(s,3H),4.62(s,2H),7.05(s,1H).
2-(5-メチルイソチアゾール-3-イル)アセトニトリルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):2.59(s,3H),3.86(s,2H),7.01(s,1H).
2-(5-メチルイソチアゾール-3-イル)酢酸の合成
1H-NMR(400MHz,CDCl3)δ(ppm):2.59(s,3H),3.88(s,2H),6.91(s,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(5-メチルイソチアゾール-3-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.08-0.12(m,2H),0.48-0.53(m,2H),0.78-0.85(m,1H),1.02-1.10(m,1H),1.53-1.62(m,1H),1.72-2.15(m,4H),2.26-2.38(m,2.6H),2.47-2.54(m,4.4H),2.67(dd,J=6,18Hz,0.6H),2.77(dd,J=6,18Hz,0.4H),2.85-2.98(m,2H),3.33-3.41(m,1.4H),3.45-3.49(m,1.2H),3.57(d,J=15Hz,0.4H),3.72(d,J=15Hz,0.4H),3.73-3.78(m,0.4H),3.78(d,J=15Hz,0.6H),3.85-3.88(m,1H),3.89(d,J=15Hz,0.6H),3.99-4.02(m,0.4H),4.46-4.52(m,0.6H),6.61-6.68(m,1.5H),6.79-6.83(m,1.5H),6.89-6.92(m,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-3-(4-(トリフルオロメチル)-1H-ピラゾール-1-イル)プロパン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.15(m,2H),0.48-0.56(m,2H),0.76-0.89(m,1H),1.04-1.15(m,1H),1.55-1.63(m,1H),1.78(ddd,J=3,12,14Hz,0.5H),1.87-2.25(m,3.5H),2.29(dd,J=6,13Hz,0.5H),2.32-2.39(m,1.5H),2.51-3.09(m,7H),3.24(ddd,J=4,4,13Hz,0.5H),3.26-3.34(m,0.5H),3.36(ddd,J=2,6,14Hz,0.5H),3.63-3.90(m,1.5H),4.03-4.18(m,1.5H),4.32(ddd,J=7,7,14Hz,0.5H),4.47(t,J=7Hz,1H),6.61(dd,J=2,8Hz,0.5H),6.64-6.69(m,1H),6.75-6.80(m,0.5H),6.91(d,J=8Hz,0.5H),6.96(d,J=8Hz,0.5H),7.66(s,0.5H),7.69(s,0.5H),7.73(s,0.5H),7.81(s,0.5H).
(5aS,6R,11bR)-5a-(ベンゾイロキシ)-14-(シクロプロピルメチル)-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-カルボン酸2,2,2-トリクロロエチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):-0.18-0.00(m,2H),0.29-0.43(m,2H),0.58-0.70(m,1H),0.83-2.84(m,11H),3.02-3.35(m,3H),3.63-3.78(m,1H),3.81(s,1.2H),3.81(s,1.8H),3.88-4.03(m,1.6H),4.40-4.51(m,1.4H),4.53(d,J=12Hz,0.6H),4.63(d,J=12Hz,0.4H),6.72-6.79(m,2H),7.05-7.11(m,1H),7.28-7.60(m,3H),8.01-8.08(m,2H).
(5aS,6R,11bR)-14-ベンゾイル-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-カルボン酸2,2,2-トリクロロエチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.88-1.39(m,1H),1.60-3.02(m,9H),3.30-3.90(m,5H),3.79(s,1.2H),3.80(s,1.8H),4.37-4.96(m,3H),6.67-6.78(m,2H),6.99-7.12(m,1H),7.34-7.51(m,5H).
((5aS,6R,11bS)-5a-ヒドロキシ-10-メトキシ-1,2,3,4,5,5a,6,7-オクタヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-14-イル)(フェニル)メタノンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.80-1.50(m,1H),1.55-3.28(m,11H),3.30-3.42(m,1H),3.73-4.00(m,1H),3.78(s,3H),4.38-4.49(m,0.5H),4.92-5.00(m,0.5H),6.70-6.86(m,2H),7.04(d,J=8Hz,0.5H),7.11(d,J=8Hz,0.5H),7.32-7.61(m,5H).
1-((5aS,6R,11bS)-14-ベンゾイル-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(4-メチル-1H-ピラゾール-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.80-4.60(m,15H),2.04(s,1.5H),2.07(s,1.5H),3.79(s,1.5H),3.81(s,1.5H),4.76-4.96(m,2H),6.66-6.74(m,1H),6.76-6.83(m,1H),6.98-7.20(m,2H),7.26-7.33(m,1H),7.34-7.50(m,5H).
(5aS,6R,11bS)-14-ベンジル-10-メトキシ-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.96-1.06(m,1H),1.34-1.43(m,1H),1.73(ddd,J=3,11,11Hz,1H),1.84(ddd,J=4,4,16Hz,1H),1.95-2.10(m,2H),1.99(s,3H),2.31-2.48(m,3H),2.64(ddd,J=4,4,13Hz,1H),2.73(d,J=6Hz,1H),2.76-2.88(m,3H),2.94-3.04(m,1H),3.09-3.20(m,2H),3.59(d,J=13Hz,1H),3.64(d,J=13Hz,1H),3.77(s,3H),3.86-4.05(m,2H),4.51(br s,1H),6.69(d,J=2Hz,1H),6.70-6.76(m,2H),7.09(d,J=8Hz,1H),7.17-7.35(m,6H).
(5aS,6R,11bS)-14-ベンジル-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.95-1.05(m,1H),1.33-1.44(m,1H),1.68-1.82(m,2H),1.91-2.13(m,2H),1.99(s,3H),2.28-2.42(m,2H),2.48-2.68(m,2H),2.70(d,J=6Hz,1H),2.79(dd,J=6,18Hz,1H),2.83-2.99(m,3H),3.05-3.23(m,2H),3.58(d,J=13Hz,1H),3.64(d,J=13Hz,1H),3.99-4.11(m,2H),6.53(d,J=2Hz,1H),6.63(dd,J=2,8Hz,1H),6.90(s,1H),6.97(d,J=8Hz,1H),7.20-7.38(m,6H).
(5aS,6R,11bR)-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.92-1.00(m,1H),1.47(dd,J=7,15Hz,1H),1.63-2.05(m,3H),2.09(s,3H),2.16(dd,J=5,15Hz,1H),2.31-2.64(m,5H),2.82-2.98(m,5H),3.17(dd,J=7,18Hz,1H),4.08-4.15(m,2H),6.62-6.68(m,2H),6.98(d,J=8Hz,1H),7.15(s,1H),7.35(s,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(5-メチルイソチアゾール-3-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.13(m,2H),0.47-0.52(m,2H),0.79-0.86(m,1H),1.00-1.07(m,1H),1.47-1.51(m,1H),1.78-1.85(m,2H),1.96-2.07(m,2H),2.30-2.35(m,3H),2.50(s,3H),2.50-2.54(m,1H)2.71-2.80(m,3H),2.87-2.96(m,7H),3.15-3.23(m,1H),4.74(br s,1H),6.44-6.49(m,1H),6.57(dd,J=2,8Hz,1H),6.71(s,1H),6.89(d,J=8Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2,2,2-トリフルオロエチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.18(m,2H),0.42-0.58(m,2H),0.75-0.91(m,1H),0.98-1.13(m,1H),1.19-1.90(m,3H),1.92-2.11(m,2H),2.25-2.42(m,3H),2.48-2.63(m,1H),2.72-2.85(m,2H),2.86-3.18(m,6H),3.23-3.31(m,1H),4.64(br s,1H),6.54-6.66(m,2H),6.96(d,J=8Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(3-(4-(トリフルオロメチル)-1H-ピラゾール-1-イル)プロピル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.16(m,2H),0.46-0.56(m,2H),0.77-0.89(m,1H),1.02-1.08(m,1H),1.46-1.53(m,1H),1.75-1.89(m,4H),1.96-2.10(m,2H),2.16-2.43(m,6H),2.49-2.60(m,2H),2.84(dd,J=6,18Hz,1H),2.91-3.04(m,4H),3.76(ddd,J=7,7,14Hz,1H),3.82(ddd,J=7,7,14Hz,1H),4.65(br s,1H),6.58(dd,J=2,8Hz,1H),6.72(d,J=2Hz,1H),6.97(d,J=8Hz,1H),7.19(s,1H),7.64(s,1H).
2-クロロ-1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.19(m,2H),0.42-0.61(m,2H),0.75-0.92(m,1H),1.02-1.18(m,1H),1.21-2.43(m,8H),2.46-3.12(m,5H),3.33-4.01(m,3H),4.06-4.32(m,2H),6.51-6.78(m,1.4H),6.79-7.04(m,1.6H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(3,3-ジフルオロピロリジン-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.19(m,2H),0.41-0.59(m,2H),0.74-0.92(m,1H),0.99-1.18(m,1H),1.19-2.43(m,10H),2.46-3.12(m,8.3H),3.17-3.28(m,1H),3.30-3.54(m,2.7H),3.60-3.72(m,0.3H),3.73-3.88(m,1H),3.90-4.05(m,0.7H),6.51-6.73(m,1.3H),6.79-7.02(m,1.7H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(3,3-ジフルオロピロリジン-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.18(m,2H),0.43-0.57(m,2H),0.76-0.92(m,1H),0.96-1.08(m,1H),1.17-1.91(m,3H),1.94-2.09(m,2H),2.11-2.26(m,2H),2.27-2.41(m,3H),2.46-3.00(m,15H),3.01-3.16(m,1H),4.73(br s,1H),6.48(d,J=2Hz,1H),6.56(dd,J=2,8Hz,1H),6.90(d,J=8Hz,1H).
(5aS,6R,11bS)-3-(2-(4-シクロプロピル-1H-ピラゾール-1-イル)エチル)-14-(シクロプロピルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,4H),0.70-0.95(m,3H),1.00-1.10(m,1H),1.20-1.40(m,1H),1.40-1.50(m,2H),1.50-2.20(m,3H),2.20-2.45(m,4H),2.50-2.60(m,2H),2.60-2.80(m,2H),2.85-3.10(m,4H),3.15-3.30(m,1H),4.00-4.20(m,2H),6.56(d,J=3Hz,1H),6.63(dd,J=3,8Hz,1H),6.94(d,J=8Hz,1H),7.00(s,1H),7.22(s,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(4-フルオロ-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,2H),0.75-1.00(m,1H),0.95-1.05(m,1H),1.40-1.90(m,3H),1.90-2.10(m,3H),2.25-2.65(m,6H),2.70-2.85(m,3H),2.85-3.05(m,2H),3.05-3.15(m,1H),3.80-4.00(m,2H),6.60-6.70(m,3H),6.97(d,J=8Hz,1H),7.19(d,J=4Hz,1H).
2-(5-メチルイソキサゾール-3-イル)酢酸の合成
1H-NMR(400MHz,CDCl3)δ(ppm):2.43(s,3H),3.76(s,2H),6.06(s,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(5-メチルイソキサゾール-3-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.08-0.13(m,2H),0.50-0.54(m,2H),0.78-0.85(m,1H),1.04-1.13(m,1H),1.55-1.64(m,1H),1.78-2.08(m,3.4H),2.16-2.38(m,6.6H),2.51-2.60(m,1.4H),2.72(dd,J=7,19Hz,0.6H),2.77(dd,J=6,20Hz,0.4H),2.87-3.01(m,2H),3.16-3.22(m,0.6H),3.36-3.48(m,2H),3.59(d,J=15Hz,0.4H),3.67(d,J=15Hz,0.6H),3.63-3.97(m,2H),4.48(br s,0.6H),5.90(s,0.4H),5.97(s,0.6H),6.61-6.68(m,1.4H),6.82-6.84(m,0.6H),6.90-6.94(m,1H),7.60(br s,0.4H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-3-(ジメチルアミノ)プロパン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.02-0.17(m,2H),0.43-0.57(m,2H),0.76-0.88(m,1H),1.02-1.14(m,1H),1.52-1.65(m,1H),1.77(ddd,J=2,12,14Hz,0.5H),1.86-2.11(m,3H),2.13-2.47(m,5.5H),2.23(s,3H),2.24(s,3H),2.49-2.81(m,4H),2.88(d,J=6Hz,0.5H),2.92(d,J=19Hz,0.5H),2.92(d,J=6Hz,0.5H),3.00(d,J=18Hz,0.5H),3.12-3.27(m,1H),3.37(ddd,J=3,3,14Hz,0.5H),3.40(ddd,J=2,6,14Hz,0.5H),3.80-3.98(m,1.5H),4.07-4.16(m,0.5H),4.47(br s,0.5H),4.53(br s,0.5H),6.58-6.63(m,0.5H),6.65(dd,J=2,8Hz,0.5H),6.68-6.71(m,0.5H),6.81(d,J=2Hz,0.5H),6.90(d,J=8Hz,0.5H),6.94(d,J=8Hz,0.5H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-3-メトキシプロパン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.17(m,2H),0.44-0.57(m,2H),0.74-0.90(m,1H),0.91-0.98(m,0.3H),1.02-1.11(m,0.7H),1.53-1.63(m,1H),1.72-2.12(m,4H),2.23-2.57(m,6H),2.74(dd,J=6,18Hz,1H),2.83-2.92(m,1.3H),2.98(d,J=18Hz,0.7H),3.27(s,2.1H),3.29(s,0.9H),3.30-3.88(m,6H),4.49(br s,1H),6.61(dd,J=2,8Hz,0.3H),6.65(d,J=2Hz,0.3H),6.69(dd,J=2,8Hz,0.7H),6.77-6.82(m,0.7H),6.86(d,J=8Hz,0.3H),6.89(d,J=8Hz,0.7H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(5-メチルイソキサゾール-3-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.08-0.11(m,2H),0.47-0.52(m,2H),0.78-0.86(m,1H),1.03-1.05(m,1H),1.49(dd,J=4,14Hz,1H),1.68-1.71(m,1H),1.78-1.84(m,2H),1.99-2.03(m,2H),2.32(s,3H),2.32-2.35(m,2H)2.52-2.54(m,1H),2.71-2.96(m,9H),3.13-3.19(m,1H),3.69-3.71(m,2H),4.71(br s,1H),5.72(s,1H),6.45(s,1H),6.54-6.59(m,1H),6.89(d,J=8Hz,1H).
1-(2-((5aS,6R,11bS)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)エチル)-1H-ピラゾール-4-カルボニトリルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.03(d,J=12Hz,1H),1.15-1.25(m,1H),1.77(dd,J=5,15Hz,1H),1.90-2.10(m,2H),2.15-2.25(m,1H),2.25-2.40(m,2H),2.45-2.70(m,3H),2.70-3.05(m,5H),3.05-3.20(m,2H),3.65-3.80(m,1H),3.85-4.05(m,2H),6.65-6.80(m,3H),7.12(d,J=8Hz,1H),7.63(s,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-3-(ピリジン-2-イル)プロパン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.17(m,2H),0.44-0.57(m,2H),0.76-0.90(m,1H),1.07-1.16(m,1H),1.52-1.63(m,1H),1.77-2.43(m,8H),2.50-2.59(m,1H),2.65-3.20(m,7H),3.25-3.37(m,1H),3.88(ddd,J=3,13,13Hz,0.3H),3.94-4.07(m,1.4H),4.22(dd,J=4,15Hz,0.3H),4.43(br s,0.3H),4.55(br s,0.7H),6.69(dd,J=2,8Hz,0.3H),6.71-6.76(m,0.7H),6.83(dd,J=2,2Hz,0.7H),6.88-6.97(m,1.3H),7.09(dd,J=5,8Hz,0.3H),7.16-7.23(m,1.7H),7.56(ddd,J=2,8,8Hz,0.3H),7.65(ddd,J=2,8,8Hz,0.7H),8.47-8.53(m,1H).
(5-エチルイソキサゾール-3-イル)メタノールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):1.30(t,J=8Hz,3H),2.77(q,J=8Hz,2H),4.73(s,2H),6.03(s,1H).
3-(クロロメチル)-5-エチルイソキサゾールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):1.31(t,J=8Hz,3H),2.77(q,J=8Hz,2H),4.56(s,2H),6.10(s,1H).
2-(5-エチルイソキサゾール-3-イル)アセトニトリルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):1.31(t,J=8Hz,3H),2.79(q,J=8Hz,2H),3.78(s,2H),6.10(s,1H).
2-(5-エチルイソキサゾール-3-イル)酢酸の合成
1H-NMR(400MHz,CDCl3)δ(ppm):1.30(t,J=8Hz,3H),2.77(q,J=8Hz,2H),3.77(s,2H),6.05(s,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(5-エチルイソキサゾール-3-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.08-0.13(m,2H),0.48-0.54(m,2H),0.80-0.86(m,1H),1.04-1.13(m,1H),1.23-1.32(m,3H),1.59-1.63(m,1H),1.70-2.10(m,3.4H),2.20-2.23(m,1H),2.28-2.39(m,2H),2.52-2.60(m,1.4H),2.68-2.81(m,3H),2.89-3.02(m,2H),3.16(ddd,J=4,9,13Hz,0.6H),3.37-3.49(m,2H),3.59(d,J=15Hz,0.4H),3.68(d,J=15Hz,0.6H),3.71-3.80(m,1H),3.83-3.88(m,0.4H),3.93(ddd,J=3,12,12Hz,0.6H),4.12-4.18(m,0.6H),5.92(s,0.4H),5.99(s,0.6H),6.61-6.67(m,1.4H),6.80-6.82(m,0.6H),6.91-6.95(m,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(4-エチル1H-ピラゾール-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.00-1.10(m,1H),1.10-1.30(m,3H),1.50-2.10(m,3H),2.10-2.25(m,1H),2.25-2.40(m,2H),2.40-2.70(m,3H),2.70-2.85(m,1H),2.85-3.15(m,2.4H),3.20-3.60(m,1.6H),3.60-3.75(m,0.6H),3.80-4.00(m,1.4H),4.05-4.25(m,1H),4.52(br s,1H),4.60(d,J=16Hz,0.6H),4.73(d,J=16Hz,0.6H),4.88(d,J=16Hz,0.4H),4.93(d,J=16Hz,0.4H),6.60-6.80(m,2H),6.90-7.00(m,1H),7.14(s,0.6H),7.21(s,0.4H),7.34(s,0.6H),7.42(s,0.4H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(4-エチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.03(d,J=10Hz,1H),1.15(t,J=8Hz,3H),1.40-1.50(m,1H),1.70-1.85(m,2H),1.90-2.10(m,2H),2.30-2.40(m,3H),2.41(q,J=8Hz,2H),2.50-2.70(m,3H),2.70-2.80(m,1H),2.80-3.00(m,5H),3.15-3.30(m,1H),4.00-4.15(m,2H),6.55(s,1H),6.61(d,J=8Hz,1H),6.92(d,J=8Hz,1H),6.96(s,1H),7.28(s,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(4-イソプロピル-1H-ピラゾール-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.00-1.10(m,1H),1.17(d,J=7Hz,3.6H),1.18(d,J=7Hz,2.4H),1.50-1.70(m,1H),1.70-1.90(m,2H),1.90-2.10(m,3H),2.20-2.40(m,2H),2.50-3.05(m,5H),3.15-3.30(m,1H),3.30-3.45(m,1H),3.70-3.95(m,2H),4.55(br s,1H),4.57(d,J=16Hz,0.6H),4.74(d,J=16Hz,0.6H),4.78(d,J=16Hz,0.4H),4.86(d,J=16Hz,0.4H),6.60-6.70(m,2H),6.90(d,J=8Hz,0.6H),6.93(d,J=8Hz,0.4H),7.15(s,0.4H),7.16(s,0.6H),7.34(s,0.4H),7.36(s,0.6H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(4-イソプロピル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.03(d,J=10Hz,1H),1.16(d,J=7Hz,3H),1.17(d,J=7Hz,3H),1.44(dd,J=2,15Hz,1H),1.70-1.85(m,2H),1.95-2.05(m,2H),2.20-2.40(m,2H),2.50-2.85(m,6H),2.85-3.00(m,5H),3.15-3.30(m,1H),4.00-4.15(m,2H),6.50(d,J=2Hz,1H),6.60(dd,J=2,8Hz,1H),6.90(d,J=8Hz,1H),7.05(s,1H),7.31(s,1H).
(5aS,6R,11bS)-14-アリル-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.95-1.10(m,1H),1.35-1.50(m,1H),1.70-1.85(m,2H),1.95-2.08(m,2H),2.00(s,3H),2.28-2.53(m,3H),2.54-2.62(m,1H),2.68-3.02(m,6H),3.07-3.19(m,3H),3.94-4.08(m,2H),5.08-5.21(m,2H),5.72-5.85(m,1H),6.56(d,J=2Hz,1H),6.62(dd,J=2,8Hz,1H),6.86(s,1H),6.95(d,J=8Hz,1H),7.23(s,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(5-エチルイソキサゾール-3-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.08-0.11(m,2H),0.48-0.52(m,2H),0.80-0.87(m,1H),1.03-1.05(m,1H),1.23(t,J=8Hz,3H),1.46-1.49(m,1H),1.77-1.87(m,2H),1.96-2.08(m,2H),2.31-2.38(m,3H),2.53-2.55(m,1H),2.65-2.83(m,9H),2.88-2.97(m,3H),3.13-3.19(m,1H),4.69(br s,1H),5.73(s,1H),6.50(d,J=2Hz,1H),6.58(dd,J=2,8Hz,1H),6.91(d,J=8Hz,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(ジメチルアミノ)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.13(m,2H),0.46-0.54(m,2H),0.77-0.87(m,1H),1.01-1.07(m,0.3H),1.09-1.15(m,0.7H),1.56-1.64(m,1H),1.78-2.12(m,3H),2.16-2.39(m,3.7H),2.21(s,4.2H),2.25(s,1.8H),2.49-2.62(m,1.3H),2.76(dd,J=6,18Hz,0.7H),2.77(dd,J=6,18Hz,0.3H),2.84-3.17(m,4H),3.20-3.29(m,0.7H),3.30-3.39(m,0.3H),3.41-3.51(m,1H),3.76(ddd,J=4,12,14Hz,0.3H),3.81-3.91(m,1H),4.09-4.17(m,0.7H),4.52(br s,1H),6.54(dd.J=3,8Hz,0.3H),6.65-6.70(m,1H),6.87(d,J=8Hz,0.3H),6.92(d,J=8Hz,0.7H),6.95(d,J=2Hz,0.7H).
(5aS,6R,11bR)-3-(3-((tert-ブチルジメチルシリル)オキシ)プロピル)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):-0.04(s,3H), -0.03(s,3H), 0.02-0.16(m,2H),0.46-0.55(m,2H),0.80-0.95(m,1H),0.84(s,9H),1.08-1.18(m,1H),1.33-1.82(m,4H),1.99-2.12(m,2H),2.28-2.45(m,2H),2.53-2.60(m,1H),2.64(d,J=15Hz,1H),2.73(dd,J=6,18Hz,1H),2.88-2.99(m,2H),3.00(d,J=18Hz,1H),3.06-3.21(m,2H),3.33-3.56(m,3H),3.81(s,3H),4.10(dd,J=11,15Hz,1H),4.72(br s,1H),6.68(dd,J=2,8Hz,1H),6.93(d,J=9Hz,1H),7.19(d,J=2Hz,1H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-3-(3-ヒドロキシプロピル)-10-メトキシ-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.18(m,2H),0.46-0.58(m,2H),0.77-0.90(m,1H),1.10-1.39(m,2H),1.44-1.80(m,3H),2.00-2.15(m,2H),2.35(dd,J=6,12Hz,1H),2.37(dd,J=6,12Hz,1H),2.53-2.67(m,2H),2.71(d,J=15Hz,1H),2.74(dd,J=7,18Hz,1H),2.84-2.96(m,2H),3.00(d,J=18Hz,1H),3.01-3.18(m,2H),3.56(d,J=15Hz,1H),3.68-3.88(m,2H),3.83(s,3H),4.17(dd,J=10,15Hz,1H),6.72(dd,J=2,8Hz,1H),6.95(d,J=9Hz,1H),7.19(d,J=2Hz,1H).
メタンスルホン酸3-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-2-オキソ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)プロピルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.18(m,2H),0.46-0.58(m,2H),0.76-0.92(m,1H),1.08-1.21(m,1H),1.55-3.18(m,16H),2.94(s,3H),3.26-3.86(m,3H),3.80(s,3H),4.15(dd,J=11,15Hz,1H),6.69(dd,J=2,8Hz,1H),6.97(d,J=9Hz,1H),7.16(d,J=2Hz,1H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-3-(3-(4-メチル-1H-ピラゾール-1-イル)プロピル)-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.15(m,2H),0.48-0.56(m,2H),0.76-0.90(m,1H),1.10-1.20(m,1H),1.56-1.77(m,3H),1.83-1.96(m,1H),2.00-2.14(m,2H),2.04(s,3H),2.35(dd,J=7,12Hz,1H),2.36(dd,J=7,12Hz,1H),2.53-2.62(m,1H),2.68(d,J=15Hz,1H),2.76(dd,J=6,18Hz,1H),2.83-2.95(m,3H),3.01(d,J=18Hz,1H),3.44(t,J=7Hz,2H),3.55(d,J=15Hz,1H),3.58-3.69(m,1H),3.78(s,3H),4.09(dd,J=11,15Hz,1H),4.68(br s,1H),6.63(dd,J=3,8Hz,1H),6.94(d,J=9Hz,1H),6.99(s,1H),7.22(s,1H),7.24(d,J=3Hz,1H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-3-(3-(4-メチル-1H-ピラゾール-1-イル)プロピル)-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オンの合成
1H-NMR(400MHz,DMSO-d6)δ(ppm):0.08-0.19(m,2H),0.46-0.58(m,2H),0.82-0.92(m,1H),1.06-1.38(m,1H),1.58-1.89(m,4H),1.99-2.19(m,2H),2.04(s,3H),2.28-2.45(m,2H),2.52-2.62(m,2H),2.75-2.88(m,2H),2.94-3.07(m,3H),3.26-3.36(m,1H),3.37-3.46(m,1H),3.56(d,J=15Hz,1H),3.61-3.72(m,1H),4.09(dd,J=11,15Hz,1H),6.52(dd,J=2,8Hz,1H),6.93(d,J=9Hz,1H),6.97(d,J=3Hz,1H),7.16(s,1H),7.20(s,1H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-3-(3-(ピロリジン-1-イル)プロピル)-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.16(m,2H),0.46-0.56(m,2H),0.75-0.90(m,1H),1.06-1.18(m,1H),1.34-1.89(m,9H),1.99-2.16(m,3H),2.17-2.42(m,6H),2.50-2.77(m,3H),2.86-3.04(m,4H),3.52(d,J=15Hz,1H),3.60-3.75(m,1H),3.81(s,3H),4.10(dd,J=11,15Hz,1H),4.70(br s,1H),6.66(dd,J=2,8Hz,1H),6.93(d,J=8Hz,1H),7.21(d,J=2Hz,1H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-3-(3-(ピロリジン-1-イル)プロピル)-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.17(m,2H),0.47-0.55(m,2H),0.72-0.96(m,1H),1.03-1.90(m,10H),1.97-2.20(m,3H),2.22-2.41(m,6H),2.52-2.59(m,1H),2.64(d,J=15Hz,1H),2.71(dd,J=6,18Hz,1H),2.86-3.03(m,4H),3.51(d,J=15Hz,1H),3.64-3.75(m,1H),4.09(dd,J=11,15Hz,1H),4.72(br s,1H),6.64(dd,J=2,8Hz,1H),6.90(d,J=8Hz,1H),7.12(d,J=2Hz,1H).
(5aS,6R,11bR)-3-(3-(4-(tert-ブチル)-1H-ピラゾール-1-イル)プロピル)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.16(m,2H),0.48-0.56(m,2H),0.77-0.90(m,1H),1.06-1.35(m,1H),1.24(s,9H),1.55-1.78(m,3H),1.86-2.15(m,3H),2.35(dd,J=7,13Hz,1H),2.36(dd,J=7,13Hz,1H),2.52-2.61(m,1H),2.70(d,J=15Hz,1H),2.76(dd,J=6,19Hz,1H),2.83-2.97(m,3H),3.01(d,J=18Hz,1H),3.34-3.53(m,2H),3.55(d,J=15Hz,1H),3.61-3.72(m,1H),3.78(s,3H),4.10(dd,J=11,15Hz,1H),4.74(br s,1H),6.65(dd,J=2,8Hz,1H),6.94(d,J=8Hz,1H),6.98(s,1H),7.25(d,J=2Hz,1H),7.30(s,1H).
(5aS,6R,11bR)-3-(3-(4-(tert-ブチル)-1H-ピラゾール-1-イル)プロピル)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.15(m,2H),0.46-0.57(m,2H),0.74-0.92(m,1H),1.08-1.33(m,1H),1.23(s,9H),1.56-1.82(m,3H),1.89-2.15(m,3H),2.28-2.42(m,2H),2.50-2.64(m,1H),2.66(d,J=15Hz,1H),2.74(dd,J=6,18Hz,1H),2.84-3.04(m,4H),3.38-3.72(m,4H),4.10(dd,J=11,15Hz,1H),6.64(dd,J=1,8Hz,1H),6.90(d,J=8Hz,1H),6.98(s,1H),7.22(d,J=1Hz,1H),7.31(s,1H).
メタンスルホン酸イソチアゾール-3-イルメチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):3.06(s,3H),5.40(s,2H),7.39(d,J=5Hz,1H),8.73(d,J=5Hz,1H).
2-(イソチアゾール-3-イル)アセトニトリルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):3.98(s,2H),7.32(d,J=5Hz,1H),8.74(d,J=5Hz,1H).
2-(イソチアゾール-3-イル)酢酸の合成
1H-NMR(400MHz,CDCl3)δ(ppm):4.00(s,2H),7.22(d,J=5Hz,1H),8.71(d,J=5Hz,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(イソチアゾール-3-イル)エタン-1-オンの合成
の合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.13(m,2H),0.49-0.53(m,2H),0.79-0.86(m,1H),1.04-1.12(m,1H),1.55-1.63(m,1H),1.75-2.10(m,3.6H),2.14-2.40(m,3H),2.44-2.57(m,1.4H),2.69(dd,J=6,18Hz,0.6H),2.78(dd,J=6,18Hz,0.4H),2.88-2.99(m,2H),3.24-3.31(m,0.6H),3.39-3.48(m,1.4H),3.70-3.77(m,0.4H),3.71(d,J=16Hz,0.4H),3.83-3.95(m,2H),4.02(d,J=16Hz,0.6H),4.06-4.12(m,0.6H),6.61-6.66(m,1.4H),6.81(s,0.6H),6.91-6.93(m,1H),7.12-7.13(m,1H),8.54-8.56(m,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(イソチアゾール-3-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.09(m,2H),0.47-0.49(m,2H),0.78-0.94(m,2H),1.26-1.39(m,2H),1.65-1.77(m,2H),1.87-2.18(m,2H),2.29-2.31(m,2H),2.45-3.68(m,13H),6.37-6.44(m,2H),6.68-6.73(m,1H),6.89(d,J=4Hz,1H),8.42(d,J=4Hz,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-3-(チアゾール-2-イル)プロパン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.17(m,2H),0.42-0.60(m,2H),0.75-0.94(m,1H),1.03-2.45(m,9H),2.49-3.46(m,10H),3.80-4.06(m,1.7H),4.13-4.27(m,0.3H),6.61-7.03(m,3H),7.16(d,J=3Hz,0.3H),7.21(d,J=3Hz,0.7H),7.65(d,J=3Hz,0.3H),7.72(d,J=3Hz,0.7H).
(5aS,6R,11bS)-3-(3-(1H-ピラゾール-1-イル)プロピル)-14-(シクロプロピルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.15(m,2H),0.44-0.54(m,2H),0.77-0.92(m,1H),0.99-1.08(m,1H),1.45-1.52(m,1H),1.67-1.95(m,4H),2.00-2.06(m,2H),2.27-2.57(m,8H),2.79(dd,J=6,18Hz,1H),2.87-3.02(m,4H),3.77-3.94(m,2H),4.69(br s,1H),6.18(dd,J=1,2Hz,1H),6.57(dd,J=2,8Hz,1H),6.61(d,J=2Hz,1H),6.90(d,J=8Hz,1H),7.15(d,J=2Hz,1H),7.48(d,J=1Hz,1H).
(5aS,6R,11bR)-3-(3-(1H-ピラゾール-1-イル)プロピル)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.17(m,2H),0.46-0.57(m,2H),0.76-0.94(m,1H),1.10-1.21(m,1H),1.58-1.78(m,2H),1.87-1.99(m,1H),2.02-2.14(m,2H),2.35(dd,J=6,13Hz,1H),2.36(dd,J=6,13Hz,1H),2.53-2.63(m,1H),2.69(d,J=15Hz,1H),2.77(dd,J=6,18Hz,1H),2.83-2.96(m,3H),3.01(d,J=18Hz,1H),3.43-3.60(m,3H),3.62-3.72(m,1H),3.77(s,3H),4.11(dd,J=11,15Hz,1H),6.13-6.17(m,1H),6.63(dd,J=2,9Hz,1H),6.94(d,J=8Hz,1H),7.20-7.26(m,2H),7.42-7.46(m,1H).
(5aS,6R,11bR)-3-(3-(1H-ピラゾール-1-イル)プロピル)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.17(m,2H),0.46-0.56(m,2H),0.76-0.92(m,1H),1.10-1.25(m,1H),1.62(dd,J=6,14Hz,1H),1.66-1.82(m,2H),1.90-2.16(m,3H),2.35(dd,J=6,13Hz,1H),2.36(dd,J=6,13Hz,1H),2.52-2.62(m,1H),2.67(d,J=15Hz,1H),2.76(dd,J=6,18Hz,1H),2.85-2.95(m,3H),3.00(d,J=18Hz,1H),3.48-3.70(m,4H),4.10(dd,J=11,15Hz,1H),6.11-6.15(m,1H),6.62(dd,J=2,8Hz,1H),6.90(d,J=8Hz,1H),7.23-7.28(m,2H),7.42-7.46(m,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(5-ヒドロキシ-1H-ピラゾール-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.20(m,2H),0.41-0.59(m,2H),0.74-2.43(m,8H),2.46-3.04(m,5H),3.06-3.45(m,2H),3.55-4.19(m,2.7H),4.23-4.49(m,1H),4.59-4.93(m,1.3H),5.70-5.77(m,1H),6.50-7.02(m,3H),7.22-7.38(m,1H).
(E)-3-(5-メチルイソチアゾール-3-イル)アクリル酸エチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):1.33(t,J=7Hz,3H),2.59(s,3H),4.27(q,J=7Hz,2H),6.56(d,J=16Hz,1H),7.15(s,1H),7.65(d,J=16Hz,1H).
(E)-3-(5-メチルイソチアゾール-3-イル)アクリル酸の合成
1H-NMR(400MHz,DMSO-d6)δ(ppm):2.57(s,3H),6.61(d,J=16Hz,1H),7.42(d,J=16Hz,1H),7,58(s,1H),12.71(br s,1H).
(E)-1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-3-(5-メチルイソチアゾール-3-イル)プロプ-2-エン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.18(m,2H),0.41-0.57(m,2H),0.75-0.93(m,1H),1.02-2.16(m,5.6H),2.18-2.42(m,3H),2.46-3.08(m,7.4H),3.11-3.24(m,0.6H),3.38-3.62(m,1.4H),3.85-4.00(m,0.6H),4.04-4.17(m,0.8H),4.29-4.40(m,0.6H),6.58(dd,J=2,8Hz,0.4H),6.65-6.73(m,1H),6.84-7.12(m,3H),7.13-7.24(m,1H),7.55(d,J=16Hz,0.6H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(3,3,3-トリフルオロ-2-フェニルプロピル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.11(m,2H),0.44-0.52(m,2H),0.75-0.86(m,1H),0.94-1.01(m,1H),1.23-1.33(m,1H),1.48(ddd,J=4,11,14Hz,1H),1.73(ddd,J=4,4,15Hz,1H),1.90-2.06(m,2H),2.20-2.38(m,4H),2.48-2.54(m,1H),2.59-2.68(m,2H),2.83(d,J=6Hz,1H),2.86-2.97(m,1H),2.90(d,J=18Hz,1H),2.96(dd,J=9,13Hz,1H),3.09(ddd,J=2,11,13Hz,1H),3.15(dd,J=5,13Hz,1H),3.26(ddq,J=5,9,9Hz,1H),6.52(d,J=2Hz,1H),6.60(dd,J=2,8Hz,1H),6.93(d,J=8Hz,1H),7.02-7.08(m,2H),7.21-7.31(m,3H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-3-(5-メチルイソチアゾール-3-イル)プロパン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.19(m,2H),0.43-0.59(m,2H),0.76-3.27(m,22H),3.28-3.44(m,1H),3.80-4.04(m,1.4H),4.16-4.33(m,0.6H),6.57-7.11(m,4H).
(5aS,6R,11bS)-14-((2,2-ジフルオロシクロプロピル)メチル)-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.95-1.10(m,2H),1.38-1.53(m,2H),1.58-1.86(m,3H),1.96-2.20(m,2H),2.00(s,3H),2.28-3.02(m,12H),3.09-3.19(m,1H),3.95-4.09(m,2H),6.57(d,J=3Hz,1H),6.63(dd,J=2,8Hz,1H),6.86-6.88(m,1H),6.94(d,J=8Hz,0.5H),6.95(d,J=8Hz,0.5H),7.24(s,1H).
(5aS,6R,11bS)-14-(((1S,2S)-2-フルオロシクロプロピル)メチル)-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
得られた粗生成物のテトラヒドロフラン(0.5mL)溶液に、0.91Mボラン-テトラヒドロフラン錯体テトラヒドロフラン溶液(0.44mL,0.40mmol)を加え、6時間加熱還流した。反応混合物を放冷後、減圧下にて濃縮した。濃縮残渣に6M塩酸(2mL)を加え、1時間加熱還流した。反応混合物を放冷後、水及び炭酸カリウムを加え塩基性とし、クロロホルムで三回抽出した。合わせた抽出物を硫酸ナトリウムで乾燥後、減圧下にて濃縮した。得られた粗生成物を分取薄層クロマトグラフィー(クロロホルム:2Mアンモニア-メタノール溶液=10:1)で精製し、表題化合物(9.0mg,49%)を無色アモルファスとして得た。
1H-NMR(400MHz,CDCl3)δ(ppm):0.60(dddd,J=3,7,7,23Hz,1H),0.73-0.85(m,1H),0.90-1.10(m,2H),1.38-1.48(m,1H),1.72-1.85(m,2H),1.96-2.09(m,2H),1.99(s,3H),2.29-2.40(m,1H),2.49-2.66(m,4H),2.68(dd,J=6,13Hz,1H),2.75-3.04(m,6H),3.16(dd,J=11,11Hz,1H),3.95-4.09(m,2H),4.55(dddd,J=3,6,6,65Hz,1H),6.53(d,J=3Hz,1H),6.61(dd,J=3,8Hz,1H),6.87(s,1H),6.93(d,J=8Hz,1H),7.24(s,1H).
1-((5aS,6R,11bS)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-3-(4-メチル-1H-ピラゾール-1-イル)プロパン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.14(m,2H),0.47-0.53(m,2H),0.76-0.88(m,1H),1.05-1.13(m,1H),1.51-1.61(m,1H),1.76-1.99(m,2H),2.00-2.23(m,2.3H),2.03(s,0.9H),2.04(s,2.1H),2.27-2.45(m,2.7H),2.49-2.59(m,1H),2.66-3.02(m,5H),3.10-3.23(m,1.3H),3.27-3.33(m,0.7H),3.60-3.69(m,0.7H),3.70-3.79(m,0.3H),3.85-4.06(m,1.7H),4.11-4.20(m,0.6H),4.31-4.37(m,0.7H),4.43(br s,0.3H),4.53(br s,0.7H),6.67(dd,J=3,8Hz,0.3H),6.72(dd,J=3,8Hz,0.7H),6.75(d,J=3Hz,0.3H),6.79(d,J=3Hz,0.7H),6.92(d,J=8Hz,0.7H),6.93(d,J=8Hz,0.3H),7.15(s,0.7H),7.19(s,0.3H),7.25-7.28(m,0.3H),7.34(s,0.7H).
(5aS,6R,11bS)-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-14-((1-メチルシクロプロピル)メチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.02-0.32(m,4H),0.99-1.10(m,1H),1.07(s,3H),1.39-1.49(m,1H),1.70-1.81(m,2H),1.90-2.08(m,2H),1.99(s,3H),2.21(d,J=12Hz,1H),2.35-2.45(m,1H),2.38(d,J=12Hz,1H),2.48-2.65(m,3H),2.70-3.00(m,6H),3.11-3.21(m,1H),3.95-4.09(m,2H),6.54(d,J=3Hz,1H),6.61(dd,J=3,8Hz,1H),6.85(s,1H),6.92(d,J=8Hz,1H),7.23(s,1H).
(S)-3-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-4,4,4-トリフルオロブタン酸エチルおよび(R)-3-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-4,4,4-トリフルオロブタン酸エチルのジアステレオマー混合物(1:1)の合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.14(m,2H),0.44-0.56(m,2H),0.76-0.89(m,1H),0.97-1.04(m,1H),1.15-1.37(m,2H),1.46-1.56(m,1H),1.73(ddd,J=3,11,14Hz,0.5H),1.79(ddd,J=3,10,14Hz,0.5H),1.84-2.11(m,3H),2.28-2.73(m,6.5H),2.74-3.10(m,6H),3.24(dd,J=11,11Hz,0.5H),3.34(dd,J=12,12Hz,0.5H),3.55-3.75(m,1H),3.78(s,1.5H),3.78(s,1.5H),3.81-4.07(m,1.5H),4.16-4.25(m,1H),6.62-6.65(m,1H),6.67(dd,J=3,8Hz,0.5H),6.68(dd,J=2,8Hz,0.5H),6.98(d,J=8Hz,0.5H),6.99(d,J=8Hz,0.5H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-3-(1,1,1-トリフルオロ-4-(4-メチル-1H-ピラゾール-1-イル)ブタン-2-イル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオール(ジアステレオマーI)および(5aS,6R,11bR)-14-(シクロプロピルメチル)-3-(1,1,1-トリフルオロ-4-(4-メチル-1H-ピラゾール-1-イル)ブタン-2-イル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオール(ジアステレオマーII)の合成
得られた粗生成物のクロロホルム(1.0mL)溶液に、0℃でN,N-ジイソプロピルエチルアミン(31.2μL,179μmol)及びメタンスルホン酸無水物(16.0mg,91.9μmol)を加え、0℃で2.5時間撹拌した。その後、メタンスルホン酸無水物(6.0mg,34.4μmol)を加え、0℃で40分間撹拌した。反応混合物に飽和炭酸水素ナトリウム水溶液(3mL)及び水(2mL)を加え、酢酸エチルで3回抽出した。有機層を合わせて飽和食塩水で洗浄し、硫酸ナトリウムで乾燥後、減圧下にて濃縮した。
得られた粗生成物のアセトニトリル(1.0mL)溶液にN,N-ジイソプロピルエチルアミン(15.6μL,89.6μmol)及び4-メチル-1H-ピラゾール(5.6μL,67.7μmol)を加え、室温で18時間撹拌した。その後、N,N-ジイソプロピルエチルアミン(15.6μL,89.6μmol)及び4-メチルピラゾール(6.0μL,72.6μmol)を加え、70℃で6.5時間撹拌した。室温に冷却後、反応混合物に飽和炭酸水素ナトリウム水溶液(3mL)を加え、酢酸エチルで3回抽出した。有機層を合わせて飽和食塩水で洗浄し、硫酸ナトリウムで乾燥後、減圧下にて濃縮した。
実施例6に記載した方法に従い、得られた粗生成物より表題化合物(ジアステレオマーI(4.3mg,4段階16%)およびジアステレオマーII(1.8mg,4段階7%)をそれぞれ得た。
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.16(m,2H),0.46-0.57(m,2H),0.77-0.89(m,1H),1.03-1.10(m,1H),1.53(dd,J=4,13Hz,1H),1.74-2.12(m,6H),2.04(s,3H),2.33(dd,J=7,13Hz,1H),2.34(dd,J=6,13Hz,1H),2.43-2.68(m,3H),2.69-2.81(m,2H),2.85(dd,J=6,18Hz,1H),2.96(d,J=6Hz,1H),3.00(d,J=18Hz,1H),3.05-3.20(m,2H),3.34-3.45(m,2H),4.55(br s,1H),6.52(dd,J=2,8Hz,1H),6.77(d,J=2Hz,1H),6.78(s,1H),6.93(d,J=8Hz,1H),7.03(s,1H).
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.17(m,2H),0.48-0.54(m,2H),0.78-0.89(m,1H),1.02-1.12(m,1H),1.51-1.72(m,2H),1.82(ddd,J=2,6,16Hz,1H),1.87-1.97(m,1H),1.98-2.09(m,3H),2.06(s,3H),2.34(dd,J=7,13Hz,1H),2.34(dd,J=7,13Hz,1H),2.49-2.68(m,3H),2.78-2.89(m,2H),2.92-3.07(m,2H),2.94(d,J=6Hz,1H),3.00(d,J=18Hz,1H),3.18-3.26(m,1H),3.34(ddd,J=5,10,19Hz,1H),3.46-3.54(m,1H),4.53(br s,1H),6.61(dd,J=2,8Hz,1H),6.78(d,J=2Hz,1H),6.94(d,J=8Hz,1H),6.96(s,1H),7.28(s,1H).
(5aS,6R,11bS)-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-14-(3-メチルブテ-2-エン-1-イル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.96-1.04(m,1H),1.38-1.46(m,1H),1.64(s,3H),1.67-1.81(m,2H),1.72(s,3H),1.93-2.06(m,2H),1.99(s,3H),2.29-2.43(m,2H),2.46-2.63(m,2H),2.67-3.08(m,8H),3.09-3.19(m,1H),3.94-4.07(m,2H),4.56(br s,1H),5.12-5.19(m,1H),6.54(d,J=3Hz,1H),6.61(dd,J=3,8Hz,1H),6.85(s,1H),6.92(d,J=8Hz,1H),7.23(s,1H).
(5aS,6R,11bS)-14-((1-ヒドロキシシクロプロピル)メチル)-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.35-0.42(m,2H),0.78-0.84(m,2H),1.02-1.09(m,1H),1.46-1.55(m,1H),1.76-1.89(m,1H),1.90-2.23(m,4H),1.99(s,3H),2.42-3.00(m,11H),3.09(ddd,J=4,12,12Hz,1H),4.00-4.09(m,2H),6.58-6.66(m,2H),6.94(d,J=8Hz,1H),6.96(s,1H),7.25-7.28(m,1H).
(5aS,6R,11bS)-14-((1-フルオロシクロプロピル)メチル)-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.52-0.67(m,2H),0.97-1.13(m,3H),1.40-1.52(m,1H),1.71-1.82(m,2H),2.00(s,3H),2.06(ddd,J=5,13,13Hz,1H),2.17(ddd,J=3,12,12Hz,1H),2.37(ddd,J=4,11,11Hz,1H),2.42-2.65(m,3H),2.68-3.05(m,8H),3.10-3.20(m,1H),3.95-4.09(m,2H),4.52(br s,1H),6.55(d,J=2Hz,1H),6.62(dd,J=2,8Hz,1H),6.87(s,1H),6.95(d,J=8Hz,1H),7.24(s,1H).
3-(4-メチル-1H-ピラゾール-1-イル)シクロブタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):2.09(s,3H),3.48-3.57(m,2H),3.71-3.80(m,2H),4.92-4.99(m,1H),7.29(s,1H),7.39(s,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(3-(4-メチル-1H-ピラゾール-1-イル)シクロブチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオール(ジアステレオマーI)および(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(3-(4-メチル-1H-ピラゾール-1-イル)シクロブチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオール(ジアステレオマーII)の合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.12(m,2H),0.47-0.52(m,2H),0.78-0.88(m,1H),0.99-1.03(m,1H),1.46-1.52(m,1H),1.76-1.85(m,2H),1.94-2.09(m,5H),2.17-2.39(m,4H),2.51-2.55(m,1H),2.58-2.79(m,6H),2.88-3.00(m,3H),3.05-3.11(m,1H),4.35-4.43(m,1H),4.75(br s,1H),6.54(d,J=2Hz,1H),6.61(dd,J=2,8Hz,1H),6.92(d,J=8Hz,1H),7.17(s,1H),7.25(s,1H).
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.11(m,2H),0.47-0.52(m,2H),0.79-0.90(m,3H),1.01-1.04(m,1H),1.48(dd,J=4,15Hz,1H),1.78-1.83(m,2H),1.96-2.08(m,5H),2.28-2.37(m,3H),2.42-2.55(m,2H),2.59-2.68(m,2H),2.72-2.79(m,2H),2.89(d,J=6Hz,1H),2.95(d,J=18Hz,1H),3.03-3.09(m,1H),3.45-3.52(m,1H),4.52-4.58(m,1H),4.76(br s,1H),6.55(d,J=2Hz,1H),6.59(dd,J=2,8Hz,1H),6.91(d,J=8Hz,1H),7.17(s,1H),7.34(s,1H).
(R)-1-(4-メチル-1H-ピラゾール-1-イル)プロパン-2-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):1.21(d,J=6Hz,3H),2.08(s,3H),3.57(d,J=3Hz,1H),3.92(dd,J=8,14Hz,1H),4.05-4.23(m,2H),7.18(s,1H),7.33(s,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-((S)-1-(4-メチル-1H-ピラゾール-1-イル)プロパン-2-イル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.02-0.17(m,2H),0.42-0.57(m,2H),0.75-0.93(m,4H),0.97-1.07(m,1H),1.45-1.56(m,1H),1.74(ddd,J=3,11,14Hz,1H),1.82-2.12(m,6H),2.24-2.40(m,3H),2.43-2.59(m,2H),2.62-3.23(m,7H),3.77(dd,J=7,14Hz,1H),3.98(dd,J=6,14Hz,1H),6.57-6.66(m,2H),6.84(s,1H),6.95(d,J=8Hz,1H),7.23(s,1H).
(S)-1-(4-メチル-1H-ピラゾール-1-イル)プロパン-2-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):1.20(d,J=6Hz,3H),2.08(s,3H),3.58(br s,1H),3.92(dd,J=8,14Hz,1H),4.05-4.22(m,2H),7.18(s,1H),7.33(s,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-((R)-1-(4-メチル-1H-ピラゾール-1-イル)プロパン-2-イル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.18(m,2H),0.44-0.57(m,2H),0.76-0.93(m,4H),0.97-1.06(m,1H),1.49-1.83(m,2H),1.88-2.13(m,6H),2.21-2.41(m,3H),2.47-2.61(m,2H),2.68-2.85(m,3H),2.88-3.17(m,4H),3.79(dd,J=7,14Hz,1H),4.02(dd,J=7,14Hz,1H),4.61(br s,1H),6.56-6.69(m,2H),6.89-7.02(m,2H),7.21(s,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(3-(4-メチル-1H-ピラゾール-1-イル)プロピル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.15(m,2H),0.44-0.54(m,2H),0.77-0.92(m,1H),0.99-1.08(m,1H),1.48(dd,J=4,14Hz,1H),1.70-1.92(m,4H),1.99-2.06(m,2H),2.04(s,3H),2.29-2.57(m,8H),2.78(dd,J=6,18Hz,1H),2.88-3.04(m,4H),3.67-3.76(m,1H),3.77-3.86(m,1H),4.68(br s,1H),6.59(dd,J=2,8Hz,1H),6.64(d,J=2Hz,1H),6.90(d,J=8Hz,1H),6.98(s,1H),7.27(s,1H).
(S)-1-(ベンジロキシ)-3-(4-メチル-1H-ピラゾール-1-イル)プロパン-2-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):2.06(s,3H),3.34(dd,J=6,9Hz,1H),3.46(dd,J=5,9Hz,1H),3.67(br s,1H),4.08-4.30(m,3H),4.51(d,J=12Hz,1H),4.55(d,J=12Hz,1H),7.14(s,1H),7.26-7.42(m,6H).
(5aS,6R,11bS)-3-((R)-1-(ベンジロキシ)-3-(4-メチル-1H-ピラゾール-1-イル)プロパン-2-イル)-14-(シクロプロピルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.16(m,2H),0.42-0.55(m,2H),0.76-0.93(m,1H),0.94-1.05(m,1H),1.39-1.74(m,2H),1.77-1.88(m,1H),1.92-2.11(m,5H),2.28-2.43(m,3H),2.46-2.61(m,2H),2.68-2.83(m,2H),2.85-3.01(m,3H),3.03-3.25(m,2H),3.35(d,J=6Hz,2H),3.91(dd,J=7,14Hz,1H),4.01(dd,J=6,14Hz,1H),4.37(d,J=12Hz,1H),4.40(d,J=12Hz,1H),6.53-6.71(m,3H),6.95(d,J=8Hz,1H),7.17-7.39(m,6H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-((R)-1-ヒドロキシ-3-(4-メチル-1H-ピラゾール-1-イル)プロパン-2-イル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.17(m,2H),0.43-0.57(m,2H),0.74-0.92(m,1H),0.96-1.12(m,1H),1.50-1.84(m,3H),1.90-2.12(m,5H),2.24-2.68(m,6H),2.76-3.23(m,8H),3.81(dd,J=6,14Hz,1H),4.07(dd,J=6,14Hz,1H),6.59(dd,J=2,8Hz,1H),6.65(d,J=2Hz,1H),6.95(d,J=8Hz,1H),7.04(s,1H),7.27(s,1H).
(R)-1-(ベンジロキシ)-3-(4-メチル-1H-ピラゾール-1-イル)プロパン-2-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):2.06(s,3H),3.34(dd,J=6,9Hz,1H),3.46(dd,J=5,9Hz,1H),3.67(br s,1H),4.08-4.28(m,3H),4.51(d,J=12Hz,1H),4.55(d,J=12Hz,1H),7.14(s,1H),7.26-7.41(m,6H).
(5aS,6R,11bS)-3-((S)-1-(ベンジロキシ)-3-(4-メチル-1H-ピラゾール-1-イル)プロパン-2-イル)-14-(シクロプロピルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.02-0.17(m,2H),0.43-0.55(m,2H),0.76-0.92(m,1H),0.94-1.05(m,1H),1.40-1.79(m,2H),1.81-2.11(m,6H),2.27-2.41(m,3H),2.46-2.67(m,2H),2.69-3.20(m,7H),3.24-3.40(m,2H),4.01(dd,J=8,14Hz,1H),4.10(dd,J=6,14Hz,1H),4.33-4.45(m,2H),6.54-6.63(m,2H),6.89-6.98(m,2H),7.19(s,1H),7.20-7.38(m,5H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-((S)-1-ヒドロキシ-3-(4-メチル-1H-ピラゾール-1-イル)プロパン-2-イル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.02-0.17(m,2H),0.43-0.56(m,2H),0.74-0.91(m,1H),0.96-1.11(m,1H),1.43-1.60(m,1H),1.73-2.10(m,7H),2.23-2.38(m,3H),2.41-2.65(m,3H),2.71-3.07(m,5H),3.15-3.42(m,3H),3.82(dd,J=6,14Hz,1H),4.10(dd,J=8,14Hz,1H),6.55-6.68(m,2H),6.95(d,J=8Hz,1H),7.05(s,1H),7.26(s,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-10-((1-フェニル-1H-テトラゾール-5-イル)オキシ)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.16(m,2H),0.46-0.58(m,2H),0.78-0.91(m,1H),0.99-1.06(m,1H),1.42-1.51(m,1H),1.68(ddd,J=3,13,13Hz,1H),1.81(ddd,J=3,3,16Hz,1H),1.92-2.01(m,1H),1.97(s,3H),2.04-2.14(m,1H),2.30-2.42(m,3H),2.50(ddd,J=5,14,14Hz,1H),2.57(dd,J=4,12Hz,1H),2.61-2.68(m,1H),2.81-2.86(m,2H),2.87-3.21(m,4H),3.94-4.08(m,2H),4.58(br s,1H),6.72(s,1H),7.11-7.26(m,4H),7.49-7.62(m,3H),7.78-7.84(m,2H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.15(m,2H),0.46-0.53(m,2H),0.77-0.90(m,1H),0.98-1.04(m,1H),1.45(ddd,J=2,5,14Hz,1H),1.74(ddd,J=3,3,13Hz,1H),1.91(ddd,J=4,4,16Hz,1H),1.94-2.00(m,1H),1.98(s,3H),2.08(ddd,J=5,13,13Hz,1H),2.30-2.49(m,4H),2.51-2.58(m,1H),2.63(ddd,J=4,4,13Hz,1H),2.74-3.01(m,5H),3.04(d,J=18Hz,1H),3.17(ddd,J=2,12,12Hz,1H),3.85-4.01(m,2H),4.63(br s,1H),6.63(s,1H),7.10-7.17(m,4H),7.20(s,1H).
(1S,3S)-3-(4-メチル-1H-ピラゾール-1-イル)シクロペンタン-1-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.83-0.90(m,1H),1.68-1.76(m,1H),1.97-2.05(m,1H),2.06(s,3H),2.14-2.41(m,3H),4.57-4.61(m,1H),4.81-4.88(m,1H),7.18(s,1H),7.31(s,1H).
メタンスルホン酸(1S,3S)-3-(4-メチル-1H-ピラゾール-1-イル)シクロペンチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):2.04-2.13(m,2H),2.06(s,3H),2.31-2.43(m,2H),2.45-2.57(m,2H),3.03(s,3H),4.79-4.86(m,1H),5.35-5.39(m,1H),7.17(s,1H),7.31(s,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-((1R,3S)-3-(4-メチル-1H-ピラゾール-1-イル)シクロペンチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールのジアステレオマー混合物の合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.12(m,2H),0.46-0.54(m,2H),0.78-0.88(m,1H),0.97-1.00(m,1H),1.49-1.53(m,1H),1.76-2.00(m,6H),2.01(s,3H),2.06-2.30(m,2H),2.34(d,J=6Hz,2H),2.40-2.51(m,2H),2.70-2.81(m,3H),2.84-2.96(m,4H),3.11-3.21(m,2H),4.51-4.59(m,1H),4.82(br s,1H),6.50(d,J=2Hz,1H),6.60(dd,J=2,8Hz,1H),6.90(d,J=8Hz,1H),7.11(s,1H),7.25(s,1H).
メタンスルホン酸(1SR,3RS)-3-(4-メチル-1H-ピラゾール-1-イル)シクロペンチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):2.02-2.12(m,1H),2.07(s,3H),2.21-2.29(m,3H),2.36-2.43(m,1H),2.69(ddd,J=7,9,15Hz,1H),3.02(s,3H),4.62-4.70(m,1H),5.18-5.23(m,1H),7.26(s,1H),7.31(s,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-((1R,3R)-3-(4-メチル-1H-ピラゾール-1-イル)シクロペンチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールおよび(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-((1S,3S)-3-(4-メチル-1H-ピラゾール-1-イル)シクロペンチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.13(m,2H),0.47-0.52(m,2H),0.78-0.88(m,1H),0.98-1.05(m,1H),1.46-1.52(m,1H),1.56-1.66(m,1H),1.76-1.82(m,2H),1.87-2.37(m,12H),2.49-2.57(m,1H),2.70-2.96(m,6H),3.09-3.18(m,1H),3.30-3.37(m,0.5H),3.39-3.47(m,0.5H),4.53-4.60(m,0.5H),4.61-4.68(m,0.5H),4.79(br s,1H),6.48(d,J=2Hz,0.5H),6.53(d,J=2Hz,0.5H),6.55(dd,J=2,8Hz,0.5H),6.58(dd,J=2,8Hz,0.5H),6.87-6.89(m,1H),7.16(s,1H),7.30(s,0.5H),7.31(s,0.5H).
ピバル酸(5aS,6R,11bS)-14-(シクロプロピルメチル)-5a-ヒドロキシ-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-1,2,3,4,5,5a,6,7-オクタヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-10-イルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.13(m,2H),0.45-0.52(m,2H),0.78-0.88(m,1H),0.99-1.06(m,1H),1.35(s,9H),1.38-1.46(m,1H),1.66(ddd,J=3,13,13Hz,1H),1.82(ddd,J=4,4,16Hz,1H),1.92-2.01(m,1H),1.98(s,3H),2.02-2.12(m,1H),2.32-2.39(m,3H),2.45(ddd,J=5,13,13Hz,1H),2.51-2.57(m,1H),2.65(ddd,J=4,13,13Hz,1H),2.78-2.86(m,3H),2.90-3.04(m,3H),3.12-3.20(m,1H),3.88-4.00(m,2H),4.58(br s,1H),6.64(s,1H),6.82(d,J=2Hz,1H),6.83-6.85(m,1H),7.12(d,J=9Hz,1H),7.20(s,1H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-カルボン酸tert-ブチル(化合物K)および(5aS,6R,11bR)-10-((tert-ブトキシカルボニル)オキシ)-14-(シクロプロピルメチル)-5a-ヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-カルボン酸tert-ブチル(化合物L)の合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.14(m,2H),0.47-0.55(m,2H),0.76-0.88(m,1H),0.99-1.09(m,1H),1.29(s,4.5H),1.31(s,4.5H),1.44-1.67(m,1H),1.76-1.90(m,1.5H),1.91-2.11(m,2.5H),2.29(dd,J=7,13Hz,0.5H),2.32-2.43(m,2H),2.47-2.57(m,1.5H),2.74-2.85(m,1H),2.88-2.97(m,1.5H),2.98(d,J=18Hz,0.5H),3.31-3.41(m,1.5H),3.46-3.63(m,2H),3.75(ddd,J=5,13,13Hz,0.5H),4.51(br s,0.5H),4.95(br s,0.5H),5.75(br s,0.5H),6.59(dd,J=2,8Hz,0.5H),6.61-6.67(m,1.5H),6.92(d,J=8Hz,0.5H),6.94(d,J=7Hz,0.5H).
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.14(m,2H),0.42-0.55(m,2H),0.77-0.90(m,1H),1.00-1.11(m,1H),1.30(s,4.5H),1.39(s,4.5H),1.50-1.62(m,1H),1.55(s,9H),1.69-2.12(m,4H),2.17-2.40(m,2.5H),2.44-2.58(m,1.5H),2.78-2.94(m,1.5H),2.93(d,J=6Hz,0.5H),2.97(d,J=19Hz,0.5H),3.00-3.11(m,0.5H),3.04(d,J=18Hz,0.5H),3.26(ddd,J=4,4,14Hz,0.5H),3.36-3.48(m,1H),3.54-3.65(m,1H),3.70(ddd,J=3,14,14Hz,0.5H),3.83-3.89(m,0.5H),4.50(br s,1H),6.90-6.94(m,1H),6.97(dd,J=2,8Hz,1H),7.07(d,J=8Hz,0.5H),7.09(d,J=8Hz,0.5H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-(((トリフルオロメチル)スルホニル)オキシ)-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-カルボン酸tert-ブチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.14(m,2H),0.49-0.56(m,2H),0.77-0.89(m,1H),0.97-1.07(m,1H),1.30(s,5.4H),1.35(s,3.6H),1.50-1.81(m,2.2H),1.82-1.97(m,1.4H),1.99-2.18(m,1.4H),2.30(dd,J=7,13Hz,0.6H),2.32-2.41(m,1.8H),2.54-2.65(m,1.6H),2.83-2.98(m,2H),3.02(d,J=19Hz,0.6H),3.07(d,J=19Hz,0.4H),3.16(ddd,J=2,12,14Hz,0.4H),3.31(ddd,J=4,4,14Hz,0.4H),3.36-3.44(m,1.2H),3.55-3.68(m,1.6H),3.77(ddd,J=4,5,15Hz,0.4H),4.47(br s,1H),7.00-7.07(m,2H),7.16(d,J=8Hz,0.6H),7.17(d,J=8Hz,0.4H).
(5aS,6R,11bR)-10-シアノ-14-(シクロプロピルメチル)-5a-ヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-カルボン酸tert-ブチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.16(m,2H),0.47-0.58(m,2H),0.77-0.89(m,1H),0.96-1.06(m,1H),1.26(s,6.3H),1.32(s,2.7H),1.44-1.75(m,2.3H),1.78-1.92(m,1.7H),2.01-2.15(m,0.3H),2.14(ddd,J=5,13,13Hz,0.7H),2.29(dd,J=7,12Hz,0.7H),2.32-2.47(m,1.6H),2.59(dd,J=4,12Hz,1H),2.67(ddd,J=6,13,16Hz,0.7H),2.88-3.00(m,1H),2.97(d,J=7Hz,0.3H),2.99(d,J=6Hz,0.7H),3.04(d,J=19Hz,0.7H),3.09(d,J=19Hz,0.3H),3.22-3.38(m,2H),3.53-3.72(m,1.3H),3.80(ddd,J=5,13,13Hz,0.7H),4.47(br s,1H),7.16-7.21(m,0.3H),7.18(d,J=8Hz,0.7H),7.39(d,J=8Hz,1H),7.46(s,1H).
(5aS,6R,11bR)-10-カルバモイル-14-(シクロプロピルメチル)-5a-ヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-カルボン酸tert-ブチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.17(m,2H),0.46-0.58(m,2H),0.77-0.89(m,1H),0.98-1.13(m,1H),1.06(s,7.2H),1.22(s,1.8H),1.48(dd,J=4,14Hz,0.8H),1.60(dd,J=4,14Hz,0.2H),1.69-2.21(m,4.2H),2.26-2.41(m,0.2H),2.29(dd,J=6,12Hz,0.2H),2.35(dd,J=7,12Hz,0.8H),2.35(dd,J=6,12Hz,0.8H),2.48-2.65(m,1.2H),2.72(ddd,J=9,11,16Hz,0.8H),2.86(dd,J=6,19Hz,0.8H),2.93-3.23(m,2H),3.01(d,J=6Hz,0.8H),3.12(d,J=19Hz,0.8H),3.30-3.38(m,0.4H),3.47-3.63(m,1H),3.77(ddd,J=4,13,13Hz,0.2H),4.28-4.39(m,0.8H),4.49(br s,0.2H),4.58(br s,0.8H),5.58(br s,1H),5.82(br s,0.2H),6.20(br s,0.8H),7.13(d,J=8Hz,0.8H),7.14(d,J=8Hz,0.2H),7.39-7.49(m,1.8H),7.73-7.75(m,0.2H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-5a-ヒドロキシ-1,2,3,4,5,5a,6,7-オクタヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-10-カルボキサミドの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.18(m,2H),0.46-0.59(m,2H),0.79-0.90(m,1H),1.07-1.14(m,1H),1.60(ddd,J=5,5,15Hz,1H),1.69(ddd,J=4,11,15Hz,1H),1.92(ddd,J=3,13,13Hz,1H),2.08(ddd,J=5,13,13Hz,1H),2.17(ddd,J=3,3,16Hz,1H),2.30-2.41(m,3H),2.54-2.60(m,1H),2.80(ddd,J=4,4,14Hz,1H),2.80-2.91(m,1H),2.92(dd,J=6,19Hz,1H),2.99(d,J=6Hz,1H),3.05(ddd,J=4,4,15Hz,1H),3.10(d,J=19Hz,1H),3.15(ddd,J=3,11,14Hz,1H),4.52(br s,1H),5.56(br s,1H),6.08(br s,1H),7.19(d,J=8Hz,1H),7.51(dd,J=2,8Hz,1H),7.71(d,J=2Hz,1H).
メタンスルホン酸2-(4-メチル-1H-ピラゾール-1-イル)エチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm): 2.07(s,3H),2.81(s,3H),4.37(t,J=5Hz,2H),4.58(t,J=5Hz,2H),7.24(s,1H),7.36(s,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-5a-ヒドロキシ-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-1,2,3,4,5,5a,6,7-オクタヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-10-カルボキサミドの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.16(m,2H),0.46-0.56(m,2H),0.78-0.89(m,1H),1.00-1.08(m,1H),1.47(ddd,J=2,4,14Hz,1H),1.68(ddd,J=3,11,14Hz,1H),1.89(ddd,J=3,13,13Hz,1H),1.93-2.01(m,1H),1.98(s,3H),2.10(ddd,J=5,13,13Hz,1H),2.34(d,J=6Hz,2H),2.40(ddd,J=4,4,13Hz,1H),2.49(ddd,J=5,12,16Hz,1H),2.53-2.59(m,1H),2.65(ddd,J=4,4,13Hz,1H),2.78(ddd,J=6,6,13Hz,1H),2.80(ddd,J=6,6,13Hz,1H),2.89(dd,J=6,19Hz,1H),2.92-3.01(m,1H),2.97(d,J=6Hz,1H),3.07(d,J=19Hz,1H),3.14(ddd,J=2,11,13Hz,1H),3.90(ddd,J=6,6,14Hz,1H),3.93(ddd,J=6,6,14Hz,1H),4.60(br s,1H),5.57(br s,1H),6.14(br s,1H),6.70(s,1H),7.18(s,1H),7.19(d,J=8Hz,1H),7.48(dd,J=2,8Hz,1H),7.69(d,J=2Hz,1H).
トリ酢酸(2S,3R,5S,6S)-2-(((5aS,6R,11bS)-14-(シクロプロピルメチル)-5a-ヒドロキシ-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-1,2,3,4,5,5a,6,7-オクタヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-10-イル)オキシ)-6-(メトキシカルボニル)テトラヒドロ-2H-ピラン-3,4,5-トリイルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.11(m,2H),0.48-0.52(m,2H),0.78-0.86(m,1H),0.97-1.00(m,1H),1.42-1.46(m,1H),1.66-1.73(m,1H),1.80(ddd,J=4,4,16Hz,1H),1.90-2.11(m,15H),2.33(d,J=7Hz,2H),2.37-2.48(m,2H),2.54(dd,J=4,12Hz,1H),2.60(ddd,J=4,4,12Hz,1H),2.76-2.83(m,3H),2.91-3.00(m,3H),3.10-3.16(m,1H),3.72(s,3H),3.85-4.01(m,2H),4.11-4.13(m,1H),5.07(d,J=8Hz,1H),5.22-5.36(m,3H),6.67(s,1H),6.79-6.81(m,2H),7.04(d,J=8Hz,1H),7.19(s,1H).
(2S,3S,5R,6S)-6-(((5aS,6R,11bS)-14-(シクロプロピルメチル)-5a-ヒドロキシ-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-1,2,3,4,5,5a,6,7-オクタヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-10-イル)オキシ)-3,4,5-トリヒドロキシテトラヒドロ-2H-ピラン-2-酢酸の合成
1H-NMR(400MHz,D2O)δ(ppm):0.35-0.45(m,2H),0.64-0.80(m,2H),1.00-1.09(m,1H),1.36-1.39(m,1H),1.62-1.66(m,1H),1.81-1.90(m,3H),2.00(s,3H),2.23-2.35(m,3H),2.59(ddd,J=4,13,13Hz,1H),2.68-3.30(m,9H),3.57-3.63(m,3H),3.81-3.86(m,2H),4.18-4.21(m,2H),5.10(d,J=7Hz,1H),6.93(d,J=2Hz,1H),7.05(dd,J=2,8Hz,1H),7.25(d,J=8Hz,1H),7.26(s,1H),7.32(s,1H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-3-(2-(ピリジン-2-イル)アセチル)-1,2,3,4,5,5a,6,7-オクタヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-10-カルボキサミドの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.17(m,2H),0.45-0.59(m,2H),0.76-0.89(m,1H),1.01-1.11(m,1H),1.52-2.15(m,5.4H),2.30(dd,J=7,13Hz,0.4H),2.33(d,J=6Hz,1.2H),2.37(dd,J=7,13Hz,0.4H),2.50-2.73(m,2.6H),2.86-2.99(m,0.4H),2.95(d,J=7Hz,0.6H),2.97(d,J=6Hz,0.4H),3.04(d,J=20Hz,1H),3.27-3.39(m,1.4H),3.46-3.84(m,3.8H),3.88-3.97(m,0.4H),4.36(br s,0.6H),4.51(br s,0.4H),5.75(br s,1H),6.88(d,J=8Hz,0.6H),7.00(d,J=8Hz,0.4H),7.08-7.18(m,2H),7.09(br s,1H),7.39-7.44(m,0.6H),7.45-7.53(m,1.6H),7.54-7.61(m,0.4H),7.65-7.68(m,0.4H),8.39-8.46(m,1H).
(4bR,8aS,9R)-3-(ベンジロキシ)-11-(シクロプロピルメチル)-4,8a-ジヒドロキシ-8,8a,9,10-テトラヒドロ-5H-9,4b-(エピミノエタノ)フェナントレン-6(7H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.09-0.15(m,2H),0.49-0.58(m,2H),0.80-0.92(m,1H),1.49-1.63(m,1H),1.78-1.86(m,1H),1.97(ddd,J=6,14,14Hz,1H),2.03-2.09(m,2H),2.11-2.19(m,1H),2.30-2.41(m,2H),2.57-2.62(m,1H),2.73-2.89(m,2H),2.92-3.03(m,2H),3.11(d,J=6Hz,1H),3.91(dd,J=2,14Hz,1H),4.72(br s,1H),5.01(d,J=11Hz,1H),5.02(d,J=11Hz,1H),6.19(br s,1H),6.55(d,J=8Hz,1H),6.73(d,J=8Hz,1H),7.32-7.42(m,5H).
(4bR,8aS,9R)-3-(ベンジロキシ)-11-(シクロプロピルメチル)-8a-ヒドロキシ-4-メトキシ-8,8a,9,10-テトラヒドロ-5H-9,4b-(エピミノエタノ)フェナントレン-6(7H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.17(m,2H),0.49-0.59(m,2H),0.80-0.91(m,1H),1.50-1.60(m,1H),1.81(dd,J=7,13Hz,1H),1.92-2.20(m,4H),2.30-2.41(m,2H),2.57-2.64(m,1H),2.74-2.89(m,2H),2.97(d,J=19Hz,1H),3.02(d,J=14Hz,1H),3.02(d,J=14Hz,1H),3.09(d,J=6Hz,1H),3.71(d,J=14Hz,1H),3.98(s,3H),5.03(s,2H),6.71(d,J=8Hz,1H),6.79(d,J=8Hz,1H),7.28-7.47(m,5H).
(5aS,6R,11bR)-10-(ベンジロキシ)-14-(シクロプロピルメチル)-5a-ヒドロキシ-11-メトキシ-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オン(M)および(5aS,6R,11bS)-10-(ベンジロキシ)-14-(シクロプロピルメチル)-5a-ヒドロキシ-11-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-c]アゼピン-3(4H)-オン(N)の合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.13(m,2H),0.45-0.56(m,2H),0.75-0.88(m,1H),1.53-1.62(m,2H),1.84-1.94(m,1H),1.96-2.11(m,2H),2.26-2.38(m,2H),2.57-2.66(m,1H),2.78-2.92(m,4H),3.20(dd,J=2,14Hz,1H),3.34(d,J=14Hz,1H),3.80(ddd,J=3,3,13Hz,1H),3.96(s,3H),4.50(br s,1H),4.97(d,J=12Hz,1H),5.10(d,J=12Hz,1H),5.49-5.56(m,1H),6.67(d,J=8Hz,1H),6.79(d,J=8Hz,1H),7.27-7.46(m,5H).
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.16(m,2H),0.46-0.58(m,2H),0.77-0.88(m,1H),1.10-1.26(m,1H),1.49-1.57(m,1H),1.81(dd,J=14,14Hz,1H),2.00(ddd,J=5,13,13Hz,1H),2.07-2.17(m,2H),2.29-2.40(m,2H),2.65(dd,J=4,11Hz,1H),2.82(dd,J=6,18Hz,1H),2.87(d,J=6Hz,1H),2.96(d,J=18Hz,1H),3.20(dd,J=14,14Hz,1H),3.46(dd,J=7,15Hz,1H),3.82(s,3H),4.12(dd,J=7,15Hz,1H),4.66(br s,1H),5.00(d,J=11Hz,1H),5.07(d,J=11Hz,1H),6.10(dd,J=6,6Hz,1H),6.75(d,J=8Hz,1H),6.82(d,J=8Hz,1H),7.30-7.47(m,5H).
(5aS,6R,11aR)-10-(ベンジロキシ)-14-(シクロプロピルメチル)-5a-ヒドロキシ-11-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-カルボン酸tert-ブチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.12(m,2H),0.48-0.53(m,2H),0.78-0.86(m,1H),1.24(s,6.3H),1.31(s,2.7H),1.32-1.66(m,4H),1.73-1.90(m,1H),1.94-2.13(m,2H),2.22-2.43(m,3.3H),2.46-2.62(m,2H),2.81-2.95(m,2.7H),3.22-3.35(m,1.3H),3.42-3.53(m,0.7H),3.55-3.62(m,0.3H),3.66-3.76(m,1H),3.81(s,2.1H),3.84(s,0.9H),4.45(br s,0.7H),5.00(d,J=11Hz,0.7H),5.07(d,J=11Hz,0.7H),5.09(d,J=12Hz,0.3H),5.13(d,J=12Hz,0.3H),6.69(d,J=8Hz,0.3H),6.72(d,J=8Hz,0.7H),6.77(d,J=8Hz,0.3H),6.80(d,J=8Hz,0.7H),7.30-7.49(m,5H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-11-メトキシ-10-(((トリフルオロメチル)スルホニル)オキシ)-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-カルボン酸tert-ブチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.14(m,2H),0.49-0.56(m,2H),0.78-0.90(m,1H),1.30-1.38(m,0.7H),1.34(s,6.3H),1.37(s,2.7H),1.45-1.84(m,2.3H),1.93(ddd,J=3,12,12Hz,1H),2.00-2.06(m,0.3H),2.15(ddd,J=5,13,13Hz,0.7H),2.25-2.39(m,3H),2.48-2.68(m,2H),2.88-3.06(m,3.3H),3.25-3.34(m,0.7H),3.39-3.49(m,1.7H),3.56-3.65(m,0.3H),3.81-3.89(m,1H),3.84(s,2.1H),3.87(s,0.9H),6.89(d,J=8Hz,1H),7.04-7.09(m,1H).
(5aS,6R,11bR)-10-シアノ-14-(シクロプロピルメチル)-5a-ヒドロキシ-11-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-カルボン酸tert-ブチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.15(m,2H),0.49-0.55(m,2H),0.76-0.88(m,1H),1.26(s,6.3H),1.28(s,2.7H),1.32-1.79(m,3.7H),1.86(ddd,J=3,12,12Hz,1H),1.99-2.17(m,1.4H),2.23-2.39(m,2.3H),2.43-2.53(m,0.3H),2.59-2.70(m,1.7H),2.87-3.04(m,3H),3.11-3.23(m,1.3H),3.37-3.56(m,1H),3.69-3.80(m,1.3H),4.08(s,2.1H),4.14(s,0.9H),6.81-6.86(m,1H),7.29-7.34(m,1H).
(5aS,6R,11bR)-10-カルバモイル-14-(シクロプロピルメチル)-5a-ヒドロキシ-11-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-tert-ブチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.14(m,2H),0.48-0.55(m,2H),0.78-0.89(m,1H),1.09(s,9H),1.30-1.37(m,1H),1.43(dd,J=4,14Hz,1H),1.55-1.83(m,1H),1.94-2.14(m,3H),2.26-2.40(m,2H),2.53-2.79(m,2H),2.86-3.02(m,4H),3.07-3.16(m,1H),3.47-3.55(m,1H),3.78(s,3H),4.43(ddd,J=7,13,13Hz,1H),5.62-5.82(m,1H),6.82(d,J=8Hz,1H),7.26(d,J=8Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-5a-ヒドロキシ-11-メトキシ-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-1,2,3,4,5,5a,6,7-オクタヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-10-カルボキサミドの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.16(m,2H),0.45-0.56(m,2H),0.77-0.92(m,1H),1.30-1.37(m,1H),1.44(dd,J=5,14Hz,1H),1.60-1.73(m,1H),1.97(s,3H),1.98-2.04(m,1H),2.06-2.18(m,2H),2.27-2.42(m,3H),2.53(ddd,J=5,13,13Hz,1H),2.60-2.68(m,2H),2.69-2.79(m,2H),2.89-3.03(m,4H),3.09-3.18(m,1H),3.75(s,3H),3.84-3.97(m,2H),4.53(br s,1H),5.72(br s,1H),6.76(s,1H),6.96(d,J=8Hz,1H),7.08(br s,1H),7.17(s,1H),7.67(d,J=8Hz,1H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-3-(2-(イソチアゾール-3-イル)アセチル)-1,2,3,4,5,5a,6,7-オクタヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-10-カルボキサミドの合成
1H-NMR(400MHz,CD3OD)δ(ppm):0.11-0.17(m,2H),0.49-0.57(m,2H),0.83-0.92(m,1H),1.07-1.10(m,1H),1.60-1.65(m,1H),1.78-1.97(m,2H),2.04-2.63(m,5.5H),2.84(dd,J=6,19Hz,0.5H),2.95(dd,J=6,19Hz,0.5H),2.99-3.18(m,2H),3.43-3.55(m,2H),3.59-3.71(m,2H),3.78-3.86(m,2H),3.94(d,J=16Hz,0.5H),6.98(d,J=4Hz,0.5H),7.00(d,J=4Hz,0.5H),7.23(d,J=8Hz,0.5H),7.27(d,J=8Hz,0.5H),7.64(dd,J=2,8Hz,0.5H),7.69(dd,J=2,8Hz,0.5H),7.73(d,J=2Hz,0.5H),7.78(d,J=2Hz,0.5H),8.77(d,J=4Hz,0.5H),8.78(d,J=4Hz,0.5H).
(4’R,4a’S,7a’R,12b’S)-3’-(シクロプロピルメチル)-4a’-ヒドロキシ-9’-メトキシ-1’,2’,3’,4’,4a’,5’-ヘキサヒドロスピロ[シクロペンタン-1,6’-[4,12]メタノベンゾフロ[3,2-e]イソキノリン]-7’(7a’H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,2H),0.90-1.00(m,1H),1.20-1.80(m,8H),2.00-2.10(m,3H),2.15-2.25(m,1H),2.30-2.50(m,3H),2.50-2.60(m,1H),2.60-2.70(m,1H),3.03(d,J=18Hz,1H),3.09(d,J=14Hz,1H),3.35-3.50(m,1H),3.92(s,3H),4.86(s,1H),6.58(d,J=8Hz,1H),6.68(d,J=8Hz,1H).
(4b’R,8a’S,9’R)-11’-(シクロプロピルメチル)-4’,8a’-ジヒドロキシ-3’-メトキシ-8’,8a’,9’,10’-テトラヒドロスピロ[シクロペンタン-1,7’-[9,4b](エピミノエタノ)フェナントレン]-6’(5’H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,2H),0.90-1.00(m,1H),1.20-1.80(m,8H),1.80-2.25(m,4H),2.25-2.50(m,3H),2.50-2.65(m,1H),2.70-2.90(m,1H),2.96(d,J=18Hz,1H),3.00-3.10(m,1H),3.21(d,J=13Hz,1H),3.74(d,J=13Hz,1H),3.82(s,3H),6.06(s,1H),6.53(d,J=8Hz,1H),6.65(d,J=8Hz,1H).
トリフルオロメタンスルホン酸(4b’R,8a’S,9’R)-11’-(シクロプロピルメチル)-8a’-ヒドロキシ-3’-メトキシ-6’-オキソ-5’,6’,8’,8a’,9’,10’-テトラヒドロスピロ[シクロペンタン-1,7’-[9,4b](エピミノエタノ)フェナントレン]-4’-イルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,2H),0.90-1.00(m,1H),1.20-1.80(m,8H),1.90-2.00(m,1H),2.00-2.15(m,3H),2.15-2.25(m,1H),2.30-2.45(m,2H),2.60-2.70(m,1H),2.80-2.90(m,1H),3.02(d,J=18Hz,1H),3.09(d,J=6Hz,1H),3.38(d,J=14Hz,1H),3.42(d,J=14Hz,1H),3.80(s,3H),6.83(d,J=8Hz,1H),7.03(d,J=8Hz,1H).
(4b’R,8a’S,9’R)-11’-(シクロプロピルメチル)-8a’-ヒドロキシ-3’-メトキシ-8’,8a’,9’,10’-テトラヒドロスピロ[シクロペンタン-1,7’-[9,4b](エピミノエタノ)フェナントレン]-6’(5’H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,2H),0.75-0.90(m,2H),1.10-1.20(m,1H),1.35-1.70(m,4H),1.67(d,J=14Hz,1H),1.79(d,J=14Hz,1H),1.85-1.95(m,1H),2.00-2.20(m,4H),2.37(d,J=6Hz,2H),2.50-2.60(m,1H),2.65-2.80(m,2H),2.95-3.10(m,2H),3.32(d,J=14Hz,1H),3.76(s,3H),6.66(dd,J=3,8Hz,1H),6.80(d,J=3Hz,1H),6.93(d,J=8Hz,1H).
(4b’R,8a’S,9’R)-11’-(シクロプロピルメチル)-8a’-ヒドロキシ-3’-メトキシ-8’,8a’,9’,10’-テトラヒドロスピロ[シクロペンタン-1,7’-[9,4b](エピミノエタノ)フェナントレン]-6’(5’H)-オン オキシムの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),0.90-1.00(m,1H),1.00-1.20(m,1H),1.40-1.80(m,6H),1.80-2.20(m,5H),2.25-2.45(m,2H),2.50(d,J=14Hz,1H),2.50-2.60(m,1H),2.60-2.80(m,1H),2.90-3.10(m,2H),3.55(s,3H),3.69(d,J=14Hz,1H),6.69(dd,J=3,8Hz,1H),6.94(d,J=8Hz,1H),7.09(d,J=3Hz,1H),8.39(br s,1H).
(5a’S,6’R,11b’R)-14’-(シクロプロピルメチル)-5a’-ヒドロキシ-10’-メトキシ-5’,5a’,6’,7’-テトラヒドロ-1’H-スピロ[シクロペンタン-1,4’-[6,11b](エピミノエタノ)ナフト[1,2-d]アゼピン]-2’(3’H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.00-1.15(m,1H),1.40-1.85(m,8H),2.00-2.25(m,4H),2.30-2.40(m,2H),2.55-2.60(m,1H),2.66(dd,J=2,15Hz,1H),2.78(dd,J=6,18Hz,1H),2.87(d,J=6Hz,1H),3.00(d,J=18Hz,1H),3.57(d,J=15Hz,1H),3.79(s,3H),4.82(br s,1H),5.40(s,1H),6.70(dd,J=3,8Hz,1H),6.97(d,J=8Hz,1H),7.12(d,J=3Hz,1H).
(5a’S,6’R,11b’S)-14’-(シクロプロピルメチル)-10’-メトキシ-2’,3’,6’,7’-テトラヒドロ-1’H-スピロ[シクロペンタン-1,4’-[6,11b](エピミノエタノ)ナフト[1,2-d]アゼピン]-5a’(5’H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.00-1.15(m,2H),1.40-1.70(m,5H),1.70-1.85(m,2H),1.85-2.10(m,3H),2.25-2.45(m,3H),2.50-2.65(m,2H),2.76(dd,J=6,18Hz,1H),2.85(d,J=6Hz,1H),2.95-3.10(m,2H),3.79(s,3H),4.46(br s,1H),6.65-6.70(m,2H),7.03(d,J=8Hz,1H).
1-((5a’S,6’R,11b’R)-14’-(シクロプロピルメチル)-5a’-ヒドロキシ-10’-メトキシ-1’,2’,5’,5a’-6’,7’-ヘキサヒドロ-3’H-スピロ[シクロペンタン-1,4’-[6,11b](エピミノエタノ)ナフト[1,2-d]アゼピン]-3’-イル)-2-(4-メチル-1H-ピラゾール-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.00-1.10(m,1H),1.30-2.60(m,21H),2.80-3.00(m,3H),3.30-3.60(m,1H),3.79(s,3H),4.60-4.80(m,2H),6.70-6.80(m,2H),7.00-7.10(m,2H),7.20-7.30(m,1H).
(5a’S,6’R,11b’R)-14’-(シクロプロピルメチル)-10’-メトキシ-3’-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2’,3’,6’7’-テトラヒドロ-1’H-スピロ[シクロペンタン-1,4’-[6,11b](エピミノエタノ)ナフト[1,2-d]アゼピン]-5a’(5’H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.30(m,2H),0.50-0.70(m,2H),0.80-1.00(m,1H),1.00-1.30(m,2H),1.30-2.10(m,18H),2.09(s,3H),2.10-2.30(m,1H),2.30-2.45(m,1H),2.45-2.70(m,2H),2.70-2.90(m,2H),3.00-3.15(m,1H),4.11(br s,1H),6.66(d,J=8Hz,1H),6.74(s,1H),6.93(d,J=8Hz,1H),7.27(s,1H),7.52(s,1H).
(5aS,6R,11bR)-9-ブロモ-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.18(m,2H),0.46-0.59(m,2H),0.76-0.88(m,1H),1.05-1.14(m,1H),1.50-1.69(m,2H),2.00-2.12(m,2H),2.34(dd,J=6,14Hz,1H),2.35(dd,J=6,14Hz,1H),2.51-2.65(m,2H),2.74(dd,J=6,18Hz,1H),2.79-2.88(m,1H),2.91(d,J=6Hz,1H),2.98(d,J=18Hz,1H),3.50(d,J=14Hz,1H),3.79-3.94(m,1H),3.90(s,3H),4.69(br s,1H),6.04(br s,1H),7.16(s,1H),7.24(s,1H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-9-メチル-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.18(m,2H),0.45-0.56(m,2H),0.77-0.89(m,1H),1.08-1.17(m,1H),1.53(dd,J=6,14Hz,1H),1.77(ddd,J=2,12,14Hz,1H),2.02-2.13(m,2H),2.14(s,3H),2.35(dd,J=6,13Hz,1H),2.36(dd,J=6,13Hz,1H),2.51-2.63(m,1H),2.60(dd,J=2,15Hz,1H),2.72(dd,J=6,18Hz,1H),2.81-2.92(m,1H),2.90(d,J=6Hz,1H),2.98(d,J=18Hz,1H),3.50(d,J=15Hz,1H),3.81-3.91(m,1H),3.84(s,3H),4.73(br s,1H),5.63-5.72(m,1H),6.82(s,1H),7.06(s,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-9-メチル-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.17(m,2H),0.43-0.57(m,2H),0.78-0.90(m,1H),1.00-1.11(m,1H),1.56(ddd,J=3,3,15Hz,1H),1.75(ddd,J=4,12,15Hz,1H),1.95-2.08(m,3H),2.17(s,3H),2.25-2.40(m,3H),2.47-2.58(m,1H),2.74-2.82(m,2H),2.89-3.00(m,1H),2.91(d,J=7Hz,1H),2.95(d,J=19Hz,1H),3.00(ddd,J=3,6,14Hz,1H),3.07(ddd,J=3,12,14Hz,1H),3.79(s,3H),4.52(br s,1H),6.61(s,1H),6.89(s,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-9-メチル-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.16(m,2H),0.46-0.55(m,2H),0.76-0.88(m,1H),0.95-1.05(m,1H),1.39-1.46(m,1H),1.72-1.82(m,2H),1.95-2.07(m,2H),2.00(s,3H),2.19(s,3H),2.28-2.40(m,3H),2.45-2.61(m,3H),2.73(dd,J=6,18Hz,1H),2.78-2.99(m,5H),3.11-3.20(m,1H),3.96-4.08(m,2H),4.62(br s,1H),6.51(s,1H),6.48(s,1H),6.87(s,1H),7.23(s,1H).
(5aS,6R,11bS)-9-ブロモ-14-(シクロプロピルメチル)-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.16(m,2H),0.43-0.57(m,2H),0.76-0.88(m,1H),0.96-1.03(m,1H),1.45(ddd,J=2,5,14Hz,1H),1.72(ddd,J=3,11,14Hz,1H),1.77(ddd,J=4,4,16Hz,1H),1.92-2.09(m,2H),2.01(s,3H),2.31-2.38(m,1H),2.34(dd,J=7,13Hz,1H),2.39(ddd,J=4,11,16Hz,1H),2.45(ddd,J=3,5,14Hz,1H),2.51-2.58(m,1H),2.59(ddd,J=4,4,13Hz,1H),2.76(dd,J=6,18Hz,1H),2.80-2.95(m,3H),2.89(d,J=6Hz,1H),2.94(d,J=18Hz,1H),3.13(ddd,J=2,11,13Hz,1H),3.97(ddd,J=6,6,14Hz,1H),4.01(ddd,J=6,6,14Hz,1H),4.58(br s,1H),6.76(s,1H),6.82(s,1H),7.21(s,1H),7.22(s,1H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-3-(3-(4-(トリフルオロメチル)-1H-ピラゾール-1-イル)プロパノイル)-1,2,3,4,5,5a,6,7-オクタヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-10-カルボキサミドの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.18(m,2H),0.46-0.58(m,2H),0.76-0.88(m,1H),1.04-1.13(m,1H),1.57-1.76(m,1.5H),1.85(ddd,J=4,12,12Hz,0.5H),1.91-2.20(m,2.5H),2.25-2.38(m,2.5H),2.41-2.73(m,3H),2.77-2.90(m,1.5H),2.95-3.00(m,0.5H),2.98(d,J=6Hz,1H),2.99(d,J=19Hz,0.5H),3.11(d,J=19Hz,0.5H),3.23-3.40(m,1.5H),3.56-3.72(m,1.5H),3.79(ddd,J=4,11,15Hz,0.5H),3.89(ddd,J=3,3,14Hz,0.5H),4.15-4.24(m,1H),4.25-4.34(m,1H),4.47(br s,1H),5.40(br s,0.5H),5.70(br s,0.5H),6.55(br s,0.5H),6.68(br s,0.5H),7.02(d,J=8Hz,0.5H),7.14(d,J=8Hz,0.5H),7.23(dd,J=2,8Hz,0.5H),7.45(dd,J=2,8Hz,0.5H),7.53(s,0.5H),7.54(d,J=2Hz,0.5H),7.63(s,1H),7.69(s,0.5H),7.74(s,0.5H).
(5aS,6R,11bR)-3-(2-(1H-インダゾール-3-イル)アセチル)-14-(シクロプロピルメチル)-5a-ヒドロキシ-1,2,3,4,5,5a,6,7-オクタヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-10-カルボキサミドの合成
1H-NMR(400MHz,CD3OD)δ(ppm):0.08-0.20(m,2H),0.46-0.58(m,2H),0.81-0.92(m,1H),1.02-1.12(m,1H),1.53-1.66(m,1.4H),1.84(ddd,J=3,12,15Hz,0.6H),1.92(ddd,J=3,12,15Hz,0.6H),2.02-2.27(m,1.4H),2.29-2.65(m,3.6H),2.70(dd,J=6,19Hz,0.4H),2.92-3.01(m,1H),3.06(d,J=6Hz,0.6H),3.08(d,J=19Hz,0.4H),3.16(d,J=19Hz,0.6H),3.27-3.39(m,2H),3.44-3.79(m,3H),3.68(d,J=16Hz,0.6H),3.85(ddd,J=7,7,15Hz,0.4H),3.93(d,J=16Hz,0.4H),3.94(d,J=16Hz,0.6H),4.05(d,J=16Hz,0.4H),6.99-7.12(m,1.4H),7.26-7.38(m,1.6H),7.41-7.50(m,2H),7.52(dd,J=2,8Hz,0.4H),7.69(dd,J=2,7Hz,0.6H),7.71(dd,J=2,8Hz,0.4H),7.81(d,J=2Hz,0.6H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-3-(2-(4-(トリフルオロメチル)-1H-ピラゾール-1-イル)アセチル)-1,2,3,4,5,5a,6,7-オクタヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-10-カルボキサミドの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.19(m,2H),0.50-0.59(m,2H),0.78-0.90(m,1H),1.07-1.17(m,1H),1.59-1.83(m,2H),1.91(ddd,J=4,12,12Hz,0.5H),1.95-2.17(m,2H),2.21(ddd,J=4,4,16Hz,0.5H),2.31(dd,J=7,13Hz,0.5H),2.36(d,J=6Hz,1H),2.38(dd,J=7,13Hz,0.5H),2.47(ddd,J=5,11,16Hz,0.5H),2.54-2.64(m,1H),2.74-2.85(m,0.5H),2.86-2.90(m,0.5H),2.91-2.97(m,0.5H),2.99(d,J=6Hz,0.5H),3.00(d,J=6Hz,0.5H),3.05(d,J=19Hz,0.5H),3.13(d,J=19Hz,0.5H),3.26-3.50(m,1.5H),3.66(ddd,J=4,12,15Hz,0.5H),3.71-3.82(m,1.5H),3.90(ddd,J=3,4,14Hz,0.5H),4.50(br s,1H),4.58(d,J=16Hz,0.5H),4.75(d,J=16Hz,0.5H),4.78(d,J=16Hz,0.5H),4.87(d,J=16Hz,0.5H),5.64(br s,1H),6.44(br s,1H),7.17(d,J=8Hz,0.5H),7.19(d,J=7Hz,0.5H),7.44(d,J=2,8Hz,0.5H),7.45-7.52(m,0.5H),7.49(s,0.5H),7.55(d,J=2Hz,0.5H),7.58(s,0.5H),7.62(s,0.5H),7.64(s,0.5H),7.76(d,J=2Hz,0.5H).
(4R,4aS,7aR,12bS)-3-(シクロプロピルメチル)-4a-ヒドロキシ-9-メトキシ-6,6-ジメチル-2,3,4,4a,5,6-ヘキサヒドロ-1H-4,12-メタノベンゾフロ[3,2-e]イソキノリン-7(7aH)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.12-0.16(m,2H),0.53-0.57(m,2H),0.82-0.88(m,1H),0.95(s,3H),1.44(s,3H),1.52-1.62(m,2H),1.73(d,J=14Hz,1H),2.09(ddd,J=4,12,12Hz,1H),2.32-2.50(m,3H),2.57(dd,J=6,19Hz,1H),2.63-2.71(m,1H),3.02(d,J=19Hz,1H),3.11(d,J=6Hz,1H),3.92(s,3H),4.87(s,1H),5.45(br s,1H),6.60(d,J=8Hz,1H),6.69(d,J=8Hz,1H).
(4bR,8aS,9R)-11-(シクロプロピルメチル)-4,8a-ジヒドロキシ-3-メトキシ-7,7-ジメチル-8,8a,9,10-テトラヒドロ-5H-9,4b-(エピミノエタノ)フェナントレン-6(7H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.09-0.13(m,2H),0.50-0.54(m,2H),0.82(s,3H),0.82-0.88(m,1H),1.40(s,3H),1.65(d,J=14Hz,1H),1.81(d,J=14Hz,1H),1.97-2.11(m,2H),2.31(dd,J=6,13Hz,1H),2.37(dd,J=6,13Hz,1H),2.56-2.60(m,1H),2.83(dd,J=6,19Hz,1H),2.96(d,J=19Hz,1H),3.06(d,J=6Hz,1H),3.23(d,J=13Hz,1H),3.73(d,J=13Hz,1H),3.82(s,3H),4.87(br s,1H),6.06(s,1H),6.54(d,J=8Hz,1H),6.64(d,J=8Hz,1H).
トリフルオロメタンスルホン酸(4bR,8aS,9R)-11-(シクロプロピルメチル)-8a-ヒドロキシ-3-メトキシ-7,7-ジメチル-6-オキソ-6,7,8,8a,9,10-ヘキサヒドロ-5H-9,4b-(エピミノエタノ)フェナントレン-4-イルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.10-0.14(m,2H),0.52-0.57(m,2H),0.78(s,3H),0.81-0.89(m,1H),1.38(s,3H),1.61-1.70(m,3H),2.06(ddd,J=3,12,12Hz,1H),2.21(ddd,J=5,12,12Hz,1H),2.33(dd,J=6,12Hz,1H),2.39(dd,J=6,12Hz,1H),2.66-2.69(m,1H),2.87(dd,J=6,18Hz,1H),3.02(d,J=18Hz,1H),3.11(d,J=6Hz,1H),3.37(d,J=14Hz,1H),3.44(d,J=14Hz,1H),3.80(s,3H),6.83(d,J=8Hz,1H),7.03(d,J=8Hz,1H).
(4bR,8aS,9R)-11-(シクロプロピルメチル)-8a-ヒドロキシ-3-メトキシ-7,7-ジメチル-8,8a,9,10-テトラヒドロ-5H-9,4b-(エピミノエタノ)フェナントレン-6(7H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.11-0.15(m,2H),0.51-0.56(m,2H),0.79(s,3H),0.80-0.91(m,1H),1.14-1.17(m,1H),1.40(s,3H),1.64(d,J=14Hz,1H),1.71(d,J=14Hz,1H),2.07(ddd,J=3,12,12Hz,1H),2.16(ddd,J=4,13,13Hz,1H),2.34(dd,J=6,13Hz,1H),2.41(dd,J=6,13Hz,1H),2.56-2.60(m,1H),2.72(d,J=14Hz,1H),2.75(dd,J=6,18Hz,1H),3.04(d,J=18Hz,1H),3.09(d,J=6Hz,1H),3.36(d,J=14Hz,1H),3.77(s,3H),6.68(dd,J=2,8Hz,1H),6.79(d,J=2Hz,1H),6.96(d,J=8Hz,1H).
(4bR,8aS,9R)-11-(シクロプロピルメチル)-8a-ヒドロキシ-3-メトキシ-7,7-ジメチル-8,8a,9,10-テトラヒドロ-5H-9,4b-(エピミノエタノ)フェナントレン-6(7H)-オン オキシムの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.09-0.13(m,2H),0.49-0.53(m,2H),0.80-0.89(m,1H),0.90(s,3H),1.12-1.15(m,1H),1.42(s,3H),1.43-1.60(m,2H),2.04-2.17(m,2H),2.32(dd,J=6,13Hz,1H),2.39(dd,J=6,13Hz,1H),2.53-2.59(m,2H),2.71(dd,J=6,18Hz,1H),2.99(d,J=6Hz,1H),3.01(d,J=18Hz,1H),3.69(d,J=14Hz,1H),3.74(s,3H),6.68(dd,J=2,8Hz,1H),6.94(d,J=8Hz,1H),6.99(br s,1H),7.08(d,J=2Hz,1H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-4,4-ジメチル-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.09-0.13(m,2H),0.50-0.54(m,2H),0.78-0.88(m,1H),1.06-1.14(m,1H),1.10(s,3H),1.55(d,J=14Hz,1H),1.62(s,3H),1.86(d,J=14Hz,1H),2.00-2.09(m,2H),2.32(dd,J=6,13Hz,1H),2.34(dd,J=6,13Hz,1H),2.52-2.61(m,1H),2.72(dd,J=2,15Hz,1H),2.78(dd,J=6,18Hz,1H),2.87(d,J=6Hz,1H),3.00(d,J=18Hz,1H),3.57(d,J=15Hz,1H),3.79(s,3H),4.90(br s,1H),5.39(s,1H),6.71(dd,J=2,8Hz,1H),6.97(d,J=8Hz,1H),7.10(d,J=2Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-4,4-ジメチル-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.13(m,2H),0.50-0.53(m,2H),0.81-0.90(m,1H),0.85(s,3H),1.04-1.10(m,1H),1.33(s,3H),1.43(d,J=15Hz,1H),1.57-1.76(m,2H),1.92-2.01(m,2H),2.26-2.39(m,3H),2.51-2.60(m,2H),2.74(dd,J=6,18Hz,1H),2.82(d,J=6Hz,1H),2.85-2.91(m,1H),2.98(d,J=18Hz,1H),3.79(s,3H),4.41(s,1H),6.71(dd,J=2,8Hz,1H),6.74(d,J=2Hz,1H),7.02(d,J=8Hz,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-4,4-ジメチル-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(4-メチル-1H-ピラゾール-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.13(m,2H),0.49-0.54(m,2H),0.79-0.88(m,1H),1.04-1.07(m,1H),1.14(s,3H),1.39(d,J=15Hz,1H),1.88(s,3H),1.92-2.15(m,4H),2.09(s,3H),2.28-2.40(m,3H),2.55-2.62(m,1H),2.76(dd,J=6,18Hz,1H),2.81(d,J=6Hz,1H),2.92-2.98(m,1H),3.01(d,J=18Hz,1H),3.57-3.63(m,1H),3.79(s,3H),4.44(s,1H),4.82(d,J=16Hz,1H),4.99(d,J=16Hz,1H),6.68(d,J=2Hz,1H),6.74(dd,J=2,8Hz,1H),7.05(d,J=8Hz,1H),7.33(s,1H),7.34(s,1H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-4,4-ジメチル-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.09(m,2H),0.43-0.49(m,2H),0.67(s,3H),0.85-0.93(m,1H),0.99-1.03(m,1H),1.25(s,3H),1.36(d,J=15Hz,1H),1.72(d,J=15Hz,1H),1.86-1.92(m,1H),1.97(ddd,J=3,12,12Hz,1H),2.08(s,3H),2.14(ddd,J=5,12,12Hz,1H),2.28(dd,J=5,15Hz,1H),2.34-2.40(m,3H),2.55-2.65(m,3H),2.76(dd,J=12,14Hz,1H),2.95-2.99(m,2H),3.04-3.11(m,1H),4.04-4.17(m,2H),4.74(br s,1H),6.61(d,J=2,8Hz,1H),6.71(d,J=2Hz,1H),6.90(d,J=8Hz,1H),7.28(s,1H),7.33(s,1H).
(4bR,8aS,9R)-11-(シクロプロピルメチル)-4,8a-ジヒドロキシ-3-メトキシ-7-メチル-8,8a,9,10-テトラヒドロ-5H-9,4b-(エピミノエタノ)フェナントレン-6(7H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.10-0.14(m,2H),0.51-0.55(m,2H),0.83-0.89(m,1H),0.88(d,J=7Hz,3H),1.63(dd,J=13,14Hz,1H),1.87(dd,J=6,13Hz,1H),1.98-2.13(m,3H),2.32-2.41(m,2H),2.58-2.62(m,1H),2.81(dd,J=7,18Hz,1H),2.89-3.01(m,3H),3.09(d,J=7Hz,1H),3.82(s,3H),3.93(d,J=13Hz,1H),6.10(s,1H),6.54(d,J=8Hz,1H),6.65(d,J=8Hz,1H).
トリフルオロメタンスルホン酸(4bR,8aS,9R)-11-(シクロプロピルメチル)-8a-ヒドロキシ-3-メトキシ-7-メチル-6-オキソ-6,7,8,8a,9,10-ヘキサヒドロ-5H-9,4b-(エピミノエタノ)フェナントレン-4-イルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.11-0.15(m,2H),0.53-0.57(m,2H),0.83(d,J=6Hz,3H),0.83-0.90(m,1H),1.44(dd,J=14,14Hz,1H),1.65-1.69(m,1H),1.89(dd,J=7,14Hz,1H),2.09(dd,J=3,12Hz,1H),2.21(ddd,J=5,13,13Hz,1H),2.38(d,J=7Hz,2H),2.67-2.71(m,1H),2.85(dd,J=7,18Hz,1H),2.87-2.96(m,1H),3.04(d,J=18Hz,1H),3.13(d,J=7Hz,1H),3.14(d,J=14Hz,1H),3.53(d,J=14Hz,1H),3.80(s,3H),6.83(d,J=8Hz,1H),7.03(d,J=8Hz,1H).
(4bR,8aS,9R)-11-(シクロプロピルメチル)-8a-ヒドロキシ-3-メトキシ-7-メチル-8,8a,9,10-テトラヒドロ-5H-9,4b-(エピミノエタノ)フェナントレン-6(7H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.12-0.16(m,2H),0.52-0.57(m,2H),0.83-0.91(m,1H),0.87(d,J=6Hz,3H),1.16-1.20(m,1H),1.54(dd,J=13,13Hz,1H),1.85(dd,J=6,13Hz,1H),2.05-2.20(m,2H),2.36-2.44(m,2H),2.57-2.61(m,1H),2.74(dd,J=6,18Hz,1H),2.83(d,J=14Hz,1H),2.88-2.98(m,1H),3.05(d,J=18Hz,1H),3.08(dd,J=1,14Hz,1H),3.12(d,J=6Hz,1H),3.77(s,3H),6.68(dd,J=2,8Hz,1H),6.81(d,J=2Hz,1H),6.97(d,J=8Hz,1H).
(4bR,8aS,9R)-11-(シクロプロピルメチル)-8a-ヒドロキシ-3-メトキシ-7-メチル-8,8a,9,10-テトラヒドロ-5H-9,4b-(エピミノエタノ)フェナントレン-6(7H)-オン オキシムの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.10-0.15(m,2H),0.50-0.55(m,2H),0.82-0.90(m,1H),0.94(d,J=6Hz,3H),1.15-1.18(m,1H),1.39(dd,J=13,13Hz,1H),1.66(dd,J=5,13Hz,1H),2.06-2.16(m,2H),2.33(d,J=14Hz,1H),2.33-2.42(m,2H),2.55-2.60(m,1H),2.71(dd,J=6,18Hz,1H),2.81-2.90(m,1H),3.03(d,J=6Hz,1H),3.04(d,J=18Hz,1H),3.77(s,3H),3.78(d,J=14Hz,1H),6.69(dd,J=2,8Hz,1H),6.87(br s,1H),6.95(d,J=8Hz,1H),7.11(d,J=2Hz,1H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-4-メチル-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.10-0.13(m,2H),0.50-0.55(m,2H),0.78-0.88(m,1H),1.09-1.14(m,1H),1.11(d,J=6Hz,3H),1.48(d,J=14Hz,1H),1.68(dd,J=10,14Hz,1H),2.03-2.11(m,2H),2.35-2.37(m,2H),2.56-2.63(m,2H),2.75(dd,J=6,18Hz,1H),2.90(d,J=6Hz,1H),3.01(d,J=18Hz,1H),3.50(d,J=14Hz,1H),3.80(s,3H),4.06-4.15(m,1H),5.23(s,1H),6.71(dd,J=2,8Hz,1H),6.97(d,J=8Hz,1H),7.15(d,J=2Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-4-メチル-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.13(m,2H),0.47-0.55(m,2H),0.78-0.88(m,1H),0.96(d,J=7Hz,3H),1.03-1.07(m,1H),1.51-1.60(m,2H),1.95-2.08(m,3H),2.30-2.38(m,3H),2.50-2.53(m,1H),2.81(dd,J=6,18Hz,1H),2.88-3.00(m,4H),3.28-3.37(m,1H),3.79(s,3H),4.55(br s,1H),6.71(dd,J=3,9Hz,1H),6.72(d,J=3Hz,1H),7.02(d,J=9Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-4-メチル-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.13(m,2H),0.46-0.54(m,2H),0.78-0.87(m,1H),0.81(d,J=6Hz,3H),1.00-1.08(m,1H),1.40(dd,J=4,15Hz,1H),1.65(dd,J=12,15Hz,1H),1.86(dd,J=6,16Hz,1H),1.99-2.02(m,2H),2.05(s,3H),2.14(dd,J=10,16Hz,1H),2.32(dd,J=6,13Hz,1H),2.38(dd,J=6,13Hz,1H),2.49-2.57(m,1H),2.62(dd,J=6,15Hz,1H),2.74(dd,J=6,18Hz,1H),2.83-2.89(m,2H),2.98(d,J=19Hz,1H),2.98-3.11(m,2H),3.16-3.24(m,1H),3.78(s,3H),4.03-4.15(m,2H),4.69(br s,1H),6.67(d,J=2Hz,1H),6.71(dd,J=2,8Hz,1H),7.01(d,J=8Hz,1H),7.19(s,1H),7.28(s,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-4-メチル-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.13(m,2H),0.45-0.53(m,2H),0.78-0.90(m,1H),0.84(d,J=6Hz,3H),1.00-1.07(m,1H),1.38(dd,J=4,15Hz,1H),1.67(dd,J=12,15Hz,1H),1.82(dd,J=6,15Hz,1H),1.99-2.01(m,2H),2.05(s,3H),2.13(dd,J=10,15Hz,1H),2.32(dd,J=6,12Hz,1H),2.37(dd,J=6,12Hz,1H),2.48-2.56(m,1H),2.62(dd,J=6,15Hz,1H),2.72(dd,J=6,18Hz,1H),2.85(d,J=19Hz,1H),2.87(d,J=13Hz,1H),2.95(d,J=19Hz,1H),2.95-3.12(m,2H),3.17-3.25(m,1H),4.04-4.16(m,2H),4.71(br s,1H),6.61(d,J=2Hz,1H),6.64(dd,J=2,8Hz,1H),6.92(d,J=8Hz,1H),7.19(s,1H),7.30(s,1H).
(4R,4aS,8aR,13bS)-3-(シクロプロピルメチル)-4a-ヒドロキシ-1,2,3,4,4a,5,6,7-オクタヒドロ-4,13-メタノベンゾフロ[2,3-c]ピリド[4,3-d]アゼピン-8(8aH)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm): 0.10-0.17(m,2H),0.52-0.59(m,2H),0.80-0.92(m,1H),1.27-1.36(m,1H),1.57-1.66(m,1H),1.87-1.98(m,1H),2.27-2.44(m,3H),2.46(ddd,J=6,13,13Hz,1H),2.63-2.77(m,2H),2.82-2.90(m,2H),3.11(d,J=7Hz,1H),3.18(d,J=19Hz,1H),4.81(d,J=2Hz,1H),4.94(br s,1H),5.93-6.02(m,1H),6.66(d,J=8Hz,1H),6.71(d,J=7Hz,1H),7.12(dd,J=8,8Hz,1H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,11-ジヒドロキシ-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm): 0.06-0.15(m,2H),0.48-0.55(m,2H),0.75-0.87(m,1H),1.40-1.62(m,3H),1.87-2.01(m,2H),2.30(dd,J=7,13Hz,1H),2.35(dd,J=6,12Hz,1H),2.50-2.62(m,1H),2.77-2.90(m,3H),2.92-3.04(m,2H),3.55(d,J=14Hz,1H),3.78-3.90(m,1H),4.66(br s,1H),6.71(d,J=7Hz,1H),6.81(d,J=8Hz,1H),6.83-6.92(m,1H),7.01(dd,J=8,8Hz,1H),8.53(br s,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,11(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm): 0.04-0.15(m,2H),0.45-0.55(m,2H),0.76-0.91(m,1H),1.48-1.82(m,3H),1.88-2.04(m,2H),2.27-2.34(m,2H),2.40-2.60(m,3H),2.77-3.04(m,6H),3.12-3.23(m,1H),4.53(br s,1H),5.93(br s,1H),6.31(d,J=8Hz,1H),6.57(d,J=7Hz,1H),6.88(dd,J=8,8Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,11(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm): 0.04-0.15(m,2H),0.45-0.55(m,2H),0.76-0.91(m,1H),1.18-2.07(m,5H),2.00(s,3H),2.24-2.64(m,6H),2.74-3.00(m,7H),3.32(dd,J=12,12Hz,1H),3.98-4.16(m,2H),4.61(br s,1H),6.47(d,J=8Hz,1H),6.65(d,J=7Hz,1H),6.91(s,1H),6.92(dd,J=8,8Hz,1H),7.23(s,1H).
トリフルオロメタンスルホン酸(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-3-(2-(ピリジン-2-イル)アセチル)-1,2,3,4,5,5a,6,7-オクタヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-10-イルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,2H),0.70-0.90(m,1H),1.00-1.10(m,1H),1.60-1.80(m,4H),1.80-2.20(m,3H),2.20-2.40(m,2H),2.45-2.65(m,1H),2.70-3.15(m,2.5H),3.40-3.60(m,1.5H),3.65-3.80(m,1H),3.80-4.00(m,2.5H),4.10-4.25(m,0.5H),4.30-4.50(m,1H),6.95-7.10(m,2H),7.10-7.20(m,2.5H),7.20-7.30(m,0.5H),7.50-7.60(m,1H),8.40-8.55(m,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-(6-メトキシピリジン-2-イル)-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(ピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,2H),0.75-0.90(m,1H),1.05-1.20(m,1H),1.50-1.70(m,1.4H),1.70-1.90(m,1.6H),1.95-2.20(m,2H),2.25-2.45(m,3H),2.50-2.70(m,1.4H),2.70-2.85(m,0.6H),2.90-3.15(m,3H),3.20-3.35(m,0.4H),3.40-3.70(m,1H),3.74(d,J=16Hz,0.6H),3.80-4.00(m,2.6H),4.00(s,1.8H),4.02(s,1.2H),4.15-4.20(m,0.4H),6.66(d,J=8Hz,1H),6.93(d,J=8Hz,0.6H),7.01(dd,J=2,3Hz,0.6H),7.03(dd,J=2,3Hz,0.4H),7.15-7.25(m,1.4H),7.25-7.30(m,1H),7.46(dt,J=2,7Hz,0.6H),7.56(dt,J=2,7Hz,0.4H),7.60-7.70(m,1H),7.73(dd,J=2,8Hz,0.6H),7.78(dd,J=2,8Hz,0.4H),7.80-7.00(m,1H),8.39(dd,J=1,4Hz,0.6H),8.49(dd,J=1,4Hz,0.4H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-4-メチル-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(ピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CD3D)δ(ppm):0.10-0.18(m,2H),0.48-0.57(m,2H),0.83-0.92(m,1H),0.92(d,J=6Hz,1.5H),0.97(d,J=6Hz,1.5H),1.06-1.09(m,1H),1.63-1.80(m,2H),1.88-2.09(m,3H),2.28(dd,J=6,15Hz,0.5H),2.33-2.46(m,2.5H),2.52-2.58(m,1H),2.62-2.68(m,0.5H),2.80(dd,J=6,19Hz,1H),2.92-3.10(m,2.5H),3.76(s,3H),3.90-4.12(m,3H),4.27-4.37(m,0.5H),4.58-4.66(m,0.5H),6.75-6.78(m,2H),7.08(d,J=8Hz,1H),7.23-7.32(m,1H),7.43(d,J=8Hz,0.5H),7.45(d,J=8Hz,0.5H),7.77-7.81(m,1H),8.45-8.49(m,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-4-メチル-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(ピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.08-0.11(m,2H),0.49-0.52(m,2H),0.76-0.81(m,1.9H),0.90(d,J=6Hz,2.1H),1.05-1.13(m,1H),1.52-1.68(m,2H),1.75-1.81(m,0.6H),1.85-1.95(m,1H),2.02-2.15(m,1.4H),2.29-2.39(m,3H),2.47-2.51(m,1H),2.65-2.75(m,1.6H),2.83-3.02(m,2.4H),3.79(dd,J=6,16Hz,0.3H),3.86(d,J=15Hz,0.3H),3.98-4.20(m,2.4H),4.35-4.41(m,0.7H),4.67-4.73(m,0.3H),6.61-6.69(m,1.3H),6.91(d,J=8Hz,0.3H),6.94(d,J=8Hz,0.7H),7.02-7.03(m,0.7H),7.15-7.22(m,1H),7.45(d,J=8Hz,0.7H),7.49(d,J=8Hz,0.3H),7.64-7.71(m,1H),8.52(d,J=4Hz,0.3H),8.55(d,J=4Hz,0.7H).
(4R,4aS,8aR,13bS)-3-(シクロプロピルメチル)-4a-ヒドロキシ-10-メトキシ-1,2,3,4,4a,5,6,7-オクタヒドロ-4,13-メタノベンゾフロ[2,3-c]ピリド[4,3-d]アゼピン-8(8aH)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm): 0.09-0.17(m,2H),0.51-0.57(m,2H),0.80-0.91(m,1H),1.28-1.36(m,1H),1.59-1.67(m,1H),1.92(ddd,J=6,14,14Hz,1H),2.28-2.42(m,3H),2.46(ddd,J=6,13,13Hz,1H),2.64(dd,J=7,19Hz,1H),2.72(dd,J=5,11Hz,1H),2.80-2.99(m,2H),3.06-3.17(m,2H),3.89(s,3H),4.86(s,1H),4.95(br s,1H),5.95(t,J=7Hz,1H),6.66(d,J=8Hz,1H),6.78(d,J=8Hz,1H).
(5aR,6R,11bR)-14-(シクロプロピルメチル)-5a,11-ジヒドロキシ-10-メトキシ-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm): 0.06-0.15(m,2H),0.47-0.55(m,2H),0.75-0.88(m,1H),1.43-1.71(m,2H),1.80-2.05(m,3H),2.32(dd,J=6,13Hz,1H),2.34(dd,J=6,13Hz,1H),2.54-2.63(m,1H),2.80-3.00(m,4H),3.15(dd,J=2,14Hz,1H),3.52(d,J=14Hz,1H),3.81(s,3H),3.84-3.96(m,1H),4.63(s,1H),5.85(br s,1H),6.66(d,J=8Hz,1H),6.72(d,J=8Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,11(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm): 0.05-0.14(m,2H),0.45-0.54(m,2H),0.76-0.89(m,1H),1.44-1.80(m,3H),1.86-2.04(m,2H),2.26-2.58(m,5H),2.72-2.80(m,1H),2.87-3.02(m,5H),3.10-3.20(m,1H),3.86(s,3H),4.47(br s,1H),6.59(d,J=8Hz,1H),6.69(d,J=8Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-10-メトキシ-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,11(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm): 0.04-0.15(m,2H),0.45-0.53(m,2H),0.76-0.88(m,1H),1.38-1.50(m,2H),1.79-2.02(m,3H),1.99(s,3H),2.24-2.58(m,6H),2.68-2.96(m,7H),3.27(dd,J=11,13Hz,1H),3.84(s,3H),3.92-4.06(m,2H),4.54(br s,1H),5.89(s,1H),6.60(d,J=9Hz,1H),6.69(d,J=8Hz,1H),6.82(s,1H),7.20(s,1H).
38/38H
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-11-フェノキシ-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
の合成
得られた粗生成物のメタノール(2mL)溶液に、水素化ホウ素ナトリウム(18.9mg,0.50mmol)を加え、室温で30分間撹拌した。反応混合物に飽和炭酸水素ナトリウム水溶液を加え、クロロホルムで三回抽出した。有機層を合わせて硫酸ナトリウムで乾燥後、減圧下にて濃縮した。得られた粗生成物は精製せずに次の反応に用いた。
得られた粗生成物のクロロホルム(2mL)溶液に、氷冷下1M三臭化ホウ素-ジクロロメタン溶液(0.5mL,0.5mmol)を加え、室温で30分間撹拌した。反応混合物に氷冷下28%アンモニア水溶液を加え、クロロホルムで三回抽出した。合わせた抽出液を硫酸ナトリウムで乾燥後、減圧下にて濃縮した。得られた粗生成物を分取薄層クロマトグラフィー(クロロホルム:2Mアンモニア-メタノール溶液=10:1)で精製し、表題化合物(2.4mg,9%)を無色アモルファスとして得た。
1H-NMR(400MHz,CDCl3)δ(ppm): 0.05-0.12(m,2H),0.44-0.52(m,2H),0.73-0.92(m,2H),1.22-1.86(m,5H),1.92-2.10(m,2H),2.02(s,3H),2.26-2.51(m,4H),2.68-3.21(m,7H),3.95-4.01(m,2H),6.65-6.73(m,2H),6.84(s,1H),6.88(d,J=8Hz,1H),6.94(d,J=8Hz,1H),7.01(t,J=7Hz,1H),7.22(s,1H),7.24-7.29(m,2H).
(4bR,8aS,9R)-3-(ベンジロキシ)-11-(シクロプロピルメチル)-8a-ヒドロキシ-8,8a,9,10-テトラヒドロ-5H-9,4b-(エピミノエタノ)フェナントレン-6(7H)-オン オキシムの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.20(m,2H),0.45-0.60(m,2H),0.79-0.93(m,1H),1.07-1.20(m,1H),1.54-1.65(m,2H),2.07-2.24(m,3H),2.31-2.45(m,2.7H),2.54-2.66(m,1.7H),2.68-2.80(m,0.6H),2.72(dd,J=7,19Hz,1H),2.98-3.11(m,2.3H),3.70(d,J=14Hz,0.7H),5.02(s,0.6H),5.04(s,1.4H),6.76(dd,J=3,8Hz,0.3H),6.77(dd,J=3,8Hz,0.7H),6.92(d,J=3Hz,0.3H),6.96(d,J=8Hz,0.7H),6.97(d,J=8Hz,0.3H),7.17(d,J=3Hz,0.7H),7.24-7.45(m,5H).
(5aS,6R,11bR)-10-(ベンジロキシ)-14-(シクロプロピルメチル)-5a-ヒドロキシ-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オン(異性体O)及び(5aS,6R,11bS)-10-(ベンジロキシ)-14-(シクロプロピルメチル)-5a-ヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-c]アゼピン-3(4H)-オン(異性体P)の混合物の合成
1H-NMR(400MHz,CDCl3)δ(ppm): 0.05-0.18(m,2H),0.45-0.59(m,2H),0.76-0.89(m,1H),0.90-0.97(m,0.3H),1.04-1.15(m,0.7H),1.54-1.59(m,1H),1.75-1.84(m,0.3H),1.79(ddd,J=2,11,14Hz,0.7H),1.92-2.21(m,2.3H),2.29-2.41(m,2H),2.52-2.64(m,1.7H),2.72-2.81(m,0.3H),2.76(dd,J=6,19Hz,0.7H),2.84-2.94(m,1H),2.92(d,J=6Hz,0.7H),2.95-3.05(m,0.6H),3.02(d,J=19Hz,0.7H),3.11-3.20(m,0.3H),3.51(d,J=14Hz,0.7H),3.87(ddd,J=4,12,15Hz,0.7H),4.08(dd,J=6,16Hz,0.3H),5.01(d,J=11Hz,0.3H),5.03(d,J=11Hz,0.3H),5.06(d,J=12Hz,0.7H),5.06(d,J=12Hz,0.7H),5.57-5.63(m,0.3H),5.66-5.73(m,0.7H),6.53(d,J=3Hz,0.3H),6.76-6.80(m,0.3H),6.78(dd,J=2,8Hz,0.7H),6.97(d,J=8Hz,0.7H),7.01(d,J=8Hz,0.3H),7.25-7.26(m,0.7H),7.27-7.49(m,5H).
(5aS,6R,11bS)-10-(ベンジロキシ)-14-(シクロプロピルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オール(異性体Q)及び(5aS,6R,11bS)-10-(ベンジロキシ)-14-(シクロプロピルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-c]アゼピン-5a(1H)-オール(異性体R)の合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.17(m,2H),0.44-0.56 (m,2H),0.78-0.89(m,1H),1.00-1.12(m,1H),1.56(ddd,J=3,3,14Hz,1H),1.73(ddd,J=4,12,15Hz,1H),1.95(ddd,J=3,3,15Hz,1H),1.99-2.07(m,2H),2.28(ddd,J=5,12,16Hz,1H),2.34(dd,J=7,13Hz,1H),2.34(dd,J=7,13Hz,1H),2.47-2.59(m,1H),2.71-2.85(m,3H),2.91(ddd,J=4,4,14Hz,1H),2.92(d,J=7Hz,1H),2.99(d,J=18Hz,1H)3.08(ddd,J=3,12,14Hz,1H),4.06(br s,1H),5.02(d,J=12Hz,1H),5.03(d,J=12Hz,1H),6.76(d,J=3Hz,1H),6.79(dd,J=3,8Hz,1H),7.02(d,J=8Hz,1H),7.29-7.44(m,5H).
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.17(m,2H),0.45-0.55(m,2H),0.78-0.90(m,1H),0.92-0.97(m,1H),1.47-1.67(m,2H),1.90(ddd,J=5,13,13Hz,1H),1.94-2.06(m,2H),2.19-2.32(m,1H),2.33(dd,J=6,13Hz,1H),2.38(dd,J=6,13Hz,1H),2.54-2.60(m,1H),2.67(ddd,J=7,9,14Hz,1H),2.80(dd,J=6,18Hz,1H),2.90(d,J=6Hz,1H),2.92-3.01(m,1H),2.98(d,J=18Hz,1H),3.13(d,J=15Hz,1H),3.16(d,J=15Hz,1H),4.64(br s,1H),5.03(d,J=12Hz,1H),5.04(d,J=12Hz,1H),6.80(dd,J=3,8Hz,1H),6.83(d,J=3Hz,1H),7.03(d,J=8Hz,1H),7.29-7.46(m,5H).
(5aS,6R,11bR)-10-(ベンジロキシ)-9-ブロモ-14-(シクロプロピルメチル)-5a-ヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-カルボン酸tert-ブチルの合成
得られた粗生成物のクロロホルム(1.5mL)溶液に0℃でトリエチルアミン(250μL,1.79mmol)及び二炭酸ジ-tert-ブチル(170μL,0.740mmol)を加え、室温で1.5時間撹拌した。0℃に冷却後、反応混合物に飽和炭酸水素ナトリウム水溶液(1mL)及び水(2mL)を加え、酢酸エチルで3回抽出した。有機層を合わせて飽和食塩水で洗浄し、硫酸ナトリウムで乾燥後、減圧下にて濃縮した。得られた粗生成物をシリカゲルカラムクロマトグラフィー(0-5%メタノール/酢酸エチル)で精製し、表題化合物(119mg,55%)を淡黄色のアモルファスとして得た。
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.16(m,2H),0.43-0.58(m,2H),0.75-0.86(m,1H),0.90-0.99(m,1H),1.29(s,4.5H),1.31(s,4.5H),1.43-1.60(m,2H),1.74-2.10(m,3H),2.28(dd,J=6,12Hz,0.5H),2.30-2.41(m,2H),2.45-2.59(m,1.5H),2.73-2.85(m,1H),2.87-2.95(m,1.5H),2.96(d,J=18Hz,0.5H),3.27-3.42(m,2H),3.46-3.61(m,2H),5.10(d,J=12Hz,0.5H),5.12(d,J=12Hz,0.5H),5.16(d,J=12Hz,0.5H),5.20(d,J=12Hz,0.5H),6.66(s,0.5H),6.69(s,0.5H),7.27(s,1H),7.29-7.51(m,5H).
(5aS,6R,11bR)-10-(ベンジロキシ)-14-(シクロプロピルメチル)-5a-ヒドロキシ-9-メチル-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-カルボン酸tert-ブチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.16(m,2H),0.44-0.55(m,2H),0.75-0.89(m,1H),0.96-1.03(m,1H),1.27(s,4.5H),1.34(s,4.5H),1.42-1.64(m,1H),1.78-2.09(m,4H),2.20(s,3H),2.24-2.40(m,2.5H),2.43-2.57(m,1.5H),2.70-2.83(m,1H),2.85-3.00(m,2H),3.22-3.45(m,2H),3.50-3.69(m,2H),4.50(br s,1H),5.02(d,J=12Hz,0.5H),5.05(d,J=12Hz,0.5H),5.07(s,1H),6.59(s,0.5H),6.61(s,0.5H),6.85(s,0.5H),6.86(s,0.5H),7.27-7.47(m,5H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-9-メチル-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
得られた粗生成物のクロロホルム(2.0mL)溶液に0℃でトリフルオロ酢酸(0.30mL)を加え、室温で1時間撹拌した。0℃に冷却後、反応混合物に2M水酸化ナトリウム水溶液(3mL)及び水(2mL)を加え、クロロホルム/メタノール=10/1(v/v)で10回及びクロロホルム/イソプロパノール=4/1(v/v)3回抽出した。有機層を合わせて硫酸ナトリウムで乾燥後、減圧下にて濃縮した。得られた粗生成物をシリカゲルカラムクロマトグラフィー(アミノ基担持シリカゲル,30-55%メタノール/酢酸エチル)で精製し、表題化合物(45.3mg,80%)を白色固体として得た。
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.16(m,2H),0.42-0.57(m,2H),0.77-0.88(m,1H),1.03-1.11(m,1H),1.48(ddd,J=3,3,15Hz,1H),1.79(ddd,J=5,12,15Hz,1H),1.94(ddd,J=5,13,13Hz,1H),2.03-2.16(m,3H),2.14(s,3H),2.34(d,J=6Hz,2H),2.48-2.56(m,1H),2.70(dd,J=6,18Hz,1H),2.74-2.82(m,2H),2.87(d,J=6Hz,1H),3.03-3.12(m,1H),3.08(d,J=18Hz,1H), 3.19(ddd,J=3,3,13Hz,1H),4.57(br s,1H),5.69(br s,1H),6.48(s,1H),6.80(s,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-9-メチル-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(ピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.16(m,2H),0.44-0.55(m,2H),0.75-0.87(m,1H),0.99-1.12(m,1H),1.49-1.61(m,1H),1.76-2.09(m,4H),2.15-2.22(m,0.5H),2.16(s,1.5H),2.17(s,1.5H),2.25-2.39(m,2H),2.47-2.58(m,1.5H),2.65(dd,J=6,18Hz,0.5H),2.73(dd,J=7,18Hz,0.5H),2.83(d,J=6Hz,0.5H),2.89(d,J=7Hz,0.5H),2.90(d,J=18Hz,0.5H),2.94(d,J=18Hz,0.5H),3.12-3.21(m,0.5H),3.25-3.34(m,1H),3.44(ddd,J=4,4,13Hz,0.5H),3.71(d,J=15Hz,0.5H),3.74(d,J=15Hz,0.5H),3.78-3.98(m,1.5H),3.90(d,J=15Hz,0.5H),3.95(d,J=15Hz,0.5H),4.14-4.22(m,0.5H),4.42(br s,0.5H),4.51(br s,0.5H),6.66(s,0.5H),6.77(s,0.5H),6.79(s,0.5H),6.79(s,0.5H),7.11-7.19(m,1H),7.21-7.25(m,1H),7.59(ddd,J=2,8,8Hz,0.5H),7.61(ddd,J=2,8,8Hz,0.5H),8.45-8.51(m,1H).
(5aS,6R,11bR)-10-(ベンジロキシ)-14-(シクロプロピルメチル)-5a-ヒドロキシ-9-ヨード-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-カルボン酸tert-ブチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.12(m,2H),0.47-0.54(m,2H),0.75-0.85(m,1H),0.85-0.99(m,1H),1.27(s,5H),1.31(s,4H),1.41-1.56(m,1H),1.71-2.12(m,4H),2.23-2.41(m,2.5H),2.45-2.58(m,1.5H),2.69-2.85(m,1H),2.86-3.00(m,2H),3.25-3.65(m,4H),4.45(br s,1H),5.00-5.24(m,2H),6.58(s,0.5H),6.61(s,0.5H),7.28-7.35(m,1H),7.35-7.45(m,2H),7.46-7.55(m,3H).
(5aS,6R,11bR)-10-(ベンジロキシ)-14-(シクロプロピルメチル)-5a-ヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3,9(4H)-ジカルボン酸3-(tert-ブチル)9-(2,4,6-トリクロロフェニル)
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.16(m,2H),0.49-0.56(m,2H),0.77-0.90(m,1H),0.97-1.06(m,1H),1.27(s,4.5H),1.29(s,4.5H),1.50-1.66(m,1H),1.75-2.20(m,4H),2.27-2.53(m,2.5H),2.54-2.68(m,1.5H),2.83-2.97(m,1H),2.98-3.12(m,2H),3.26-3.64(m,3.5H),3.73(ddd,J=4,14,14Hz,0.5H),5.17(d,J=12Hz,0.5H),5.23(d,J=12Hz,0.5H),5.25(d,J=12Hz,0.5H),5.32(d,J=12Hz,0.5H),6.83(s,0.5H),6.86(s,0.5H),7.25-7.31(m,1H),7.31-7.38(m,2H),7.40(s,2H),7.46-7.52(m,2H),7.85(s,0.5H),7.86(s,0.5H).
(5aS,6R,11bR)-10-(ベンジロキシ)-9-カルバモイル-14-(シクロプロピルメチル)-5a-ヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-カルボン酸tert-ブチル
この混合物をテトラヒドロフラン(1mL)へ溶解し、28%アンモニア水溶液(1mL)を加え、45℃で1時間撹拌した。反応液に飽和炭酸水素ナトリウム水溶液を加え、酢酸エチルで抽出した。有機層を硫酸ナトリウムで乾燥し、減圧下にて濃縮した。得られた粗生成物を分取薄層クロマトグラフィー(クロロホルム:メタノール=20:1)で精製し、表題化合物(19.5mg,36%)および原料化合物(実施例292記載の化合物)(32.3mg,51%)をそれぞれ無色アモルファスとして得た。
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.15(m,2H),0.45-0.57(m,2H),0.76-0.89(m,1H),0.95-1.05(m,1H),1.25(s,6.3H),1.30(s,2.7H),1.51(ddd,J=3,3,15Hz,0.7H),1.57-1.64(m,0.3H),1.71-2.14(m,5H),2.23-2.42(m,2H),2.46-2.61(m,2H),2.79-3.11(m,3H),3.31-3.49(m,2.7H),3.51-3.76(m,1.3H),5.14(d,J=11Hz,0.3H),5.18(d,J=11Hz,0.3H),5.23(d,J=11Hz,0.7H),5.33(d,J=11Hz,0.7H),5.63-5.75(m,1H),6.79(s,0.3H),6.82(s,0.7H),7.34-7.49(m,5H),7.66-7.77(m,1H),7.93(s,0.7H),7.95(s,0.3H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-1,2,3,4,5,5a,6,7-オクタヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-9-カルボキサミド
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.12(m,2H),0.48-0.55(m,2H),0.77-0.89(m,1H),1.01-1.08(m,1H),1.48(ddd,J=2,4,14Hz,1H),1.70(ddd,J=3,11,14Hz,1H),1.85(ddd,J=3,3,16Hz,1H),1.92-2.01(m,1H),1.99(s,3H),2.08(ddd,J=4,13,13Hz,1H),2.35(d,J=6Hz,2H),2.36-2.47(m,2H),2.53-2.60(m,1H),2.63(ddd,J=4,4,13Hz,1H),2.74-2.88(m,3H),2.89-3.02(m,3H),3.07-3.18(m,1H),3.90-4.06(m,2H),6.80(s,1H),6.85(s,1H),7.15(s,1H),7.21(s,1H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-9-ヨード-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,2H),0.70-0.90(m,1H),0.95-1.10(m,1H),1.50-2.20(m,4H),2.20-2.40(m,2H),2.40-2.65(m,2H),2.65-2.80(m,1H),2.80-3.00(m,3H),3.40-3.60(m,1H),3.70-3.90(m,1H),6.14(br s,0.1H),6.39(br s,0.9H),6.98(s,0.1H),7.10(s,0.9H),7.36(s,0.9H),7.45(s,0.1H),8.94(br s,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-9-ヨード-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,2H),0.70-0.85(m,1H),1.00-1.10(m,1H),1.30-1.50(m,1H),1.50-1.65(m,2H),1.65-1.90(m,1H),1.90-2.25(m,4H),2.25-2.40(m,2H),2.45-2.60(m,1H),2.65-3.40(m,5H),6.63(s,1H),7.42(s,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-9-ヨード-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオール
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.16(m,2H),0.44-0.56(m,2H),0.76-0.88(m,1H),0.95-1.03(m,1H),1.42-1.50(m,1H),1.69-1.81(m,2H),1.92-2.09(m,2H),2.02(s,3H),2.28-2.42(m,3H),2.47-2.57(m,2H),2.60(ddd,J=4,4,13Hz,1H),2.76(dd,J=6,18Hz,1H),2.82-2.98(m,5H),3.11-3.20(m,1H),3.98-4.10(m,2H),6.67(s,1H),6.90(s,1H),7.23(s,1H),7.41(s,1H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-(6-オキソ-1,6-ジヒドロピリジン-2-イル)-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-カルボン酸tert-ブチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.50-0.70(m,2H),0.80-1.00(m,1H),1.08(s,6.3H),1.16(s,2.7H),1.40-2.20(m,10H),2.30-2.40(m,2H),2.50-2.65(m,1H),2.80-3.10(m,1.7H),3.10-3.30(m,1.3H),3.30-3.40(m,0.3H),3.50-3.60(m,0.7H),4.25-4.40(m,1H),6.20-6.35(m,1H),6.50-6.65(m,2H),7.10-7.30(m,2H),7.30-7.40(m,1H).
6-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-3-(2-(ピリジン-2-イル)アセチル)-1,2,3,4,5,5a,6,7-オクタヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-10-イル)ピリジン-2(1H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.30(m,2H),0.50-0.70(m,2H),0.80-1.00(m,1H),1.00-1.90(m,5H),1.90-2.20(m,2.5H),2.20-2.50(m,2.5H),2.50-2.80(m,2H),2.80-3.20(m,3H),3.20-3.80(m,4H),3.80-4.00(m,1H),4.20-4.50(m,1H),6.31(d,J=7Hz,0.5H),6.40-6.60(m,1.5H),7.00-7.30(m,4H),7.30-7.55(m,2.5H),7.60(dt,J=2,8Hz,0.5H),8.35-8.45(m,0.5H),8.75-8.80(m,0.5H).
(5aS,6R,11bR)-10-(ベンジロキシ)-9-シクロプロピル-14-(シクロプロピルメチル)-5a-ヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)カルボン酸tert-ブチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.13(m,2H),0.46-0.60(m,3H),0.63-0.72(m,1H),0.76-0.91(m,3H),0.94-1.02(m,1H),1.28(s,4.5H),1.33(s,4.5H),1.42-1.50(m,0.5H),1.76-1.89(m,1.5H),1.90-2.09(m,3H),2.13-2.23(m,1H),2.24-2.39(m,2.5H),2.42-2.57(m,1.5H),2.68-2.81(m,1H),2.84-2.92(m,1.5H),2.93(d,J=18Hz,0.5H),3.24-3.45(m,2H),3.49-3.67(m,2H),4.48(br s,1H),5.05(d,J=11Hz,0.5H),5.08(d,J=11Hz,0.5H),5.11(s,1H),6.52(s,0.5H),6.53(s,0.5H),6.61(s,0.5H),6.63(s,0.5H),7.28-7.51(m,5H).
(5aS,6R,11bS)-9-シクロプロピル-14-(シクロプロピルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.16(m,2H),0.47-0.54(m,2H),0.56-0.67(m,2H),0.77-0.97(m,3H),1.02-1.11(m,1H),1.49(ddd,J=3,3,15Hz,1H),1.77(ddd,J=5,12,15Hz,1H),1.95(ddd,J=5,12,12Hz,1H),1.99-2.21(m,4H),2.33(d,J=6Hz,2H),2.47-2.56(m,1H),2.69(dd,J=6,18Hz,1H),2.72-2.85(m,2H),2.89(d,J=6Hz,1H),2.92(d,J=18Hz,1H),3.06(ddd,J=4,4,14Hz,1H),3.17(ddd,J=3,13,13Hz,1H),4.50(br s,1H),6.54(s,1H),6.55(s,1H).
1-((5aS,6R,11bR)-9-シクロプロピル-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(ピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.15(m,2H),0.44-0.54(m,2H),0.55-0.70(m,2H),0.75-0.98(m,3H),0.99-1.09(m,1H),1.49-1.62(m,1H),1.74-2.06(m,4.6H),2.08-2.26(m,1H),2.27-2.38(m,0.8H),2.30(dd,J=7,13Hz,0.6H),2.34(dd,J=6,13Hz,0.6H),2.44-2.56(m,1.6H),2.64(dd,J=6,18Hz,0.4H),2.73(dd,J=6,18Hz,0.6H),2.82(d,J=6Hz,0.4H),2.89(d,J=18Hz,0.6H),2.89(d,J=6Hz,0.6H),2.92(d,J=18Hz,0.4H),3.12-3.22(m,0.4H),3.31-3.41(m,1H),3.45(ddd,J=4,4,14Hz,0.4H),3.68(d,J=15Hz,0.6H),3.73-3.82(m,0.4H),3.78(d,J=15Hz,0.6H),3.84-3.95(m,1.2H),3.90(s,0.8H),4.09-4.17(m,0.4H),4.43(br s,0.4H),4.52(br s,0.6H),6.64(s,0.4H),6.65(s,0.6H),6.71(s,0.6H),6.72(s,0.4H),7.11-7.17(m,1H),7.20(d,J=8Hz,0.6H),7.22(d,J=8Hz,0.4H),7.58(ddd,J=2,8,8Hz,0.4H),7.60(ddd,J=2,8,8Hz,0.6H),8.46-8.50(m,1H).
(5aS,6R,11bS)-9-シクロプロピル-14-(シクロプロピルメチル)-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.02-0.15(m,2H),0.43-0.54(m,2H),0.58-0.67(m,2H),0.76-1.05(m,4H),1.41(ddd,J=2,5,14Hz,1H),1.75(ddd,J=3,11,14Hz,1H),1.77-1.86(m,2H),1.94-2.08(m,2H),2.00(s,3H),2.29-2.39(m,1H),2.33(d,J=7Hz,2H),2.44(ddd,J=4,4,13Hz,1H),2.49-2.54(m,1H),2.61(ddd,J=4,4,13Hz,1H),2.72(dd,J=6,18Hz,1H),2.82(ddd,J=6,6,13Hz,1H),2.84(ddd,J=6,6,13Hz,1H),2.86-2.98(m,1H),2.88(d,J=6Hz,1H),2.92(d,J=18Hz,1H),3.17(ddd,J=2,11,14Hz,1H),3.98(ddd,J=6,6,14Hz,1H),4.01(ddd,J=6,6,14Hz,1H),4.60(br s,1H),6.61(s,1H),6.75(s,1H),6.79(s,1H),7.22(s,1H).
(5aS,6R,11bR)-9-クロロ-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オン(異性体S)および(5aS,6R,11bR)-11-クロロ-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オン(異性体T)の合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.16(m,2H),0.48-0.57(m,2H),0.76-0.87(m,1H),1.02-1.11(m,1H),1.29-1.44(m,1H),1.48-1.58(m,1H),1.95-2.12(m,2H),2.29-2.40(m,2H),2.46-2.60(m,2H),2.67-2.82(m,2H),2.86-2.99(m,2H),3.44-3.51(m,1H),3.74-3.85(m,1H),3.87(s,3H),4.66(br s,1H),6.61-6.91(m,1H),7.03(s,1H),7.15(s,1H).
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.15(m,2H),0.45-0.57(m,2H),0.76-0.88(m,1H),1.53-1.63(m,1H),1.78-2.07(m,4H),2.26-2.38(m,2H),2.58-3.02(m,5H),3.37-3.59(m,2H),3.71-3.85(m,1H),3.81(s,3H),4.54(br s,1H),5.74-6.04(m,1H),6.75(d,J=8Hz,1H),6.94(d,J=8Hz,1H).
(5aS,6R,11bS)-9-クロロ-14-(シクロプロピルメチル)-10-メトキシ-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.14(m,2H),0.47-0.56(m,2H),0.77-0.89(m,1H),1.02-1.10(m,1H),1.58(ddd,J=3,3,15Hz,1H),1.66-1.76(m,1H),1.94-2.10(m,3H),2.28-2.44(m,3H),2.52-2.59(m,1H),2.74-3.14(m,7H),3.86(s,3H),4.49(brs,1H),6.72(s,1H),7.11(s,1H).
1-((5aS,6R,11bR)-9-クロロ-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(ピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.13(m,2H),0.47-0.55(m,2H),0.75-0.86(m,1H),0.96-1.09(m,1H),1.51-1.59(m,0.5H),1.61-1.80(m,1.5H),1.87-2.12(m,3H),2.25-2.46(m,2.5H),2.48-2.58(m,1.5H),2.62(dd,J=6,18Hz,0.5H),2.77(dd,J=6,18Hz,0.5H),2.84-2.95(m,2H),3.44-3.67(m,2H),3.74-3.96(m,3H),3.81(s,1.5H),3.88(s,1.5H),4.40-4.51(m,1H),6.53(s,0.5H),6.67(s,0.5H),7.03(s,0.5H),7.08(s,0.5H),7.09-7.16(m,2H),7.52(ddd,J=2,8,8Hz,0.5H),7.57(ddd,J=2,8,8Hz,0.5H),8.40-8.50(m,1H).
1-((5aS,6R,11bR)-9-クロロ-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(ピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.12(m,2H),0.45-0.54(m,2H),0.72-0.84(m,1H),0.87-0.96(m,1H),1.42-1.62(m,1.5H),1.70-2.04(m,3.5H),2.23-2.38(m,2.5H),2.40-2.54(m,2H),2.67-2.91(m,2.5H),3.27-3.57(m,2H),3.61-3.95(m,4H),6.75(s,0.5H),6.76(s,0.5H),6.86(s,0.5H),6.96-7.03(m,1H),7.06-7.18(m,1.5H),7.51-7.60(m,1H),8.39-8.47(m,1H).
1-((5aS,6R,11bR)-9,11-ジブロモ-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2,2,2-トリフルオロエタン-1-オンの合成
得られた粗生成物のメタノール(1mL)溶液に、10%臭化水素酸(1mL)及びヨードベンゼンジアセテート(257mg,0.80mmol)を加え、室温で18時間撹拌した。反応混合物に飽和チオ硫酸ナトリウム水溶液を加え、室温で30分撹拌した後、飽和炭酸水素ナトリウム水溶液を加え、クロロホルムで三回抽出した。有機層を合わせて硫酸ナトリウムで乾燥後、減圧下にて濃縮した。得られた粗生成物をシリカゲルカラムクロマトグラフィー(アミノ基担持シリカゲル、0-10%メタノール/クロロホルム)で精製し、表題化合物(66.1mg,53%)を無色アモルファスとして得た。
1H-NMR(400MHz,CDCl3)δ(ppm): 0.06-0.14(m,2H),0.49-0.57(m,2H),0.76-0.90(m,1H),1.62-2.06(m,5H),2.24-2.40(m,2H),2.58-3.10(m,6H),3.31-4.04(m,5H),7.23(s,1H).
(5aS,6R,11bS)-9,11-ジブロモ-14-(シクロプロピルメチル)-10-メトキシ-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
得られた粗生成物のエタノール(2mL)溶液に、炭酸カリウム(69.1mg,0.50mmol)を加え、80℃で3時間撹拌した。反応混合物を放冷後、水を加え、クロロホルムで三回抽出した。合わせた抽出物を硫酸ナトリウムで乾燥後、減圧下にて濃縮した。得られた粗生成物をシリカゲルカラムクロマトグラフィー(アミノ基担持シリカゲル、0-50%メタノール/クロロホルム)で精製し、表題化合物(44.2mg,88%)を無色アモルファスとして得た。
1H-NMR(400MHz,CDCl3)δ(ppm): 0.06-0.14(m,2H),0.48-0.56(m,2H),0.76-0.90(m,1H),1.55-1.73(m,2H),1.84-2.04(m,3H),2.25-2.38(m,2H),2.52-2.80(m,4H),2.82-3.13(m,6H),3.85(s,3H),4.47(br s,1H),7.29(s,1H).
(5aS,6R,11bS)-9,11-ジブロモ-14-(シクロプロピルメチル)-10-メトキシ-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm): 0.05-0.15(m,2H),0.46-0.56(m,2H),0.75-0.87(m,1H),1.46(dd,J=6,14Hz,1H),1.63-2.05(m,4H),2.02(s,3H),2.29(dd,J=7,13Hz,1H),2.31(dd,J=7,13Hz,1H),2.33-3.03(m,11H),3.08-3.20(m,1H),3.76-4.06(m,2H),3.80(s,3H),6.77(s,1H),7.21(s,1H),7.30(s,1H).
(5aS,6R,11bS)-9,11-ジブロモ-14-(シクロプロピルメチル)-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm): 0.05-0.12(m,2H),0.47-0.54(m,2H),0.74-0.85(m,1H),1.51(dd,J=6,15Hz,1H),1.73-1.99(m,4H),2.03(s,3H),2.23-2.46(m,3H),2.55-3.03(m,10H),3.15-3.25(m,1H),4.06-4.26(m,2H),6.98(s,1H),7.21(s,1H),7.25(s,1H).
(5aS,6R,11bS)-11-ブロモ-14-(シクロプロピルメチル)-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
得られた粗体のアセトニトリル(1mL)溶液に、参考例33で得られた化合物(12.1mg,0.060mmol)及びN,N-ジイソプロピルエチルアミン(15.7μL,0.090mmol)を加え、60℃で18時間撹拌した。放冷後、反応混合物に飽和炭酸水素ナトリウム水溶液を加え、クロロホルムで三回抽出した。合わせた抽出液を硫酸ナトリウムで乾燥後、減圧下にて濃縮した。得られた粗生成物は精製せずに次の反応に用いた。
得られた粗生成物のクロロホルム(2mL)溶液に、氷冷下1M三臭化ホウ素-ジクロロメタン溶液(0.50mL,0.50mmol)を加え、室温で30分間撹拌した。反応混合物に氷冷下28%アンモニア水溶液を加え、クロロホルムで三回抽出した。合わせた抽出液を硫酸ナトリウムで乾燥後、減圧下にて濃縮した。得られた粗生成物を分取薄層クロマトグラフィー(クロロホルム:2Mアンモニア-メタノール溶液=10:1)で精製し、表題化合物(2.3mg,15%)を無色アモルファスとして得た。
1H-NMR(400MHz,CDCl3)δ(ppm): 0.04-0.14(m,2H),0.46-0.55(m,2H),0.76-0.90(m,1H),1.40-2.04(m,5H),2.00(s,3H),2.25-2.40(m,3H),2.49-3.00(m,10H),3.14(dd,J=11,14Hz,1H),3.82-3.99(m,2H),4.55(s,1H),6.76(s,1H),6.87(d,J=9Hz,1H),6.98(d,J=8Hz,1H),7.19(s,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-9-メチル-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(イミダゾ[1,2-a]ピリジン-2-イル)エタン-1-オンの合成
の合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.02-0.15(m,2H),0.41-0.56(m,2H),0.74-0.91(m,1H),0.95-1.08(m,1H),1.50-1.61(m,1H),1.75-2.24(m,5H),2.11(s,3H),2.25-2.39(m,2H),2.46-2.62(m,1H),2.61(dd,J=6,18Hz,0.5H),2.66(dd,J=6,18Hz,0.5H),2.82(d,J=6Hz,0.5H),2.88(d,J=18Hz,0.5H),2.89(d,J=6Hz,0.5H),2.91(d,J=18Hz,0.5H),3.10-3.30(m,1.5H),3.45-3.55(m,0.5H),3.68(d,J=16Hz,0.5H),3.71(d,J=16Hz,0.5H),3.87(d,J=16Hz,0.5H),3.89-4.03(m,1.5H),3.93(d,J=16Hz,0.5H),4.06-4.16(m,0.5H),4.51(br s,1H),6.70-6.80(m,3H),7.07-7.18(m,1H),7.42-7.54(m,1.5H),7.45(s,0.5H),7.98-8.04(m,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-9-メチル-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-((R)-2-メチルピロリジン-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.17(m,2H),0.45-0.56(m,2H),0.76-0.90(m,1H),0.99-1.13(m,1.6H),1.05(d,J=6Hz,2.4H),1.22-1.44(m,1H),1.50-2.20(m,9H),2.17(s,3H),2.21-2.40(m,4H),2.42-2.65(m,2H),2.72(dd,J=6,18Hz,0.8H),2.75-2.83(m,0.2H),2.79(d,J=13Hz,0.8H),2.85-2.93(m,0.4H),2.87(d,J=6Hz,0.8H),2.96(d,J=18Hz,0.8H),2.97-3.06(m,0.2H),3.36-3.52(m,1.2H),3.53-3.65(m,0.2H),3.61(ddd,J=4,4,14Hz,0.8H),3.66-3.84(m,1.2H),3.69(d,J=13Hz,0.8H),3.93-4.04(m,0.8H),4.40-4.67(m,1H),6.61(s,0.2H),6.79(s,0.8H),6.81(s,0.2H),6.85(s,0.8H).
(5aS,6R,11bR)-5a-アセトキシ-10-(ベンジロキシ)-14-(シクロプロピルメチル)-9-ヨード-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-カルボン酸tert-ブチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.01-0.09(m,2H),0.39-0.51(m,2H),0.68-0.79(m,1H),0.93-1.03(m,1H),1.41(s,3.6H),1.44(s,5.4H),1.80-1.90(m,1H),1.92-2.07(m,2H),2.08-2.18(m,2H),2.10(s,1H),2.12(s,2H),2.19-2.45(m,3H),2.48-2.56(m,1H),2.60-2.78(m,2H),2.92-3.16(m,2H),3.42(ddd,J=4,13,13Hz,0.4H),3.50(ddd,J=2,5,15Hz,0.6H),3.60(ddd,J=4,13,13Hz,0.6H),3.74(ddd,J=2,5,15Hz,0.4H),4.18(d,J=6Hz,0.4H),4.26(d,J=6Hz,0.6H),5.00-5.20(m,2H),6.58(s,0.4H),6.59(s,0.6H),7.28-7.35(m,1H),7.36-7.43(m,2H),7.44-7.51(m,2H),7.54(s,0.4H),7.55(s,0.6H).
(5aS,6R,11bR)-5a-アセトキシ-10-(ベンジロキシ)-14-(シクロプロピルメチル)-9-(トリフルオロメチル)-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-カルボン酸tert-ブチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.01-0.10(m,2H),0.41-0.51(m,2H),0.68-0.80(m,1H),0.94-1.04(m,1H),1.39(s,3.6H),1.43(s,5.4H),1.75-1.86(m,1H),1.95(ddd,J=3,12,12Hz,1H),1.98-2.09(m,1H),2.11(s,1.2H),2.13(s,1.8H),2.14-2.34(m,4H),2.35-2.49(m,1H),2.50-2.58(m,1H),2.64-2.84(m,2H),2.97-3.18(m,2H),3.40(ddd,J=4,13,13Hz,0.4H),3.49(ddd,J=3,5,15Hz,0.6H),3.58(ddd,J=4,13,13Hz,0.6H),3.69(ddd,J=3,5,15Hz,0.4H),4.23(d,J=6Hz,0.6H),4.30(d,J=6Hz,0.4H),5.08-5.24(m,2H),6.76(s,1H),7.28-7.50(m,6H).
(5aS,6R,11bS)-10-(ベンジロキシ)-14-(シクロプロピルメチル)-9-(トリフルオロメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.14(m,2H),0.47-0.56(m,2H),0.76-0.88(m,1H),0.95-1.03(m,1H),1.51-1.68(m,2H),1.84(ddd,J=3,3,16Hz,1H),1.89-2.09(m,2H),2.26-2.39(m,3H),2.44-2.58(m,2H),2.74(ddd,J=4,4,14Hz,1H),2.78-2.86(m,2H),2.87-3.10(m,3H),4.47(br s,1H),5.12(d,J=13Hz,1H),5.21(d,J=13Hz,1H),6.75(s,1H),7.28-7.48(m,6H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-9-(トリフルオロメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.14(m,2H),0.46-0.56(m,2H),0.75-0.87(m,1H),0.98-1.07(m,1H),1.47-1.57(m,1H),1.69-1.81(m,1H),1.88-2.07(m,2H),2.10-2.18(m,2H),2.34(d,J=6Hz,2H),2.48-2.57(m,1H),2.62-2.76(m,2H),2.79-3.02(m,3H),3.08-3.20(m,1H),3.23-3.36(m,1H),6.59(s,1H),7.18(s,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-9-(トリフルオロメチル)-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(ピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.13(m,2H),0.47-0.54(m,2H),0.75-0.86(m,1H),0.96-1.09(m,1H),1.49-1.85(m,2H),1.88-2.15(m,3H),2.25-2.39(m,2H),2.47-2.67(m,1.7H),2.76(dd,J=6,18Hz,0.3H),2.83-2.99(m,2.3H),3.10-3.21(m,0.7H),3.46-3.72(m,2.7H),3.77-4.04(m,3.3H),6.88(s,0.3H),6.98(s,0.7H),7.07-7.18(m,2.7H),7.24-7.28(m,0.3H),7.57(ddd,J=2,8,8Hz,0.7H),7.62(ddd,J=2,8,8Hz,0.3H),8.36-8.40(m,0.3H),8.42-8.46(m,0.7H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-9-(トリフルオロメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.13(m,2H),0.47-0.54(m,2H),0.75-0.86(m,1H),0.95-1.03(m,1H),1.42-1.51(m,1H),1.61-1.79(m,2H),1.90-2.04(m,2H),1.97(s,3H),2.27-2.39(m,3H),2.47-2.57(m,2H),2.62(ddd,J=2,5,13Hz,1H),2.69-2.82(m,2H),2.86-3.03(m,4H),3.05-3.15(m,1H),4.03-4.11(m,2H),6.42(s,1H),7.03(s,1H),7.15(s,1H),7.24(s,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-9-メチル-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(6-(トリフルオロメチル)ピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.16(m,2H),0.43-0.56(m,2H),0.76-0.87(m,1H),0.99-1.12(m,1H),1.53-1.63(m,0.7H),1.79-2.09(m,4H),2.12(s,2.1H),2.16-2.23(m,1.4H),2.18(s,0.9H),2.26-2.39(m,2H),2.46(ddd,J=5,12,16Hz,0.3H),2.48-2.56(m,1H),2.66(dd,J=6,18Hz,0.7H),2.75(dd,J=6,18Hz,0.3H),2.84(d,J=6Hz,0.7H),2.90(d,J=6Hz,0.3H),2.91(d,J=18Hz,0.3H),2.94(d,J=18Hz,0.7H),3.12-3.21(m,0.7H),3.38-3.54(m,1.3H),3.67-3.77(m,0.3H),3.73(d,J=15Hz,0.3H),3.82(ddd,J=3,4,14Hz,0.3H),3.87(d,J=15Hz,0.3H),3.90-4.01(m,0.3H),3.96(d,J=15Hz,0.7H),4.02(d,J=15Hz,0.7H),4.15(ddd,J=4,4,14Hz,0.7H),4.41(br s,0.7H),4.51(br s,0.3H),6.58(s,0.3H),6.77(s,1.4H),6.83(s,0.3H),7.38(d,J=8Hz,0.3H),7.46(d,J=8Hz,0.7H),7.52-7.56(m,0.3H),7.54(d,J=8Hz,0.7H),7.75(dd,J=8,8Hz,0.3H),7.77(dd,J=8,8Hz,0.7H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-9-メチル-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(5-メチルイソチアゾール-3-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.17(m,2H),0.45-0.55(m,2H),0.76-0.88(m,1H),1.00-1.12(m,1H),1.51-1.61(m,1H),1.76-2.10(m,3.4H),2.14-2.23(m,1H),2.18(s,3H),2.28(dd,J=6,12Hz,0.6H),2.32-2.39(m,0.8H),2.36(dd,J=6,12Hz,0.6H),2.45-2.59(m,1.6H),2.51(s,1.2H),2.52(s,1.8H),2.67(dd,J=6,18Hz,0.6H),2.73(dd,J=6,18Hz,0.4H),2.84(d,J=6Hz,0.6H),2.89(d,J=6Hz,0.4H),2.90(d,J=18Hz,0.4H),2.95(d,J=18Hz,0.6H),3.19(ddd,J=4,10,14Hz,0.6H),3.30-3.42(m,0.8H),3.42(ddd,J=4,4,13Hz,0.6H),3.63(d,J=15Hz,0.4H),3.69(d,J=15Hz,0.4H),3.73-3.97(m,1.4H),3.83(d,J=16Hz,0.6H),3.91(d,J=16Hz,0.6H),4.11-4.19(m,0.6H),4.44(br s,0.6H),4.52(br s,0.4H),6.64(s,0.4H),6.79(s,0.6H),6.81(s,1H),6.83(s,0.4H),6.87(s,0.6H).
1-((5aS,6R,11bR)-10-(ベンジロキシ)-14-(シクロプロピルメチル)-5a-ヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2,2,2-トリフルオロエタン-1-オン
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.15(m,2H),0.47-0.56(m,2H),0.76-0.86(m,1H),1.01-1.13(m,1H),1.66(ddd,J=4,4,15Hz,1H),1.82-1.93(m,1H),1.96-2.15(m,3H),2.27-2.41(m,3H),2.52-2.62(m,1H),2.74-2.84(m,1H),2.88-2.94(m,1H),2.97-3.05(m,1H),3.13-3.23(m,0.5H),3.28-3.38(m,0.5H),3.46-3.56(m,1H),3.59-3.67(m,0.5H),3.78-4.06(m,1.5H),4.98-5.08(m,2H),6.66(d,J=2Hz,0.5H),6.72(d,J=2Hz,0.5H),6.77-6.83(m,1H),7.03(d,J=8Hz,1H),7.30-7.45(m,5H).
(5aS,6R,11bS)-9-クロロ-14-(シクロプロピルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオール(化合物U)、(5aS,6R,11bS)-11-クロロ-14-(シクロプロピルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオール(化合物V)および(5aS,6R,11bS)-9,11-ジクロロ-14-(シクロプロピルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオール(化合物UV)の合成
1H-NMR(400MHz,CD3OD)δ(ppm):0.09-0.18(m,2H),0.46-0.56(m,2H),0.81-0.91(m,1H),1.04-1.12(m,1H),1.53-1.62(m,1H),1.84-1.94(m,1H),1.96-2.14(m,3H),2.17-2.27(m,1H),2.33-2.43(m,2H),2.53-2.61(m,1H),2.74(dd,J=6,18Hz,1H),2.79-2.87(m,1H),2.90-3.06(m,4H),3.24-3.34(m,1H),6.59(s,1H),6.98(s,1H).
1H-NMR(400MHz,CD3OD)δ(ppm):0.07-0.17(m,2H),0.46-0.55(m,2H),0.80-0.92(m,1H),1.60-2.05(m,5H),2.29-2.41(m,2H),2.45-2.66(m,2H),2.73-2.87(m,2H),2.88-3.11(m,5H),3.26-3.33(m,1H),6.66(d,J=8Hz,1H),6.81(d,J=8Hz,1H).
1H-NMR(400MHz,CD3OD)δ(ppm):0.07-0.17(m,2H),0.44-0.55(m,2H),0.78-0.90(m,1H),1.58-1.72(m,2H),1.86-2.04(m,2H),2.19-2.49(m,4H),2.56-2.63(m,1H),2.76-2.94(m,5H),3.01(dd,J=6,13Hz,1H),3.10-3.18(m,1H),3.41-3.50(m,1H),6.84(s,1H).
(5aS,6R,11bS)-9-クロロ-14-(シクロプロピルメチル)-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオール
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.12(m,2H),0.46-0.52(m,2H),0.75-0.85(m,1H),0.92-1.00(m,1H),1.40-1.48(m,1H),1.66-1.77(m,2H),1.92-2.05(m,2H),1.99(s,3H),2.27-2.40(m,3H),2.41-2.60(m,3H),2.68-2.96(m,6H),3.07-3.16(m,1H),3.92-4.06(m,2H),6.71(s,1H),6.84(s,1H),7.04(s,1H),7.21(s,1H).
1-((5aS,6R,11bR)-11-クロロ-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(ピリジン-2-イル)エタン-1-オン
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.12(m,2H),0.47-0.54(m,2H),0.74-0.86(m,1H),1.49-1.55(m,0.3H),1.58-1.73(m,1.7H),1.76-2.06(m,2.7H),2.17-2.39(m,2.3H),2.48-2.75(m,2.7H),2.76-2.97(m,3.3H),3.16-3.26(m,0.7H),3.40(ddd,J=3,5,13Hz,0.7H),3.48(d,J=16Hz,0.7H),3.58-3.81(m,3.2H),4.18(ddd,J=2,5,14Hz,0.7H),4.49(br s,1H),6.80-6.85(m,1.3H),6.90(d,J=8Hz,0.7H),7.03-7.14(m,2H),7.50-7.57(m,1H),8.44-8.48(m,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-9-メチル-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(4-メチル-1H-ピラゾール-1-イル)エタン-1-オン
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.16(m,2H),0.44-0.57(m,2H),0.75-0.88(m,1H),0.99-1.11(m,1H),1.50-1.61(m,1H),1.78-2.11(m,4H),2.04(s,1.5H),2.07(s,1.5H),2.11-2.21(m,0.5H),2.18(s,1.5H),2.19(s,1.5H),2.28(dd,J=6,13Hz,0.5H),2.28-2.39(m,1H),2.35(dd,J=6,13Hz,0.5H),2.48-2.77(m,2.5H),2.86(d,J=7Hz,0.5H),2.89(d,J=19Hz,0.5H),2.90(d,J=6Hz,0.5H),2.96(d,J=18Hz,0.5H),3.06(ddd,J=3,13,14Hz,0.5H),3.17-3.28(m,1H),3.33(ddd,J=4,4,13Hz,0.5H),3.73(ddd,J=5,12,14Hz,0.5H),3.80-3.90(m,1H),4.07-4.16(m,0.5H),4.45(br s,0.5H),4.53(br s,0.5H),4.66(s,1H),4.91(d,J=16Hz,0.5H),4.92(d,J=16Hz,0.5H),6.65(s,1H),6.81(s,0.5H),6.83(s,0.5H),7.10(s,0.5H),7.19(s,0.5H),7.28(s,0.5H),7.30(s,0.5H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-9-メチル-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(4-(トリフルオロメチル)-1H-ピラゾール-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.18(m,2H),0.47-0.57(m,2H),0.76-0.89(m,1H),1.04-1.13(m,1H),1.55-1.65(m,1H),1.83(ddd,J=2,12,15Hz,0.4H),1.88-2.24(m,4.2H),2.17(s,1.8H),2.19(s,1.2H),2.29(dd,J=6,13Hz,0.4H),2.35(d,J=6Hz,1.2H),2.36(dd,J=6,13Hz,0.4H),2.49-2.59(m,1H),2.61-2.80(m,1.4H),2.86-2.93(m,1.4H),2.96-3.03(m,0.6H),2.99(d,J=18Hz,0.6H),3.30-3.40(m,1H),3.44(ddd,J=2,6,14Hz,0.4H),3.72(ddd,J=5,11,14Hz,0.4H),3.81-3.91(m,1H),4.17(ddd,J=2,5,14Hz,0.6H),4.76(d,J=16Hz,0.4H),4.81(d,J=16Hz,0.4H),4.99(d,J=16Hz,0.6H),5.04(d,J=16Hz,0.6H),6.62(s,0.4H),6.65(s,0.6H),6.84(s,0.6H),6.85(s,0.4H),7.55(s,0.4H),7.66(s,0.4H),7.71(s,0.6H),7.80(s,0.6H).
(4R,4aS,8aR,13bS)-3-(シクロプロピルメチル)-4a,10-ジヒドロキシ-1,2,3,4,4a,5,6,7-オクタヒドロ-4,13-メタノベンゾフロ[2,3-c]ピリド[4,3-d]アゼピン-8(8aH)-オンの合成
1H-NMR(400MHz,CD3ОD)δ(ppm):0.13-0.20(m,2H),0.50-0.59(m,2H),0.84-0.95(m,1H),1.35-1.43(m,1H),1.55-1.62(m,1H),1.79-1.90(m,1H),2.29-2.47(m,4H),2.67(dd,J=7,19Hz,1H),2.69-2.75(m,1H),2.80-2.91(m,2H),3.11(d,J=7Hz,1H),3.15(d,J=5Hz,1H),4.71(s,1H),6.60(d,J=8Hz,1H),6.68(d,J=8Hz,1H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,11-ジヒドロキシ-10-(メトキシメトキシ)-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オンの合成
得られた粗生成物のエチレンジアミン(10mL)溶液に、氷冷下ナトリウムシリカゲル ステージI(1g)を加え、室温で1時間撹拌した。反応混合物に、氷冷下テトラヒドロフラン(50mL)を加えた後、そのままの温度でゆっくりと水(100mL)を加えて撹拌した。反応混合物を室温へ戻し、飽和炭酸水素ナトリウム水溶液を加え、クロロホルムで三回抽出した。合わせた抽出液を硫酸ナトリウムで乾燥後、減圧下にて濃縮した。得られた粗生成物をシリカゲルカラムクロマトグラフィー(アミノ基担持シリカゲル、0-30%メタノール/クロロホルム)で精製し、表題化合物(93.0mg,77%)を無色アモルファスとして得た。
1H-NMR(400MHz,CDCl3)δ(ppm): 0.06-0.13(m,2H),0.47-0.55(m,2H),0.76-0.88(m,1H),1.52-1.68(m,1H),1.81-1.90(m,1H),1.93-2.05(m,2H),2.32(dd,J=6,12Hz,1H),2.34(dd,J=7,13Hz,1H),2.54-2.64(m,1H),2.80-3.00(m,4H),3.11(dd,J=2,14Hz,1H),3.51(s,3H),3.54(d,J=14Hz,1H),3.86-3.96(m,1H),4.65(br s,1H),5.15(d,J=12Hz,1H),5.16(d,J=12Hz,1H),5.83-5.92(m,1H),6.64(d,J=8Hz,1H),6.95(d,J=9Hz,1H),7.61(s,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-11-メトキシ-10-(メトキシメトキシ)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オール(化合物W)及び(5aS,6R,11bS)-14-(シクロプロピルメチル)-11-メトキシ-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオール(化合物X)の合成
得られた粗生成物のテトラヒドロフラン(1mL)溶液に、0.91Mボラン-テトラヒドロフラン錯体テトラヒドロフラン溶液(1.0mL,0.91mmol)を加え、2時間加熱還流した。反応混合物を放冷後、減圧下にて濃縮した。残渣に2M水酸化ナトリウム水溶液(2mL)を加え、室温で1時間撹拌した。反応混合物に水を加え、クロロホルムで三回抽出した。合わせた抽出物を硫酸ナトリウムで乾燥後、減圧下にて濃縮した。得られた粗生成物をシリカゲルカラムクロマトグラフィー(アミノ基担持シリカゲル、0-50%メタノール/クロロホルム)で精製し、表題の化合物W(12.1mg,30%)及び、粗精製品をそれぞれ無色アモルファスとして得た。
得られた粗生成品に2M塩酸(5.0mL,10mmol)を加え、室温で30分間撹拌した。反応混合物に氷冷下28%アンモニア水溶液を加え、クロロホルムで三回抽出した。有機層を合わせて硫酸ナトリウムで乾燥後、減圧下にて濃縮した。得られた粗生成物を分取薄層クロマトグラフィー(クロロホルム:2Mアンモニア-メタノール溶液=5:1)で精製し、表題化合物X(21.0mg,59%)を無色アモルファスとして得た。
1H-NMR(400MHz,CDCl3)δ(ppm): 0.05-0.14(m,2H),0.46-0.55(m,2H),0.76-0.90(m,1H),1.31-1.40(m,1H),1.55-1.85(m,2H),1.94-2.14(m,2H),2.25-2.39(m,3H),2.41-2.51(m,1H),2.54-2.63(m,1H),2.71-2.80(m,1H),2.86-3.02(m,5H),3.08-3.18(m,1H),3.51(s,3H),3.79(s,3H),4.47(br s,1H),5.16(s,2H),6.77(d,J=9Hz,1H),6.97(d,J=9Hz,1H).
1H-NMR(400MHz,CDCl3)δ(ppm): 0.06-0.13(m,2H),0.47-0.54(m,2H),0.77-0.88(m,1H),1.29-1.38(m,1H),1.55-1.70(m,2H),2.02-2.14(m,2H),2.20-2.63(m,6H),2.75-3.02(m,5H),3.06-3.16(m,1H),3.71(s,3H),4.53(br s,1H),6.69(d,J=8Hz,1H),6.73(d,J=8Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-11-メトキシ-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
得られた粗生成物に2M塩酸(2.0mL,4.0mmol)を加え、室温で30分間撹拌した。反応混合物に氷冷下28%アンモニア水溶液を加え、クロロホルムで三回抽出した。有機層を合わせて硫酸ナトリウムで乾燥後、減圧下にて濃縮した。得られた粗生成物を分取薄層クロマトグラフィー(クロロホルム:2Mアンモニア-メタノール溶液=10:1)で精製し、表題化合物(3.5mg,30%)を無色アモルファスとして得た。
1H-NMR(400MHz,CDCl3)δ(ppm): 0.07-0.13(m,2H),0.47-0.53(m,2H),0.77-0.89(m,1H),1.29-1.44(m,2H),1.70-1.80(m,1H),2.00(s,3H),2.02-2.24(m,3H),2.27-2.49(m,4H),2.55-2.97(m,8H),3.14-3.24(m,1H),3.74(s,3H),3.89-4.05(m,2H),6.75(d,J=8Hz,1H),6.77(d,J=8Hz,1H),6.83(s,1H),7.21(s,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-11-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(ピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm): 0.06-0.15(m,2H),0.47-0.55(m,2H),0.77-0.89(m,1H),1.20-1.60(m,2H),1.72-1.88(m,0.7H),2.00-4.10(m,16.3H),3.71(s,0.9H),3.80(s,2.1H),4.48(br s,1H),6.65-6.70(m,0.3H),6.69(d,J=8Hz,0.7H),6.76(d,J=8Hz,0.7H),6.80(d,J=8Hz,0.3H),7.04-7.16(m,2H),7.51-7.60(m,1H),8.42-8.46(m,1H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-(メチルカルバモイル)-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-カルボン酸tert-ブチルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.30(m,2H),0.45-0.60(m,2H),0.80-1.00(m,1H),1.00-1.10(m,9H),1.30-2.10(m,5H),2.30-2.40(m,2H),2.50-2.60(m,1H),2.60-2.80(m,1H),2.80-3.30(m,10H),3.50-3.60(m,1H),4.25-4.40(m,1H),7.05-7.15(m,1H),7.20-7.30(m,1H),7.35-7.45(m,1H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-N-メチル-3-(2-(ピリジン-2-イル)アセチル)-1,2,3,4,5,5a,6,7-オクタヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-10-カルボキサミドの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.30(m,2H),0.50-0.70(m,2H),0.80-1.00(m,1H),1.00-1.30(m,2H),1.30-2.10(m,3H),2.20-2.45(m,3H),2.45-2.80(m,3H),2.80-3.10(m,5H),3.20-3.40(m,2H),3.45-4.00(m,4H),4.20-4.60(m,1H),5.00-5.50(m,1H),6.85(d,J=7Hz,0.5H),7.00-7.70(m,5.5H),8.30-8.50(m,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-9-メチル-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-((R)-3-メチルピロリジン-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.16(m,2H),0.44-0.56(m,2H),0.76-0.89(m,1H),0.96-1.12(m,1H),0.99(d,J=6Hz,3H),1.19-1.38(m,1H),1.53-1.62(m,1H),1.82(ddd,J=2,12,15Hz,0.3H),1.90-2.39(m,10.3H),2.17(s,3H),2.45-2.57(m,1.4H),2.59-2.80(m,3H),2.85-2.93(m,0.6H),2.87(d,J=6Hz,0.7H),2.96(d,J=18Hz,0.7H),3.15(d,J=15Hz,0.3H),3.18(d,J=14Hz,0.7H),3.20(d,J=15Hz,0.3H),3.32(d,J=14Hz,0.7H),3.35-3.50(m,1.7H),3.55(ddd,J=4,5,14Hz,0.3H),3.63(ddd,J=4,11,14Hz,0.3H),3.72-3.83(m,1H),3.96-4.03(m,0.7H),4.51(br s,1H),6.61(s,0.3H),6.80(s,0.7H),6.81(s,0.3H),6.84(s,0.7H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-9-メトキシ-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
得られた粗体にトリフルオロ酢酸(1mL)を加え、室温で30分間撹拌した。反応混合物を減圧下にて濃縮し、28%アンモニア水溶液を加え、クロロホルムで三回抽出した。有機層を合わせて硫酸ナトリウムで乾燥後、減圧下にて濃縮した。得られた粗生成物は精製せずに次の反応に用いた。
得られた粗生成物のアセトニトリル(1mL)溶液に、参考例33で得られた化合物(20.4mg,0.10mmol)及びN,N-ジイソプロピルエチルアミン(26.1μL,0.15mmol)を加え、70℃で18時間撹拌した。放冷後、反応混合物に28%アンモニア水溶液を加え、クロロホルムで三回抽出した。合わせた抽出液を硫酸ナトリウムで乾燥後、減圧下にて濃縮した。得られた粗生成物は精製せずに次の反応に用いた。
得られた粗生成物のメタノール(1mL)溶液に10%パラジウム-活性炭素(32.2mg)及びギ酸カリウム(84.1mg,1.0mmol)を加え、室温で30分間撹拌した。反応混合物をセライトろ過し、ろ液に28%アンモニア水溶液を加え、クロロホルムで三回抽出した。有機層を合わせて硫酸ナトリウムで乾燥後、減圧下にて濃縮した。得られた粗生成物を分取薄層クロマトグラフィー(クロロホルム:2Mアンモニア-メタノール溶液=10:1)で精製し、表題化合物(3.5mg,13%)を無色アモルファスとして得た。
1H-NMR(400MHz,CDCl3)δ(ppm): 0.06-0.14(m,2H),0.46-0.54(m,2H),0.77-0.90(m,1H),0.96-1.04(m,1H),1.38-1.48(m,1H),1.76-1.88(m,2H),1.94-2.10(m,2H),2.00(s,3H),2.27-2.41(m,3H),2.48-2.59(m,2H),2.64-2.72(m,1H),2.77(dd,J=6,18Hz,1H),2.85-2.99(m,5H),3.18-3.26(m,1H),3.86(s,3H),3.98-4.18(m,2H),6.57(s,1H),6.66(s,1H),6.90(s,1H),7.23(s,1H).
(4’R,4a’S,7a’R,12b’S)-3’-(シクロプロピルメチル)-4a’-ヒドロキシ-9’-メトキシ-1’,2’,3’,4’,4a’,5’-ヘキサヒドロスピロ[シクロプロパン-1,6’-[4a,12]メタノベンゾフロ[3,2-e]イソキノリン]-7’(7a’H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.13-0.17(m,2H),0.43-0.48(m,1H),0.53-0.58(m,2H),0.82-0.91(m,1H),1.08-1.19(m,3H),1.57-1.62(m,2H),2.14(d,J=14Hz,1H),2.25(ddd,J=3,12,12Hz,1H),2.33-2.47(m,3H),2.58(dd,J=6,18Hz,1H),2.71(dd,J=5,12Hz,1H),3.10(d,J=18Hz,1H),3.15(d,J=6Hz,1H),3.87(s,3H),4.53(s,1H),6.64(d,J=8Hz,1H),6.72(d,J=8Hz,1H).
(4b’R,8a’S,9’R)-11’-(シクロプロピルメチル)-4’,8a’-ジヒドロキシ-3’-メトキシ-8’,8a’,9’,10’-テトラヒドロスピロ[シクロプロパン-1,7’-[9,4b](エピミノエタノ)フェナントレン]-6’(5’H)-オン(化合物Y)および(4bR,8aS,9R)-11-(シクロプロピルメチル)-7-エチル-4,8a-ジヒドロキシ-3-メトキシ-8,8a,9,10-テトラヒドロ-5H-9,4b-(エピミノエタノ)フェナントレン-6(7H)-オン(化合物Z)の合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.10-0.14(m,2H),0.20-0.25(m,1H),0.50-0.55(m,2H),0.82-0.88(m,2H),0.93-0.98(m,1H),1.29(d,J=14Hz,1H),1.37-1.42(m,1H),1.59-1.62(m,1H),2.06-2.09(m,2H),2.32-2.41(m,3H),2.61-2.64(m,1H),2.85(dd,J=6,19Hz,1H),3.00-3.09(m,3H),3.83(s,3H),3.98(d,J=16Hz,1H),4.71(br s,1H),6.05(s,1H),6.58(d,J=8Hz,1H),6.69(d,J=8Hz,1H).
1H-NMR(400MHz,CDCl3)δ(ppm):0.10-0.14(m,2H),0.51-0.56(m,2H),0.82(t,J=8Hz,3H),0.82-0.89(m,2H),0.94-1.05(m,1H),1.53-1.60(m,1H),1.67-1.78(m,1H),1.92(dd,J=6,13Hz,1H),1.99-2.12(m,2H),2.33-2.41(m,2H),2.58-2.61(m,1H),2.67-2.75(m,1H),2.82(dd,J=6,18Hz,1H),2.96(d,J=13Hz,1H),2.98(d,J=18Hz,1H),3.10(d,J=6Hz,1H),3.82(s,3H),3.91(d,J=13Hz,1H),4.77(br s,1H),6.09(s,1H),6.53(d,J=8Hz,1H),6.65(d,J=8Hz,1H).
トリフルオロメタンスルホン酸(4b’R,8a’S,9’R)-11’-(シクロプロピルメチル)-8a’-ヒドロキシ-3’-メトキシ-6’-オキソ-5’,6’,8’,8a’,9’,10’-ヘキサヒドロスピロ[シクロプロパン-1,7’-[9,4b](エピミノエタノ)フェナントレン]-4’-イルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.11-0.19(m,3H),0.53-0.57(m,2H),0.79-0.89(m,2H),0.94-0.99(m,1H),1.30-1.35(m,1H),1.36(d,J=14Hz,1H),1.70-1.73(m,1H),2.10-2.24(m,3H),2.33-2.43(m,2H),2.68-2.72(m,1H),2.90(dd,J=7,18Hz,1H),3.08(d,J=18Hz,1H),3.13(d,J=7Hz,1H),3.23(d,J=16Hz,1H),3.60(d,J=16Hz,1H),3.80(s,3H),6.87(d,J=8Hz,1H),7.07(d,J=8Hz,1H).
(4b’R,8a’S,9’R)-11’-(シクロプロピルメチル)-8a’-ヒドロキシ-3’-メトキシ-8’,8a’,9’,10’-テトラヒドロスピロ[シクロプロパン-1,7’-[9,4b](エピミノエタノ)フェナントレン]-6’(5’H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.11-0.15(m,2H),0.20-0.25(m,1H),0.52-0.56(m,2H),0.83-0.93(m,3H),1.17-1.28(m,2H),1.43-1.48(m,1H),2.10-2.19(m,2H),2.27(d,J=14Hz,1H),2.37(dd,J=6,12Hz,1H),2.42(dd,J=6,12Hz,1H),2.60-2.62(m,1H),2.77(dd,J=7,19Hz,1H),2.92(d,J=16Hz,1H),3.04-3.14(m,3H),3.75(s,3H),6.71(dd,J=2,8Hz,1H),6.77(d,J=2Hz,1H),7.01(d,J=8Hz,1H).
(4b’R,8a’S,9’R)-11’-(シクロプロピルメチル)-8a’-ヒドロキシ-3’-メトキシ-8’,8a’,9’,10’-テトラヒドロスピロ[シクロプロパン-1,7’-[9,4b](エピミノエタノ)フェナントレン]-6’(5’H)-オン オキシムの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.10-0.17(m,3H),0.50-0.54(m,2H),0.59-0.63(m,1H),0.82-0.88(m,2H),0.93(d,J=14Hz,1H),1.18-1.29(m,2H),2.10-2.18(m,3H),2.34(dd,J=6,13Hz,1H),2.40(dd,J=6,13Hz,1H),2.55(d,J=14Hz,1H),2.59-2.61(m,1H),2.70(dd,J=6,18Hz,1H),3.01(d,J=6Hz,1H),3.04(d,J=18Hz,1H),3.74(d,J=16Hz,1H),3.76(s,3H),6.69(dd,J=3,8Hz,1H),6.73(br s,1H),6.96(d,J=8Hz,1H),7.05(d,J=3Hz,1H).
(5a’S,6’R,11b’R)-14’-(シクロプロピルメチル)-5a’-ヒドロキシ-10’-メトキシ-5’,5a’,6’,7’-テトラヒドロ-1’H-スピロ[シクロプロパン-1,4’-[6,11b](エピミノエタノ)ナフト[1,2-d]アゼピン]-2’(3’H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.09-0.12(m,2H),0.47-0.55(m,4H),0.78-0.85(m,1H),0.90-0.95(m,1H),0.98(d,J=14Hz,1H),1.14-1.17(m,1H),1.43-1.49(m,1H),2.01-2.17(m,2H),2.30-2.39(m,2H),2.40(dd,J=2,14Hz,1H),2.57-2.61(m,2H),2.77(dd,J=6,18Hz,1H),2.85(d,J=6Hz,1H),3.00(d,J=18Hz,1H),3.76(d,J=15Hz,1H),3.80(s,3H),4.73(br s,1H),5.42(br s,1H),6.71(dd,J=2,8Hz,1H),6.97(d,J=8Hz,1H),7.16(d,J=2Hz,1H).
(5a’S,6’R,11b’S)-14’-(シクロプロピルメチル)-10’-メトキシ-2’,3’,6’,7’-テトラヒドロ-1’H-スピロ[シクロプロパン-1,4’-[6,11b](エピミノエタノ)ナフト[1,2-d]アゼピン]-5a’(5’H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.15(m,3H),0.34-0.39(m,1H),0.48-0.53(m,2H),0.72-0.76(m,2H),0.79-0.87(m,1H),1.06-1.13(m,2H),2.00-2.06(m,3H),2.27-2.45(m,4H),2.51-2.54(m,1H),2.79(dd,J=6,18Hz,1H),2.84-3.02(m,4H),3.79(s,3H),4.52(br s,1H),6.72(dd,J=2,8Hz,1H),6.77(d,J=2Hz,1H),7.03(d,J=8Hz,1H).
1-((5a’S,6’R,11b’R)-14’-(シクロプロピルメチル)-5a’-ヒドロキシ-10’-メトキシ-1’,2’,5’,5a’,6’,7’-ヘキサヒドロ-3’H-スピロ[シクロプロパン-1,4’-[6,11b](エピミノエタノ)ナフト[1,2-d]アゼピン]-3’-イル)-2-(ピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.10(m,2H),0.46-0.53(m,2H),0.66-1.18(m,6H),1.48-1.54(m,0.7H),1.78-1.86(m,1H),1.90-1.97(m,1H),2.07-2.17(m,1H),2.25-2.36(m,2.3H),2.48-2.60(m,2H),2.72(dd,J=6,19Hz,0.7H),2.83-2.90(m,3H),2.98-3.24(m,1.3H),3.54(d,J=15Hz,0.3H),3.68(d,J=15Hz,0.7H),3.78-3.86(m,4H),3.95-4.03(m,0.3H),4.71-4.79(m,0.7H),6.55(dd,J=3,8Hz,0.7H),6.63-6.82(m,3.3H),7.03-7.09(m,1H),7.42(ddd,J=2,8,8Hz,0.7H),7.51(ddd,J=2,8,8Hz,0.3H),8.37-8.40(m,0.7H),8.42-8.45(m,0.3H).
1-((5a’S,6’R,11b’R)-14’-(シクロプロピルメチル)-5a’,10’-ジヒドロキシ-1’,2’,5’,5a’,6’,7’-ヘキサヒドロ-3’H-スピロ[シクロプロパン-1,4’-[6,11b](エピミノエタノ)ナフト[1,2-d]アゼピン]-3’-イル)-2-(ピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.09(m,2H),0.46-0.51(m,2H),0.66-0.82(m,2H),0.92-1.06(m,3H),1.14-1.26(m,1H),1.52-1.55(m,0.7H),1.68-1.81(m,1H),1.94-2.13(m,2.3H),2.23-2.35(m,2H),2.45-2.71(m,2.6H),2.82-3.04(m,4.4H),3.38(d,J=15Hz,0.3H),3.61(d,J=15Hz,0.3H),3.71(d,J=15Hz,0.7H),3.83(d,J=15Hz,0.7H),3.95-4.04(m,0.3H),4.72-4.80(m,0.7H),6.50(dd,J=3,9Hz,0.7H),6.61-6.68(m,2.4H),6.80(d,J=2Hz,0.3H),6.91(d,J=8Hz,0.3H),7.00-7.05(m,1H),7.14-7.17(m,0.3H),7.40(ddd,J=2,8,8Hz,0.7H),7.59(ddd,J=2,8,8Hz,0.3H),8.37-8.40(m,0.7H),8.45-8.47(m,0.3H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-4,4-ジメチル-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(ピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.13(m,2H),0.48-0.54(m,2H),0.80-0.87(m,1H),1.02-1.05(m,1H),1.14(s,3H),1.38(d,J=15Hz,1H),1.91(s,3H),1.95-1.98(m,2H),2.11(dd,J=10,15Hz,1H),2.27-2.40(m,3H),2.58-2.60(m,1H),2.73-2.90(m,3H),3.00(d,J=18Hz,1H),3.72-3.78(m,1H),3.78(s,3H),3.88(d,J=15Hz,1H),3.99(d,J=15Hz,1H),4.46(br s,1H),6.67(d,J=3Hz,1H),6.72(dd,J=3,8Hz,1H),7.03(d,J=8Hz,1H),7.16(ddd,J=1,5,8Hz,1H),7.40(d,J=8Hz,1H),7.64(ddd,J=2,8,8Hz,1H),8.52-8.56(m,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-4,4-ジメチル-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(ピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.13(m,2H),0.47-0.53(m,2H),0.78-0.87(m,1H),1.00(s,3H),1.05-1.08(m,1H),1.34(d,J=15Hz,1H),1.89(s,3H),1.90-2.08(m,4H),2.29(dd,J=6,12Hz,1H),2.36(dd,J=6,12Hz,1H),2.42(dd,J=7,15Hz,1H),2.57(dd,J=4,12Hz,1H),2.71(dd,J=6,18Hz,1H),2.78(d,J=6Hz,1H),2.86(dd,J=10,16Hz,1H),2.97(d,J=18Hz,1H),3.82(d,J=14Hz,1H),3.85(dd,J=7,17Hz,1H),4.12(d,J=14Hz,1H),4.49(br s,1H),6.67(d,J=2,8Hz,1H),6.80(d,J=2Hz,1H),6.91(d,J=8Hz,1H),7.22(ddd,J=1,5,8Hz,1H),7.54(d,J=8Hz,1H),7.71(ddd,J=2,8,8Hz,1H),8.51-8.53(m,1H).
トリフルオロメタンスルホン酸(4bR,8aS,9R)-11-(シクロプロピルメチル)-7-エチル-8a-ヒドロキシ-3-メトキシ-6-オキソ-6,7,8,8a,9,10-ヘキサヒドロ-5H-9,4b-(エピミノエタノ)フェナントレン-4-イルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.12-0.15(m,2H),0.53-0.58(m,2H),0.80(t,J=7Hz,3H),0.83-1.00(m,2H),1.39(dd,J=13,13Hz,1H),1.60-1.71(m,2H),1.92(dd,J=6,13Hz,1H),2.08(ddd,J=3,12,12Hz,1H),2.21(ddd,J=5,13,13Hz,1H),2.38-2.40(m,2H),2.68-2.75(m,2H),2.86(dd,J=7,19Hz,1H),3.04(d,J=19Hz,1H),3.13-3.17(m,2H),3.50(d,J=14Hz,1H),3.79(s,3H),6.83(d,J=8Hz,1H),7.03(d,J=8Hz,1H).
(4bR,8aS,9R)-11-(シクロプロピルメチル)-7-エチル-8a-ヒドロキシ-3-メトキシ-8,8a,9,10-テトラヒドロ-5H-9,4b-(エピミノエタノ)フェナントレン-6(7H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.11-0.18(m,2H),0.51-0.59(m,2H),0.79(t,J=7Hz,3H),0.84-1.04(m,2H),1.17-1.21(m,1H),1.48(dd,J=13,13Hz,1H),1.64-1.74(m,1H),1.91(dd,J=6,13Hz,1H),2.06-2.21(m,2H),2.41-2.42(m,2H),2.58-2.63(m,1H),2.68-2.78(m,2H),2.81(d,J=14Hz,1H),3.05(d,J=18Hz,1H),3.09(d,J=14Hz,1H),3.16(d,J=6Hz,1H),3.77(s,3H),6.68(dd,J=2,8Hz,1H),6.82(d,J=2Hz,1H),6.97(d,J=8Hz,1H).
(4bR,8aS,9R)-11-(シクロプロピルメチル)-7-エチル-8a-ヒドロキシ-3-メトキシ-8,8a,9,10-テトラヒドロ-5H-9,4b-(エピミノエタノ)フェナントレン-6(7H)-オン オキシムの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.11-0.16(m,2H),0.49-0.57(m,2H),0.81-0.90(m,1H),0.87(t,J=8Hz,3H),0.99-1.10(m,1H),1.15-1.18(m,1H),1.30(dd,J=13,13Hz,1H),1.71-1.80(m,2H),2.07-2.16(m,2H),2.32(d,J=14Hz,1H),2.37-2.39(m,2H),2.55-2.67(m,2H),2.72(dd,J=6,18Hz,1H),3.03(d,J=18Hz,1H),3.05(d,J=6Hz,1H),3.71(s,3H),3.78(d,J=14Hz,1H),6.68(dd,J=2,8Hz,1H),6.94(d,J=8Hz,1H),7.12(d,J=2Hz,1H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-4-エチル-5a-ヒドロキシ-10-メトキシ-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.10-0.13(m,2H),0.50-0.55(m,2H),0.80-0.86(m,1H),0.94(t,J=7Hz,3H),1.12-1.14(m,1H),1.34-1.46(m,1H),1.49(d,J=14Hz,1H),1.57-1.66(m,2H),2.02-2.11(m,2H),2.34-2.36(m,2H),2.56-2.63(m,2H),2.75(dd,J=6,18Hz,1H),2.89(d,J=6Hz,1H),3.01(d,J=18Hz,1H),3.49(d,J=15Hz,1H),3.81(s,3H),3.82-3.89(m,1H),5.22(br s,1H),6.70(dd,J=2,8Hz,1H),6.96(d,J=8Hz,1H),7.16(d,J=2Hz,1H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-4-エチル-10-メトキシ-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a(1H)-オールの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.09-0.12(m,2H),0.47-0.55(m,2H),0.79-0.89(m,1H),0.87(t,J=7Hz,3H),1.04-1.08(m,1H),1.24-1.35(m,3H),1.48-1.61(m,2H),1.95-2.08(m,3H),2.31-2.39(m,3H),2.49-2.58(m,1H),2.81(dd,J=6,18Hz,1H),2.89-3.04(m,4H),3.08-3.15(m,1H),3.77(s,3H),4.59(br s,1H),6.70-6.73(m,2H),7.02(d,J=8Hz,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-4-エチル-5a-ヒドロキシ-10-メトキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(ピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.07-0.12(m,2H),0.48-0.55(m,2H),0.71(t,J=7Hz,1.5H),0.80(t,J=7Hz,1.5H),0.80-0.85(m,1H),1.06-1.09(m,1H),1.16-1.37(m,2.5H),1.55-1.76(m,2.5H),1.88-2.24(m,3.5H),2.32-2.37(m,2.5H),2.49-2.58(m,1.5H),2.74-2.92(m,2.5H),3.03(dd,J=6,18Hz,1H),3.78(s,1.5H),3.79(s,1.5H),3.79-3.86(m,0.5H),3.91-4.16(m,3H),4.58-4.66(m,0.5H),6.68-6.77(m,2H),7.05(d,J=8Hz,1H),7.13-7.17(m,1H),7.43(d,J=8Hz,0.5H),7.47(d,J=8Hz,0.5H),7.61-7.66(m,1H),8.52-8.54(m,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-4-エチル-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(ピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.08-0.12(m,2H),0.48-0.52(m,2H),0.63(t,J=7Hz,0.9H),0.78(t,J=7Hz,2.1H),0.82-0.91(m,1H),1.07-1.34(m,3H),1.50-1.77(m,2H),1.85-1.98(m,1H),2.03-2.17(m,2H),2.29-2.40(m,3H),2.47-2.51(m,1H),2.63-2.86(m,3H),2.95-3.02(m,1H),3.83(d,J=14Hz,0.3H),3.87(dd,J=5,16Hz,0.3H),3.98-4.27(m,3.1H),4.49-4.57(m,0.3H),6.59(dd,J=2,8Hz,0.3H),6.64(dd,J=2,8Hz,0.7H),6.70(d,J=2Hz,0.3H),6.89(d,J=8Hz,0.3H),6.94(d,J=8Hz,0.7H),7.00(d,J=2Hz,0.7H),7.15-7.18(m,0.7H),7.21-7.24(m,0.3H),7.43(d,J=8Hz,0.7H),7.54(d,J=8Hz,0.3H),7.66(ddd,J=2,8,8Hz,0.7H),7.71(ddd,J=2,8,8Hz,0.3H),7.85(br s,0.7H),8.04(br s,0.3H),8.51-8.56(m,1H).
1-((5aS,6R,11bR)-9,11-ジクロロ-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(ピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.10(m,2H),0.45-0.53(m,2H),0.73-0.85(m,1H),1.43-1.58(m,1H),1.61-1.97(m,3H),2.04-2.34(m,4H),2.38-2.91(m,5.7H),3.07-3.20(m,0.3H),3.33-3.49(m,2H),3.53-3.74(m,1.7H),3.79-3.94(m,0.3H),4.08-4.17(m,0.3H),4.44(br s,1H),4.60-4.75(m,0.7H),6.69(s,0.7H),6.74(s,0.3H),6.79-7.02(m,1.7H),7.09-7.15(m,0.3H),7.36-7.45(m,0.7H),7.50-7.57(m,0.3H),8.26-8.32(m,1H).
(5aS,6R,11bR)-11-(ベンジロキシ)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-(メトキシメトキシ)-3,4,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-2(1H)-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm): 0.06-0.13(m,2H),0.47-0.54(m,2H),0.74-0.86(m,1H),1.36-1.62(m,3H),1.82-2.04(m,3H),2.25-2.38(m,2H),2.52-2.64(m,1H),2.75-2.97(m,3H),3.16-3.28(m,2H),3.43(s,3H),3.72-3.83(m,1H),4.98(d,J=12Hz,1H),4.99(d,J=6Hz,1H),5.08(d,J=6Hz,1H),5.42-5.49(m,1H),5.56(d,J=12Hz,1H),6.72(d,J=8Hz,1H),6.97(d,J=9Hz,1H),7.22-7.40(m,3H),7.55-7.60(m,2H).
(5aS,6R,11bS)-11-(ベンジロキシ)-14-(シクロプロピルメチル)-2,3,4,5,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-5a,10(1H)-ジオールの合成
の合成
1H-NMR(400MHz,CDCl3)δ(ppm): 0.06-0.12(m,2H),0.46-0.53(m,2H),0.74-0.86(m,1H),1.23-1.32(m,1H),1.45-1.55(m,1H),1.57-1.69(m,1H),1.95(ddd,J=5,12,12Hz,1H),2.04-2.22(m,2H),2.26-2.38(m,3H),2.54(dd,J=3,12Hz,1H),2.67-2.95(m,6H),3.04(dd,J=12,12Hz,1H),4.69(d,J=11Hz,1H),5.05(d,J=11Hz,1H),6.68(d,J=8Hz,1H),6.72(d,J=8Hz,1H),7.32-7.44(m,5H).
トリフルオロメタンスルホン酸(5aS,6R,11bR)-11-(ベンジロキシ)-14-(シクロプロピルメチル)-5a-ヒドロキシ-3-(2-(ピリジン-2-イル)アセチル)-1,2,3,4,5,5a,6,7-オクタヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-10-イルの合成
得られた粗生成物のN,N-ジメチルホルムアミド(1mL)溶液に炭酸カリウム(55.3mg,0.40mmol)及びN-フェニルビス(トリフルオロメタンスルホンイミド)(143mg,0.40mmol)を加え、室温で1時間撹拌した。反応混合物に飽和炭酸水素ナトリウム水溶液を加え、クロロホルムで三回抽出した。有機層を合わせて硫酸ナトリウムで乾燥後、減圧下にて濃縮た。得られた粗生成物をシリカゲルカラムクロマトグラフィー(アミノ基担持シリカゲル、0-30%メタノール/クロロホルム)で精製し、表題化合物(56.1mg,82%)を無色のアモルファスとして得た。
1H-NMR(400MHz,CDCl3)δ(ppm): 0.06-0.15(m,2H),0.46-0.56(m,2H),0.75-0.90(m,1H),1.20-1.30(m,1H),1.45-1.68(m,2H),1.90-2.23(m,3H),2.25-2.42(m,2H),2.43-2.55(m,1H),2.56-2.70(m,1H),2.71-3.46(m,5H),3.50-3.90(m,3H),3.92-4.02(m,0.3H),4.15-4.24(m,0.7H),4.65(d,J=11Hz,0.7H),4.74(d,J=11Hz,0.3H),5.26(d,J=11Hz,0.3H),5.37(d,J=11Hz,0.7H),6.90(d,J=9Hz,0.3H),6.97(d,J=9Hz,0.7H),7.06-7.20(m,3H),7.30-7.44(m,5H),7.53(ddd,J=2,8,8Hz,0.3H),7.55(ddd,J=2,8,8Hz,0.7H),8.44-8.51(m,1H).
(5aS,6R,11bR)-11-(ベンジロキシ)-14-(シクロプロピルメチル)-5a-ヒドロキシ-3-(2-(ピリジン-2-イル)アセチル)-1,2,3,4,5,5a,6,7-オクタヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-10-カルボニトリルの合成
1H-NMR(400MHz,CDCl3)δ(ppm): 0.06-0.14(m,2H),0.46-0.56(m,2H),0.75-0.92(m,1H),1.20-4.40(m,19H),5.01(d,J=11Hz,0.7H),5.12(d,J=11Hz,0.3H),5.52(d,J=11Hz,0.3H),5.54(d,J=11Hz,0.7H),6.85(d,J=8Hz,0.3H),6.93(d,J=8Hz,0.7H),7.00-7.22(m,2H),7.32-7.60(m,7H),8.42-8.54(m,1H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,11-ジヒドロキシ-3-(2-(ピリジン-2-イル)アセチル)-1,2,3,4,5,5a,6,7-オクタヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-10-カルボキサミドの合成
得られた粗生成物のメタノール(0.5mL)溶液に、10%パラジウム-活性炭素(15.0mg)及びギ酸カリウム(15.0mg,0.178mmol)を加え、室温で30分間撹拌した。反応混合物をセライトろ過し、ろ液に28%アンモニア水溶液を加え、クロロホルムで三回抽出した。有機層を合わせて硫酸ナトリウムで乾燥後、減圧下にて濃縮した。得られた粗生成物を分取薄層クロマトグラフィー(クロロホルム:2Mアンモニア-メタノール溶液=10:1)で精製し、表題化合物(1.7mg,39%)を無色アモルファスとして得た。
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.15(m,2H),0.45-0.56(m,2H),0.75-0.92(m,1H),1.01-2.08(m,6H),2.20-3.00(m,8H),3.20-4.85(m,5.3H),4.10-4.61(m,1.7H),6.54(d,J=8Hz,0.3H),6.60(d,J=8Hz,0.7H),6.98-7.21(m,3H),7.35-7.79(m,2H),8.40-8.48(m,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-9-メチル-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(4-(トリフルオロメチル)ピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.04-0.17(m,2H),0.44-0.56(m,2H),0.75-0.91(m,1H),1.01-1.11(m,1H),1.59(ddd,J=4,4,15Hz,0.5H),1.60-1.67(m,0.5H),1.83(ddd,J=3,12,15Hz,0.5H),1.89-2.11(m,3H),2.15(s,1.5H),2.15(s,1.5H),2.17-2.25(m,1H),2.26-2.40(m,2H),2.50-2.60(m,1.5H),2.72(dd,J=6,18Hz,0.5H),2.77(dd,J=6,18Hz,0.5H),2.87(d,J=6Hz,0.5H),2.90(d,J=18Hz,0.5H),2.91(d,J=6Hz,0.5H),2.97(d,J=18Hz,0.5H),3.11(ddd,J=2,10,14Hz,0.5H),3.46(ddd,J=4,4,13Hz,0.5H),3.52(ddd,J=2,12,14Hz,0.5H),3.62(ddd,J=4,4,14Hz,0.5H),3.67-3.98(m,1.5H),3.73(d,J=15Hz,0.5H),3.78(s,1.5H),3.80(s,1.5H),3.84(d,J=15Hz,0.5H),3.93(d,J=15Hz,0.5H),3.99(d,J=15Hz,0.5H),4.20(ddd,J=2,6,14Hz,0.5H),6.49(s,0.5H),6.55(s,0.5H),6.85(s,1H),7.32-7.38(m,1.5H),7.56-7.59(m,0.5H),8.64(d,J=5Hz,0.5H),8.68(d,J=5Hz,0.5H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-9-メチル-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(4-(トリフルオロメチル)ピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.16(m,2H),0.43-0.56(m,2H),0.75-0.88(m,1H),1.01-1.15(m,1H),1.51-1.63(m,1H),1.77-1.86(m,1H),1.87-1.96(m,0.3H),1.92(ddd,J=4,13,13Hz,0.7H),1.98-2.19(m,2H),2.10(s,2.1H),2.17(s,0.9H),2.23-2.39(m,2.7H),2.49-2.62(m,1.3H),2.70(dd,J=6,18Hz,0.7H),2.71-2.78(m,0.3H),2.84(d,J=6Hz,0.7H),2.90(d,J=6Hz,0.3H),2.91(d,J=18Hz,0.3H),2.94-3.02(m,0.7H),2.96(d,J=18Hz,0.7H),3.32-3.48(m,1.3H),3.77-3.86(m,0.3H),3.78(d,J=15Hz,0.3H),3.81(d,J=15Hz,0.3H),3.89(ddd,J=3,5,14Hz,0.3H),3.97(ddd,J=4,13,13Hz,0.7H),4.01(d,J=15Hz,0.7H),4.03(d,J=15Hz,0.7H),4.27-4.34(m,0.7H),4.42(br s,0.7H),4.52(br s,0.3H),6.63(s,0.3H),6.79(s,1.4H),6.81(s,0.3H),7.35-7.43(m,1.3H),7.58-7.61(m,0.7H),8.64(d,J=5Hz,0.3H),8.70(d,J=5Hz,0.7H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-9-メチル-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(1H-インダゾール-3-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.15(m,2H),0.44-0.57(m,2H),0.75-0.91(m,1H),0.99-1.11(m,1H),1.50-1.64(m,1H),1.76(ddd,J=3,9,12Hz,0.5H),1.80(ddd,J=3,8,11Hz,0.5H),1.91-2.19(m,3H),2.15(s,1.5H),2.16(s,1.5H),2.26-2.35(m,1.5H),2.28(dd,J=6,13Hz,0.5H),2.35(dd,J=6,13Hz,0.5H),2.45-2.56(m,1.5H),2.64(dd,J=6,18Hz,0.5H),2.73(dd,J=6,18Hz,0.5H),2.85(d,J=6Hz,0.5H),2.88(d,J=18Hz,0.5H),2.89(d,J=6Hz,0.5H),2.92(d,J=18Hz,0.5H),3.27(ddd,J=2,12,14Hz,0.5H),3.44-3.56(m,1H),3.60(ddd,J=4,4,14Hz,0.5H),3.72-3.84(m,0.5H),3.77(s,1.5H),3.81(s,1.5H),3.85-3.98(m,1H),3.85(d,J=15Hz,0.5H),3.92(d,J=15Hz,0.5H),4.03(d,J=16Hz,0.5H),4.06(d,J=16Hz,0.5H),4.07-4.14(m,0.5H),4.50(br s,1H),6.52(s,0.5H),6.53(s,0.5H),6.79(s,0.5H),6.81(s,0.5H),7.06(ddd,J=1,6,6Hz,0.5H),7.07(ddd,J=1,6,6Hz,0.5H),7.27-7.37(m,2H),7.62-7.69(m,1H),10.1(br s,1H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-9-メチル-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(1H-インダゾール-3-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.16(m,2H),0.40-0.56(m,2H),0.73-1.00(m,2H),1.47-2.06(m,5.5H),2.17(s,1.5H),2.21(s,1.5H),2.22-2.40(m,1H),2.26(dd,J=7,13Hz,0.5H),2.31(d,J=6Hz,1H),2.33(dd,J=7,13Hz,0.5H),2.42-2.52(m,1H),2.59(dd,J=6,18Hz,0.5H),2.68(dd,J=6,18Hz,0.5H),2.81-2.89(m,1H),2.83(d,J=6Hz,0.5H),2.90(d,J=18Hz,0.5H),2.97-3.10(m,0.5H),3.13-3.27(m,0.5H),3.40-3.59(m,1H),3.70-4.00(m,3.5H),4.54(br s,1H),6.63(s,0.5H),6.69(s,0.5H),6.74(s,0.5H),6.76(s,0.5H),6.93-7.06(m,1H),7.16-7.35(m,2H),7.49-7.57(m,0.5H),7.60-7.69(m,0.5H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-9-メチル-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(3-フルオロピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.17(m,2H),0.46-0.54(m,2H),0.76-0.88(m,1H),1.03-1.11(m,1H),1.56-1.65(m,1H),1.84(ddd,J=2,12,15Hz,0.4H),1.91-2.39(m,5.4H),2.16(s,1.8H),2.18(s,1.2H),2.37(dd,J=7,13Hz,0.6H),2.50-2.59(m,0.8H),2.61(ddd,J=4,12,16Hz,0.6H),2.73-2.82(m,0.4H),2.74(dd,J=6,18Hz,0.6H),2.89(d,J=6Hz,0.6H),2.91(d,J=6Hz,0.4H),2.91(d,J=18Hz,0.4H),2.98(d,J=18Hz,0.6H),3.04-3.13(m,0.6H),3.44(ddd,J=4,4,13Hz,0.6H),3.45-3.54(m,0.4H),3.57(ddd,J=4,4,14Hz,0.4H),3.67(dd,J=2,16Hz,0.4H),3.68-3.82(m,0.6H),3.77(s,1.8H),3.80(s,1.2H),3.81(dd,J=2,16Hz,0.4H),3.88-4.01(m,1H),3.89(dd,J=2,16Hz,0.6H),3.98(dd,J=2,16Hz,0.6H),4.24(ddd,J=2,6,15Hz,0.6H),6.52(s,0.4H),6.55(s,0.6H),6.86(s,1H),7.16(ddd,J=4,4,9Hz,0.4H),7.19(ddd,J=4,4,8Hz,0.6H),7.32(ddd,J=1,9,10Hz,0.4H),7.34(ddd,J=1,8,10Hz,0.6H),8.29(ddd,J=1,1,4Hz,0.4H),8.33(ddd,J=1,1,4Hz,0.6H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-9-メチル-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(3-フルオロピリジン-2-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.16(m,2H),0.44-0.57(m,2H),0.76-0.90(m,1H),1.01-1.11(m,1H),1.52-1.64(m,1H),1.79-2.07(m,2.7H),2.08-2.26(m,2H),2.09(s,2.1H),2.19(s,0.9H),2.29(dd,J=6,12Hz,0.3H),2.32-2.39(m,0.3H),2.34(d,J=6Hz,1.4H),2.48-2.56(m,1H),2.59(ddd,J=5,11,16Hz,0.3H),2.70(dd,J=6,18Hz,0.7H),2.74(dd,J=6,18Hz,0.3H),2.86(d,J=6Hz,0.7H),2.90(d,J=6Hz,0.3H),2.90(d,J=18Hz,0.3H),2.94-3.03(m,0.7H),2.95(d,J=18Hz,0.7H),3.30-3.47(m,1.3H),3.74(dd,J=2,16Hz,0.3H),3.78(dd,J=2,16Hz,0.3H),3.79-3.92(m,1H),3.93-3.99(m,0.3H),3.94(dd,J=2,16Hz,0.7H),4.01(dd,J=2,16Hz,0.7H),4.30(ddd,J=2,6,14Hz,0.7H),4.48(br s,1H),6.64(s,0.3H),6.75(s,0.7H),6.78(s,0.7H),6.82(s,0.3H),7.19(ddd,J=4,4,8Hz,0.3H),7.21(ddd,J=4,4,8Hz,0.7H),7.34(ddd,J=1,8,10Hz,0.3H),7.37(ddd,J=1,8,10Hz,0.7H),8.29(ddd,J=1,1,4Hz,0.3H),8.35(ddd,J=1,1,4Hz,0.7H).
(5aS,6R,11bS)-14-(シクロプロピルメチル)-5a-ヒドロキシ-N-メチル-3-(2-(4-メチル-1H-ピラゾール-1-イル)エチル)-1,2,3,4,5,5a,6,7-オクタヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-10-カルボキサミドの合成
の合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.20(m,2H),0.45-0.60(m,2H),0.80-1.00(m,2H),1.00-1.10(m,1H),1.20-1.40(m,1H),1.40-1.55(m,1H),1.55-2.20(m,7H),2.20-2.65(m,5H),2.65-2.80(m,1H),2.80-3.15(m,7H),3.15-3.30(m,1H),3.90-4.10(m,2H),6.20-6.40(m,1H),6.80(s,1H),7.17(d,J=8Hz,1H),7.21(s,1H),7.43(dd,J=2,8Hz,1H),7.60(d,J=2Hz,1H).
(5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-カルボン酸フェニルの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.06-0.16(m,2H),0.48-0.55(m,2H),0.77-0.88(m,1H),1.02-1.11(m,1H),1.56-1.66(m,1H),1.86-2.12(m,4H),2.28-2.49(m,2.5H),2.51-2.64(m,1.5H),2.76-2.85(m,1H),2.91-3.03(m,2H),3.50-3.74(m,3H),3.76-3.96(m,1H),6.60-6.68(m,2H),6.85-6.91(m,2H),6.92-6.98(m,1H),7.09-7.17(m,1H),7.24-7.32(m,2H).
(5aS,6R,11bR)-N-(4-クロロフェニル)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-カルボキサミドの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.14(m,2H),0.46-0.55(m,2H),0.75-0.87(m,1H),0.97-1.05(m,1H),1.53-1.62(m,1H),1.85-2.07(m,4H),2.16-2.40(m,3H),2.47-2.57(m,1H),2.69-2.79(m,1H),2.85-3.00(m,2H),3.11-3.31(m,1H),3.38-3.55(m,1H),3.60-3.92(m,2H),6.49(br s,1H),6.58-6.68(m,2H),6.89(d,J=8Hz,1H),7.11-7.20(m,4H).
(5aS,6R,11bR)-N-(4-クロロフェニル)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-N-メチル-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-カルボキサミドの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.12(m,2H),0.45-0.52(m,2H),0.74-0.85(m,1H),1.05-1.15(m,1H),1.27-1.36(m,1H),1.64-1.76(m,1H),1.93-2.13(m,3H),2.26-2.36(m,2H),2.44-2.57(m,2H),2.66(dd,J=6,18Hz,1H),2.77-2.83(m,1H),2.89-3.00(m,2H),3.09(s,3H),3.21-3.33(m,2H),3.51-3.63(m,1H),4.46(br s,1H),6.66(dd,J=2,8Hz,1H),6.79-6.88(m,3H),6.94(d,J=8Hz,1H),7.16-7.22(m,2H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a-ヒドロキシ-10-メトキシ-9-メチル-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(4-フルオロ-1H-ピラゾール-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.05-0.18(m,2H),0.45-0.59(m,2H),0.76-0.90(m,1H),1.03-1.12(m,1H),1.55-1.65(m,1H),1.80-1.91(m,1H),1.92-2.09(m,2.4H),2.10-2.29(m,1.2H),2.17(s,1.8H),2.17(s,1.2H),2.30-2.40(m,2H),2.49-2.61(m,1.4H),2.71(dd,J=6,18Hz,0.6H),2.77(dd,J=6,19Hz,0.4H),2.88(d,J=6Hz,0.6H),2.91(d,J=18Hz,0.4H),2.91(d,J=6Hz,0.4H),2.97(d,J=18Hz,0.6H),3.16(ddd,J=2,11,14Hz,0.6H),3.34(ddd,J=4,4,13Hz,0.6H),3.46-3.55(m,0.8H),3.64(ddd,J=4,12,14Hz,0.4H),3.76-3.88(m,1.2H),3.79(s,1.8H),3.82(s,1.2H),4.10(ddd,J=3,6,14Hz,0.4H),4.52(d,J=16Hz,0.4H),4.77(d,J=16Hz,0.4H),4.86(s,1.2H),6.51(s,0.4H),6.55(s,0.6H),6.87(s,0.6H),6.87(s,0.4H),7.16(dd,J=1,4Hz,0.4H),7.27-7.29(m,0.6H),7.31(dd,J=1,4Hz,0.4H),7.32-7.34(m,0.6H).
1-((5aS,6R,11bR)-14-(シクロプロピルメチル)-5a,10-ジヒドロキシ-9-メチル-1,2,5,5a,6,7-ヘキサヒドロ-6,11b-(エピミノエタノ)ナフト[1,2-d]アゼピン-3(4H)-イル)-2-(4-フルオロ-1H-ピラゾール-1-イル)エタン-1-オンの合成
1H-NMR(400MHz,CDCl3)δ(ppm):0.03-0.16(m,2H),0.43-0.57(m,2H),0.76-0.90(m,1H),1.02-1.11(m,1H),1.54-1.62(m,1H),1.78-2.24(m,4.6H),2.18(s,1.8H),2.19(s,1.2H),2.29(dd,J=6,13Hz,0.4H),2.30-2.39(m,1.2H),2.39(dd,J=6,12Hz,0.4H),2.51-2.70(m,1.4H),2.70(dd,J=6,18Hz,0.6H),2.74(dd,J=6,19Hz,0.4H),2.89(d,J=6Hz,0.6H),2.90(d,J=19Hz,0.4H),2.91(d,J=6Hz,0.4H),2.97(d,J=18Hz,0.6H),3.08-3.17(m,0.6H),3.27-3.39(m,1.4H),3.71(ddd,J=5,12,14Hz,0.4H),3.79-3.89(m,1H),4.08(ddd,J=2,5,14Hz,0.6H),4.46(br s,0.4H),4.52(br s,0.6H),4.65(d,J=16Hz,0.4H),4.67(d,J=16Hz,0.4H),4.87(d,J=17Hz,0.6H),4.87(d,J=17Hz,0.6H),6.11(br s,0.4H),6.26(br s,0.6H),6.62(s,0.4H),6.64(s,0.6H),6.83(s,0.4H),6.84(s,0.6H),7.19(d,J=5Hz,0.4H),7.30(d,J=5Hz,0.6H),7.31(d,J=5Hz,0.4H),7.34(d,J=5Hz,0.6H).
オピオイド受容体機能試験
本発明化合物のκオピオイド受容体に対する機能活性を調べた。
方法:Lance Ultra cAMP kit(パーキンエルマー社)を用い、所定の方法に従って実施した。アゴニスト活性の評価では、ヒトκオピオイド受容体発現CHO細胞(Catalog No.CT6606,accession No.NM_000912)と被験化合物を10μM フォルスコリン存在下にて、アッセイバッファー(1×HBSS,5mM HEPES,pH7.4,0.5mM IBMX(Isobutylmethylxanthine),0.1% BSA)中で30分間反応させた。続けて、キット中のcAMP検出試薬を添加し、1時間後にEnVisionプレートリーダー(パーキンエルマー社)を用いて時間分解蛍光測定を行った。被験化合物の評価は、κオピオイド受容体機能試験は10-14~10-7Mの濃度範囲で実施した。
代謝安定性試験
ヒト肝ミクロソームと被験化合物を所定時間(0~30分)反応させ、反応試料中の被験化合物の未変化体残存率を求めた。反応時間0時間における未変化体残存率を100%とし、インキュベーション後の残存率を時間に対してlog-linearプロットし、回帰直線(y=100e-kt,k=直線の傾き:消失速度定数)を求め、以下の式を用いて代謝クリアランスCLint(mL/min/kg)を算出した。
CLint*=k(-min)×45(mg MS protein/g liver)×21(g liver/kg)/MS protein(mg MS protein/mL)
*:Yamazaki S.;Skaptason J.; Romero D, Vekich S.;Jones HM.;Tan W.;Wilner KD.;Koudriakova T. Drug Metab.Dispos.2011 Mar;39(3):383-393.
マウス酢酸ライジング試験
被験化合物の鎮痛作用は、酢酸ライジング試験により評価した。実験には、ICR系雄性マウスを用い、試験開始前にプラスチック製オープンフィールドへ30分間馴化させた。馴化後、マウスは、被験化合物(30~3000μg/kg)あるいは注射用水を皮下あるいは経口にて投与され、一度オープンフィールドへ戻された。被験化合物投与30分後、0.6%酢酸水溶液を腹腔内投与で同じマウスに追加投与した。0.6%酢酸水溶液投与10分後より、マウスにおいて誘発されるライジング反応(腹腔を床に押し付けて伸びをするような身もだえ反応)回数を10分間計測し、このライジング反応回数を対照群(注射用水投与群)と比較して、被験化合物の鎮痛効果を評価した。その結果を表4に記載する。
ロータロッド試験
被験化合物の鎮静作用(運動協調性障害作用)は、ロータロッド試験により評価した。実験には、ICR系雄性マウスを用い、事前にロータロッド訓練により運動課題を習得したマウスを使用した。ロータロッド訓練は、マウスが、3rpmで回転する回転軸棒上(直径3cm、KN-75、夏目製作所)に60秒間馴化して運動学習を獲得するまで、適度な休息時間を設けながら繰り返し訓練し、その後、3rpm 180秒間、4rpm 180秒間、および5rpm 180秒間の計三回のトレーニングを設けた。すべての訓練の後、90分から120分間の休息を設け、マウスの負担を軽減させた。なお、訓練によっても運動学習を獲得できなかったマウスは、実験には使用しなかった。
ロータロッド試験では、被験化合物投与前にプレ値として5rpm 300秒間 (カットオフ値300秒) における落下回数を測定した。プレ値の測定後、被験化合物(3~500μg/kg)もしくは注射用水をマウスに皮下投与(s.c.)あるいは経口投与(p.o.)で処置し、被験化合物投与後30分、60分、90分、120分の4時点で、プレ値の測定と同様にそれぞれ5rpm 300秒間における落下回数を測定した。この4時点における落下回数の合計を総落下回数(Total falls)として、被験化合物の鎮静作用を評価した。その結果を図1~5に記載する。なお、被験化合物は塩酸塩を用いた。また、図1~5中、Mean±SEM ns;not significant(Welch’s t test)、Mean±SEM *;p<0.05,***;p<0.001(Bonferroni’s test)である。
Claims (13)
- 次の一般式(I)、
R2及びR3は同一又は異なって水素原子、置換基を有していてもよいC1-6アルキル基、置換基を有していてもよいC1-6アルコキシ基、ハロゲン原子、保護されていてもよいヒドロキシ基又はR2及びR3が一緒になってカルボニル基を示すかR2及びR3が結合して置換基を有していてもよいC3-6飽和炭化水素環又は置換基を有していてもよい環状ケタールを示し、
R4及びR5は同一又は異なって水素原子、置換基を有していてもよいC1-6アルキル基、置換基を有していてもよいC1-6アルコキシ基、置換基を有していてもよいC3-6シクロアルキル基、置換基を有していてもよいアミノ基、保護されたアミノ基、ハロゲン原子、保護されていてもよいヒドロキシ基、カルボキシ基、カルボン酸エステル基又は置換基を有していてもよいカルバモイル基を示し、
R6は水素原子、置換基を有していてもよいC1-6アルコキシ基、置換基を有していてもよいアミノ基、保護されたアミノ基、ハロゲン原子、保護されていてもよいヒドロキシ基、置換基を有していてもよいテトラゾリルオキシ基、シアノ基、カルボキシ基、カルボン酸エステル基、置換基を有していてもよいカルバモイル基、置換基を有していてもよいC6-10アリール基、置換基を有していてもよいヘテロアリール基、C6-10アリールオキシ基又は糖類を示し、
R7及びR8は同一又は異なって水素原子、置換基を有していてもよいC1-6アルキル基、置換基を有していてもよいC1-6アルコキシ基、ハロゲン原子、保護されていてもよいヒドロキシ基又はR7及びR8が一緒になってカルボニル基、チオカルボニル基を示すかR7及びR8が結合して置換基を有していてもよいC3-6飽和炭化水素環又は置換基を有していてもよい環状ケタールを示し、
R9及びR10は同一又は異なって水素原子、置換基を有していてもよいC1-6アルキル基、置換基を有していてもよいC1-6アルコキシ基、ハロゲン原子、保護されていてもよいヒドロキシ基又はR9及びR10が一緒になってカルボニル基、チオカルボニル基を示すかR9及びR10が結合して置換基を有していてもよいC3-6飽和炭化水素環又は置換基を有していてもよい環状ケタールを示し、
R11は水素原子、置換基を有していてもよいC1-6アルキル基、置換基を有していてもよいC1-6アルコキシ基、置換基を有していてもよいアラルキルオキシ基、置換基を有していてもよいアミノ基、保護されたアミノ基、ハロゲン原子、保護されていてもよいヒドロキシ基又はシアノ基を示し、
A及びBは異なってNR18(R18は水素原子又はアミノ保護基を示す。)、メチレン基、カルボニル基又は下記一般式(II):
R14は水素原子、置換基を有していてもよいC1-6アルキル基、置換基を有していてもよいC3-6シクロアルキル基、置換基を有していてもよいC2-6アルケニル基、置換基を有していてもよいC2-6アルキニル基、置換基を有していてもよいC1-6アルコキシ基、置換基を有していてもよいアミノ基、保護されたアミノ基、ハロゲン原子、保護されていてもよいヒドロキシ基、置換基を有していてもよいC6-10アリール基、置換基を有していてもよいヘテロアリール基、置換基を有していてもよい飽和複素環基、置換基を有していてもよい環状アミノ基を示す。*は結合手を示す。)で表される基を示し(ただし、A、Bのいずれか一方は式(II)を示す)、
Xは窒素原子又はN-オキシドを示し、
Yは置換基を有していてもよいメチレン基、カルボニル基又はチオカルボニル基を示し、
ZはNR15、酸素原子、結合手、置換基を有しても良いエテニレン基又はエチニレン基を示し(ただし、mが0の時はnは0及びZはNR15を示さない。)、
R15は水素原子、置換基を有していてもよいC1-6アルキル基を示すか、R15とR14が結合して置換基を有していてもよい含窒素飽和複素環を示し、
R17は水素原子、ハロゲン原子、保護されていてもよいヒドロキシ基、置換基を有していてもよいアルコキシ基又は置換基を有していてもよいテトラゾリルオキシ基を示し、
mは0~1の整数を示し、
nは0~3の整数を示す。
(ただし、Zが結合手の場合、mとnは同時に0を示さない。))
で表されるアゼパン誘導体及びその薬学的に許容される塩。 - R6がヒドロキシ基、置換基を有していてもよいC1-6アルコキシ基又は置換基を有していてもよいカルバモイル基である請求項1記載のアゼパン誘導体及びその薬学的に許容される塩。
- R6がヒドロキシ基である請求項1又は2記載のアゼパン誘導体及びその薬学的に許容される塩。
- R1が置換基を有していてもよいC1-6アルキル基又は置換基を有していてもよいC3-6シクロアルキルC1-6アルキル基である請求項1~3のいずれか一項に記載のアゼパン誘導体及びその薬学的に許容される塩。
- Zが結合手である請求項1~4のいずれか一項に記載のアゼパン誘導体及びその薬学的に許容される塩。
- nが1~3である請求項1~5のいずれか一項に記載のアゼパン誘導体及びその薬学的に許容される塩。
- R14が置換基を有していてもよいヘテロアリール基である請求項1~6のいずれか一項に記載のアゼパン誘導体及びその薬学的に許容される塩。
- Aが前記一般式(II)で表される基を示し、Bがメチレン基を示す請求項1~7のいずれか一項に記載のアゼパン誘導体及びその薬学的に許容される塩。
- R11がヒドロキシ基である請求項1~8のいずれか一項に記載のアゼパン誘導体及びその薬学的に許容される塩。
- 請求項1~9いずれか一項に記載のアゼパン誘導体及びその薬学的に許容される塩を有効成分として含有する医薬組成物。
- κオピオイド受容体に関連する疾患の治療又は改善、予防剤である請求項10記載の医薬組成物。
- 鎮痛薬である請求項10又は11記載の医薬組成物。
- 止痒薬である請求項10又は11記載の医薬組成物。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20871687.8A EP4039331A4 (en) | 2019-09-30 | 2020-09-29 | AZEPANE DERIVATIVE |
JP2021551303A JPWO2021065898A1 (ja) | 2019-09-30 | 2020-09-29 | |
CN202080082166.6A CN114761082A (zh) | 2019-09-30 | 2020-09-29 | 氮杂环庚烷衍生物 |
US17/762,134 US20230087342A1 (en) | 2019-09-30 | 2020-09-29 | Azepane derivative |
CA3152485A CA3152485A1 (en) | 2019-09-30 | 2020-09-29 | Azepane derivative |
KR1020227013317A KR20220071223A (ko) | 2019-09-30 | 2020-09-29 | 아제판 유도체 |
AU2020360928A AU2020360928A1 (en) | 2019-09-30 | 2020-09-29 | Azepan derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019179727 | 2019-09-30 | ||
JP2019-179727 | 2019-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021065898A1 true WO2021065898A1 (ja) | 2021-04-08 |
Family
ID=75338310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/036868 WO2021065898A1 (ja) | 2019-09-30 | 2020-09-29 | アゼパン誘導体 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230087342A1 (ja) |
EP (1) | EP4039331A4 (ja) |
JP (1) | JPWO2021065898A1 (ja) |
KR (1) | KR20220071223A (ja) |
CN (1) | CN114761082A (ja) |
AU (1) | AU2020360928A1 (ja) |
CA (1) | CA3152485A1 (ja) |
WO (1) | WO2021065898A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022210479A1 (ja) * | 2021-03-29 | 2022-10-06 | 日本ケミファ株式会社 | アゼパン誘導体のκオピオイド受容体関連疾患の治療、改善又は予防のための使用 |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US963460A (en) | 1910-02-23 | 1910-07-05 | Peter N Moore | Roller side bearing. |
JP2525552B2 (ja) | 1992-01-23 | 1996-08-21 | 東レ株式会社 | モルヒナン誘導体および医薬用途 |
WO1999005095A1 (fr) | 1997-07-24 | 1999-02-04 | Mitsubishi-Tokyo Pharmaceuticals, Inc. | Composes d'aminocycloalcane |
JP2008179554A (ja) | 2007-01-24 | 2008-08-07 | Toray Ind Inc | ピロール縮合モルヒナン誘導体およびその医薬用途 |
WO2008143263A1 (ja) * | 2007-05-22 | 2008-11-27 | Astellas Pharma Inc. | 1位置換テトラヒドロイソキノリン化合物 |
WO2010021149A1 (ja) | 2008-08-21 | 2010-02-25 | 武田薬品工業株式会社 | 酸分泌抑制スピロ化合物 |
JP2010511717A (ja) * | 2006-12-05 | 2010-04-15 | ニューロジェシックス, インコーポレイテッド | プロドラッグおよびその作成ならびに使用方法 |
WO2010105179A2 (en) | 2009-03-13 | 2010-09-16 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
WO2011045383A2 (en) | 2009-10-15 | 2011-04-21 | Ac Immune S.A. | 2, 6 -diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases |
JP2015500245A (ja) * | 2011-12-05 | 2015-01-05 | マリンクロッド エルエルシー | 7員環ラクタムモルヒナンの製造のためのプロセス |
WO2016040515A1 (en) | 2014-09-10 | 2016-03-17 | Epizyme, Inc. | Substituted piperidine compounds |
WO2017223239A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
WO2018148576A1 (en) | 2017-02-10 | 2018-08-16 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
WO2018160878A1 (en) | 2017-03-02 | 2018-09-07 | Assembly Biosciences, Inc. | Cyclic sulfamide compounds and methods of using same |
JP2019179727A (ja) | 2018-03-30 | 2019-10-17 | 古河電気工業株式会社 | カーボンナノチューブ線材、カーボンナノチューブ被覆電線、カーボンナノチューブ線材の製造方法及びカーボンナノチューブ被覆電線の加工方法 |
WO2020085234A1 (ja) * | 2018-10-22 | 2020-04-30 | 日本ケミファ株式会社 | モルヒナン誘導体 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2525552Y2 (ja) | 1990-10-26 | 1997-02-12 | 株式会社間組 | シャワールームユニット |
GB9118597D0 (en) | 1991-08-30 | 1991-10-16 | Biocompatibles Ltd | Polymer treatments |
WO2015192053A1 (en) * | 2014-06-13 | 2015-12-17 | Purdue Pharma L.P. | Azamophinan derivatives and use thereof |
WO2018125716A1 (en) * | 2017-01-02 | 2018-07-05 | Purdue Pharma L.P. | Morphinan derivatives and use thereof |
JPWO2019045006A1 (ja) * | 2017-08-31 | 2020-10-01 | 国立大学法人 筑波大学 | モルヒナン誘導体 |
-
2020
- 2020-09-29 AU AU2020360928A patent/AU2020360928A1/en active Pending
- 2020-09-29 EP EP20871687.8A patent/EP4039331A4/en active Pending
- 2020-09-29 JP JP2021551303A patent/JPWO2021065898A1/ja active Pending
- 2020-09-29 CN CN202080082166.6A patent/CN114761082A/zh active Pending
- 2020-09-29 CA CA3152485A patent/CA3152485A1/en active Pending
- 2020-09-29 KR KR1020227013317A patent/KR20220071223A/ko unknown
- 2020-09-29 WO PCT/JP2020/036868 patent/WO2021065898A1/ja unknown
- 2020-09-29 US US17/762,134 patent/US20230087342A1/en active Pending
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US963460A (en) | 1910-02-23 | 1910-07-05 | Peter N Moore | Roller side bearing. |
JP2525552B2 (ja) | 1992-01-23 | 1996-08-21 | 東レ株式会社 | モルヒナン誘導体および医薬用途 |
WO1999005095A1 (fr) | 1997-07-24 | 1999-02-04 | Mitsubishi-Tokyo Pharmaceuticals, Inc. | Composes d'aminocycloalcane |
JP2010511717A (ja) * | 2006-12-05 | 2010-04-15 | ニューロジェシックス, インコーポレイテッド | プロドラッグおよびその作成ならびに使用方法 |
JP2008179554A (ja) | 2007-01-24 | 2008-08-07 | Toray Ind Inc | ピロール縮合モルヒナン誘導体およびその医薬用途 |
WO2008143263A1 (ja) * | 2007-05-22 | 2008-11-27 | Astellas Pharma Inc. | 1位置換テトラヒドロイソキノリン化合物 |
WO2010021149A1 (ja) | 2008-08-21 | 2010-02-25 | 武田薬品工業株式会社 | 酸分泌抑制スピロ化合物 |
WO2010105179A2 (en) | 2009-03-13 | 2010-09-16 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
WO2011045383A2 (en) | 2009-10-15 | 2011-04-21 | Ac Immune S.A. | 2, 6 -diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases |
JP2015500245A (ja) * | 2011-12-05 | 2015-01-05 | マリンクロッド エルエルシー | 7員環ラクタムモルヒナンの製造のためのプロセス |
WO2016040515A1 (en) | 2014-09-10 | 2016-03-17 | Epizyme, Inc. | Substituted piperidine compounds |
WO2017223239A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
WO2018148576A1 (en) | 2017-02-10 | 2018-08-16 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
WO2018160878A1 (en) | 2017-03-02 | 2018-09-07 | Assembly Biosciences, Inc. | Cyclic sulfamide compounds and methods of using same |
JP2019179727A (ja) | 2018-03-30 | 2019-10-17 | 古河電気工業株式会社 | カーボンナノチューブ線材、カーボンナノチューブ被覆電線、カーボンナノチューブ線材の製造方法及びカーボンナノチューブ被覆電線の加工方法 |
WO2020085234A1 (ja) * | 2018-10-22 | 2020-04-30 | 日本ケミファ株式会社 | モルヒナン誘導体 |
Non-Patent Citations (11)
Title |
---|
"Symposium Program and Abstract of 36th Annual Meeting of Japanese Narcotics Research Conference", JAPANESE NARCOTICS RESEARCH CONFERENCE, 2016, pages 37 |
ISHIKAWA, KYOKO ET AL.: "C-homomorphinan derivatives as lead compounds to obtain safer and more clinically useful analgesics", CHEM. PHARM. BULL., vol. 65, 2017, pages 920 - 929, XP055815434 * |
JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, 1996, pages 2615 |
JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, 2015, pages 5842 |
JOURNAL OF MEDICINAL CHEMISTRY, vol. 61, 2018, pages 8797 |
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 134, 2012, pages 11408 |
ORGANIC LETTERS, vol. 11, 2009, pages 539 |
See also references of EP4039331A4 |
SUZUKI, SHINYA ET AL.: "Discovery of highly selective kappa-opioid receptor agnists: 10 alpha-hydroxy TRK-820 derivatives", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 27, 2017, pages 3920 - 3924, XP055710940 * |
TETRAHEDRON LETT., vol. 51, 2010, pages 2359 |
TETRAHEDRON LETTERS, vol. 48, 2007, pages 7413 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022210479A1 (ja) * | 2021-03-29 | 2022-10-06 | 日本ケミファ株式会社 | アゼパン誘導体のκオピオイド受容体関連疾患の治療、改善又は予防のための使用 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2021065898A1 (ja) | 2021-04-08 |
EP4039331A4 (en) | 2024-01-17 |
KR20220071223A (ko) | 2022-05-31 |
AU2020360928A1 (en) | 2022-04-14 |
US20230087342A1 (en) | 2023-03-23 |
CA3152485A1 (en) | 2021-04-08 |
EP4039331A1 (en) | 2022-08-10 |
CN114761082A (zh) | 2022-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102482271B1 (ko) | 낭포성 섬유증 막관통 전도성 조절인자의 조절제로서의 매크로사이클, 그의 약제학적 조성물, 낭포성 섬유증의 치료에서의 그의 용도, 및 그의 제조 방법 | |
JP6492128B2 (ja) | 二環式縮合ヘテロアリールまたはアリール化合物およびirak4阻害剤としてのそれらの使用 | |
KR102642203B1 (ko) | 급속 진행형 섬유육종 폴리펩티드의 표적화 분해를 위한 다중 고리 화합물 및 방법 | |
RU2476430C2 (ru) | Производные аминодигидротиазина, замещенные циклической группой | |
AU2024203058A1 (en) | BRM targeting compounds and associated methods of use | |
BR112021001044A2 (pt) | Compostos de sulfonimidamida como inibidores da atividade de interleucina-1 | |
KR20200101423A (ko) | Nlrp3 인플라마좀 조절제로서의 설포닐 우레아 유도체 | |
AU2016293446A1 (en) | Substituted aza compounds as IRAK-4 inhibitors | |
EA039808B1 (ru) | Аминотриазолопиридины в качестве ингибиторов киназ | |
JP2022517901A (ja) | 環状尿素 | |
CN112236423A (zh) | 哌啶基-3-(芳氧基)丙酰胺和丙酸酯 | |
US11352357B2 (en) | Cycloalkylurea derivative | |
CN113292559B (zh) | 吗啡喃衍生物 | |
US20230088694A1 (en) | Cycloalkylurea derivative | |
WO2023015164A1 (en) | Cyanopyridine and cyanopyrimidine bcl6 degraders | |
WO2020085234A1 (ja) | モルヒナン誘導体 | |
WO2021065898A1 (ja) | アゼパン誘導体 | |
JPWO2019045006A1 (ja) | モルヒナン誘導体 | |
WO2021132524A1 (ja) | エポキシアゼパン誘導体 | |
WO2022210479A1 (ja) | アゼパン誘導体のκオピオイド受容体関連疾患の治療、改善又は予防のための使用 | |
TW200303197A (en) | Chemokine receptor antagonists and methods of use therefor | |
JP2005513132A (ja) | ベンズヒドリル誘導体 | |
RU2820289C2 (ru) | Соединения сульфонимидамида в качестве ингибиторов активности интерлейкина-1 | |
EP4380919A1 (en) | Cyanopyridine and cyanopyrimidine bcl6 degraders | |
WO2023204308A1 (ja) | オキサゼピン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20871687 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021551303 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3152485 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020360928 Country of ref document: AU Date of ref document: 20200929 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20227013317 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020871687 Country of ref document: EP Effective date: 20220502 |